As filed with the Securities and Exchange Commission on July 1, 2024.
Registration No. 333-280194
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
(Exact Name of Registrant as Specified in Its Charter)
| 8900 | 85-4359258 | |||
| (State or jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | ||
| incorporation or organization) | Classification Code Number) | Identification No.) |
780 Lynnhaven Parkway
Suite 400
Virginia Beach, Virginia 23452
Telephone: (757) 734-5464
(Address, Including Zip Code, and Telephone Number, Including
Area Code, of Registrant’s Principal Executive Offices)
The Crone Law Group, PC
One East Liberty
Suite 600
Reno, Nevada 89501
Telephone: 646-861-7891
(Name, address, including zip code, and telephone
number,
including area code, of agent for service)
Copies to:
Mark E. Crone, Esq. Joe Laxague, Esq. Cassi Olson, Esq. The Crone Law Group, PC 420 Lexington Avenue Suite 2446 New York, NY 10170 (775) 234-5221 |
Ross Carmel, Esq. Jeffrey P. Wofford, Esq. Sichenzia Ross Ference Carmel LLP 1185 Avenue of the Americas, 31st Floor New York, NY, 10036 (212) 930-9700 |
Approximate date of commencement of proposed sale to the public: As soon as practicable after this registration statement becomes effective.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company in Rule 12b-2 of the Exchange Act. (Check one):
| Large accelerated filer: ☐ | Accelerated filer: ☐ | |
| Smaller reporting company: | ||
| Emerging Growth Company: |
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission acting pursuant to said Section 8(a), may determine.
The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
Subject to completion. Dated July 1, 2024
PROSPECTUS
INSPIRE VETERINARY PARTNERS, INC.
Up
to 9,125,475 Units, Each Unit Consisting of One Share of Class A Common Stock or One Pre-Funded
Warrant to Purchase One Share of Class A Common Stock
One Warrant to Purchase One Share of Class A Common Stock
Up to 9,125,475 shares of Class A Common Stock underlying the Warrants
Up to 9,125,475 shares of Class A Common Stock underlying the Pre-Funded Warrants
Inspire Veterinary Partners, Inc. (“Inspire” or the “Company”) is offering on a reasonable best efforts basis, 9,125,475 units (the “Units”), at an assumed offering price of 1.315 per Unit, which is equal to the closing price of our common stock on the Nasdaq Stock Market LLC on June 20, 2024. Each Unit consists of one share of the Company’s Class A common stock, $0.001 par value per share and one warrant (“Warrant”) to purchase one share of Class A common stock.
The Units have no stand-alone rights and will not be certificated or issued as stand-alone securities. The Warrants will have an exercise price of $[*] (100% of the public offering price per Unit) and will be exercisable for a period of six months commencing upon issuance. The Class A common Stock and Pre-Funded Warrants can each be purchased in this offering only with the accompanying Warrants that are part of a Unit, but the components of the Units will be immediately separable and will be issued separately in this offering. A holder of a Warrant may not exercise any portion of a Warrant to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would own more than 4.99% (or, at the election of the investor, 9.99%) of our outstanding shares of Class A common stock after exercise, as such ownership percentage is determined in accordance with the terms of the Warrants, except that upon notice from the holder to us, the holder may waive such limitation up to a percentage, not in excess of 9.99%. To better understand the terms of the Warrants, you should carefully read the “Description of Capital Stock” section on page 86 of this prospectus.
We are also offering to each purchaser of Units that would otherwise result in the purchaser’s beneficial ownership exceeding 4.99% of our outstanding Class A common stock immediately following the consummation of this offering, the opportunity to purchase Units consisting of one pre-funded warrant (in lieu of one share of Class A Common Stock, each a “Pre-Funded Warrant”). Subject to limited exceptions, a holder of Pre-Funded Warrants will not have the right to exercise any portion of its Pre-Funded Warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or, at the election of the holder, such limit may be increased to up to 9.99%) of the number of Class A common stock outstanding immediately after giving effect to such exercise. Each Pre-Funded Warrant will be exercisable for one share of Class A Common Stock. The purchase price of each Unit including a Pre-Funded Warrant will be $[*], and the remaining exercise price of each Pre-Funded Warrant will equal $0.001 per share. The Pre-Funded Warrants will be immediately exercisable (subject to the beneficial ownership cap) and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. For each Unit including a Pre-Funded Warrant we sell (without regard to any limitation on exercise set forth therein), the number of Units including a share of Class A common stock we are offering will be decreased on a one-for-one basis.
The securities are expected to be issued in a single closing. We expect this offering to be completed not later than two business days following the commencement of sales in this offering (the effective date of the registration statement of which this prospectus forms a part) and we will deliver all securities to be issued in connection with this offering delivery versus payment/receipt versus payment upon receipt of investor funds received by us. Accordingly, neither we nor the placement agent have made any arrangements to place investor funds in an escrow account or trust account since the placement agent will not receive investor funds in connection with the sale of the securities offered hereunder.
Our Class A Common Stock is listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “IVP.” On June 20, 2024, the last reported closing price of our Class A common stock was $1.315 per share. There is no established public trading market for the Warrants or Pre-Funded Warrants, and we do not intend to list the Warrants or Pre-Funded Warrants on any national securities exchange or trading system. Without an active trading market, the liquidity of the Warrants or Pre-Funded Warrants will be limited.
We have engaged Spartan Capital Securities, LLC (“Spartan” or “Placement Agent”) as our exclusive Placement Agent to use its reasonable best efforts to solicit offers to purchase our securities in this offering. The Placement Agent has no obligation to purchase any of the securities from us or to arrange for the purchase or sale of any specific number or dollar amount of our Class A common stock, Warrants or Pre-Funded Warrants. Because there is no minimum offering amount required as a condition to closing in this offering, the actual public offering amount, Placement Agent’s fee and proceeds to us, if any, are not presently determinable and may be substantially less than the total maximum offering amounts set forth above and throughout this prospectus. We have agreed to pay the Placement Agent the Placement Agent’s fee and other compensation and reimbursement of expenses set forth in the table below.
We expect to use the net proceeds from sales of our Class A common stock, Warrants and Pre-Funded Warrants, if any, in this offering for general working capital. See “Use of Proceeds.”
| Per Unit | Total | |||||||
| Assumed Public offering price | ||||||||
| Placement Agent fees (1) | ||||||||
| Proceeds to Inspire Veterinary Partners, Inc. before expenses(2) | ||||||||
| (1) | We have agreed to pay the Placement Agent a cash fee equal to 8.0% of the gross proceeds raised in this offering. We have also agreed to reimburse the Placement Agent for certain of its offering related expenses, including non-accountable expenses in an amount equal to 1.0% of the aggregate gross proceeds raised in this offering, and legal fees and other out-of-pocket expenses in the amount of up to $125,000. See “Plan of Distribution” for a description of the compensation to be received by the Placement Agent. |
| (2) | The amount of offering proceeds to us presented in this table does not give effect to any exercise of the Warrants or the Pre-Funded Warrants. |
We will also pay any fees and expenses incurred in registering the Units (including the Class A common stock, Warrants, the Class A Common Stock underlying the Warrants and Pre-Funded Warrants, and the Class A Common Stock underlying the Pre-Funded Warrants) under the U.S. Securities Act of 1933, as amended (the “Securities Act”), including legal and accounting fees, if any. See “Plan of Distribution” beginning on page 93 of this prospectus for more information.
We are an “emerging growth company” as defined in Section 2(a) of the Securities Act, and are subject to reduced public company reporting requirements. This prospectus complies with the requirements that apply to an issuer that is an emerging growth company.
Investing in our Class A common stock involves risks. You should carefully read the “Risk Factors” beginning on page 14 of this prospectus before deciding to invest in shares of our Class A common stock.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
Spartan Capital Securities, LLC
The date of this prospectus is , 2024.
TABLE OF CONTENTS
We and the Placement Agent have not authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus. We do not take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby and only under circumstances and in jurisdictions where it is lawful to do so. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus. This prospectus is not an offer to sell securities, and it is not soliciting an offer to buy securities, in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus is accurate only as of the date on the front of this prospectus only, regardless of the time of delivery of this prospectus or any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates.
i
PROSPECTUS SUMMARY
This summary highlights information contained in more detail elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our Class A common stock. You should carefully read this prospectus in its entirety before investing in our Class A common stock, including the sections titled “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Cautionary Statement Regarding Forward-Looking Statements,” and our consolidated financial statements and the accompanying notes thereto included elsewhere in this prospectus.
Unless the context requires otherwise, references to “Inspire Veterinary,” the “Company,” “we,” “us,” and “our,” refer to Inspire Veterinary Partners, Inc. and its consolidated subsidiaries. On April 22, 2024, we amended our Amended and Restated Articles of Incorporation to effect a reverse stock split of our authorized and issued and outstanding shares of Class A common stock by a ratio of 1-for-100 (the “Reverse Stock Split”). The Reverse Stock Split was effected on May 8, 2024. Unless expressly stated in this registration statement, all share and per share information included herein has been adjusted to account for the Reverse Stock Split.
About Inspire Veterinary Partners
Inspire Veterinary owns and operates veterinary hospitals throughout the United States. The Company specializes in small animal general practice hospitals which serve all manner of companion pets, emphasizing canine and feline breeds and including equine care. As the Company expands, it expects to acquire additional veterinary hospitals, including general practice, mixed animal facilities, and critical and emergency care.
The Company completed its initial public offering on August 31, 2023 and its shares of Class A common stock are quoted on The Nasdaq Capital Market under the symbol “IVP.”
As of the date of this prospectus, the Company currently has fourteen veterinary hospitals located in ten states. Inspire Veterinary has expanded and plans to further expand through acquisitions of existing hospitals which have the financial track record, marketplace advantages and future growth potential. Because the Company leverages a leadership and support structure which is distributed throughout the United States, acquisitions are not centralized to one geographic area.
Services provided at the Company’s hospitals include preventive care for companion animals consisting of annual health exams which include: parasite control; dental health; nutrition and body condition counseling; neurological examinations; radiology; bloodwork; skin and coat health and many breed specific preventive care services. Surgical offerings include all soft tissue procedures such as spays and neuters, mass removals, splenectomies and can also include gastropexies, orthopedic procedures and other types of surgical offerings based on a doctor’s training. In many locations additional means of care and alternative procedures are also offered such as acupuncture, chiropractic and various other health and wellness offerings.
Corporate Information
Inspire was incorporated as a corporation in the state of Delaware in 2020. In June 2022, the Company converted into a Nevada c-corporation. The Company has two consolidating holding companies: IVP Practice Holdings Co., LLC and IVP Real Estate Co., LLC. Each of IVP Practice Holdings Co., LLC and IVP Real Estate Co., LLC are passive intermediate holding companies with no employees, no operations and no assets other than the equity in the respective subsidiaries.
The Company’s principal executive offices are located at 780 Lynnhaven Parkway, Suite 400, Virginia Beach, Virginia 23452. Our telephone number is (757) 734-5464. Our website address is www.inspirevet.com. Information contained on our website or connected thereto does not constitute part of, and is not incorporated by reference into, this prospectus or the registration statement of which it forms a part.
Recent Developments
On March 26, 2024 Inspire Veterinary entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors. Pursuant to the Purchase Agreement, Inspire Veterinary issued to certain investors two Increasing OID Senior Notes (each a “Note” and collectively the “Notes”) each for $250,000. The Notes have a maturity date of the earlier of December 26, 2024 or the consummation of a capital raise (the “Maturity Date”).
The Purchase Agreement contains a number of representations and warranties by Inspire Veterinary and the investors which are qualified by materiality or Material Adverse Effect as defined in the Purchase Agreement. The representations and warranties are customary for transactions of this nature and are subject to specified exceptions and qualification. The Purchase Agreement also contains customary confidentiality and indemnification provisions.
1
The Notes contain an original issue discount (“OID”) which shall be: (i) fifteen percent (15%) if the Notes are satisfied and paid in full on or before the forty-fifth (45th) day after the Original Issue Date (as such term is defined in the Notes), (ii) twenty percent (20%) if the Notes are satisfied and paid in full after such 45th day but on or before the ninetieth (90th) day after the Original Issue Date, and (iii) thirty percent (30%) after such 90th day. The Notes can be prepaid at any time prior to the Maturity Date without any penalties.
The Notes must be repaid in full from any future capital raises (debt, equity or any other form of capital raise) of Inspire Veterinary. All of the funds raised must be used to repay the Notes until the Notes are repaid in full.
The Notes are convertible into shares of Class A common stock of Inspire Veterinary, in full or in part, at any time after issuance at the discretion of the noteholder at a fixed conversion price of $0.03 per share (the “Fixed Conversion Price”).
If the Notes are not repaid by the Maturity Date the default provisions are as follow: (i) The Face Value (as such term is defined in the Notes) of the Notes will increase by 20% (to a 50% OID -- $1,000,000 Face Value); (ii) the conversion price of the Notes will become convertible at the lower of (a) the Fixed Conversion Price or (b) 20% discount to a 3-Day volume-weighted average price (the “Default Conversion Price”).
Inspire Veterinary must keep enough shares of Class A common stock in reserve in order to facilitate the conversion of the Notes at the Default Conversion Price. Additionally, Inspire Veterinary agrees to lower the floor price of the existing Series A Preferred Stock to $0.01.
In the event a noteholder agrees to release the funds to the Inspire Veterinary prior to the floor price on the Series A Preferred Stock being officially lowered and Inspire Veterinary then fails to officially lower the floor price within 7 calendar days, the Notes will be immediately considered in default.
The use of proceeds from the Notes will be used for general corporate purposes and acquisitions.
Nasdaq Delisting Notifications
On March 8, 2024, we received a staff determination from Nasdaq to delist the Company’s securities from the Nasdaq Capital Market (the “Staff Determination”). The Staff Determination was issued because, as of March 7, 2024, the Company’s securities had a closing bid price of $0.10 or less for at least ten consecutive trading days. Accordingly, the Company is subject to the provisions contemplated under Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stocks Rule”). The Company appealed the Staff Determination, however, to a Hearings Panel by filing a hearing request with Nasdaq.
In addition, on April 11, 2024, we received a staff determination from Nasdaq notifying the Company that, based on the Company’s stockholders’ deficit of ($788,259) as reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission, the Company does not meet the alternatives of market value of listed securities or net income from continuing operations. As such, the Company no longer complies with Nasdaq listing rules regarding minimal stockholder’s equity for continued listing. Accordingly, this matter serves as an additional basis for delisting the Company’s securities from Nasdaq. The Company’s hearing date with the Nasdaq Hearings Panel was held on May 14, 2024.
In order to address the bid price deficiency, on April 15, 2024, our board of directors approved a reverse stock split of the Company’s authorized and issued and outstanding shares of Class A common stock, par value $0.0001 per share (the “Common Stock”), at a ratio of 1 for 100 (the “Reverse Stock Split”). The Reverse Stock Split was effective on May 8, 2024. On the effective date, every one hundred (100) shares of Class A Common Stock issued and outstanding or held as treasury stock was automatically reclassified into one (1) new share of Common Stock. The total number of shares of Class A Common Stock authorized for issuance was reduced by a corresponding proportion from 100,000,000 shares to 1,000,000 shares.
We believe that the Reverse Split will allow us to regain compliance with both the Low Priced Stocks Rule and the Bid Price Rule. In addition, we believe that the raising of additional equity capital, including the additional equity capital to be raised in this offer, will allow us to regain compliance with the shareholder’s equity requirement for continued listing on Nasdaq.
2
On June 6, 2024, the Company received a letter from the Panel indicating that our request for continued on Nasdaq was granted subject to the following: (i) on or before June 15, 2024, the Company shall file a registration statement with the Securities and Exchange Commission for a public offering that will be led by Spartan Capital Securities, LLC, and (ii) on or before September 4, 2024, we shall demonstrate compliance with Listing Rule 5550(b)(1).
Additionally, we were advised that September 4, 2024, represents the full extent of the Panel’s discretion to grant continued listing while we are non-compliant with the Exchange’s Listing Rules. It is a requirement during the exception period that we provide prompt notification of any significant events that occur during this time that may affect our compliance with Nasdaq requirements.
There can be no assurance, however, that the Company will be able to regain compliance with the Bid Price Rule and the Low Priced Stocks Rule or that it will be able to regain compliance with the minimum shareholder’s equity rule.
Increase of Authorized
On April 26, 2024, the holders of a majority of the issued and outstanding voting securities of the Company (the “Majority Stockholders”), approved, by written consent an amendment to the Company’s Articles of Incorporation to increase the total number of authorized shares of Class A Common Stock to one hundred million (100,000,000) shares (the “Amendment”). The effectiveness of the Majority Stockholders’ approval of the Amendment shall automatically take effect on June 16, 2024.
Richard Frank Employment Agreement
We entered into an employment agreement (the “Employment Agreement”) with Richard Frank, the Company’s current Chief Financial Officer. Mr. Frank’s appointment as Chief Financial Officer had previously become effective upon consummation of Inspire’s initial public offering on August 31, 2023 and his Employment Agreement is effective as of January 1, 2024. The Employment Agreement provides for an initial one-year term with the ability to renew, upon the affirmative vote of the board of directors of the Company, for successive one-year terms. The Employment Agreement provides that Mr. Frank will receive a base salary of $210,000 per annum. The base salary will be reviewed at the end of each fiscal year and any recommended changes will be subject to approval of the board of directors of the Company. Mr. Frank is eligible for annual bonuses subject to satisfaction of both a “Revenue Target” and a “Profit Target”, as further described in the Employment Agreement. The Employment Agreement contains certain non-disclosure and confidentiality provisions applicable to Mr. Frank for the benefit of the Company. Mr. Frank has also agreed, during the term of his employment and for a two-year period following the termination of his employment not to solicit for employment any employee or any person who was employed by the Company within the prior six months. Mr. Frank is also barred from soliciting any clients or certain former clients of the Company for a period of two years following the termination of his employment with the Company. The Company has the right to terminate Mr. Frank’s employment immediately for cause upon certain specified acts, and he may be entitled to severance payments in certain circumstances.
Charles Keiser Consulting Agreement
On March 6, 2024, we entered into a consulting agreement (the “Consulting Agreement”) with Charles “Chuck” Keiser, DVM, an experienced professional of veterinary medicine and the business of veterinary medicine, and a former member of the board of directors of the Company, pursuant to which we agreed to compensate Dr. Keiser for certain consulting services that he has provided to the Company relating to veterinary medicine business support and other related activities. As consideration for Dr. Keiser’s consulting services, Inspire agreed to issue to Dr. Kesier $151,695.60 worth of restricted shares of Class A common stock of the Company, which resulted in the issuance of 18,659 shares of Class A common stock based on the closing price of $0.0813 per share on the last trading day immediately prior to the date of the Consulting Agreement, as quoted on The Nasdaq Capital Market. The Consulting Agreement contains certain non-disclosure and confidentiality provisions applicable to Dr. Keiser for the benefit of the Company. Dr. Keiser released the Company from any and all claims he may have had against the Company.
The Consulting Agreement terminated upon delivery of the shares to Dr. Keiser on March 7, 2024.
General Release
On March 6, 2024, Inspire entered into a general release agreement with Kenneth Seth Lundquist, DVM, Charles “Chuck” Keiser, DVM, and Don I. Williamson, Jr. DVM, and the Estate of Gregory Armstrong (each, a “Releasor” and collectively, the “Releasors”), pursuant to which the Company agreed to issue to each Releasor $5,000 worth of restricted shares of Class A common stock of the Company, which resulted in the issuance of 615 shares of Class A common stock to each Releasor, based on the closing price of $0.0813 per share on the last trading day immediately prior to the date of the General Release Agreement, as quoted on The Nasdaq Capital Market. As partial consideration for the issuance of the shares pursuant to the General Release Agreement, each Releasor agreed to release Inspire from all potential, pending, or alleged claims, issues or complaints, whether asserted or which could be asserted by the Releasors against the Company, including any such claims, issues or complaints arising from or in connection with Inspire Veterinary’s previous acquisition from the Releasors of their ownership interest in Kauai Veterinary Clinic, Inc., located in Lihue, Hawaii, and associated real estate.
3
The Tumim Transaction
On November 30, 2023, we entered into a common stock purchase agreement (the “Purchase Agreement”) with Tumim Stone Capital LLC (“Tumim”), pursuant to which Tumim committed to purchase, subject to certain conditions and limitations, up to $30.0 million of shares of Class A common stock, at our direction from time to time, subject to the satisfaction of the terms and conditions in the Purchase Agreement. Also, on the same date, we entered into a registration rights agreement (the “Registration Rights Agreement”) with Tumim, pursuant to which we agreed to file with the U.S. Securities and Exchange Commission (the “Commission”) a registration statement to register for resale under the Securities Act of 1933, as amended (the “Securities Act”), the shares of our Class A common stock that may be issued to Tumim under the Purchase Agreement. We and Tumim subsequently agreed in a letter agreement (the “Letter Agreement”) to certain amendments to the Purchase Agreement and the Registration Rights Agreement relating to the commitment shares and initial registration statement filing deadline, as reflected below.
Our sales of Class A common stock to Tumim, if any, will be subject to certain limitations, and may occur from time-to-time in Inspire Veterinary’s sole discretion, over the period commencing once certain customary conditions are satisfied, including securing effectiveness of a resale registration statement with the Commission, and ending on the first day of the month following the 24-month anniversary of the date on which the resale registration statement is declared effective by the Commission. Tumim has no right to require Inspire to sell any shares of Class A common stock to Tumim, but Tumim is obligated to purchase shares of Class A common stock pursuant to a valid purchase notice delivered by Inspire, subject to certain conditions and limitations.
Purchase Price
The shares of Class A common stock to be issued by Inspire and purchased by Tumim will be sold at a purchase price equal to 95% of the lowest daily volume-weighted average price of the Class A common stock on Nasdaq (or any other eligible national stock exchange, as applicable) during the three consecutive trading days immediately following the trading date on which a valid purchase notice is delivered to Tumim by Inspire. Such purchase price will be adjusted for reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction by Inspire with respect to its Class A common stock.
Actual sales of shares of Class A common stock to Tumim will depend on a variety of factors to be determined by Inspire from time-to-time, including, among other things, market conditions, the trading price of the Class A common stock, and the working capital needs, if any, of the Company.
The net proceeds from sales, if any, under the Purchase Agreement to Inspire will depend on the frequency and prices at which Inspire sells shares of Class A common stock to Tumim. Inspire expects that any proceeds received by Inspire from such sales to Tumim will be used for working capital and general corporate purposes.
Purchase Limits
Pursuant to the Purchase Agreement, Inspire may not require Tumim to purchase, and Tumim will have no obligation to purchase, in any single transaction, shares of Class A common stock in excess of a number equal to the lowest of:
| (i) | 100% of the average daily trading volume in the Class A common stock on Nasdaq (or any other eligible national stock exchange, as applicable) for the five consecutive trading days immediately prior to the trading date on which a valid purchase notice is delivered to Tumim, |
| (ii) | a 30% discount to the daily trading volume in the Class A common stock on Nasdaq (or any other eligible national stock exchange, as applicable), and |
| (iii) | $2.0 million divided by the volume-weighted average price for the Class A common stock on the trading day immediately prior to the trading date on which a valid purchase notice is delivered to Tumim. |
Consistent with applicable Nasdaq rules, Inspire may not issue to Tumim more than 12,143 shares of its Class A common stock (the “Exchange Cap”), which number of shares is equal to 19.99% of the shares of the Company’s Class A common stock issued and outstanding immediately prior to the execution of the Purchase Agreement, unless Inspire obtains stockholder approval to issue shares of its Class A common stock in excess of such limit in accordance with applicable rules of Nasdaq or any other applicable national stock exchange.
4
However, the Exchange Cap will not apply to the extent that and for so long as the average price of all shares of Class A common stock purchased pursuant to the Purchase Agreement is equal to or greater than $0.4954, which was the official closing price of the Class A common stock on Nasdaq on the date of signing the Purchase Agreement.
Moreover, Inspire may not issue or sell any shares of Class A common stock to Tumim which, when aggregated with all other shares of the Company’s Class A common stock then beneficially owned by Tumim and its affiliates (as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Rule 13d-3 promulgated thereunder), would result in Tumim beneficially owning more than 4.99% of the issued and outstanding shares of the Company’s Class A common stock (the “Beneficial Ownership Limitation”), unless such limit is increased or waived by Tumim.
Commitment Shares
Pursuant to the terms of the Purchase Agreement, as consideration for Tumim’s irrevocable commitment to purchase shares of the Company’s Class A common stock, we became obligated to issue to Tumim a number of shares of Class A common stock (the “Commitment Shares”) equal to $600,000 divided by the average daily volume-weighted average price for the Class A common stock on Nasdaq during the five (5) consecutive trading days ending on the trading date immediately prior to Inspire Veterinary’s filing of a resale registration statement covering Tumim’s resales pursuant to the Registration Rights Agreement described below. The Commitment Shares are due on the trading day immediately following the date the resale registration statement is declared effective by the Commission.
If the number of Commitment Shares due to Tumim would exceed the Beneficial Ownership Limitation, then we will become obligated to issue to Tumim a pre-funded warrant (the “Tumim pre-funded warrant”) to purchase shares of Class A common stock (the “Warrant Shares”), with an exercise price equal to $0.0001 per share, in an amount equal to the difference between $600,000 and the value of the Commitment Shares issued below the Beneficial Ownership Limitation, calculated using the same pricing mechanism as the pricing mechanism used to determine the Commitment Shares paid as Class A common stock. For each share of Class A common stock which may be exercised as a Warrant Share upon exercise of the Tumim pre-funded warrant, the number of shares of Class A common stock to be issued as Commitment Shares will be decreased on a one-for-one basis.
If the aggregate number of Commitment Shares and Warrant Shares due to Tumim would exceed the Exchange Cap, and the Company has not obtained stockholder approval for the issuance of Class A common stock in excess of the Exchange Cap in accordance with the applicable rules of Nasdaq (or any eligible substitute exchange) by May 24, 2024, then the Company shall be obligated to pay to Tumim an amount in cash equal to $600,000 minus the value of the shares of Class A common stock issuable to Tumim as Commitment Shares and the value of the Warrant Shares issuable upon exercise of the Tumim pre-funded warrant.
In certain other circumstances, including our failure to file registration statements with respect to the shares of Class A common stock issuable to Tumim under the Purchase Agreement or the failure of such registration statements to be declared effective by the Commission within certain deadlines, Inspire may become obligated to pay to Tumim a cash fee equal to $600,000 in lieu of issuing such shares of Class A common stock and Warrant Shares, under the terms and subject to the conditions described more fully in the Purchase Agreement, as amended.
The Registration Rights Agreement
Pursuant to the Registration Rights Agreement, we are required to file an initial resale registration statement on Form S-1 with the Commission permitting the resale of the Commitment Shares, the Warrant Shares, and certain other shares of Class A common stock issued to Tumim pursuant to the Purchase Agreement by no later than January 31, 2024. The Registration Rights Agreement also obligates Inspire in some circumstances and subject to certain conditions, to file additional resale registration statements to permit the resale of shares of Class A common stock issued to Tumim pursuant to the Purchase Agreement. Such registration statements are required to identify Tumim as the “Selling Stockholder”. Such registration statements are required to permit the resale of such shares of Class A common stock of the Company held by Tumim pursuant to Rule 415 under the Securities Act.
Also pursuant to the Registration Rights Agreement, Inspire is required to use its commercially reasonable efforts to have each registration statement declared effective by the Commission as soon as reasonably practicable, but in no event later than May 28, 2024 (with respect to this initial resale registration statement), which is the 180th calendar day following the date of signing of the Registration Rights Agreement, or the 180th calendar day following the date on which the Company was required to file any such additional registration statement, in each case if such registration statement is subject to comment by the Commission, or the 75th calendar day after the date of signing the Registration Rights Agreement with respect to the initial registration statement or the 75th calendar day after the date on which the Company was required to any additional registration statement, in each case if such registration statement is not subject to comment by the Commission.
5
On February 13, 2024, we issued a warrant (the “Warrant”) to purchase up to 16,549 shares of Class A common stock of the Company, par value $0.0001 per share (the “Warrant Shares”), to Tumim pursuant to the Purchase Agreement and the Letter Agreement. Inspire issued the shares and the Warrant in fulfilment of its obligation to issue “Commitment Shares” to Tumim.
We issued the shares and the Warrant to Tumim pursuant to a privately negotiated transaction exempt from registration pursuant to Rule 506(b) of Regulation D under the Securities Act of 1933, as amended. We did not receive any proceeds with respect to the issuance of the Commitment Shares or the Warrant and do not expect to receive any material proceeds from Tumim’s exercise, if any, of the Warrant for the purchase of Warrant Shares.
The Valley Veterinary Services Acquisition
On November 8, 2023, pursuant to an asset purchase agreement, dated October 27, 2023 (the “Asset Purchase Agreement”), by and among the Company, IVP PA Holding Company, LLC (“Acquisition Sub”), a Delaware limited liability company and wholly-owned subsidiary of the Company and Valley Veterinary Service, Inc., a Pennsylvania corporation (the “Seller”), Michelle Bartus, VMD and Peter Nelson, VMD (the “Owners” and together with the Seller, the “Seller Parties”), the Company completed the acquisition of Valley Veterinary Services animal hospital.
The aggregate purchase consideration for the Valley Veterinary Services animal hospital practice was $1,400,000 plus certain assumed liabilities, with the purchase consideration consisting of $1,000,000 paid in cash plus 408,163 restricted shares of the Company’s Class A common stock which was equal to the quotient obtained by dividing $400,000 by the official closing price of one share of Class A common stock as reported by the Nasdaq Capital Market on the trading date immediately prior to the closing.
Pursuant to the Asset Purchase Agreement, Acquisition Sub acquired substantially all of the assets comprising the veterinary clinic operating under the name “Valley Veterinary Service”, including all equipment and other tangible personal property, inventory, customer deposits, prepaid expenses, permits, licenses, franchises, variances, business contracts and equipment leases, books and records, telephone numbers, yellow pages listings, internet websites, electronic mail addresses (including, without limitation, any and all content therein), and social media sites and accounts, goodwill and intangible assets and other proprietary rights relating to the veterinary practice. The acquisition excluded certain assets, including certain excess cash, patient and medical records and files to the extent non-transferable by applicable law, personal licenses held by individual veterinary professionals, and other stipulated assets. Also pursuant to the Asset Purchase Agreement, Acquisition Sub assumed liabilities arising from business contracts that may arise after the closing.
Series A Preferred Stock Issuance
On January 2, 2024, we issued 200 shares of our Series A preferred stock to Target Capital 1, LLC (“Target”), an existing investor and holder of certain shares of our previously issued and outstanding Series A preferred stock, for gross proceeds of $200,000. The issuance and sale of the Series A preferred stock to Target was consummated in a privately negotiated transaction exempt from registration pursuant to Rule 506(b) of Regulation D under the Securities Act. We expect to use the proceeds of the sale of the Series A preferred stock for general working capital purposes.
Series A Preferred Stock Conversions
Between November 14, 2023 and January 29, 2024, our existing holders of the previously issued and outstanding shares of Series A preferred stock converted an aggregate of 4,166 shares of Series A preferred stock for 166,169 shares of Class A common stock, in each case pursuant to the terms of the Certificate of Designations relating to such Series A preferred stock.
“Best-Efforts” Offering of Class A Common Stock
On February 13, 2024, the Company closed a reasonable best-efforts offering of up to 265,816 shares of Class A common stock at an offering price of $0.085 (the “Best-Efforts Offering”), for gross proceeds of approximately $4,000,000.
6
Best-Efforts Offering Spartan Agent’s Warrant
In connection with their role as placement agent in the Best-Efforts Offering, we agreed to issue to Spartan a warrant (the “Best-Efforts Offering Spartan Warrant”) to purchase a number of shares of Class A common stock equal to 4.0% of the aggregate number of shares of Class A common stock sold in the Best-Efforts Offering, subject to certain conditions.
The Best-Efforts Offering Spartan Warrant was issued upon the consummation of the issuance of shares of Class A common stock pursuant to the Best-Efforts Offering. On June 25, 2024, Spartan and the Company entered into an agreement whereby the Best-Efforts Spartan Warrant was terminated, canceled and no longer exercisable as of June 25, 2024.
Best-Efforts Offering Lock-Ups
In connection with the Best-Efforts Offering, we have agreed that, without the prior written consent of Spartan, we will not, for a period of 360 days after our entry into the placement agent agreement with respect to the Best-Efforts Offering, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of any capital stock of the Company, or agree to or engage in certain related or similar transactions, other than with respect to certain exempt securities issuances.
Also in connection with the Best-Efforts Offering, our directors and executive officers and holders of 5% or more of Class A common stock will not, for a period of ninety days after the effective date of the registration statement on Form S-1 relating to the Best-Efforts Offering, offer, sell, agree to offer or sell, solicit offers to purchase, pledge, encumber, assign, borrow or otherwise dispose of any Class A common stock, or grant any call option or purchase any put option with respect to the same, or agree to or engage in certain related or similar transactions, or otherwise publicly disclose the intention to do so, subject to certain customary exceptions.
Implications of Being an Emerging Growth Company and a Smaller Reporting Company
We are an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended and as modified by the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies. We will remain an emerging growth company under the JOBS Act until the earliest of (a) the last day of our first fiscal year following the fifth anniversary of our initial public offering, which was consummated on August 31, 2023, (b) the last date of our fiscal year in which we have total annual gross revenue of at least $1.07 billion, (c) the date on which we are deemed to be a “large accelerated filer” under the rules of the SEC with at least $700.0 million of outstanding securities held by non-affiliates, (d) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the previous three year, or (e) the date on which we affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act.
We are also a “smaller reporting company” as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as the market value of our Class A common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and the market value of our Class A common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.
As a result of being an emerging growth company and a smaller reporting company, the information and financial statements in this prospectus and that we provide to our investors in the future may be different than what you might receive from other public reporting companies.
7
SUMMARY OF RISK FACTORS
Risks Related to our Business
| ● | We have a limited operating history, are not profitable and may never become profitable. |
| ● | If our business plan is not successful, we may not be able to continue operations as a going concern and our shareholders may lose their entire investment in us. |
| ● | If we fail to attract and keep senior management, we may be unable to successfully integrate acquisitions, scale our offerings of veterinary services, and deliver enhanced customer services, which may impact our results of operations and financial results. |
| ● | We may need to raise additional capital to achieve our goals. |
| ● | The Company incurs significant increased expenses and administrative burdens as a public company, which could have an adverse effect on its business, financial condition and results of operations. |
| ● | If we fail to manage our growth effectively, our brand, business and operating results could be harmed. |
| ● | We may seek to grow our business through acquisitions of, or investments in, new or complementary businesses, and facilities, or through strategic alliances, and the failure to manage these acquisitions or strategic alliances, or to integrate them with our existing business, could have a material adverse effect on us. |
| ● | We may seek to raise additional funds in the future through debt financing which may impose operational restrictions on our business and may result in dilution to existing or future holders of our common shares. |
| ● | We may acquire other businesses that may be unsuccessful and could adversely dilute your ownership of our company. |
| ● | We have generated net operating loss carryforwards for U.S. income tax purposes, but our ability to use these net operating losses may be limited by our inability to generate future taxable income. |
| ● | Our management does not have experience as senior management of a public company or ensuring compliance with public company obligations, and fulfilling these obligations will be expensive and time consuming, which may divert management’s attention from the day-to-day operation of its business. |
| ● | Failure to maintain effective internal controls over financial reporting could have a material adverse effect on the Company’s business, operating results and stock price. |
8
| ● | We may incur successor liabilities due to conduct arising prior to the completion of the various acquisitions. |
| ● | Purchasing real estate with hospital acquisitions brings additional complexity and cost. |
| ● | Our estimate of the size of our addressable market may prove to be inaccurate. |
| ● | We may be unable to execute our growth strategies successfully or manage and sustain our growth, and as a result, our business may be adversely affected. |
| ● | We may experience difficulties recruiting and retaining skilled veterinarians due to shortages that could disrupt our business. |
| ● | Negative publicity arising from claims that we do not properly care for animals we handle could adversely affect how we are perceived by the public and reduce our sales and profitability. |
| ● | Our quarterly operating results may fluctuate due to the timing of expenses, veterinary facility acquisitions, veterinary facility closures, and other factors. |
| ● | The COVID-19 outbreak has previously disrupted our business, and any future outbreak of a health epidemic or other adverse public health developments could materially and adversely affect our business and operating results. |
| ● | Our continued success is largely dependent on positive perceptions of our company. |
| ● | Our business may be harmed if our computer network containing employee or other information is compromised, which could adversely affect our results of operations. |
| ● | Labor disputes may have an adverse effect on our operations. |
| ● | We may be subject to personal injury, workers’ compensation, discrimination, harassment, wrongful termination, wage and hour, and other claims in the ordinary course of business. |
| ● | A decline in consumer spending or a change in consumer preferences or demographics could reduce our sales or profitability and adversely affect our business. |
| ● | Our reputation and business may be harmed if our or our vendors’ computer network security or any of the databases containing customer, employee, or other personal information maintained by us or our third-party providers is compromised, which could materially adversely affect our results of operations. |
| ● | The animal health industry is highly competitive. |
| ● | We may be unable to adequately protect our intellectual property rights. |
| ● | We may be subject to litigation. |
| ● | Natural disasters and other events beyond our control could harm our business. |
9
Risks Related to Government Regulation
| ● | Various government regulations could limit or delay our ability to develop and commercialize our services or otherwise negatively impact our business. |
| ● | Changes in laws or regulations, or a failure to comply with any laws and regulations, may adversely affect our business, investments and results of operations. |
| ● | Failure to comply with governmental regulations or the expansion of existing or the enactment of new laws or regulations applicable to our veterinary services could adversely affect our business and our financial condition or lead to fines, litigation, or our inability to offer veterinary products or services in certain states. |
| ● | We may fail to comply with various state or federal regulations covering the dispensing of prescription pet medications, including controlled substances, through our veterinary services businesses, which may subject us to reprimands, sanctions, probations, fines, or suspensions. |
| ● | We are subject to environmental, health, and safety laws and regulations that could result in costs to us. |
Risks Related to our Common Shares
| ● | We have received a listing deficiency notice from Nasdaq regarding our Class A common stock. |
| ● | It is not possible to predict the actual number of shares we will sell under the Purchase Agreement, or the actual gross proceeds resulting from those sales. We may not have access to the full amount available under the Purchase Agreement with Tumim. |
| ● | Investors who buy shares at different times will likely pay different prices. |
| ● | If securities or industry analysts do not publish research or reports about our company, or if they issue adverse or misleading opinions regarding us or our stock, our stock price and trading volume could decline. |
| ● | We do not intend to pay cash dividends for the foreseeable future. |
| ● | Our shares will be subordinate to all of our debts and liabilities, which increases the risk that you could lose your entire investment. |
| ● | Our board of directors may designate and issue shares of new classes of stock, including the issuance of up to 157,000 additional shares of Class B common stock, that could be superior to or adversely affect you as a holder of our Class A common stock. Although a majority of our board of directors are independent, our non-independent directors, officers, and their affiliates control approximately 37.2% of the voting power of our outstanding common stock prior to this offering. |
| ● | The trading price of our Class A common stock is volatile, which could result in substantial losses to investors. |
| ● | The sale or availability for sale of substantial amounts of our Class A common stock could adversely affect their market price. |
| ● | We are an “emerging growth company” and a “smaller reporting company” and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies and a smaller reporting companies will make our Class A common stock less attractive to investors. |
| ● | We may be deemed a “controlled company” within the meaning of the rules of Nasdaq and, as a result, may qualify for, but do not intend to rely on, exemptions from certain corporate governance requirements. |
| ● | Sales of a significant number of shares of our Class A common stock in the public markets, or the perception that such sales could occur, could depress the market price of our Class A common stock. |
10
THE OFFERING
| Units offered | 9,125,475 Units(1) on a reasonable best efforts basis. Each Unit will consist of one share of Class A common stock (or Pre-Funded Warrant to purchase one share of our Class A common stock in lieu thereof) and one Warrant to purchase one share of Class A common stock. The Units have no stand-alone rights and will not be certificated or issued as stand-alone securities. The shares of Class A common stock and Warrants can only be purchased together in this offering, but the components of the Units will be immediately separable and will be issued separately in this offering. |
| Warrants offered | Each Unit includes one share of Class A common stock and one Warrant to purchase one share of Class A common stock exercisable at a price of $[*] (100% of the public offering price per Unit) and will be exercisable for a period of six months commencing upon issuance. See “Description of Capital Stock –Warrants Offered in this Offering” | |
| Pre-Funded Warrants | We are also offering to certain purchasers whose purchase of Units in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding Class A common stock immediately following the consummation of this offering, the opportunity to purchase, if such purchasers so choose, in lieu of Units including shares of Class A common stock, Units including Pre-Funded Warrants in lieu of shares of Class A common stock that would otherwise result in any such purchaser’s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding Class A common stock. The purchase price of each Unit including a Pre-Funded Warrant will be equal to $[*], and the exercise price of each Pre-Funded Warrant will be $0.001 per share.
Each Pre-Funded Warrant will be exercisable for one share of our Class A common stock and will be exercisable at any time after its original issuance until exercised in full. |
| Assumed Offering price | $1.315 per Unit |
| Class A common stock outstanding before this offering | 958,033 shares of Class A common stock |
| Class B common stock outstanding | 3,891,500 shares of Class B common stock.
|
| Class A common stock outstanding after this offering †† | 10,083,508 shares of Class A common stock.
|
| Use of proceeds | We expect to receive up to $12 million in aggregate gross proceeds from this offering. We expect to use the net proceeds from this offering for general working capital. See “Use of Proceeds.” |
| Risk factors | Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 14 and the other information included in this prospectus for a discussion of factors you should consider carefully before deciding to invest in our securities. |
| Nasdaq symbol for our Class A common stock | “IVP” |
| Transfer Agent | VStock Transfer, LLC |
| † | The number of shares of our Class A common stock to be outstanding immediately prior to this offering is comprised of 958,033 shares of our Class A common stock issued and outstanding as the date of this prospectus and excludes shares that are potentially issuable: |
| ● | upon the exercise of warrants outstanding as of the date of this prospectus (1); |
11
| ● | upon the conversion of shares of Series A preferred stock outstanding as of the date of this prospectus(2); |
| ● | to Tumim under the Purchase Agreement (including the Commitment Shares); and |
| ● | upon the conversion of 3,891,500 shares of Class B common stock(3) outstanding as of the date of this prospectus. |
| †† | The number of shares of our Class A common stock to be outstanding following this offering of a fully-diluted basis consist of: |
| ● | 28,540 shares of Class A common stock that are potentially issuable upon the exercise of warrants outstanding as of the date of this prospectus(1); |
| ● | 263,710 shares of Class A common stock that are potentially issuable upon conversion of 28,591 shares of Series A preferred stock(2) outstanding as of the date of this prospectus; the holders of Series A preferred stock have the right to vote as-if-converted, on all matters submitted to a vote of holders of the Company’s Class A common stock, including the election of directors, and all other matters as required by law, subject to the certain limits on beneficial ownership contained in the Certificate of Designations relating to the Series A preferred stock; and |
| ● | 38,915 shares of Class A common stock that are potentially issuable upon conversion of 3,891,500 shares of Class B common stock(3) outstanding as of the date of this prospectus. |
| 1) | Shares that are potentially issuable upon exercise of warrants include: |
| ● | 500 shares of Class A common stock issued to our Chair, President and Chief Executive Officer Kimball Carr in connection with his personal guaranty of certain loans to the Company; |
| ● | 19,624 shares of Class A common stock that are potentially issuable upon exercise of warrants issued in connection with the initial public offering and held by Spartan Capital Securities, LLC, the underwriter in our initial public offering; |
| ● | 120 shares of Class A common stock that are potentially issuable upon exercise of warrants held by Exchange Listing, LLC, pursuant to a capital market advisory agreement (the “Advisory Agreement”), dated as of December 28, 2021; and |
| ● | 8,296 shares of Class A common stock that are potentially issuable upon exercise of the New Warrants held by Target Capital 1, LLC, Dragon Dynamic Catalytic Bridge SAC Fund and 622 Capital LLC (the “New Warrant Holders”). |
| 2) | 263,710 shares of Class A common stock are issuable upon conversion of 28,591 shares of Series A preferred stock, $0.0001 par value. Each share of Series A preferred stock may convert, at the option of the holders at any time and from time, into a number of shares of Class A common stock equal to the stated value divided by a conversion price. The conversion price is equal to 60% of the dollar volume-weighted average price for shares for the Company’s Class A common stock for the three trading days immediately preceding the date of the conversion. However, the conversion price can never be less than $0.25 per-share. |
| 3) | Each share of Class B common stock entitles the holder of record to twenty-five (25) votes on all matters submitted to a vote of stockholders and is convertible into one share of Class A Common Stock at the option of the holder. |
Unless otherwise indicated, this prospectus reflects and assumes the following:
| ● | no exercise of outstanding options or warrants described above; |
| ● | no exercise of the Warrants, Pre-Funded Warrant, which, if sold, would reduce the number of Units that we are offering on a one-for-one basis, and ; and |
| ● | no exercise by the Placement Agent of the Placement Agent Warrant. |
12
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This prospectus contains forward-looking statements. Forward-looking statements are based upon our current assumptions, expectations and beliefs concerning future developments and their potential effect on our business. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although the absence of these words does not necessarily mean that a statement is not forward-looking. This information may involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from the future results, performance or achievements expressed or implied by any forward-looking statements.
We cannot predict all of the risks and uncertainties. Accordingly, such information should not be regarded as representations that the results or conditions described in such statements or that our objectives and plans will be achieved and we do not assume any responsibility for the accuracy or completeness of any of these forward-looking statements. These forward-looking statements are found at various places throughout this prospectus and include information concerning possible or assumed future results of our operations, including statements about potential acquisition or merger targets; business strategies; future cash flows; financing plans; plans and objectives of management; any other statements regarding future acquisitions, future cash needs, future operations, business plans and future financial results, and any other statements that are not historical facts.
All forward-looking statements speak only as of the date of this prospectus. We undertake no obligation to update any forward-looking statements or other information contained herein. Shareholders and potential investors should not place undue reliance on these forward-looking statements. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements in this report are reasonable, we cannot assure stockholders and potential investors that these plans, intentions or expectations will be achieved.
These forward-looking statements represent our intentions, plans, expectations, assumptions ‘and beliefs about future events and are subject to risks, uncertainties and other factors. Many of those factors are outside of our control and could cause actual results to differ materially from the results expressed or implied by those forward-looking statements. Considering these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this prospectus. All subsequent written and oral forward-looking statements concerning other matters addressed in this prospectus and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein.
Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise.
13
RISK FACTORS
Investing in our Class A common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with all of the other information in this prospectus, including the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and the accompanying notes thereto included elsewhere in this prospectus, before deciding whether to invest in our Class A common stock. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of or that we deem immaterial may also become important factors that adversely affect our business. The realization of any of these risks and uncertainties could have a material adverse effect on our reputation, business, financial condition, results of operations, growth and future prospects, as well as our ability to accomplish our strategic objectives. In that event, the market price of our Class A common stock could decline and you could lose part or all of your investment.
Unless the context otherwise requires, references in this section to “we,” “us,” “our,” “Inspire Veterinary” and the “Company” refer to Inspire Veterinary Partners, Inc.
Risks Related to our Business
We have a limited operating history, are not profitable and may never become profitable.
We have not generated any net profits to date, and we expect to continue to incur significant acquisition related costs and other expenses. Our net loss for the twelve months ended December 31, 2023 was $14,792,886 and for the years ended December 31, 2022 and 2021 was $(4,911,926) and $(1,331,062), respectively. Our accumulated deficit as of December 31, 2023 was $21,215,257. As of December 31, 2023, we had total stockholders’ deficit of approximately $788,259. We expect to continue to incur net losses for the foreseeable future, as we continue our development and acquisition of veterinary hospitals and related veterinary servicing activities. If we fail to achieve or maintain profitability, then we may be unable to continue our operations at planned levels and be forced to reduce or cease operations.
If our business plan is not successful, we may not be able to continue operations as a going concern and our shareholders may lose their entire investment in us.
As discussed in the Notes to Financial Statements included in this Registration Statement, as of December 31, 2023, we had $378,961 cash and restricted cash.
If we fail to raise sufficient capital pursuant to the Purchase Agreement, we will have to explore other financing activities to provide us with the liquidity and capital resources we need to meet our working capital requirements and to make capital investments in connection with ongoing operations. We cannot give assurance that we will be able to secure the necessary capital when needed. Consequently, we raise substantial doubt that we will be able to continue operations as a going concern, and our independent auditors included an explanatory paragraph regarding this uncertainty in their report on our financial statements for the year ended December 31, 2023. Our ability to continue as a going concern is dependent upon our generating cash flow sufficient to fund operations and reducing operating expenses. Our business plans may not be successful in addressing the cash flow issues. If we cannot continue as a going concern, our shareholders may lose their entire investment in us. If we fail to raise sufficient capital, we will have to explore other financing activities to provide us with the liquidity and capital resources we need to meet our working capital requirements and to make capital investments in connection with ongoing operations. We cannot give assurance that we will be able to secure the necessary capital when needed. Consequently, we raise substantial doubt that we will be able to continue operations as a going concern, and our independent auditors included an explanatory paragraph regarding this uncertainty in their report on our financial statements for the years ended December 31, 2023 and 2022. Our ability to continue as a going concern is dependent upon our generating cash flow sufficient to fund operations and reducing operating expenses. Our business plans may not be successful in addressing the cash flow issues. If we cannot continue as a going concern, our shareholders may lose their entire investment in us.
If we fail to attract and keep senior management, we may be unable to successfully integrate acquisitions, scale our offerings of veterinary services, and deliver enhanced customer services, which may impact our results of operations and financial results.
Our success depends in part on our continued ability to attract, retain and motivate highly qualified management and senior personnel. We are highly dependent upon our senior management, particularly Kimball Carr, our Chair, President and Chief Executive Officer, and Richard Frank, our Chief Executive Officer. The loss of services of any of these individuals could negatively impact our ability to successfully integrate acquisitions, scale our employee roster, and deliver enhanced veterinary services, which may impact our results of operations and financial results. Although we have entered an employment agreement with Kimball Carr, our Chair, President and Chief Executive Officer, for one 3-year term (automatically extending for one-year terms thereafter) there can be no assurance that Mr. Carr or any other senior executive officer will extend their terms of service.
14
We may need to raise additional capital to achieve our goals.
We currently incur operate at a net loss and a comprehensive loss and anticipate incurring additional expenses as a public company. We are also seeking to identify potential complementary acquisition opportunities in the veterinary services and animal health sectors. Some of our anticipated future expenditures will include: costs of identifying additional potential acquisitions; costs of obtaining regulatory approvals; and costs associated with marketing and selling our services. We also may incur unanticipated costs. Because the outcome of our development activities and commercialization efforts is inherently uncertain, the actual amounts necessary to successfully complete the development and commercialization of our existing or future veterinary services s may be greater or less than we anticipate.
As a result, we will need to obtain additional capital to fund the development of our business. We have no master agreements or arrangements with respect to any financings, and any such financings may result in dilution to our shareholders, the imposition of debt covenants and repayment obligations or other restrictions that may adversely affect our business or the value of our common shares.
Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, reduce or terminate one or more of our veterinary service programs or any future commercialization efforts.
The Company incurs significant increased expenses and administrative burdens as a public company, which could have an adverse effect on its business, financial condition and results of operations.
The Company will face a significant increase in insurance, legal, accounting, administrative and other costs and expenses as a public company that none of the formerly corporate or company privately-held acquisition targets that we may attempt to purchase incur as a private company. The Sarbanes-Oxley Act of 2002, as amended (“Sarbanes-Oxley Act”), including the requirements of Section 404, as well as rules and regulations subsequently implemented by the Securities and Exchange Commission (the “Commission”), the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the “Dodd-Frank Act”) and the rules and regulations promulgated and to be promulgated thereunder, the Public Company Accounting Oversight Board, the Commission and the securities exchanges, impose additional reporting and other obligations on public companies. Compliance with public company requirements will increase costs and make certain activities more time-consuming. A number of those requirements will require the Company to carry out activities that it previously has not done. For example, the Company will adopt new internal controls and disclosure controls and procedures. In addition, additional expenses associated with the Commission’s reporting requirements will be incurred. Furthermore, if any issues in complying with those requirements are identified (for example, if the auditors identify a material weakness or significant deficiency in the internal control over financial reporting), The Company could incur additional costs rectifying those issues, and the existence of those issues could adversely affect the Company’s reputation or investor perceptions of it. Being a public company could make it more difficult or costly for the Company to obtain certain types of insurance, including director and officer liability insurance, and the Company may be forced to accept reduced policy limits and coverage with increased self-retention risk or incur substantially higher costs to obtain the same or similar coverage. Being a public company could also make it more difficult and expensive for the Company to attract and retain qualified persons to serve on the board, board committees or as executive officers. Furthermore, if the Company is unable to satisfy its obligations as a public company, it could be subject to fines, sanctions and other regulatory action and potentially civil litigation.
The additional reporting and other obligations imposed by various rules and regulations applicable to public companies will increase legal and financial compliance costs and the costs of related legal, accounting and administrative activities. These increased costs will require the Company to divert a significant amount of money that could otherwise be used to expand the business and achieve strategic objectives. Advocacy efforts by shareholders and third parties may also prompt additional changes in governance and reporting requirements, which could further increase costs.
If we fail to manage our growth effectively, our brand, business and operating results could be harmed.
We have experienced, and expect to continue to experience, rapid growth in our headcount and operations, which places substantial demands on management and our operational infrastructure. We will need to significantly expand our organization and systems to support our future expected growth. If we fail to manage our growth effectively, we will not be successful, and our business could fail. To manage the expected growth of our operations and personnel, we will be required to improve existing, and implement new, transaction-processing, operational and financial systems, procedures and controls. We will also be required to expand our finance, administrative and operations staff. We intend to continue making substantial investments in our technology, sales and data infrastructure. As we continue to grow, we must effectively integrate, develop and motivate a significant number of new employees, while maintaining the beneficial aspects of our existing corporate culture, which we believe fosters innovation, teamwork and a passion for our veterinary services and clients. In addition, our revenue may not grow at the same rate as the expansion of our business. There can be no assurance that our current and planned personnel, systems, procedures and controls will be adequate to support our future operations or that management will be able to hire, train, retrain, motivate and manage required personnel. If we are unable to manage our growth effectively, the quality of our platform, efficiency of our operations, and management of our expenses could suffer, which could negatively impact our brand, business, operating results and profitability.
15
We may seek to grow our business through acquisitions of, or investments in, new or complementary businesses, and facilities, or through strategic alliances, and the failure to manage these acquisitions or strategic alliances, or to integrate them with our existing business, could have a material adverse effect on us.
The pet care industry is highly fragmented. We have completed acquisitions in the past and may pursue expansion, acquisition, investment and other strategic alliance opportunities in the future. If we are unable to manage acquisitions, or strategic ventures, or integrate any acquired businesses effectively, we may not realize the expected benefits from the transaction relative to the consideration paid, and our business, financial condition, and results of operations may be adversely affected. Acquisitions, investments and other strategic alliances involve numerous risks, including:
| ● | problems integrating the acquired business, facilities or services, including issues maintaining uniform standards, procedures, controls and policies; |
| ● | unanticipated costs associated with acquisitions or strategic alliances; |
| ● | losses we may incur as a result of declines in the value of an investment or as a result of incorporating an investee’s financial performance into our financial results; |
| ● | diversion of management’s attention from our existing business; |
| ● | risks associated with entering new markets in which we may have limited or no experience; |
| ● | potential loss of key employees of acquired businesses; |
| ● | the risks associated with businesses we acquire or invest in, which may differ from or be more significant than the risks our other businesses face; |
| ● | potential unknown liabilities associated with a business we acquire or in which we invest; and |
| ● | increased legal and accounting compliance costs. |
Our ability to successfully grow through strategic transactions depends upon our ability to identify, negotiate, complete and integrate suitable target businesses, facilities and services and to obtain any necessary financing. These efforts could be expensive and time-consuming and may disrupt our ongoing business and prevent management from focusing on our operations. As a result of future strategic transactions, we might need to issue additional equity securities, spend our cash, or incur debt (which may only be available on unfavorable terms, if at all), contingent liabilities, or amortization expenses related to intangible assets, any of which could reduce our profitability and harm our business. If we are unable to identify suitable acquisitions, investments or strategic relationships, or if we are unable to integrate any acquired businesses, facilities and services effectively, our business, financial condition, and results of operations could be materially and adversely affected. Also, while we employ several different methodologies to assess potential business opportunities, the new businesses or investments may not meet or exceed our expectations or desired objectives.
We may seek to raise additional funds in the future through debt financing which may impose operational restrictions on our business and may result in dilution to existing or future holders of our common shares.
We expect that we will need to raise additional capital in the future to help fund our business operations. Debt financing, if available, may require restrictive covenants, which may limit our operating flexibility and may restrict or prohibit us from:
| ● | paying dividends or making certain distributions, investments and other restricted payments; |
| ● | incurring additional indebtedness or issuing certain preferred shares; |
| ● | selling some or all of our assets; |
| ● | entering into transactions with affiliates; |
| ● | creating certain liens or encumbrances; |
| ● | merging, consolidating, selling or otherwise disposing of all or substantially all of our assets; and |
| ● | designating our subsidiaries as unrestricted subsidiaries. |
Debt financing may also involve debt instruments that are convertible into or exercisable for our common shares. The conversion of the debt-to-equity financing may dilute the equity position of our existing shareholders.
16
We may acquire other businesses that may be unsuccessful and could adversely dilute your ownership of our company.
As part of our business strategy, we intend to pursue acquisitions of other complementary assets and businesses and may also pursue strategic alliances. We may not be able to successfully integrate any acquisitions into our existing business, and we could assume unknown or contingent liabilities or become subject to possible stockholder claims in connection with any related-party or third-party acquisitions or other transactions. We also could experience adverse effects on our reported results of operations from acquisition-related charges, amortization of acquired technology and other intangibles and impairment charges relating to write-offs of goodwill and other intangible assets from time to time following an acquisition. Integration of an acquired company requires management resources that otherwise would be available for ongoing development of our existing business. We may not realize the anticipated benefits of any acquisition, technology license or strategic alliance.
To finance future acquisitions, we may choose to issue shares of our Class A common stock as consideration, which would dilute your ownership interest in us. Alternatively, it may be necessary for us to raise additional funds through public or private financings. Additional funds may not be available on terms that are favorable to us and, in the case of equity financings, may result in dilution to our stockholders.
We have generated net operating loss carryforwards for U.S. income tax purposes, but our ability to use these net operating losses may be limited by our inability to generate future taxable income.
Our U.S. businesses have generated consolidated net operating loss carryforwards (“U.S. NOLs”) for U.S. federal and state income tax purposes of $14,792,886 as of December 31, 2023. These U.S. NOLs can be available to reduce income taxes that might otherwise be incurred on future U.S. taxable income. The utilization of these U.S. NOLs would have a positive effect on our cash flow. However, there can be no assurance that we will generate the taxable income in the future necessary to utilize these U.S. NOLs and realize the positive cash flow benefit. A portion of our U.S. NOLs have expiration dates. There can be no assurance that, if and when we generate taxable income in the future from operations or the sale of assets or businesses, we will generate such taxable income before such portion of our U.S. NOLs expire. Under the Tax Cuts and Jobs Act (the “TCJA”), federal NOLs generated in tax years ending after December 31, 2017 may be carried forward indefinitely. Under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), federal NOL carryforwards arising in tax years beginning after December 31, 2017 and before January 1, 2021 may be carried back to each of the five tax years preceding the tax year of such loss. Due to our cumulative losses through December 31, 2023, we do not anticipate that such provision of the CARES Act will be relevant to us. The deductibility of federal NOLs may be limited. It is uncertain if and to what extent various states will conform to TCJA or the CARES Act.
Our ability to utilize the U.S. NOLs after an “ownership change” is subject to the rules of the United States Internal Revenue Code of 1986, as amended (the “Code”) Section 382. An ownership change occurs if, among other things, the shareholders (or specified groups of shareholders) who own or have owned, directly or indirectly, 5% percent or more of the value of our shares or are otherwise treated as 5% percent shareholders under Code Section 382 and the Treasury Regulations promulgated thereunder increase their aggregate percentage ownership of the value of our shares by more than 50 percentage points over the lowest percentage of the value of the shares owned by these shareholders over a three-year rolling period. An ownership change could also be triggered by other activities, including the sale of our shares that are owned by our 5% shareholders. In the event of an ownership change, Section 382 would impose an annual limitation on the amount of taxable income we may offset with U.S. NOLs. This annual limitation is generally equal to the product of the value of our shares on the date of the ownership change multiplied by the long-term tax-exempt rate in effect on the date of the ownership change. The long-term tax-exempt rate is published monthly by the IRS. Any unused Section 382 annual limitation may be carried over to later years until the applicable expiration date for the respective U.S. NOLs (if any). In the event an ownership change as defined under Section 382 were to occur, our ability to utilize our U.S. NOLs would become substantially limited. The consequence of this limitation would be the potential loss of a significant future cash flow benefit because we would no longer be able to substantially offset future taxable income with U.S. NOLs. There can be no assurance that such ownership change will not occur in the future.
Our management does not have experience as senior management of a public company or ensuring compliance with public company obligations, and fulfilling these obligations will be expensive and time consuming, which may divert management’s attention from the day-to-day operation of its business.
Our senior management does not have experience as senior management a publicly traded company and have limited experience complying with the increasingly complex laws pertaining to public companies. In particular, the significant regulatory oversight and reporting obligations imposed on public companies will require substantial attention from senior management and may divert attention away from the day-to-day management of its business, which could have a material adverse effect on our business, financial condition and results of operations. Similarly, corporate governance obligations, including with respect to the development and implementation of appropriate corporate governance policies will impose additional burdens on the Company’s non-executive directors.
Failure to maintain effective internal controls over financial reporting could have a material adverse effect on the Company’s business, operating results and stock price.
Effective internal control over financial reporting is necessary to increase the reliability of the Company’s financial reports. The standards required for a public company under Section 404(a) of the Sarbanes-Oxley Act are significantly more stringent than those of a privately held company. Management may not be able to effectively and timely implement controls and procedures that adequately respond to the increased regulatory compliance and reporting requirements. If the Company is not able to implement the additional requirements of Section 404(a) in a timely manner or with adequate compliance, it may not be able to assess whether its internal controls over financial reporting are effective, which may subject it to adverse regulatory consequences and could harm investor confidence and the market price of the Class A common stock.
17
The Company and its auditors were not required to perform an evaluation of internal control over financial reporting as of or for the years ended December 31, 2023 or 2022 in accordance with the provisions of the Sarbanes-Oxley Act. The Company’s independent registered public accounting firm will not be required to report on the effectiveness of its internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act until the Company’s first annual report on Form 10-K following the date on which it ceases to qualify as an “emerging growth company,” which may be up to five full fiscal years following the date of the first sale of common equity securities pursuant to an effective registration statement. If such evaluation were performed, control deficiencies could be identified by our management, and those control deficiencies could also represent one or more material weaknesses. In addition, the Company cannot, at this time, predict the outcome of this determination and whether the Company will need to implement remedial actions in order to implement effective control over financial reporting. If in subsequent years the Company is unable to assert that the Company’s internal control over financial reporting is effective, or if the Company’s auditors express an opinion that the Company’s internal control over financial reporting is ineffective, the Company may fail to meet the future reporting obligations in a timely and reliable manner and its financial statements may contain material misstatements. Any such failure could also adversely cause our investors to have less confidence in the accuracy and completeness of our financial reports, which could have a material adverse effect on the price of the Company’s Class A common stock.
We may incur successor liabilities due to conduct arising prior to the completion of the various acquisitions.
We may become subject to certain successor liabilities of recently acquired subsidiary businesses. We may also become subject to litigation claims in the operation of such businesses prior to the closing of such subsidiary acquisitions, including, but not limited to, with respect to tax, regulatory, employee or contract matters. Any litigation may be expensive and time-consuming and could divert the attention of management from its business and negatively affect its operating results or financial condition. Furthermore, the outcome of any litigation cannot be guaranteed, and adverse outcomes can affect our results of operations negatively.
Purchasing real estate with hospital acquisitions brings additional complexity and cost.
By purchasing buildings and land with many of the acquisitions that the Company completes, the financing, due diligence and regulatory requirements of these purchases are much more complex. Issues such as building inspections and related delays, zoning requirements and permitting variabilities across many states all have the potential to cause delays with the purchase of acquisitions and increase the costs of acquiring target locations.
Our estimate of the size of our addressable market may prove to be inaccurate.
Data for retail veterinary services to domestic pets is collected for most, but not all channels, and as a result, it is difficult to estimate the size of the market and predict the rate at which the market for our services will grow, if at all. While our market size estimates have been made in good faith and is based on assumptions and estimates we believe to be reasonable, this estimate may not be accurate. If our estimates of the size of our addressable market are not accurate, our potential for future growth may be less than we currently anticipate, which could have a material adverse effect on our business, financial condition, and results of operations.
We may be unable to execute our growth strategies successfully or manage and sustain our growth, and as a result, our business may be adversely affected.
Our strategies include expanding our veterinary service offerings and building out our digital and data capabilities, growing our market share in services like grooming and training, enhancing our owned brand portfolio, and introducing new offerings to better connect with our customers. However, we may not be able to execute on these strategies as effectively as anticipated. Our ability to execute on these strategies depends on a number of factors, including:
| ● | whether we have adequate capital resources to expand our offerings and build out our digital and data capabilities; |
| ● | our ability to relocate our pet care centers and obtain favorable sites and negotiate acceptable lease terms; |
| ● | our ability to hire, train and retain skilled managers and personnel, including veterinarians, information technology professionals, owned brand merchants, and groomers and trainers; and |
| ● | our ability to continue to upgrade our information and other operating systems and to make use of the data that we collect through these systems to offer better products and services to our customers. |
Our existing locations may not maintain their current levels of sales and profitability, and our growth strategies may not generate sales levels necessary to achieve pet care center level profitability comparable to that of our existing locations. To the extent that we are unable to execute on our growth strategies in accordance with our expectations, our sales growth would come primarily from the organic growth of existing product and service offerings.
We may experience difficulties recruiting and retaining skilled veterinarians due to shortages that could disrupt our business.
The successful growth of our veterinary services business depends on our ability to recruit and retain skilled veterinarians and other veterinary technical staff. We face competition from other veterinary service providers in the labor market for veterinarians, and from time to time, we may experience shortages of skilled veterinarians in markets in which we operate our veterinary service businesses, which may require us or our affiliated veterinary practices to increase wages and enhance benefits to recruit and retain enough qualified veterinarians to adequately staff our veterinary services operations. If we are unable to recruit and retain qualified veterinarians, or to control our labor costs, our business, financial condition, and results of operations may be materially adversely affected.
18
Negative publicity arising from claims that we do not properly care for animals we handle could adversely affect how we are perceived by the public and reduce our sales and profitability.
From time to time, we receive claims or complaints alleging that we do not properly care for some of the pets we handle or for companion animals we handle, which mainly includes dogs and cats but may include other animals as we acquire additional facilities. Deaths or injuries may occur in the future while animals are in our care. As a result, we may be subject to claims that our animal care practices do not provide the proper level of care. Any such claims or complaints, as well as any related news reports or reports on social media, even if inaccurate or untrue, could cause negative publicity, which in turn could harm our business and have a material adverse effect on our results of operations.
Our quarterly operating results may fluctuate due to the timing of expenses, veterinary facility acquisitions, veterinary facility closures, and other factors.
Our expansion plans, including the timing of new and remodeled veterinary facility acquisitions, and related pre-opening costs, the amount of net sales contributed by new and existing veterinary facilities, and the timing of and estimated costs associated with veterinary facility closings or relocations, may cause our quarterly results of operations to fluctuate. Quarterly operating results are not necessarily accurate predictors of performance.
Quarterly operating results may also vary depending on a number of factors, many of which are outside our control, including:
| ● | changes in our pricing policies or those of our competitors; |
| ● | our sales and channels mix and the relevant gross margins of the products and services sold; |
| ● | the hiring and retention of key personnel; |
| ● | wage and cost pressures; |
| ● | changes in fuel prices or electrical rates; |
| ● | costs related to acquisitions of businesses; and |
| ● | general economic factors. |
The COVID-19 outbreak has previously disrupted our business, and any future outbreak of a health epidemic or other adverse public health developments could materially and adversely affect our business and operating results.
The COVID-19 outbreak previously disrupted our business and any future outbreak of a health epidemic or other adverse public health developments could materially and adversely affect our business and operating results. There is continuing uncertainty relating to the potential effect of COVID-19 on our business. Infections may become more widespread and should that cause supply disruptions it would have a negative impact on our business, financial condition and operating results. In addition, a significant health epidemic could adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could affect the market for our veterinary services, which could have a material adverse effect on our business, operating results and financial condition. The extent to which the COVID-19 pandemic impacts our business will depend on future developments that are uncertain and unpredictable, including the duration and severity of the COVID-19 pandemic, its impact on capital and financial markets, the continued timing of widespread availability of COVID-19 vaccines, the willingness of individuals to become vaccinated, the efficacy of vaccinations, virus mutations and variants, the length of time COVID-19 related restrictions continue to stay in place or are reinstituted and for economic and operating conditions to return to prior levels, together with resulting consumer behaviors, and numerous other uncertainties, all of which remain uncertain. Any of these events could have a material adverse impact on our business, financial condition, results of operations and ability to execute and capitalize on our strategies for a period of time that is currently unknown.
Our continued success is largely dependent on positive perceptions of our company.
Management believes our continued success is largely dependent on positive perceptions of our company as a high-quality employer and operator within the veterinary space. We may receive claims or complaints alleging that we do not properly care for some of the pets we handle or for companion animals we handle and sell, which may include dogs, cats, birds, fish, reptiles, and other small animals. Deaths or injuries sometimes occur while animals are in our care. As a result, we may be subject to claims that our animal care services, including grooming, training, veterinary, and other services, or the related training of our associates or handling of animals by them, do not provide the proper level of care. Our efforts to establish our reputation as a “health and wellness” company increase the risk of claims or complaints regarding our practices. Any such claims or complaints, as well as any related news reports or reports on social media, even if inaccurate or untrue, could cause negative publicity, which in turn could harm our business and have a material adverse effect on our results of operations.
To be successful in the future, we must continue to preserve, grow, and leverage the value of our reputation and our brand. Reputational value is based in large part on perceptions of subjective qualities, and even isolated incidents may erode trust and confidence and have adverse effects on our business and financial results, particularly if they result in adverse publicity or widespread reaction on social media, governmental investigations, or litigation. Our brand could be adversely affected if our public image or reputation were to be tarnished by negative publicity. Failure to comply or accusations of failure to comply with ethical, social, labor, data privacy, and environmental standards could also jeopardize our reputation and potentially lead to various adverse consumer actions. Any of these events could adversely affect our business.
19
As the Company grows, expanding the mergers and acquisitions team in order to select and properly integrate new locations will be necessary. We also will have to build our marketing, sales, managerial and other non-technical capabilities and make arrangements with third parties to perform certain of these other services, and we may not be successful in doing so. Building an internal sales organization is time consuming and expensive and will significantly increase our compensation expense. If we are unable to market and build proven client-acquisition processes at local level our future revenue could suffer.
Our business may be harmed if our computer network containing employee or other information is compromised, which could adversely affect our results of operations.
We occasionally collect or store proprietary or confidential information regarding our employees or customers, and others, including credit card information and potentially personally identifiable information. We may also collect, store, and transmit employees’ health information in order to administer employee benefits; accommodate disabilities and injuries; and comply with public health requirements. We cannot assure you that future potential cyber-attacks will not expose us to material liability. Security could be compromised and confidential information, such as customer credit card numbers, employee information, or other personally identifiable information could be misappropriated, or system disruptions could occur. In addition, cyber-attacks such as ransomware attacks could lock us out of our information systems and disrupt our operations. If our information systems or infrastructure fail to perform as designed or are interrupted for a significant period of time, our business could be adversely affected.
In addition, the Company plans to expand its service offering to include, among other services, tele-veterinarian services. The Company has not implemented such tele-veterinarian services as of the date of this prospectus. However, in order to implement such services, the Company will likely require significant investments in information technology and information technology training. There can be no assurance that such investments will generate commiserate increases in revenue or profitability. In implemented, cyber-attacks such as ransomware attacks against our tele-veterinarian infrastructure could interrupt our ability to provide such services and could adversely affect that line of business.
Labor disputes may have an adverse effect on our operations.
We are not currently party to a collective bargaining agreement with any of our employees. If we were to experience a union organizing campaign, this activity could be disruptive to our operations, increase our labor costs and decrease our operational flexibility. We cannot assure you that some or all of our employees will not become covered by a collective bargaining agreement or that we will not encounter labor conflicts or strikes. In addition, organized labor may benefit from new legislation or legal interpretations by the current presidential administration, as well as current or future unionization efforts among other large employers. Particularly, in light of current support for changes to federal and state labor laws, we cannot provide any assurance that we will not experience additional and more successful union organization activity in the future. Any labor disruptions could have an adverse effect on our business or results of operations and could cause us to lose customers. Further, our responses to any union organizing efforts could negatively impact our reputation and have adverse effects on our business, including on our financial results.
We may be subject to personal injury, workers’ compensation, discrimination, harassment, wrongful termination, wage and hour, and other claims in the ordinary course of business.
Our business involves a risk of personal injury, workers’ compensation, discrimination, harassment, wrongful termination, wage and hour, and other claims in the ordinary course of business. We maintain general liability insurance with a self-insured retention and workers’ compensation insurance with a deductible for each occurrence. We also maintain umbrella insurance above the primary general liability coverage. No assurance can be given that our insurance coverage will be available or sufficient in any claims brought against us.
Additionally, we are subject to U.S. federal, state, and local employment laws that expose us to potential liability if we are determined to have violated such employment laws, including but not limited to, laws pertaining to minimum wage rates, overtime pay, discrimination, harassment, and wrongful termination. Compliance with these laws, including the remediation of any alleged violation, may have a material adverse effect on our business or results of operations.
A decline in consumer spending or a change in consumer preferences or demographics could reduce our sales or profitability and adversely affect our business.
Some of our product sales depend on consumer spending, which is influenced by factors beyond our control, including general economic conditions, disruption or volatility in global financial markets, changes in interest rates, the availability of discretionary income and credit, weather, consumer confidence, unemployment levels and government orders restricting freedom of movement. We may experience declines in sales or changes in the types of products and services sold during economic downturns. Our business could be harmed by any material decline in the amount of consumer spending, which could reduce our sales, or a decrease in the sales of higher-margin products, which could reduce our profitability and adversely affect our business.
We have also benefited from increasing pet ownership, discretionary spending on pets and current trends in humanization and premiumization in the pet industry, as well as favorable pet ownership demographics. To the extent these trends slow or reverse, our sales and profitability would be adversely affected. In particular, COVID-19 has driven an increase in pet ownership and consumer demand for our products that may not be sustained or may reverse at any time. The success of our business depends in part on our ability to identify and respond to evolving trends in demographics and consumer preferences. Failure to timely identify or effectively respond to changing consumer tastes, preferences, spending patterns and pet care needs could adversely affect our relationship with our customers, the demand for our products and services, our market share and our profitability.
20
Our reputation and business may be harmed if our or our vendors’ computer network security or any of the databases containing customer, employee, or other personal information maintained by us or our third-party providers is compromised, which could materially adversely affect our results of operations.
We collect, store, and transmit proprietary or confidential information regarding our customers, employees, job applicants, and others, including credit card information and personally identifiable information. We also collect, store, and transmit employees’ health information in order to administer employee benefits; accommodate disabilities and injuries; to comply with public health requirements; and to mitigate the spread of COVID-19 in the workplace. The protection of customer, employee, and company data in the information technology systems we use (including those maintained by third-party providers) is critical. In the normal course of business, we are and have been the target of malicious cyber-attack attempts and have experienced other security incidents.
Security could be compromised and confidential information, such as customer credit card numbers, employee information, or other personally identifiable information that we or our vendors collect, transmit, or store, could be misappropriated or system disruptions could occur. In addition, cyber-attacks such as ransomware attacks could lock us out of our information systems and disrupt our operations. We may not have the resources or technical sophistication to anticipate or prevent rapidly evolving types of cyber-attacks. Attacks may be targeted at us, our customers, our employees, or others who have entrusted us with information. Actual or anticipated attacks may cause us to incur increasing costs, including costs to deploy additional personnel and protection technologies, train employees, and engage third-party experts and consultants. Advances in computer capabilities, new technological discoveries, or other developments may result in the breach or compromise of the technology used by us to protect transactions or other sensitive data. In addition, data and security breaches could also occur as a result of non-technical issues, including intentional or inadvertent breach by our employees or by persons with whom we have commercial relationships, that result in the unauthorized release of personal or confidential information. Any compromise or breach of our or our vendors’ computer network security could result in a violation of applicable privacy and other laws, costly investigations, litigation, including class actions, and notification, as well as potential regulatory or other actions by governmental agencies and harm to our brand, business, and results of operations. As a result of any of the foregoing, we could experience adverse publicity, loss of sales, the cost of remedial measures and significant expenditures to reimburse third parties for damages, which could adversely impact our results of operations. Any insurance we maintain against the risk of this type of loss may not be sufficient to cover actual losses or may not apply to the circumstances relating to any particular loss.
The animal health industry is highly competitive.
The animal health industry is highly competitive. The Company is not currently engaged in product development and does not depend on product development for any of its revenue, however, the Company believes that it may face competition if the Company decides to engage in product development in future years. In such a case, the Company’s competitors may include standalone animal health businesses, the animal health businesses of large pharmaceutical companies, specialty animal health businesses and companies that mainly produce generic products or offer generic services. We believe many of such competitors are conducting R&D activities in areas served by our products and or services. There are also several new start-up companies competing in the animal health industry. We may also face competition from manufacturers of drugs globally, as well as producers of nutritional health products and animal health service providers. These competitors may have access to greater financial, marketing, technical and other resources. As a result, they may be able to devote more resources to developing, manufacturing, marketing and selling their products, initiating or withstanding substantial price competition or more readily taking advantage of acquisitions or other opportunities.
We may be unable to adequately protect our intellectual property rights.
We regard our brand, customer lists, trademarks, trade dress, domain names, trade secrets, proprietary technology and similar intellectual property as critical to our success. We rely on trademark law, trade secret protection, agreements and other methods with our employees and others to protect our proprietary rights. The protection of our intellectual property rights may require the expenditure of significant financial, managerial and operational resources. Moreover, the steps we take to protect our intellectual property may not adequately protect our rights or prevent third parties from infringing or misappropriating our proprietary rights, and we may be unable to broadly enforce all of our intellectual property rights. Any of our intellectual property rights may be challenged by others or invalidated through administrative process or litigation. Our trademark applications may never be granted. Furthermore, our confidentiality agreements may not effectively prevent disclosure of our proprietary information, technologies and processes and may not provide an adequate remedy in the event of unauthorized disclosure of such information.
We might be required to spend resources to monitor and protect our intellectual property rights. For example, we may initiate claims or litigation against others for infringement, misappropriation or violation of our intellectual property rights or other proprietary rights or to establish the validity of such rights. However, we may be unable to discover or determine the extent of any infringement, misappropriation or other violation of our intellectual property rights and other proprietary rights. Despite our efforts, we may be unable to prevent third parties from infringing upon, misappropriating or otherwise violating our intellectual property rights and other proprietary rights. Any litigation, whether or not it is resolved in our favor, could result in significant expense to us and divert the efforts of our technical and management personnel, which may materially and adversely affect our business, financial condition, and results of operations.
21
We may be subject to litigation.
We may become party to litigation from time to time in the ordinary course of business, which could adversely affect our business. Should any litigation in which we become involved be determined against us, such a decision could adversely affect our ability to continue operating and the market price for our Class A common stock and could potentially use significant resources. Even if we are involved in litigation and win, litigation can redirect significant resources of management and the Company.
Natural disasters and other events beyond our control could harm our business.
Natural disasters or other catastrophic events, such as earthquakes, flooding, wildfires, power shortages, pandemics such as COVID-19, terrorism, political unrest, telecommunications failure, vandalism, cyberattacks, geopolitical instability, war, drought, sea level rise and other events beyond our control may cause damage or disruption to our operations, the operations of our suppliers and service providers, international commerce and the global economy, and could seriously harm our revenue and financial condition and increase our costs and expenses. A natural disaster or other catastrophic event in any of our major markets could have a material adverse impact on our business, financial condition, results of operations, or cash flows. Also, in the event of damage or interruption, our insurance policies may not adequately compensate us for any losses that we may incur.
Risks Related to Government Regulation
Various government regulations could limit or delay our ability to develop and commercialize our services or otherwise negatively impact our business.
We are subject to a variety of federal, state and local laws and regulations that govern, among other things, our business practices in the U.S., such as anti-corruption and anti-competition laws. rules and regulations promulgated by the Occupational Safety and Health Administration (“OSHA”), state veterinary practice acts, state veterinary ownership regulations, and by various other federal, state and local authorities regarding the medical treatment of domestic animals. See “Our Business—Government Regulation.” In addition, we are subject to additional regulatory requirements, including environmental, health and safety laws and regulations administered by the U.S. Environmental Protection Agency, state, local and foreign environmental, health and safety legislative and regulatory authorities and the National Labor Relations Board, covering such areas as discharges and emissions to air and water, the use, management, disposal and remediation of, and human exposure to, hazardous materials and wastes, and public and worker health and safety. These laws and regulations also govern our relationships with employees, including minimum wage requirements, overtime, terms and conditions of employment, working conditions and citizenship requirements. Violations of or liability under any of these laws and regulations may result in administrative, civil or criminal fines, penalties or sanctions against us, revocation or modification of applicable permits, licenses or authorizations, environmental, health and safety investigations or remedial activities, warning or untitled letters or cease and desist orders against operations that are not in compliance, among other things. Such laws and regulations generally have become more stringent over time and may become more so in the future, and we may incur (directly, or indirectly through our outsourced proprietary brand manufacturing partners) material costs to comply with current or future laws and regulations. Liabilities under, and/or costs of compliance, and the impacts on us of any non-compliance, with any such laws and regulations could materially and adversely affect our business, financial condition, and results of operations. These legal and regulatory requirements differ among jurisdictions across the country and are rapidly changing and increasingly complex. The costs associated with compliance with these legal and regulatory requirements are significant and likely to increase in the future.
Any failure to comply with applicable legal and regulatory requirements could result in fines, penalties and sanctions and damage to our reputation. These developments and others related to government regulation could have a material adverse effect on our reputation, business, financial condition, and results of operations.
Additionally, some states require veterinary para-professional team members to be licensed before performing tasks and duties which are critical to the workflow of a veterinary clinic. These regulations require that we are selective in where we choose to purchase hospitals, or, allocate funds and resources to finding, training and paying for licensing for employees. As of the date of this filing, the Company has no clinics located in states where these restrictions are in place.
Further risks to our business include certain states which prohibit non-veterinarians from owning or operating a veterinary clinic. These regulations are designed to limit corporate ownership in the veterinary space and, while there are feasible workarounds which our company and others have employed, these regulations represent additional cost and complexity. Currently, the Company operates in Texas, a state in which only doctors of veterinary medicine may own veterinary hospitals. Pursuant to a management agreement between the Company and a veterinarian-owned state entity, this location is owned via a structure which complies with state regulations and allows the Company to manage necessary aspects of daily operations and derive revenue. Similarly, although no such statute exists in Indiana, the Company operates one location there and has chosen to employ a similar structure out of an abundance of caution due to uncertainty in the regulatory climate.
Changes in laws or regulations, or a failure to comply with any laws and regulations, may adversely affect our business, investments and results of operations.
We are subject to laws and regulations enacted by national, regional and local governments. In particular, we will be required to comply with certain Commission and other legal requirements. Compliance with, and monitoring of, applicable laws and regulations may be difficult, time consuming and costly. Those laws and regulations and their interpretation and application may also change from time to time and those changes could have a material adverse effect on our business, investments and results of operations. In addition, a failure to comply with applicable laws or regulations, as interpreted and applied, could have a material adverse effect on our business and results of operations.
22
Failure to comply with governmental regulations or the expansion of existing or the enactment of new laws or regulations applicable to our veterinary services could adversely affect our business and our financial condition or lead to fines, litigation, or our inability to offer veterinary products or services in certain states.
All of the states in which we operate impose various registration, permit, and/or licensing requirements relating to the provision of veterinary products and services. To fulfill these requirements, we believe that we have registered with appropriate governmental agencies and, where required, have appointed a licensed veterinarian to act on behalf of each facility. All veterinarians practicing in our veterinary service businesses are required to maintain valid state licenses to practice.
In addition, certain states have laws, rules, and regulations which require that veterinary medical practices be owned by licensed veterinarians and that corporations which are not owned by licensed veterinarians refrain from providing, or holding themselves out as providers of, veterinary medical care, or directly employing or otherwise exercising control over veterinarians providing such care. We may experience difficulty in expanding our operations into other states or jurisdictions with similar laws, rules, and regulations. Our provision of veterinary services through tele-veterinarian offerings is also subject to an evolving set of state laws, rules, and regulations. Although we believe that we have structured our operations to comply with our understanding of the veterinary medicine laws of each state or jurisdiction in which we operate, interpretive legal precedent and regulatory guidance varies by jurisdiction and is often sparse and not fully developed. A determination that we are in violation of applicable restrictions on the practice of veterinary medicine in any jurisdiction in which we operate could have a material adverse effect on us, particularly if we are unable to restructure our operations to comply with the requirements of that jurisdiction.
We strive to comply with all applicable laws, regulations and other legal obligations applicable to our veterinary services. It is possible, however, that these requirements may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another or may conflict with other rules or our practices. We cannot guarantee that our practices have complied, comply, or will comply fully with all such laws, regulations, requirements, and obligations. Any failure, or perceived failure, by us to comply with our filed permits and licenses with any applicable federal-, state-, or international-related laws, industry standards or codes of conduct, regulatory guidance, orders to which we may be subject, or other legal obligations relating to privacy or consumer protection could adversely affect our reputation, brand, and business, and may result in claims, proceedings or actions against us by governmental entities or others or other liabilities. Any such claim, proceeding, or action could hurt our reputation, brand and business, force us to incur significant expenses in defending such proceedings, distract our management, increase our costs of doing business, result in a loss of customers and vendors, and may result in the imposition of monetary liability. We may also be contractually liable to indemnify and hold harmless third parties from the costs or consequences of non-compliance with any laws or regulations applicable to our veterinary services. In addition, various federal, state, and foreign legislative and regulatory bodies may expand existing laws or regulations, enact new laws or regulations, or issue revised rules or guidance applicable to our veterinary services. Any such changes may force us to incur substantial costs or require us to change our business practices. This could compromise our ability to pursue our growth strategy effectively and may adversely affect our ability to acquire customers or otherwise harm our business, financial condition, and results of operations.
We may fail to comply with various state or federal regulations covering the dispensing of prescription pet medications, including controlled substances, through our veterinary services businesses, which may subject us to reprimands, sanctions, probations, fines, or suspensions.
The sale and delivery of prescription pet medications and controlled substances through our veterinary services businesses are governed by extensive regulation and oversight by federal and state governmental authorities. The laws and regulations governing our operations and interpretations of those laws and regulations are increasing in number and complexity, change frequently, and can be inconsistent or conflicting. In addition, the governmental authorities that regulate our business have broad latitude to make, interpret, and enforce the laws and regulations that govern our operations and continue to interpret and enforce those laws and regulations more strictly and more aggressively each year. In the future, we may be subject to routine administrative complaints incidental to the dispensing of prescription pet medications through our veterinary services businesses.
We are subject to environmental, health, and safety laws and regulations that could result in costs to us.
In connection with the ownership and operations of our pet care centers and distribution centers, we are subject to laws and regulations relating to the protection of the environment and health and safety matters, including those governing the management and disposal of wastes and the cleanup of contaminated sites. We could incur costs, including fines and other sanctions, cleanup costs, and third-party claims, as a result of violations of or liabilities under environmental laws and regulations. Although we are not aware of any of our sites at which we currently have material remedial obligations, the imposition of remedial obligations as a result of the discovery of contaminants in the future could result in additional costs.
Risks Related to our Common Shares and Securities
We have received delisting notices from Nasdaq regarding our Class A common stock.
On March 8, 2024, we received a staff determination from Nasdaq to delist the Company’s securities from the Nasdaq Capital Market (the “Staff Determination”). The Staff Determination was issued because, as of March 7, 2024, the Company’s securities had a closing bid price of $0.10 or less for at least ten consecutive trading days. Accordingly, the Company is subject to the provisions contemplated under Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stocks Rule”). The Company has appealed the Staff Determination, however, to a Hearings Panel by filing a hearing request with Nasdaq. Pending the hearing before the Panel, the Company’s securities will continue to be listed on the Nasdaq Capital Market.
23
In addition, on April 11, 2024, we received an staff determination from Nasdaq notifying the Company that, based on the Company’s stockholders’ deficit of ($788,259) as reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission, the Company does not meet the alternatives of market value of listed securities or net income from continuing operations. As such, the Company no longer complies with Nasdaq listing rules regarding minimal stockholder’s equity for continued listing. Accordingly, this matter serves as an additional basis for delisting the Company’s securities from Nasdaq. The Company’s hearing date with the Nasdaq Hearings Panel was held May 14, 2024.
In order to address the bid price deficiency, on April 15, 2024, our board of directors approved a reverse stock split of the Company’s authorized and issued and outstanding shares of Class A common stock, par value $0.0001 per share (the “Common Stock”), at a ratio of 1 for 100 (the “Reverse Stock Split”). The Reverse Stock Split was effective on May 8, 2024. On the effective date, every one hundred (100) shares of Class A Common Stock issued and outstanding or held as treasury stock was automatically reclassified into one (1) new share of Common Stock. The total number of shares of Class A Common Stock authorized for issuance was reduced by a corresponding proportion from 100,000,000 shares to 1,000,000 shares.
We believe that the Reverse Split will allow us to regain compliance with both the Low Priced Stocks Rule and the Bid Price Rule. In addition, we believe that the raising of additional equity capital, including the additional equity capital to be raised in this offer, will allow us to regain compliance with the shareholder’s equity requirement for continued listing on Nasdaq.
On June 6, 2024, the Company received a letter from the Panel indicating that our request for continued on Nasdaq was granted subject to the following: (i) on or before June 15, 2024, the Company shall file a registration statement with the Securities and Exchange Commission for a public offering that will be led by Spartan Capital Securities, LLC, and (ii) on or before September 4, 2024, we shall demonstrate compliance with Listing Rule 5550(b)(1).
Additionally, we were advised that September 4, 2024, represents the full extent of the Panel’s discretion to grant continued listing while we are non-compliant with the Exchange’s Listing Rules. It is a requirement during the exception period that we provide prompt notification of any significant events that occur during this time that may affect our compliance with Nasdaq requirements.
There can be no assurance, however, that the Company will be able to regain compliance with the Bid Price Rule and the Low Priced Stocks Rule or that it will be able to regain compliance with the minimum shareholder’s equity rule.
If the Class A common stock is not continued to be listed on Nasdaq, we could face significant material adverse consequences, including:
| ● | a limited availability of market quotations for our securities; |
| ● | reduced liquidity; |
| ● | a determination that the common shares are a “penny stock” which will require brokers trading in our shares to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for the common shares; |
| ● | a decrease in news about and analyst coverage for our Company; and |
| ● | a decreased ability to issue additional securities or obtain additional financing in the future. |
Upon delisting from Nasdaq, our Class A common stock may be traded, if at all in the over-the-counter inter-dealer quotation system, more commonly known as the OTC. OTC transactions involve risks in addition to those associated with transactions in securities traded on securities exchanges such as Nasdaq. Many OTC stocks trade less frequently and in smaller volumes than exchange-listed Stocks. Accordingly, our stock would be less liquid than it would be otherwise. Also, the values of OTC stocks are often more volatile than exchange-listed stocks. Additionally, institutional investors are often prohibited from investing in OTC stocks, and it might be more challenging to raise capital when needed.
In addition, if our Class A Common Stock is delisted, your ability to transfer or sell your Class A common stock may be limited and the value of those securities will be materially adversely affected.
If our Class A common stock becomes subject to the penny stock rules, it may be more difficult to sell our Class A common stock.
The Commission has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00 (other than securities registered on certain national securities exchanges or authorized for quotation on certain automated quotation systems, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system). The OTC Bulletin Board does not meet such requirements and if the price of our Class A common stock is less than $5.00 and our Class A common stock is no longer listed on a national securities exchange such as Nasdaq, our stock may be deemed a penny stock. The penny stock rules require a broker-dealer, at least two business days prior to a transaction in a penny stock not otherwise exempt from those rules, to deliver to the customer a standardized risk disclosure document containing specified information and to obtain from the customer a signed and dated acknowledgment of receipt of that document. In addition, the penny stock rules require that prior to effecting any transaction in a penny stock not otherwise exempt from those rules, a broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive: (i) the purchaser’s written acknowledgment of the receipt of a risk disclosure statement; (ii) a written agreement to transactions involving penny stocks; and (iii) a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our Class A common stock, and therefore shareholders may have difficulty selling their shares.
24
It is not possible to predict the actual number of shares we will sell under the Purchase Agreement, or the actual gross proceeds resulting from those sales. We may not have access to the full amount available under the Purchase Agreement with Tumim.
On November 30, 2023, we entered into the Purchase Agreement with Tumim, pursuant to which Tumim committed to purchase up to $30.0 million in shares of our Class A common stock, at our direction from time to time after the date of this prospectus, subject to the satisfaction of the conditions in the Purchase Agreement. Sales of Class A common stock by us to Tumim, if any, will be subject to certain limitations, and may occur from time-to-time in our sole discretion, over the period commencing once certain customary conditions are satisfied, including securing effectiveness of this resale registration statement with the Commission and ending on the first day of the month following the 24-month anniversary of the date on which the resale registration statement is declared effective by the Commission.
Sales of our Class A common stock to Tumim under the Purchase Agreement will depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to Tumim all or a portion of the shares of our Class A common stock that may be available pursuant to the Purchase Agreement or decide to not sell to Tumim any shares of our Class A common stock that may be available for us to sell to Tumim pursuant to the Purchase Agreement.
Because the purchase price per share to be paid by Tumim for the shares of our Class A common stock that we may elect to sell to Tumim under the Purchase Agreements will fluctuate based on the market prices of our Class A common stock during the applicable purchase valuation period for each purchase, it is not possible for us to predict, as of the date of this prospectus, the number of shares of our Class A common stock that we will sell to Tumim, the purchase price per share that Tumim will pay for shares purchased from us, or the aggregate gross proceeds that we will receive from those purchases by Tumim under the Purchase Agreement.
Any issuance and sale by us under the Purchase Agreement of a substantial amount of shares of our Class A common stock that are being registered for resale by Tumim under this prospectus could cause additional substantial dilution to our stockholders. The number of shares of our Class A common stock ultimately offered for resale by Tumim is dependent upon the number of shares of our Class A common stock we ultimately sell to Tumim under the Purchase Agreement.
Our inability to access a portion or the full amount available under the Purchase Agreement, in the absence of any other financing sources, could have a material adverse effect on our business. The extent to which we rely on Tumim as a source of funding will depend on a number of factors including the prevailing market price of our Class A common stock and the extent to which we are able to secure working capital from other sources. If obtaining sufficient funding from Tumim were to prove unavailable or prohibitively dilutive, we may need to secure another source of funding in order to satisfy our working capital needs. Even if we were to receive all $30.0 million in gross proceeds under the Purchase Agreement, we may still need additional capital to fully implement our business, operating and development plans. Should the financing we require to sustain our working capital needs be unavailable or prohibitively expensive when we require it, there could be a material adverse effect on our business, operating results, financial condition and prospects.
Investors who buy shares at different times will likely pay different prices.
Pursuant to the Purchase Agreement, we will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold to Tumim. If and when we do elect to sell shares of our Class A common stock to Tumim under the Purchase Agreement, after Tumim has acquired such shares, Tumim may resell all or a portion of such shares from time to time in its discretion and at different prices. As a result, investors who purchase shares from Tumim at different times will likely pay different prices for those shares, and so may experience different levels of dilution and in some cases substantial dilution and different outcomes in their investment results. Investors may experience a decline in the value of the shares they purchase from Tumim as a result of future sales made by us to Tumim at prices lower than the prices such investors paid for their shares.
If securities or industry analysts do not publish research or reports about our company, or if they issue adverse or misleading opinions regarding us or our stock, our stock price and trading volume could decline.
We will have to be obtain research coverage by securities and industry analysts; if coverage is not maintained, the market price for our stock may be adversely affected. Our stock price also may decline if any analyst who covers us issues an adverse or erroneous opinion regarding us, our business model or our stock performance, or if our operating results fail to meet analysts’ expectations. If one or more analysts cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our stock price or trading volume to decline and possibly adversely affect our ability to engage in future financings.
We do not intend to pay cash dividends for the foreseeable future.
We currently intend to retain our future earnings, if any, to finance the further development and expansion of our business and do not intend to pay cash dividends in the foreseeable future. We intend to invest our future earnings, if any, to fund our growth and not to pay any cash dividends on our common shares. Since we do not intend to pay dividends, your ability to receive a return on your investment will depend on any future appreciation in the market price of our common shares. There is no assurance that our common shares will appreciate in price. Any future determination to pay dividends will be at the discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements, restrictions contained in future agreements and financing instruments, business prospects and such other factors as our board of directors deems relevant.
25
Our shares will be subordinate to all of our debts and liabilities, which increases the risk that you could lose your entire investment.
Our shares are equity interests that will be subordinate to all of our current and future indebtedness with respect to claims on our assets. In any liquidation, all of our debts and liabilities must be paid before any payment is made to our shareholders. The amount of any debt financing we incur creates a substantial risk that in the event of our bankruptcy, liquidation or reorganization, we may have no assets remaining for distribution to our shareholders after payment of our debts.
Our board of directors may designate and issue shares of new classes of stock, including the issuance of up to 15,700,000 additional shares of Class B common stock, that could be superior to or adversely affect you as a holder of our Class A common stock. Although a majority of our board of directors are independent, our non-independent directors, officers, and their affiliates control approximately 63% of the voting power of our outstanding common stock prior to this offering.
Our board of directors has the power to designate and issue shares of classes of stock, including preferred stock that have voting powers, designations, preferences, limitations and special rights, including preferred distribution rights, conversion rights, redemption rights and liquidation rights without further shareholder approval which could adversely affect the rights of the holders of our Class A common stock. In addition, our board could authorize the issuance of a series of preferred stock that has greater voting power than our Class A common stock or that is convertible into our Class A common stock, which could decrease the relative voting power of our Class A common stock or result in dilution to our existing common stockholders. Although a majority of our board of directors are independent, our non-independent directors, officers, and their affiliates control approximately 77.7% of the voting power of our outstanding common stock. Our non-independent directors, officers and their affiliates may, through their control of over a significant portion of the voting power of our outstanding common stock, could influence the Company to take corporate actions or engage in transactions that may be at odds with the interests of other investors in our Class A common stock.
Any of these actions could significantly adversely affect the investment made by holders of our Class A Common Stock. Holders of common stock could potentially not receive dividends that they might otherwise have received. In addition, holders of our Class A common stock could receive less proceeds in connection with any future sale of the Company, whether in liquidation or on any other basis.
Our articles of incorporation authorize the issuance of one hundred million (100,000,000) shares of Class A common stock, twenty million (20,000,000) shares of Class B common stock, and fifty million (50,000,000) shares of preferred stock. We currently have 958,401 3,891,500 and 28,591 shares of Class A common stock, Class B common stock and Series A preferred stock, respectively, issued and outstanding. The Class B common stock is identical to the Class A common stock, except that each share of Class B common stock entitles the holder of such share 25 votes per share and is convertible into one share of Class A common stock. If our board of directors determined to issue the remaining 16,108,500 unissued Class B shares, such shares would represent an additional 3,925,000 votes and non-affiliated investors in our Class A Common Stock would have voting power of less than 1%.
Charles Stith Keiser, our director and Vice-Chair, the holder of 2,150,000 shares of our Class B common stock and 245 shares of our Class A common stock, controls approximately 54.6% of the voting power of the outstanding common stock of the Company.
Our directors Messrs. Carr, Keiser, and Lau hold a combined 3,020,750 shares of our Class B common stock and 1,023 shares of our Class A common stock, control approximately 77.7% of the voting power of the outstanding common stock prior to the issuance of any additional shares. See “Security Ownership of Certain Beneficial Owners and Management.”
Because we do not expect any single holder or entity to hold more than 50% of the outstanding voting power of the Company, we do not believe we will qualify as a “controlled company” under the Nasdaq listing rules. See “—We may be deemed a ‘controlled company’ within the meaning of the rules of Nasdaq and, as a result, may qualify for, but do not intend to rely on, exemptions from certain corporate governance requirements.”
However, any future issuance of Class A common stock or Class B common stock will result in substantial dilution in the percentage of our Class A common stock held by our then existing shareholders. We may value any common stock issued in the future on an arbitrary basis. The issuance of common stock for future services or acquisitions or other corporate actions may have the effect of diluting the value of the shares held by our investors and might have an adverse effect on any trading market for our Class A Common Stock.
The trading price of our Class A common stock is volatile, which could result in substantial losses to investors.
The trading price of our Class A common stock is volatile and could fluctuate widely due to factors beyond our control. This may happen because of broad market and industry factors, including the performance and fluctuation of the market prices of other companies with business operations located outside of the United States. In addition to market and industry factors, the price and trading volume for our Class A common stock may be highly volatile for factors specific to our own operations, including the following:
| ● | the potential delisting of our common stock from The Nasdaq Capital Market (as more fully described below); | |
| ● | variations in our revenues, earnings and cash flow; |
26
| ● | announcements of new investments, acquisitions, strategic partnerships or joint ventures by us or our competitors; |
| ● | announcements of new offerings, solutions and expansions by us or our competitors; | |
| ● | changes in financial estimates by securities analysts; |
| ● | detrimental adverse publicity about us, our brand, our services or our industry; |
| ● | additions or departures of key personnel; |
| ● | sales of additional equity securities; and |
| ● | potential litigation or regulatory investigations. |
Any of these factors may result in large and sudden changes in the volume and price at which our Class A common stock will trade.
In the past, shareholders of public companies have often brought securities class action suits against those companies following periods of instability in the market price of their securities. If we were involved in a class action suit, it could divert a significant amount of our management’s attention and other resources from our business and operations and require us to incur significant expenses to defend the suit, which could harm our results of operations. Any such class action suit, whether or not successful, could harm our reputation and restrict our ability to raise capital in the future. In addition, if a claim is successfully made against us, we may be required to pay significant damages, which could have a material adverse effect on our financial condition and results of operations.
The sale or availability for sale of substantial amounts of our Class A common stock could adversely affect their market price.
Sales of substantial amounts of our Class A common stock in the public market, or the perception that these sales could occur, could adversely affect the market price of our Class A common stock and could materially impair our ability to raise capital through equity offerings in the future. We are registering up to 78,692 shares of Class A common stock (including the Commitment Shares and the Warrant Shares, if any) issuable under the Purchase Agreement, which may be sold pursuant to this prospectus, which such shares may be sold at then prevailing market prices, at prices related to the prevailing market prices, at negotiated prices, or at fixed prices, which may be changed. The sale of a significant number of shares being offered could depress the market price of the Company’s Class A common stock.
Such volatility, including any stock-run up, may be unrelated to our actual or expected operating performance and financial condition or prospects, making it difficult for prospective investors to assess the rapidly changing value of our stock. Furthermore, the stock market in general experiences price and volume fluctuations that are often unrelated or disproportionate to the operating performance of companies like us. Volatility or a lack of positive performance in the price of our shares of Class A common stock may also adversely affect our ability to retain key employees.
In addition, the stock market, in general, or the market for stocks in our industry, in particular, may experience broad market fluctuations, which may adversely affect the market price or liquidity of our common shares. Any sudden decline in the market price of our common shares could trigger securities class-action lawsuits against us. If any of our shareholders were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit and the time and attention of our management would be diverted from our business and operations. We also could be subject to damages claims if we are found to be at fault in connection with a decline in our stock price.
We are an “emerging growth company” and a “smaller reporting company” and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies and a smaller reporting companies will make our Class A common stock less attractive to investors.
We are an “emerging growth company,” as defined in the JOBS Act, and we expect to take advantage of certain exemptions and relief from various reporting requirements that are applicable to other public companies that are not emerging growth companies. In particular, while we are an emerging growth company: we will not be required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act; we will be exempt from any rules that could be adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotations or a supplement to the auditor’s report on financial statements; we will be subject to reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and we will not be required to hold nonbinding advisory votes on executive compensation or stockholder approval of any golden parachute payments not previously approved.
In addition, while we are an emerging growth company we can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of this extended transition period and, as a result, our operating results and financial statements may not be comparable to the operating results and financial statements of companies who have adopted the new or revised accounting standards.
27
We may remain an emerging growth company until as late as December 31, 2026, though we may cease to be an emerging growth company earlier under certain circumstances, including if (i) we have more than $1.235 billion in annual revenue in any fiscal year, (ii) the market value of our Class A common stock that is held by non-affiliates exceeds $700 million as of the last business day of its most recently completed second fiscal quarter or (iii) we issue more than $1.0 billion of non-convertible debt over a three-year period.
Even after we no longer qualify as an emerging growth company, we may still qualify as a smaller reporting company, which would allow us to continue to take advantage of many of the same exemptions from disclosure requirements, including, among other things, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, presenting only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements.
Investors may find our Class A common stock less attractive to the extent we rely on the exemptions and relief granted by the JOBS Act. If some investors find our Class A common stock less attractive as a result, there may be a less active trading market for our Class A common stock and our stock price may decline or become more volatile.
We may be deemed a “controlled company” within the meaning of the rules of Nasdaq and, as a result, may qualify for, but do not intend to rely on, exemptions from certain corporate governance requirements.
Charles Stith Keiser, our director and Vice-Chair and the holder of 2,150,000 shares of our Class B common stock and 245 shares of our Class A common stock, controls approximately 54.6% of the voting power of the Company as of the date of this prospectus. However, if Mr. Keiser were to control greater than 50% of the voting power of our Class A common stock, the Company may be deemed a “controlled company” within the meaning of the corporate governance standards of Nasdaq. Under the rules of Nasdaq, a company of which more than 50% of the outstanding voting power is held by an individual, group or another company is a “controlled company” and may elect not to comply with certain stock exchange corporate governance requirements, including the requirement that a majority of the board of directors consists of independent directors, have a nominating and governance committee and compensation committee that is composed entirely of independent directors and the requirement for an annual performance evaluation of the nominating and governance committee and compensation committee.
We do not intend to rely on these exemptions and instead intend to comply with all of the corporate governance requirements imposed by state and federal law, the rules and regulations of the Securities and Exchange Commission and Nasdaq.
Sales of a significant number of shares of our Class A common stock in the public markets, or the perception that such sales could occur, could depress the market price of our Class A common stock.
Sales of a substantial number of shares of our Class A common stock in the public markets could depress the market price of our Class A common stock and impair our ability to raise capital through the sale of additional equity securities. We cannot predict the effect that future sales of our Class A common stock would have on the market price of our Class A common stock.
Risks Related to this Offering
The Warrants and Pre-Funded Warrants are speculative in nature.
The Warrants and Pre-Funded Warrants do not confer any rights of Class A common stock ownership on their holders, such as voting rights or the right to receive dividends, but rather merely represent the right to acquire shares of our Class A common stock at a fixed price for a limited period of time. Specifically, holders of the Warrants may exercise their right to acquire the Class A common stock and pay the exercise price. However, upon expiration of the Warrants and Pre-Funded Warrants, they have no further value.
28
Holders of Warrants will have no rights as a Class A common stockholder unless such holders exercise their Warrants and acquire our Class A common stock.
Until holders of Warrants and Pre-Funded Warrants acquire shares of our Class A common stock upon exercise of the Warrants and Pre-Funded Warrants, holders will have no rights with respect to the shares of our Class A common stock underlying such Warrants and Pre-Funded Warrants. Upon exercise of the Warrants and Pre-Funded Warrants, the holders thereof will be entitled to exercise the rights of a Class A common stockholder only as to matters for which the record date occurs after the exercise date.
There is no public market for the Warrants and Pre-Funded Warrants in this offering, which may limit your ability to resell the Warrants and Pre-Funded Warrants.
There is no established public trading market for the Warrants and Pre-Funded Warrants, and we do not expect a market to develop. In addition, we do not intend to apply for listing of the Warrants and Pre-Funded Warrants on any securities exchange or recognized trading system. As a result, the Warrants and Pre-Funded Warrants may not be widely distributed and purchasers of the Warrants and Pre-Funded Warrants may be unable to resell them or sell them only at an unfavorable price for an extended period of time, if at all.
We will not receive any meaningful amount of additional funds upon the exercise of the Pre-Funded Warrants.
Each Pre-Funded Warrant will be exercisable and will have no expiration date and by means of payment of the nominal cash purchase price upon exercise. Accordingly, we will not receive any or any meaningful additional funds upon the exercise of the Pre-Funded Warrants.
The market price of our Class A common stock may never exceed the exercise price of the Warrants issued in connection with this offering.
The Warrants being issued in connection with this offering become exercisable upon issuance and will expire six months from the date of issuance. The market price of our Class A common stock may never exceed the exercise price of the Warrants prior to their date of expiration. Any warrants not exercised by their date of expiration will expire worthless and we will be under no further obligation to the warrant holder.
Additional stock offerings in the future may dilute then-existing shareholders’ percentage ownership of the Company.
Given our plans and expectations that we will need additional capital and personnel, we anticipate that we will need to issue additional shares of Class A common stock or securities convertible or exercisable for shares of Class A common stock, including convertible preferred stock, convertible notes, stock options or warrants. The issuance of additional securities in the future will dilute the percentage ownership of then current stockholders.
Management will have broad discretion as to the use of the proceeds from this offering and may not use the proceeds effectively.
Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that may not improve our results of operations or enhance the value of our Class A common stock. Our failure to apply these funds effectively could have a material adverse effect on our business and cause the price of our Class A common stock to decline.
29
CAPITALIZATION
The following table sets forth our cash and capitalization: as of March 31, 2024:
| ● | On an actual basis; | |
| ● | On a pro forma basis to give effect to the issuance of 198,992 shares of Class A Common Stock upon conversion of 52,551 shares of Series A preferred stock, (ii) 16,548 shares of Class A Common Stock issued upon exercise of 16,548 Pre-Funded Warrant; and | |
| ● | On a pro forma as adjusted basis to give effect to the issuance and sale of 9,125,475 Units at an assumed offering price of $1.315 per Unit, which was the closing price of our Class Common Stock on June 20, 2024 (assuming no sale of Units including a Pre-Funded Warrant), after deducting estimated investment banking commissions and estimated offering expenses payable by us. |
The pro forma and pro forma as adjusted information below is illustrative only, and our capitalization following the completion of this offering will be adjusted based on the actual public offering price and other terms of this offering determined at the pricing of this offering. You should read the information in this table together with our consolidated financial statements and the related notes appearing at the end of this prospectus and the sections titled “Use of Proceeds” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
| Pro Forma | ||||||||||||
| Actual | Pro Forma | As Adjusted | ||||||||||
| (unaudited) | (unaudited) | (unaudited) | ||||||||||
| Cash and restricted cash | $ | 269,077 | $ | 269,077 | $ | 11,184,077 | ||||||
| Debt: | ||||||||||||
| Notes payable, net of discount | 14,692,230 | 14,692,230 | 14,692,230 | |||||||||
| Loan payable | 2,338,067 | 2,338,067 | 2,338,067 | |||||||||
| Convertible notes payable | 500,000 | 500,000 | 500,000 | |||||||||
| Total Debt | 17,530,297 | 17,530,297 | 17,530,297 | |||||||||
| Stockholders’ equity (deficit): | ||||||||||||
| Common stock – Class A, $0.0001 par value, 1 million shares authorized, 742,563 issued and outstanding on an actual basis, 958,033 issued and outstanding on a pro forma basis and 10,083,508 shares issued and outstanding on a pro forma as adjusted basis | 74 | 96 | 1,009 | |||||||||
| Common stock – Class B, $0.0001 par value, 20,000,000 shares authorized, 3,891,500 shares issued and outstanding on an actual, pro forma and pro forma as adjusted basis | 389 | 389 | 389 | |||||||||
| Convertible Series A preferred stock, $0.0001 par value, 2,000,000 shares authorized, 81,142 issued and outstanding on an actual basis, 28,591 issued and outstanding on a pro forma and on a pro forma as adjusted basis | 8 | 3 | 3 | |||||||||
| Additional paid-in Capital | 25,118,701 | 25,118,684 | 36,032,771 | |||||||||
| Accumulated deficit | (24,849,319 | ) | (24,849,319 | ) | (24,849,319 | ) | ||||||
| Total shareholders’ equity | 269,853 | 269,853 | 11,184,853 | |||||||||
| Total capitalization | $ | 17,800,150 | $ | 17,800,150 | $ | 28,715,150 | ||||||
30
DILUTION
The issuance of securities pursuant to this prospectus (attributing no value to the Warrants and assuming no sale of a Unit including a Pre-Funded Warrant) will dilute the value of our shares of our Class A Common Stock. Our net tangible book value (deficit) as of March 31, 2024 was $(10,182,751) or $(13.71) per share of Class A Common Stock (based upon 742,563 outstanding shares of Class A common stock as of March 31, 2024). “Net tangible book value (deficit)” is total assets minus the sum of liabilities and intangible assets. “Net tangible book value (deficit) per share” is net tangible book value (deficit) divided by the total number of shares of common stock outstanding.
After giving pro forma effect to the issuance of 198,992 shares of Class A Common Stock upon conversion of 52,551 shares of Series A preferred stock, (ii) 16,548 shares of Class A Common Stock issued upon exercise of 16,548 Pre-Funded Warrant, pro forma net tangible book value as of March 31, 2024 would have been $(10,182,751), or $(13.71) per share of Class A Common Stock (based upon 958,033 outstanding shares of Class A common stock as of March 31, 2024).
After giving pro forma as adjusted effect to the sale by us in this offering of 9,125,475 Units, at an assumed offering price of $1.315 per Unit, which was the closing price of our Class A Common Stock on June 20, 2024 (assuming no sale of a Unit including a Pre-Funded Warrant), after deducting estimated investment banking commissions and estimated offering expenses payable by us, our pro forma net tangible book value as of March 31, 2024 would have been $732,249, or $0.07 per share of common stock. This amount represents an immediate increase in net tangible book value of $10.70 per share to existing stockholders and an immediate dilution of $1.24 per share to purchasers in this offering.
The following table illustrates the dilution:
| Public offering price per common share | $ | |||||||
| Net tangible book deficit per share as of March 31, 2024 | $ | (13.71 | ) | |||||
| Pro forma net tangible book deficit per share, as of March 31, 2024, before giving effect to this offering | $ | (10.63 | ) | |||||
| Increase in pro forma as adjusted net tangible book value per share | $ | 10.70 | ||||||
| Pro forma as adjusted, net tangible book value per common share after this offering | $ | 0.07 | ||||||
| Dilution per share to new investors | $ | 1.24 |
The above discussion and table are based on shares of our Class A Common Stock outstanding as of March 31, 2024.
To the extent that outstanding options or warrants are exercised, you will experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities may result in further dilution to our stockholders.
31
USE OF PROCEEDS
We expect to receive up to $12 million in aggregate gross proceeds from sales of our securities pursuant to this prospectus (assuming no sale of Pre-Funded Warrants). We expect to use the net proceeds from sales of our securities pursuant to this prospectus for as follows:
| ● | $1,000,000 for digital marketing; |
| ● | $1,000,000 for strategic marketing; |
| ● | $1,000,000 for market awareness; |
| ● | $1,000,000 for investor relations; |
| ● | $1,000,000 for shareholder outreach; |
| ● | $1,000,000 for capital markets advisory; |
| ● | $750,000 for repayment of promissory notes; |
| ● | $650,000 for buyback of Series B common stock; |
| ● | $ 960,000 to Placement Agent for commission fees; |
| ● | 120,000 for expense allowance to Placement Agent; and |
| ● | $3,520,000 for general working capital, including for strategic acquisitions and business consultants. |
The amounts and timing of these expenditures will depend on a number of factors, such as the availability and identification of potential complementary acquisition opportunities in the veterinary services and animal health sectors. As of the date of this prospectus, we cannot specify with certainty all of the particular uses, and the respective amounts we may allocate to those uses, for any net proceeds we receive. Accordingly, we will retain broad discretion over the use of these proceeds. Pending our use of the net proceeds as described above, we intend to invest the net proceeds pursuant to the offering in interest-bearing, investment-grade instruments or FDIC-insured bank accounts.
32
MARKET FOR OUR COMMON STOCK
Our Class A common stock is listed on Nasdaq under the symbol “IVP”.
Holders
As of the date of this prospectus, there were 43 stockholders of record for our Class A common stock, 5 stockholders of record for our Class B common stock and 1 stockholder of record for our Series A preferred stock.
Dividend Policy
We do not anticipate declaring or paying, in the foreseeable future, any cash dividends on our capital stock. We intend to retain all available funds and future earnings, if any, to fund the development and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination regarding the declaration and payment of dividends, if any, will be at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant.
Nasdaq Delisting Notice; Reverse Split
On March 8, 2024, we received a staff determination from Nasdaq to delist the Company’s securities from the Nasdaq Capital Market (the “Staff Determination”). The Staff Determination was issued because, as of March 7, 2024, the Company’s securities had a closing bid price of $0.10 or less for at least ten consecutive trading days. Accordingly, the Company is subject to the provisions contemplated under Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stocks Rule”). The Company appealed the Staff Determination, however, to a Hearings Panel by filing a hearing request with Nasdaq
In addition, on April 11, 2024, we received an staff determination from Nasdaq notifying the Company that, based on the Company’s stockholders’ deficit of ($788,259) as reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission, the Company does not meet the alternatives of market value of listed securities or net income from continuing operations. As such, the Company no longer complies with Nasdaq listing rules regarding minimal stockholder’s equity for continued listing. Accordingly, this matter serves as an additional basis for delisting the Company’s securities from Nasdaq. The Company’s hearing date with the Nasdaq Hearings Panel was held May 14, 2024.
In order to address the bid price deficiency, on April 15, 2024, our board of directors approved a reverse stock split of the Company’s authorized and issued and outstanding shares of Class A common stock, par value $0.0001 per share (the “Common Stock”), at a ratio of 1 for 100 (the “Reverse Stock Split”). The Reverse Stock Split was effective on May 8, 2024. On the effective date, every one hundred (100) shares of Class A Common Stock issued and outstanding or held as treasury stock was automatically reclassified into one (1) new share of Common Stock. The total number of shares of Class A Common Stock authorized for issuance were reduced by a corresponding proportion from 100,00,000 shares to 1,000,000 shares.
We believe that the Reverse Split will allow us to regain compliance with both the Low Priced Stocks Rule and the Bid Price Rule. In addition, we believe that the raising of additional equity capital, including the additional equity capital to be raised in this offer, will allow us to regain compliance with the shareholder’s equity requirement for continued listing on Nasdaq.
On June 6, 2024, the Company received a letter from the Panel indicating that our request for continued on Nasdaq was granted subject to the following: (i) on or before June 15, 2024, the Company shall file a registration statement with the Securities and Exchange Commission for a public offering that will be led by Spartan Capital Securities, LLC, and (ii) on or before September 4, 2024, we shall demonstrate compliance with Listing Rule 5550(b)(1).
Additionally, we were advised that September 4, 2024, represents the full extent of the Panel’s discretion to grant continued listing while we are non-compliant with the Exchange’s Listing Rules. It is a requirement during the exception period that we provide prompt notification of any significant events that occur during this time that may affect our compliance with Nasdaq requirements.
There can be no assurance, however, that the Company will be able to regain compliance with the Bid Price Rule and the Low Priced Stocks Rule, that it will be able to regain compliance with the minimum shareholder’s equity rule, or that the Nasdaq the hearing panel will not determine to delist us at the May 14, 2024 hearing.
33
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements and the accompanying notes thereto included elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this prospectus, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You should read the sections titled “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
Overview
Inspire Veterinary is a corporation incorporated in the state of Delaware in 2020. On June 29, 2022, the Company converted into a Nevada corporation. The Company completed its initial public offering on August 31, 2023 and its shares of Class A common stock are quoted on The Nasdaq Capital Market under the symbol “IVP.”
The Company owns and operates veterinary hospitals throughout the United States. The Company specializes in small animal general practice hospitals which serve all manner of companion pets, emphasizing canine and feline breeds. As the Company expands, additional modalities are expected to become a part of the offerings at its hospitals. With the acquisition of The Pony Express Veterinary Hospital, Inc. including equine care and emergency and specialty services and intends to continue to expand such services.
With fourteen clinics located in eleven states as of the date of this filing, Inspire Veterinary purchases existing hospitals which have the financial track record, marketplace advantages and future growth potential which make them worthy acquisition targets. Because the Company leverages a leadership and support structure which is distributed throughout the United States, acquisitions are not centralized to one geographic area. The Company operates it business as one operating and one reportable segment.
The Company is the managing member of IVP Practice Holdings Co., LLC (“Holdco”), a Delaware limited liability company, which is the managing member of IVP CO Holding, LLC (“CO Holdco”), a Delaware limited liability company, IVP FL Holding Co., LLC (“FL Holdco”), a Delaware limited liability company, IVP Texas Holding Company, LLC (“TX Holdco”), a Delaware limited liability company, KVC Holding Company, LLC (“KVC Holdco”), a Hawaii limited liability company, and IVP CA Holding Co., LLC (“CA Holdco”), a Delaware limited liability company, IVP MD Holding Company, LLC (“MD Holdco”), a Delaware limited liability company, IVP OH Holding (“OH Holdco”), Co, LLC, a Delaware limited liability company, IVP IN Holding Co., LLC (“IN Holdco”), a Delaware limited liability company, IVP MA Managing Co., LLC, a Delaware limited liability company (“MA Holdco”), and IVP PA Holding Company, LLC, a Delaware limited liability company (“PA Holdco”). The Company through Holdco, operates and controls all business and affairs of CO Holdco, FL Holdco, TX Holdco, KVC Holdco, CA Holdco, and MD Holdco. Holdco, OH Holdco, IN Holdco, MA Holdco and PA Holdco are used to acquire hospitals in various states and jurisdictions.
The Company is the managing member of IVP Real Estate Holding Co., LLC (“IVP RE”), a Delaware limited liability company, which is the managing member of IVP CO Properties, LLC (“CO RE”), a Delaware limited liability company, IVP FL Properties, LLC (“FL RE”), a Delaware limited liability company, IVP TX Properties, LLC (“TX RE”), a Delaware limited liability company, KVC Properties, LLC, (“KVC RE”), a Hawaii limited liability company, IVP CA Properties, LLC (“CA RE”), a Delaware limited liability company, IVP MD Properties, LLC (“MD RE”), a Delaware limited liability company, IVP OH Properties, LLC (“OH RE”), a Delaware limited liability company, IVP IN Properties, LLC (“IN RE”), a Delaware limited liability company, and IVP PA Properties, LLC (“PA RE”), a Delaware limited liability company. The Company through IVP RE operates and controls all business and affairs of CO RE, FL RE, TX RE, KVC RE, CA RE, MD RE, OH RE, IN RE and PA RE. IVP RE are used to acquire real property in various states and jurisdictions.
COVID-19
Impacts resulting from the COVID-19 pandemic have resulted in a widespread health crisis that has already adversely affected the economies and financial markets of many countries around the world. The international response to the spread of COVID-19 has led to significant restrictions on travel; temporary business closures; quarantines; global stock market and financial market volatility; a general reduction in consumer activity; operating, supply chain and project development delays and disruptions; and declining trade and market sentiment; all of which have and could further affect the world economy.
34
The extent to which the novel coronavirus may impact the Company’s business, will depend on future developments which are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, travel restrictions and social distancing in the United States, business closures or business disruptions and the effectiveness of actions taken by governments around the globe to contain and treat the disease. We are unable to predict with certainty the effects of the COVID-19 pandemic on our customers, suppliers and vendors and its impact on the Company’s business.
Our Business Model
Services provided at owned hospitals include preventive care for companion animals consisting of annual health exams which include: parasite control; dental health; nutrition and body condition counseling; neurological examinations; radiology; bloodwork; skin and coat health and many breed specific preventive care services. Surgical offerings include all soft tissue procedures such as spays and neuters, mass removals, splenectomies and can also include gastropexies, orthopedic procedures and other types of surgical offerings based on a doctor’s training. In many locations additional means of care and alternative procedures are also offered such as acupuncture, chiropractic and various other health and wellness offerings.
With acquisitions serving as one key driver of growth, the Company has developed metrics and processes for assessing, valuing, acquiring and integrating new hospitals into its network. With a focus in its early years on general practice, small companion animal hospitals, the Company selects hospitals in markets with large addressable pet populations, but not necessarily in city/urban centers. The Company recently entered the equine care, or the care of horses, sector with the addition of the Pony Express Veterinary Hospital into the Company’s small-animal-only mix of locations.
Growth strategies and expansion plans call for the Company to enter emergency care and mixed animal (such as bovine and additional equine care) in future years of growth. Staffing, ownership transition plans, demographics, quality of medicine, financial performance and quality of existing leadership are some of the many factors that are analyzed before a pending acquisition is offered a letter of intent. The Company uses a field support structure that is nationally distributed and therefore the targets for acquisition can be in most states within the United States, taking special care with more complex states which have very specific veterinary practice ownership and operations guidelines.
Risks to the ability to swiftly acquire and integrate new hospitals include: (i) national staffing shortages of veterinarians and technicians which pre-existed the current market conditions which make finding credentialed talent even more difficult; (ii) costs and time associated with finding suitable targets and performing due diligence; and (iii) difficulties in achieving growth targets post purchase which ensure hospitals grow revenue and earnings in the years post purchase.
Post purchase pressures include rising talent acquisition and staffing costs in addition to challenges in achieving productivity and average patient charges necessary to achieve growth and profitability.
Results of Operations
Acquisition and Growth Strategy
With an emphasis on general practice hospitals in its first seven to eight quarters, the Company expanded into purchase of mixed animal hospitals in late 2022, adding equine care to its mix. Further, in the last quarter of 2023 and beyond, the Company intends to continue to conduct the due diligence necessary to strategically acquire existing general practices, specialty hospitals, and/or expand existing locations to include emergency care and more complex surgeries, holistic care and comprehensive diagnostics which allow it to offer more complex surgeries and internal medicine work ups.
During its third calendar year, the Company has plans to seek multi-unit practices with regional presence to facilitate growth for the Company and also to move more swiftly into being a prime provider in select markets. While purchases of individual clinics will remain a focus for the Company, these opportunities to acquire hospitals in clusters of 2 to 6 will significantly increase our pace of growth and provide numerous internal benefits such as internal case referrals and career pathing for clinicians and leadership.
35
We account for acquisitions under the acquisition method and are required to measure identifiable assets acquired and liabilities assumed of the acquiree at the fair values on the closing date. The Company makes an initial allocation of the purchase price at the date of acquisition based upon its understanding of the fair value of the acquired assets and assumed liabilities. Below is a summary of the acquisitions that closed from the inception of the Company through March 31, 2024, and the related transaction price
| Name | Closing Date | Transaction Value1 | ||||
| Kauai Veterinary Clinic3 | January 2021 | $ | 1,505,000 | |||
| Chiefland Animal Hospital2 | August 2021 | $ | 564,500 | |||
| Pets & Friends Animal Hospital2 | October 2021 | $ | 630,000 | |||
| Advanced Veterinary Care of Pasco3 | January 2022 | $ | 1,014,000 | |||
| Lytle Veterinary Clinic2 | March 2022 | $ | 1,442,469 | |||
| Southern Kern Veterinary Clinic2 | March 2022 | $ | 2,000,000 | |||
| Bartow Animal Clinic3,4 | May 2022 | $ | 1,405,000 | |||
| Dietz Family Pet Hospital2 | June 2022 | $ | 500,000 | |||
| Aberdeen Veterinary Clinic3 | July 2022 | $ | 574,683 | |||
| All Breed Pet Care Veterinary Clinic2 | August 2022 | $ | 2,152,000 | |||
| Pony Express Veterinary Hospital, Inc.2 | October 2022 | $ | 3,108,652 | |||
| Williamsburg Animal Clinic3 | December 2022 | $ | 850,000 | |||
| The Old 41 Animal Hospital2 | December 2022 | $ | 1,465,000 | |||
| Valley Veterinary Services3,5 | November 2023 | $ | 1,790,000 | |||
| 1. | The transaction value is the amount of consideration paid for the acquisition of the veterinary practice (and as denoted the real estate operations) that was accounted for as a single business combination, in accordance with ASC Topic 805. |
| 2. | Acquisition includes both the veterinary practice and related assets and the real estate operations in the transaction value. |
| 3. | Acquisition was for the veterinary practice and related assets only. |
| 4. | Acquisition includes the purchase of personal goodwill of $105,000 that was included in the purchase price of the veterinary practice and related assets. The total transaction value is made up of $955,000 for the veterinary practice and related assets and $350,000 for the real estate operations. |
| 5. | The transaction value excludes $200,000 for the Holdback Agreement associated with the acquisition. |
Kauai Veterinary Clinic Acquisition
On January 25, 2021, the Company acquired Kauai Veterinary Clinic, Inc., located in Lihue, Hawaii on the island of Kauai providing regional and local veterinary services for $1,505,000 dollars through the Company’s wholly-owned subsidiary, IVP Practice Holding Company, LLC. Simultaneously to the closing of KVC, the Company acquired the underlying real estate from a third party in exchange for $1,300,000 through the Company’s wholly-owned subsidiary, IVP Real Estate Holding Co., LLC. These acquisitions were financed with threes loans provided by First Southern National Bank for a total of $2,383,400.
Chiefland Animal Hospital Acquisition
On August 20, 2021, the Company acquired the veterinary practice and related assets of Chiefland Animal Hospital from Polycontec, Inc. for $285,000 through the Company’s wholly-owned subsidiary, IVP Practice Holding Company, LLC. Simultaneously, the Company the real estate operations, consisting of land and buildings, utilized by the Chiefland practice for $279,500 through the Company’s wholly-owned subsidiary, IVP Real Estate Holding Co., LLC. These acquisitions were financed with two loans provided by Farmers National Bank of Danville for a total of $469,259.
36
Pets& Friends Animal Hospital Acquisition
On October 7, 2021, the Company acquired the veterinary practice and related assets of the Pets & Friends Animal Hospital from Pets& Friends Animal Hospital, LLC for $375,000 through the Company’s wholly-owned subsidiary, IVP Practice Holding Company, LLC. Simultaneously, the Company the real estate operations, consisting of land and buildings, utilized by the Pets & Friends practice for $255,000 through the Company’s wholly-owned subsidiary, IVP Real Estate Holding Co., LLC. These acquisitions were financed with two loans provided by Farmers National Bank of Danville for a total of $535,500.
Advanced Veterinary Care of Pasco
On January 14, 2022, the Company acquired the veterinary practice and related assets of Advanced Veterinary Care of Pasco in Hudson, Florida from Advanced Veterinary Care of Pasco, LLC for $1,014,000 through the Company’s wholly-owned subsidiary, IVP FL Holding Company, LLC. This acquisition was financed by a loan provided by Farmers National Bank of Danville for a total of $817,135.
Lytle Veterinary Clinic
On March 15, 2022, the Company acquired the veterinary practice and related assets of Lytle Veterinary Clinic in Texas from Lytle Veterinary Clinic, Inc. for $662,469 through the Company’s wholly-owned subsidiary IVP Texas Holding Company, LLC and its wholly-owned subsidiary, IVP Texas Managing Co., LLC. Simultaneously, the Company acquired the real estate operations, consisting of land and buildings, utilized by the Lytle practice for $780,000 from the Lytle practice through the Company’s wholly-owned subsidiary, IVP Texas Properties, LLC. This acquisition was financed by two loans provided by Farmers National Bank of Danville for a total of $1,141,098.
Southern Kern Veterinary Clinic
On March 22, 2022, the Company acquired the veterinary practice and related assets of Southern Kern Veterinary Clinic in California from Southern Kern Veterinary Clinic, Inc. for $1,500,000 through the Company’s wholly-owned subsidiary IVP CA Holding Co., LLC and its wholly-owned subsidiary, IVP Texas Managing Co., LLC. Simultaneously, the real estate operations, consisting of land and buildings,) utilized by the Kern practice was purchased for $500,000 through the Company’s wholly-owned subsidiary, IVP CA Properties, LLC. This acquisition was financed by two loans provided by Farmers National Bank of Danville for a total of $1,700,000.
Bartow Animal Clinic
On May 18, 2022, the Company acquired the veterinary practice and related assets of Bartow Animal Clinic in Bartow, Florida from Winter Park Veterinary Clinic, Inc. for $1,055,000 through the Company’s wholly-owned subsidiary IVP FL Holding Company LLC. Simultaneously, the real estate operations, consisting of land and buildings, utilized by the Bartow practice was purchased for $350,000 through the Company’s wholly-owned subsidiary, IVP CA Properties, LLC. This acquisition was financed by two loans provided by Farmers National Bank of Danville for a total of $969,000.
Dietz Family Pet Hospital
On June 15, 2022, the Company acquired the veterinary practice and related assets of Dietz Family Pet Hospital in Richmond, Texas from Dietz Family Pet Hospital, P.A. for $500,000 through the Company’s wholly-owned subsidiary IVP Texas Holding Company LLC and its wholly-owned subsidiary, IVP Texas Managing Co. LLC. This acquisition was financed by a loan provided by Farmers National Bank of Danville for a total of $382,500.
Aberdeen Veterinary Clinic
On July 29, 2022, the Company acquired the veterinary practice and related assets of Aberdeen Veterinary Clinic in Aberdeen, Maryland from Fritz Enterprises, Inc. for $574,683 through the Company’s wholly-owned subsidiary IVP MD Holding Company LLC. This acquisition was financed by a loan provided by WealthSouth for a total of $445,981.
All Breed Pet Care Veterinary Clinic
On August 12, 2022, the Company acquired the veterinary practice and related assets of All Breed Pet Care veterinary clinic in Newburgh, Indiana from Tejal Rege for $952,000 through the Company’s wholly-owned subsidiary IVP IN Holding Company LLC. Simultaneously, the real estate operations, consisting of land and buildings, utilized by the All Breed practice was purchased for $1,200,000 through the Company’s wholly-owned subsidiary, IVP IN Properties, LLC. This acquisition was financed by three loans provided by Farmers National Bank of Danville for a total of $1,765,450.
37
Pony Express Veterinary Hospital
On October 31, 2022, the Company acquired the veterinary practice and related assets of the Pony Express Veterinary Hospital, Inc. in Xenia, Ohio from Pony Express Veterinary Hospital, Inc. for $2,608,652 through the Company’s wholly-owned subsidiary IVP OH Holding Company, LLC. Simultaneously, the real estate operations, consisting of land and buildings, utilized by the Pony Express Veterinary Hospital practice was purchased for $500,000 through the Company’s wholly-owned subsidiary, IVP OH Properties, LLC. This acquisition was financed by three loans provided by First Southern National Bank for a total of $2,853,314.
Williamsburg Animal Clinic
On December 9, 2022, the Company acquired the veterinary practice and related assets of Williamsburg Veterinary Clinic in Williamsburg, MA from Williamsburg Animal Clinic, LLC for $850,000 through the Company’s wholly owned subsidiary, IVP MA Holding Company, LLC. This acquisition was financed by a loan provided by Farmers National Bank of Danville for a total of $637,500.
The Old 41 Animal Hospital
On December 16, 2022, the Company acquired the veterinary practice and related assets of The Old 41 Veterinary Clinic in Bonita Springs, FL from The Old 41 Animal Hospital, LLC for $665,000 through the Company’s wholly owned subsidiary, IVP FL Holding Company, LLC. Simultaneously, the real estate operations consisting of land and building utilized by the Old 41 practice for $800,000 from Scott A. Gregory DVM, LLC through the Company’s wholly owned subsidiary, IVP FL Properties, LLC. This acquisition was financed by two loans provided by First Southern National Bank for a total of $1,208,000.
Valley Veterinary Service Acquisition
On November 8, 2023, the Company acquired the animal hospital and related assets of Valley Veterinary Service, Inc in Rostraver Township, Pennsylvania for $800,000 in cash, a holdback agreement for $200,000 in cash that may be paid out at the end of the two year period following the acquisition based on continued employment by the two former owners and revenue targets for year 1 and year 2 following the effective date of the acquisition, which is not included in the consideration transferred, and issuance of restricted shares of the Company’s Class A common stock equal to $400,000 through the Company’s wholly owned subsidiary IVP PA Holding Company, LLC. Simultaneously, the real estate operations consisting of land and building utilized by Valley Veterinary Services, Inc animal hospital for $590,000 from the owners of Valley Veterinary Services, Inc through the Company’s wholly owned subsidiary, IVP PA Properties, LLC. This acquisition was financed by one loan provided by First Southern National Bank for $375,000 and one loan provided by Farmers National Bank of Danville for $850,000.
38
Comparability of Our Results of Operations
Results of Operations for the three months ended March 31, 2024 compared to the three months ended March 31, 2023:
Summary of Results of Operations
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Service revenue | $ | 3,545,599 | $ | 3,072,885 | ||||
| Product revenue | 1,285,968 | 1,209,630 | ||||||
| Total revenue | 4,831,567 | 4,282,515 | ||||||
| Operating expenses | ||||||||
| Cost of service revenue (exclusive of depreciation and amortization, shown separately below) | 2,709,147 | 2,307,903 | ||||||
| Cost of product revenue (exclusive of depreciation and amortization, shown separately below) | 1,016,107 | 879,400 | ||||||
| General and administrative expenses | 2,873,343 | 1,801,659 | ||||||
| Debt extinguishment loss | 728,278 | - | ||||||
| Depreciation and amortization | 367,197 | 298,492 | ||||||
| Total operating expenses | 7,694,072 | 5,287,454 | ||||||
| Loss from operations | (2,862,505 | ) | (1,004,939 | ) | ||||
| Other income (expense): | ||||||||
| Interest income | 2 | 1 | ||||||
| Interest expense | (559,289 | ) | (545,435 | ) | ||||
| Other income | - | 11,424 | ||||||
| Total other expense | (559,287 | ) | (534,010 | ) | ||||
| Loss before income taxes | (3,421,792 | ) | (1,538,949 | ) | ||||
| Benefit for income taxes | - | - | ||||||
| Net loss | (3,421,792 | ) | (1,538,949 | ) | ||||
| Dividend on convertible series A preferred stock | (214,520 | ) | - | |||||
| Net loss attributable to class A and B common stockholders | $ | (3,636,312 | ) | (1,538,949 | ) | |||
| Net loss per Class A and B common shares: | ||||||||
| Basic and diluted | $ | (8.97 | ) | (29.20 | ) | |||
| Weighted average shares outstanding per Class A and B common shares: | ||||||||
| Basic and diluted | 405,484 | 52,705 | ||||||
39
Revenue
The following table presents the breakdown of revenue between products and services:
| For the Three Months Ended | March 31, 2024 vs. 2023 | |||||||||||||||
| March 31, 2024 | March 31, 2023 | $ Change | % Change | |||||||||||||
| Revenue: | ||||||||||||||||
| Service Revenue | $ | 3,545,599 | $ | 3,072,885 | $ | 472,714 | 15 | % | ||||||||
| Percentage of revenue | 73 | % | 72 | % | ||||||||||||
| Product Revenue | 1,285,968 | 1,209,630 | 76,338 | 6 | % | |||||||||||
| Percentage of revenue | 27 | % | 28 | % | ||||||||||||
| Total | $ | 4,831,567 | $ | 4,282,515 | $ | 549,052 | 13 | % | ||||||||
| Average daily service revenue for the three months ended | March 31, 2024 vs. 2023 | |||||||||||||||
| Animal Hospital & Clinics | March 31, 2024 | March 31, 2023 | $ Change | % Change | ||||||||||||
| Kauai Veterinary Clinic | $ | 4,320 | $ | 4,673 | $ | (354 | ) | -8 | % | |||||||
| Chiefland Animal Hospital | 1,807 | 1,874 | (67 | ) | -4 | % | ||||||||||
| Pets & Friends Animal Hospital | 4,108 | 2,537 | 1,570 | 62 | % | |||||||||||
| Advanced Veterinary Care of Pasco | 2,257 | 2,594 | (337 | ) | -13 | % | ||||||||||
| Lytle Veterinary Clinic | 2,088 | 2,130 | (42 | ) | -2 | % | ||||||||||
| Southern Kern Veterinary Clinic | 4,204 | 2,610 | 1,594 | 61 | % | |||||||||||
| Bartow Animal Clinic | 2,304 | 2,892 | (588 | ) | -20 | % | ||||||||||
| Dietz Family Pet Hospital | 1,521 | 2,196 | (675 | ) | -31 | % | ||||||||||
| Aberdeen Veterinary Clinic | 1,648 | 1,696 | (143 | ) | -8 | % | ||||||||||
| All Breed Pet Care Veterinary Clinic | 2,916 | 2,660 | 256 | 10 | % | |||||||||||
| Pony Express Veterinary Hospital | 4,079 | 3,625 | 454 | 13 | % | |||||||||||
| Williamsburg Animal Clinic | 2,629 | 2,350 | 278 | 12 | % | |||||||||||
| Old 41 Animal Hospital | 1,956 | 2,594 | (638 | ) | -25 | % | ||||||||||
| Valley Veterinary Services Animal Hospital | 3,127 | - | 3,127 | 100 | % | |||||||||||
| Total Daily Service Revenue | $ | 38,963 | $ | 34,527 | $ | 4,436 | ||||||||||
| Average daily product revenue for the three months ended | March 31, 2024 vs. 2023 | |||||||||||||||
| Animal Hospital & Clinics | March 31, 2024 | March 31, 2023 | $ Change | % Change | ||||||||||||
| Kauai Veterinary Clinic | $ | 1,614 | $ | 1,833 | $ | (219 | ) | -12 | % | |||||||
| Chiefland Animal Hospital | 1,127 | 1,234 | (107 | ) | -9 | % | ||||||||||
| Pets & Friends Animal Hospital | 1,137 | 785 | 352 | 45 | % | |||||||||||
| Advanced Veterinary Care of Pasco | 652 | 843 | (191 | ) | -23 | % | ||||||||||
| Lytle Veterinary Clinic | 1,086 | 1,017 | 69 | 7 | % | |||||||||||
| Southern Kern Veterinary Clinic | 767 | 634 | 133 | 21 | % | |||||||||||
| Bartow Animal Clinic | 1,164 | 1,235 | (71 | ) | -6 | % | ||||||||||
| Dietz Family Pet Hospital | 739 | 820 | (81 | ) | -10 | % | ||||||||||
| Aberdeen Veterinary Clinic | 628 | 547 | 81 | 15 | % | |||||||||||
| All Breed Pet Care Veterinary Clinic | 820 | 1,580 | (760 | ) | -48 | % | ||||||||||
| Pony Express Veterinary Hospital | 1,290 | 1,665 | (375 | ) | -23 | % | ||||||||||
| Williamsburg Animal Clinic | 718 | 685 | 34 | 5 | % | |||||||||||
| Old 41 Animal Hospital | 606 | 714 | (108 | ) | -15 | % | ||||||||||
| Valley Veterinary Services Animal Hospital | 1,783 | - | 1,783 | 100 | % | |||||||||||
| Total Daily Product Revenue | $ | 14,132 | $ | 13,591 | $ | 540 | ||||||||||
Revenue in General: The Company believes the breakdown of gross revenue into service revenue and product revenue categories produces meaningful measures to Company management and the Company’s investors in light of the Company’s objective to protect the service channel and derive the majority of its revenue from services and expertise which are not capable of disruption from other channels. To achieve this objective, the Company seeks to match the industry target metric of 70% to 80% of gross revenue being derived from services: examination fees, diagnostics fees, laboratory work, surgery and others veterinary services. The Company believes these service revenue sources require veterinary professionals to preside over care delivery and, unlike some veterinary care products, cannot be replaced or sold by other non-veterinary hospital channels such as retail (including over-the-counter and online). Accordingly, the Company views products such as parasite controls, veterinary nutrition products and additives as important, but the Company does not rely on product revenue to account for more than 20% to 30% of gross revenue. Medications and therapeutics which only a licensed veterinary doctor or licensed technician can administer, while still making up part of the 20% to 30% of gross revenue, are less easily diverted to non-veterinary hospital channels as they require licensed professionals to prescribe or utilize them.
40
The Company uses these percentages in concert with metrics such as Revenue Per Patient Per day (“RPP”) and Average Patient Charge (“APC”) to analyze the comprehensive nature of diagnostics and services provided by each veterinary hospital. Sometimes referred to “quality medicine” metrics within the veterinary service industry, the Company uses RPP and APC to determine how a doctor’s time is being utilized (inclusive of all diagnostics and therapies). RPP and APC metrics are consolidated into the presentation of average daily service revenue and average daily product revenue. The Company believes these analyses helps the Company ensure that its caseload is revenue positive to avoid clinicians spending time on patient work which underutilizes their time and erodes labor profitability. The Company also believes these metrics are useful to investors and potential investors to compare the Company’s service-to-product revenue mix against generally accepted industry targets and specific veterinary care service provider competitors.
The services revenue and product revenue metrics are measured in dollars as calculated by the practice management software we provide to each of our clinics to track medical notes, treatment plans, services and products prescribed and provided, as well as to manage invoicing related to all of the above. Reports are generated which allow Company management to view each of these as line-items as well as measure the ratio of service revenue versus product revenue within our revenue mix.
The Company believes the ratio metric is useful for the management and its investors for several reasons:
| ● | The Company and its medical leadership teach and enable its medical staff to provide comprehensive medical care which is appropriate for each animal patient. For example, charges to a client which skew too heavily toward products and do not include necessary services may be indicator that medical cases are not being fully diagnosed using an appropriate standard of available and appropriate diagnostics and care. This broad analysis can indicate more questions should be asked about how cases are managed by certain providers, particularly if patterns emerge; |
| ● | Comprehensive care for pets means physical exams, dental care, blood work and many other service related line-items. An overreliance on product revenue alone (which products may be available over-the-counter outside of the veterinary channel) leaves veterinary clinics susceptible to sales transfer to other channels. In addition, appropriate veterinary care (as defined by market practice and some state licensing boards) does not include prescribing products without the delivery of diagnostic and care services. |
| ● | Advancements in veterinary care within the last decade such as anesthetic protocols, pain management, fear free medicine and other services have shown great efficacy for the betterment of patients and their recovery from illness or surgeries. The absence of certain services and procedures within, for instance, a surgery package for a patient, would indicate an opportunity to improve outcomes for a patient and extend life expectancy. These are positive outcomes for clients and, therefore, of interest and value to the Company and our investors. |
Service Revenues: The Company recognizes service revenue from health exams, pet grooming, veterinary care, and certain other services performed at our animal hospitals or clinics and is recognized once the service is completed, as this is when the customer has the ability to direct the use of and obtain the benefits of the services. Payment terms are at the point of sale but may also occur upon completion of the service. Service revenue increased $472,714 or 15%, to $3,545,599 for the three months ended March 31, 2024 as compared to $3,072,885 for the three months ended March 31, 2023. The increase was driven by an increase in revenue for six animal hospitals and clinics of $405,902 and one new animal hospital acquired in Q4 2023 resulting in $284,555 increase offset by the decrease of $217,743 by the seven animal hospitals and clinics already in operations.
41
Product Revenues: Product revenue is recognized when control passes, which occurs at a point in time when the customer completes a transaction at our animal hospitals or clinics and receives the product. Product revenue increased $76,338, or 6%, to $1,285,968 for the three months ended March 31, 2024 as compared to $1,209,630 for the three months ended March 31, 2023. The increase in product revenue was driven primarily by the acquisition of an animal hospital during Q4 2023. The acquisition provided an increase in revenue of $162,267 offset by the decrease of $85,929 in the remaining thirteen (13) animal hospitals and clinics in operations for the three months ended March 31, 2024.
Cost of service revenue (exclusive of depreciation and amortization): Cost of service revenue consists of cost directly related to the animal services provided at the Company’s veterinary clinics and animal hospitals, which primarily includes personnel-related compensation costs of the employees at the Company’s veterinary clinics or animal hospitals, laboratory costs, pet supply costs, third-party veterinarian contractors, office rent, utilities, supplies, and other cost arising as a result of the services being performed, excluding depreciation and amortization. Cost of service revenue increased $401,244, or 17%, to $2,709,147 for the three months ended March 31, 2024, as compared to $2,307,903 for the three months ended March 31, 2023. The increase in cost of service revenue sold excluding depreciation and amortization was driven primarily by acquisition of Valley Veterinary animal hospital and increase to payroll costs.
Cost of product revenue (exclusive of depreciation and amortization): Cost of product revenue consists of cost directly related to the product sales at the Company’s veterinary clinics and animal hospitals, which primarily includes personnel-related compensation costs of the employees at the Company’s veterinary clinics or animal hospitals, purchase price of the medication we dispense, and purchase price of product sold, excluding depreciation and amortization. Cost of product revenue increased $136,707, or 16%, to $1,016,107 for the three months ended March 31, 2024 as compared to $879,400 for the three months ended March 31, 2023. The increase in was driven primarily by the acquisition of Valley Veterinary animal hospital, an increase to payroll costs and increase in product cost.
General and Administrative Expense: General and administrative expenses include personnel-related compensation costs for corporate employees, such as management, accounting, legal, acquisition related and non-recurring expenses, insurance and other expenses used to operate the business. General and administrative expenses increased $1,071,684, or 59% to $2,873,343 for the three months ended March 31, 2024 compared to $1,801,659 for the three months ended March 31, 2023. The increase was primarily due to the expenses generated by the Company’s animal hospitals and clinics acquired and the IR agency contracts and consulting contracts the Company entered into during the first quarter of 2024.
Depreciation and Amortization Expense: Depreciation and amortization expenses mainly relate to the assets used in generating revenue. Depreciation and amortization increased $68,705, or 23%, to $367,197 for the three months ended March 31, 2024 as compared to $298,492 for the three months ended March 31, 2023. The increase was primarily due to the acquisition of depreciable or amortizable assets as part of the acquisitions of animal hospitals and clinics.
Other Expense: Other expense are composed primarily of interest expenses and small denomination bank fee charges. Other expense increased $25,277, or 5%, to $559,289 for the three months ended March 31, 2024 as compared to $545,435 for the three months ended March 31, 2023. The increase was the result of the Company incurring interest due to bank loans and other indebtedness to finance the acquisition of animal hospitals and clinics.
Net Loss: Net Loss increased $1,882,843, or 122%, to $3,421,792 for the three months ended March 31, 2024 as compared to $1,538,949 for the three months ended March 31, 2023. The net loss is primarily attributable to the operating expenses associated with the Company’s animal hospitals and clinics, the cost associated with the public raise during the quarter, the IR Agency Consulting Agreement and other 3rd party consulting arrangements entered into to increase customer outreach and improve operations.
42
Liquidity and Capital Resources
Since inception, we have financed our operations from a combination of:
| ● | issuances and sales of senior convertible notes; |
| ● | issuance of convertible debentures; |
| ● | borrowings under other debt consisting of: (i) a principal lending relationship with Farmers National Bank of Danville; (ii)a principal lending relationship with First Southern National Bank; (iii) short term financing arrangements under merchant cash advance agreement; |
| ● | common stock purchase agreement with Tumim Stone Capital LLC, |
| ● | proceeds from issuance of equity; and |
| ● | cash generated from operations. |
The Company has experienced operating losses since its inception and had a total accumulated deficit of $24,849,319 as of March 31, 2024. The Company expects to incur additional costs and require additional capital as the Company continues to acquire additional veterinary hospitals, clinics and practices. During the three months ended March 31, 2024 the Company’s cash used in operations was $3,169,029.
The Company’s primary short-term cash requirements are to fund working capital, lease obligations and short-term debt, including current maturities of long-term debt. Working capital requirements can vary significantly from period to period, particularly as a result of additional business acquisitions. The Company’s medium-term to long-term cash requirements are to service and repay debt, to expand through acquisitions, and to invest in facilities and equipment for growth initiatives.
The Company’s ability to fund its cash needs will depend, in part, on its ability to generate cash in the future, which depends on future financial results. The Company’s future results are subject to general economic, financial, competitive, legislative and regulatory factors that may be outside of our control. The Company’s future access to, and the availability of credit on acceptable terms and conditions, is impacted by many factors, including capital market liquidity and overall economic conditions.
These financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred recurring losses and as of March 31, 2024, had an accumulated deficit of $24,849,319. For the three, the Company sustained a net loss of $3,421,792. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern for the next twelve months from the date these financial statements were issued. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that may be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is contingent upon its ability to obtain additional financing and to generate revenue and cash flow to meet its obligations on a timely basis. The Company will continue to seek to raise additional funding through debt or equity financing during the next twelve months. Management believes that actions presently being taken to obtain additional funding provide the opportunity for the Company to continue as a going concern. There is no guarantee the Company will be successful in achieving these objectives.
We cannot be sure that future funding will be available to us on acceptable terms, or at all. Due to often volatile nature of the financial markets, equity and debt financing may be difficult to obtain.
We may seek to raise any necessary additional capital through a combination of private or public equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights or future revenue streams on terms that may not be favorable to us. If we raise additional capital through private or public equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.
As of the date of this filing, the Company was in compliance with all covenants and restrictions associated with our debt agreements. The Company is not aware of any instances of breaches or non-compliance with its covenants and commitments under its debt agreements.
43
Master Lending and Credit Facility
On June 25, 2021, the Company entered into a master line of credit loan agreement (“MLOCA”) with Wealth South a division of Farmers National Bank of Danville, Kentucky (“FNBD”). The MLOCA provides for a $2,000,000 revolving secured credit facility (“Revolving Line”) to be drawn for the initial purchase of veterinary clinical practices (“Practices”) and a $8,000,000 closed end line of credit (“Closed End Line”) to be disbursed as individual loans (Term Loans) to paydown draws on the Revolving Line and to provide longer term financing of the purchase of Practices. Each draw on the Revolving Line shall be repaid with a Term Loan out of the Closed End Line within one hundred and twenty (120) days of the draw on the Revolving Line. Each draw on the Revolving Line and the Closed End Line shall not exceed eighty-five (85%) percent of the purchase price of the Practice. The Company shall contribute and maintain equity of a minimum of fifteen (15%) percent of the initial purchase price of a Practice as long as any draw on the Revolving Line or a Term Loan remains unpaid with FNBD. The Revolving Line has an interest rate equal to the New York Prime Rate plus 0.50% that shall never be less than 3.57%. Each Term Loan issued under the Closed End Line shall have a fixed interest rate of 3.98% for the first five years of the loan. Immediately following the fixed rate period, the rate of interest rate will equal to the New York Prime Rate plus 0.65% that shall never be less than 3.57%. Each Practice to be acquired must have a minimum projected debt-service coverage ratio (“DSCR”) of 1.0x, defined as earnings before interest depreciation and amortization (“EBIDA”)/Annual Debt Service Requirement. The MLOCA terminates and the Revolving Line matures on June 25, 2023.
Under the MLOCA the Term Loans to acquire a Practice shall not exceed 10 years. The first twelve months of the Term Loan may be interest only. Thereafter, the Loan will convert to an amortizing loan with monthly principal and interest payments. For Practice only Term Loans (“Practice Term Loans”), after the initial twelve-month interest only period, the balance will amortize over 9 years. For Loans made to purchase real property (“RE Term Loans”), after the initial twelve-month interest only period, the balance will amortize over a 19-year period.
There is no prepayment penalty on payments on the Revolving Line. The Term Loans are subject to a refinance fee of 2% of the then outstanding principal balance of the Term Loan if paid within two years of entering into the Term Loan and 1% of the then outstanding principal balance of the Term Loan if paid within three to five years of entering into the Term Loan. The refinance fee is due only if the Term Loan is paid off by refinancing. Borrowing under the MLOCA are guaranteed by Kimball Carr, CEO & President of the Company.
On August 18, 2022 the MLOCA was amended and restated to terminate the revolving feature on the Revolving Line and convert the line of credit to a closed end draw note (“Closed End Draw Note”) that mature on August 18, 2024. Each draw on the Closed End Draw Note shall not exceed eighty-five (85%) percent of the purchase price of the Practice. The Company shall contribute and maintain equity of a minimum of fifteen (15%) percent of the initial purchase price of a Practice as long as any draw on the Closed End Draw Note or a Term Loan remains unpaid with FNBD. The interest rate charge on all sums advance under the amended and restated MLOCA shall be 5.25% for the first five years of the loan. Immediately following the fixed rate period, the rate of interest will be equal to the New York Prime Rate plus 0.65% that shall never be less than 4.75%. Each Practice to be acquired must have a minimum projected DSCR of 1.0x, defined as EBIDA/Annual Debt Service Requirement. The MLOCA terminates and the Closed End Draw Note matures on August 18, 2024.
44
Notes payable to FNBD as of March 31, 2024 and December 31, 2023 consisted of the following:
| Original Principal | Acquisition | Entered | Maturity | Interest | March 31, 2024 | December 31, 2023 | Issuance Cost | |||||||||||||||||
| $ | 237,272 | CAH | 12/27/21 | 12/27/41 | 3.98 | % | $ | 235,150 | $ | 237,272 | $ | 6,108 | ||||||||||||
| 231,987 | CAH | 12/27/21 | 12/27/31 | 3.98 | % | 226,582 | 231,987 | 6,108 | ||||||||||||||||
| 216,750 | P&F | 12/27/21 | 12/27/41 | 3.98 | % | 214,812 | 216,750 | 5,370 | ||||||||||||||||
| 318,750 | P&F | 12/27/21 | 12/27/31 | 3.98 | % | 311,323 | 318,750 | 5,370 | ||||||||||||||||
| 817,135 | Pasco | 1/14/22 | 1/14/32 | 3.98 | % | 804,374 | 817,135 | 3,085 | ||||||||||||||||
| 478,098 | Lytle | 3/15/22 | 3/15/32 | 3.98 | % | 478,098 | 478,098 | 1,898 | ||||||||||||||||
| 663,000 | Lytle | 3/15/22 | 3/15/42 | 3.98 | % | 663,000 | 663,000 | 11,875 | ||||||||||||||||
| 425,000 | Kern | 3/22/22 | 3/22/42 | 3.98 | % | 425,000 | 425,000 | 7,855 | ||||||||||||||||
| 1,275,000 | Kern | 3/22/22 | 3/22/32 | 3.98 | % | 1,275,000 | 1,275,000 | 4,688 | ||||||||||||||||
| 246,500 | Bartow | 5/18/22 | 5/18/42 | 3.98 | % | 246,500 | 246,500 | 5,072 | ||||||||||||||||
| 722,500 | Bartow | 5/18/22 | 5/18/32 | 3.98 | % | 722,500 | 722,500 | 2,754 | ||||||||||||||||
| 382,500 | Dietz | 6/15/22 | 6/15/32 | 3.98 | % | 382,500 | 382,500 | 1,564 | ||||||||||||||||
| 445,981 | Aberdeen | 7/19/22 | 7/29/32 | 3.98 | % | 445,981 | 445,981 | 1,786 | ||||||||||||||||
| 1,020,000 | All Breed | 8/12/22 | 8/12/42 | 3.98 | % | 1,020,000 | 1,020,000 | 8,702 | ||||||||||||||||
| 519,527 | All Breed | 8/12/22 | 8/12/32 | 3.98 | % | 519,527 | 519,527 | 3,159 | ||||||||||||||||
| 225,923 | All Breed | 8/12/22 | 8/12/32 | 5.25 | % | 225,923 | 225,923 | 3,159 | ||||||||||||||||
| 637,500 | Williamsburg | 12/8/22 | 12/8/32 | 5.25 | % | 637,500 | 637,500 | 2,556 | ||||||||||||||||
| 850,000 | Valley Vet | 11/8/23 | 11/8/33 | 5.25 | % | 850,000 | 850,000 | 3,315 | ||||||||||||||||
| $ | 9,713,423 | $ | 9,141,096 | $ | 9,309,286 | $ | 84,424 | |||||||||||||||||
The Company amortized $1,543 and $2,082 of issuance cost in the aggregate during the three months ending March 31, 2024 and 2023, respectively, for the FNBD notes payable.
FSB Commercial Loans
On January 11, 2021, the Company entered into three separate commercial loans with First Southern National Bank (“FSB”) as part of the Kauai Veterinary Clinic, LLC acquisition. The first commercial loan in the amount of $1,105,000 has a fixed interest rate of 4.35% and a maturity date of January 15, 2024. The commercial loan was modified in January 2021 to extend the maturity date to February 25, 2041. The fixed rate loan has monthly payments of $6,903 and the interest rate remained at 4.35%. The commercial loan had issuance costs of $13,264 for the year ended December 31, 2021 that was capitalized and is being amortized straight line over the life of the loan. The Company amortized $165 and $163 of issuance cost during the three months ended March 31, 2024 and 2023, respectively.
The second commercial loan with FSB entered into on January 11, 2021 in the amount of $1,278,400 has a fixed interest rate of 4.35% and a maturity date of September 1, 2024. The commercial loan was modified in January 2021 to extend the maturity date to January 25, 2031. The fixed rate loan has monthly payments of $13,157 and the interest rate remained at 4.35%. The commercial loan had issuance costs of $10,085 for the year ended December 31, 2021 that was capitalized and is being amortized straight line over the life of the loan. The Company amortized $253 and $251 of issuance cost during the three months ended March 31, 2024 and 2023, respectively.
The third commercial loan with FSB entered into on January 11, 2021 in the amount of $450,000 has a fixed interest rate of 5.05% and a maturity date of September 11, 2021. The commercial loan was modified on August 25, 2021 to extend the maturity date to February 25, 2023 and increase the principal amount to $469,914. The fixed rate loan has monthly payments of $27,164 and the interest rate remained at 5.05%. The commercial loan had issuance costs of $753 for the year ended December 31, 2021 that was capitalized and is being amortized straight line over the life of the loan. The Company amortized $0 and $58 of issuance cost during the three months ended March 31, 2024 and 2023, respectively.
On October 31, 2022 the company entered into three separate commercial loans with FSB as part of the Pony Express Practice acquisition. The first loan with FSB that was entered into on October 31, 2022, was in the amount of $2,086,921. The loan has a fixed interest rate of 5.97% and a maturity date of October 31, 2025. The fixed rate loan has monthly payments of $23,138 except for a final monthly payment of $1,608,530. The commercial loan had issuance costs of $25,575 for the year ended December 31, 2022, that was capitalized and is being amortized straight line over the life of the loan. The Company amortized $2,123 and $2,100 of issuance cost during the three months ended March 31, 2024 and 2023, respectively.
45
The second loan with FSB that was entered into on October 31, 2022, was in the amount of $400,000. The loan has a fixed interest rate of 5.97% and a maturity date of October 31, 2042. The fixed rate loan has monthly payments of $2,859. The commercial loan had issuance costs of $3,277 for the year ended December 31, 2022, that was capitalized and is being amortized straight line over the life of the loan. The Company amortized $41 and $40 of issuance cost during the three months ended March 31, 2024 and 2023, respectively.
The third loan with FSB that was entered into on October 31, 2022, was in the amount of $700,000. The loan has a fixed interest rate of 6.75% and a maturity date of April 1, 2023. The fixed rate loan has monthly payments of $6,903 except for a final monthly payment of $423,278. The commercial loan did not have any issuance costs that were capitalized.
On December 16, 2022, the company entered into two separate commercial loans with FSB as part of the Old 41 Practice acquisition. The first loan with FSB that was entered into on December 16, 2022, was in the amount of $568,000. The loan has a fixed interest rate of 6.50% and a maturity date of December 16, 2025. The fixed rate loan has monthly payments of $4,772, except for a final payment of 593,039. The loan had issuance costs of $4,531 for the year ended December 31, 2022, that was capitalized and is being amortized straight line over the life of the loan. The Company amortized $376 and $372 of issuance cost during the three months ended March 31, 2024 and 2023, respectively.
The second loan with FSB that was entered into December 16, 2022, was in the amount of $640,000. The loan has a fixed interest rate of 6.50% and a maturity date of December 16, 2025. The fixed rate loan has twelve monthly payments of approximately $2,830, followed by monthly payments of $7,443. and the interest rate is 6.50%. The loan had issuance costs of $5,077 for the year ended December 31, 2022, that was capitalized and is being amortized straight line over the life of the loan. The Company amortized $422 and $417 of issuance cost during the three months ended March 31, 2024 and 2023, respectively.
The FSB commercial loans are guaranteed by Kimball Carr, Chief Executive Officer and President and Charles Stith Keiser, our Vice Chairman and Chief Operating Officer.
Notes payable to FSB as of March 31, 2024 and December 31, 2023 consisted of the following:
| Original Principal | Acquisition | Entered | Maturity | Interest | March 31, 2024 | December 31, 2023 | Issuance Cost | |||||||||||||||||
| $ | 1,105,000 | KVC | 1/25/21 | 2/25/41 | 4.35 | % | $ | 987,082 | $ | 997,010 | $ | 13,264 | ||||||||||||
| 1,278,400 | KVC | 1/25/21 | 1/25/31 | 4.35 | % | 931,696 | 960,849 | 10,085 | ||||||||||||||||
| 469,914 | KVC | 1/25/21 | 2/25/23 | 5.05 | % | - | - | 753 | ||||||||||||||||
| 2,086,921 | Pony Express | 10/31/22 | 10/31/25 | 5.97 | % | 1,861,227 | 1,902,452 | 25,575 | ||||||||||||||||
| 400,000 | Pony Express | 10/31/22 | 10/31/42 | 5.97 | % | 384,624 | 387,433 | 3,277 | ||||||||||||||||
| 568,000 | Old 41 | 12/16/22 | 12/16/25 | 6.5 | % | 508,385 | 520,697 | 4,531 | ||||||||||||||||
| 640,000 | Old 41 | 12/16/22 | 12/16/25 | 6.5 | % | 619,660 | 623,861 | 5,077 | ||||||||||||||||
| 375,000 | Valley Vet | 11/8/2023 | 11/8/2024 | 8.5 | % | 375,000 | 375,000 | 6,877 | ||||||||||||||||
| $ | 7,623,235 | $ | 5,667,674 | $ | 5,767,302 | $ | 69,439 | |||||||||||||||||
Notes payable as of March 31, 2024 and December 31, 2023 consisted of the following:
| March 31, | December 31, | |||||||
| 2024 | 2023 | |||||||
| FNBD Notes Payable | $ | 9,141,096 | $ | 9,309,286 | ||||
| FSNB Notes Payable | 5,667,674 | 5,767,302 | ||||||
| Total notes payable | 14,808,770 | 15,076,588 | ||||||
| Unamortized debt issuance costs | (116,540 | ) | (124,170 | ) | ||||
| Notes payable, net of issuance cost | 14,692,230 | 14,952,418 | ||||||
| Less current portion | (1,203,402 | ) | (1,469,043 | ) | ||||
| Long-term portion | $ | 13,488,828 | $ | 13,483,375 | ||||
46
Notes payable repayment requirements as of March 31, 2024, in the succeeding years are summarized as follows:
| Remainder of 2024 | $ | 1,203,402 | ||
| 2025 | 3,776,189 | |||
| 2026 | 1,008,110 | |||
| 2027 | 1,052,832 | |||
| 2028 | 1,098,387 | |||
| Thereafter | $ | 6,669,850 |
Loan Payable
On May 30, 2023, the Company entered into a Merchant Cash Advance Agreement for gross proceeds of $1,050,000 with an unrelated third-party financial institution. Under the terms of the agreement, the Company must pay $57,346 each week for 26 weeks with the first payment being due June 6, 2023. The financing arrangement has an effective interest rate of 49%. The financing arrangement includes an original issuance discount (“OID”) of $441,000 and issuance costs of $50,000. The OID and issuance cost associated with the financing arrangement are presented in the balance sheets as a direct deduction from the carrying amount of the financing arrangement and is amortized using the effective interest method.
On August 10, 2023, the Company amended the financing arrangement to borrow an additional $507,460 resulting in the weekly repayments increasing to $76,071 to be paid over 28 weeks. This amendment decreased the effective interest rate to 41%. The refinancing resulted in a loss on debt modification of $441,618
On November 28, 2023, the Company amended the financing arrangement to borrow an additional $531,071 resulting in the weekly payments to decrease to $56,800 to be paid over 40 weeks. This amendment increased the effective rate to 49%. The refinancing resulted in a loss on debt modification of $485,436.
On January 18, 2024, the Company amended the financing arrangement to borrow an additional $549,185 resulting in the weekly payments to increase to $86,214 to be paid over 43 weeks. This amendment increased the effective interest rate to 52%. The refinancing resulted in a loss on debt modification of $728,278.
During the three months ended March 31, 2024, the Company amortized $379,313 of OID and issuance cost included in interest expense on the statement of operations. During the three months ended March 31, 2024, the Company made $1,032,540 in payments on the loan payable. The outstanding balance of the loan payable as of December 31, 2023, is $2,809,820. The financing arrangement is secured by an interest in virtually all assets of the Company with a first security interest in accounts receivable. The financing arrangement is guaranteed by the Company’s CEO.
Convertible Note Payable
On March 26, Inspire Veterinary entered into a securities purchase agreement (the “Purchase Agreement”) with certain investor. Pursuant to the Purchase Agreement, Inspire Veterinary issued to investors Increasing OID Senior Note (“Convertible Note Payable”) for $250,000. The Convertible Note Payable has a maturity date of the earlier of December 26, 2024 or the consummation of a capital raise (the “Maturity Date”).
The Convertible Note Payable contain an original issued discount (“OID”) which shall be: (i) fifteen percent (15%) if the Convertible Note Payable is satisfied and paid in full on or before the forty-fifth (45th) day after the Original Issue Date (as such term is defined in the Notes), (ii) twenty percent (20%) if the Convertible Note Payable is satisfied and paid in full after such 45th day but on or before the ninetieth (90th) day after the Original Issue Date, and (iii) thirty percent (30%) after such 90th day. The Convertible Note Payable can be prepaid at any time prior to the Maturity Date without any penalties.
The Convertible Note Payable must be repaid in full from any future capital raises (debt, equity or any other form of capital raise) of Inspire Veterinary. All of the funds raised must be used to repay the Convertible Note Payable until the Convertible Note Payable are repaid in full
47
The Convertible Note Payable are convertible into shares of common stock of Inspire Veterinary, in full or in part, at any time after issuance at the discretion of the noteholder at a fixed conversion price of $0.03 per share (the “Fixed Conversion Price”).
If the Convertible Note Payable is not repaid by the Maturity Date the default provisions are as follow: (i) The Face Value (as such term is defined in the Convertible Note Payable) of the Convertible Note Payable will increase by 20% (to a 50% OID -- $1,000,000 Face Value); (ii) the conversion price of the Convertible Note Payable will become convertible at the lower of (a) the Fixed Conversion Price or (b) 20% discount to a 3-Day volume-weighted average price (the “Default Conversion Price”).
Cash Flows for The Three Months Ended March 31, 2024 and 2023
The following table provides detailed information about our net cash flows for the periods indicated:
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Net cash used in operating activities | $ | (3,169,029 | ) | $ | (309,455 | ) | ||
| Net cash used in investing activities | (156,945 | ) | (14,002 | ) | ||||
| Net cash provided by financing activities | 3,216,090 | 473,069 | ||||||
| Net increase (decrease) in cash and cash equivalents | $ | (109,884 | ) | $ | 149,612 | |||
Operating Activities
For the three months ended March 31, 2024, operating activities used $3,169,029 of cash compared to $309,455 net cash provided for the three months ended March 31, 2023. The cash used was primarily due to the Company’s net loss of $3,421,792 offset by non-cash expense of $2,431,325, which consisted of $347,382 of depreciation and amortization, $15,825 of amortization of issuance costs, $379,313 of amortization of debt discount, $53,831 of amortization of operating rights of use assets, $286,696 for issuance of class A common stock for services, $728,278 for loss on debt modification, $20,000 for issuance of class A common stock for general release agreement, $600,000 for issuance of Class A common stock and pre-funded warrants in connection with commitment shares and positive working capital of $1,965,647, including increase in accounts receivables of $312,915, $48,874 increase in refundable income tax, $12,220 increase in other assets, $403,107 increase in accrued expenses, $92,322 increase in cumulative series A preferred stock dividends payable, $1,642,552 increase in prepaid expenses and other current assets, and $40,108 increase in operating lease liabilities. These increases were offset by decreases of $32,519 due from former owners, $25,852 decrease in inventory, and $315,165 decrease in accounts payable.
For the three months ended March 31, 2023, the cash used was primarily due to the Company’s net loss of $1,538,949 offset by non-cash expense of $673,072, which consisted of $298,492 of depreciation and amortization, $70,212 of amortization of issuance costs, $ 242,631 of amortization of debt discount, $ 59,036 of amortization of operating rights of use assets, $2,701 for issuance of warrants to the CEO, and negative working capital of $556,422, including decrease of $37,425 in due from former owners, $60,414 decrease in prepaid expenses and other current assets, $550,043 decrease in accounts payable, and $118,450 decrease in accrued expenses, offset by an increase of $70,553 increase in accounts receivable, $18,459 increase in inventory, $70,431 increase in other assets, and $50,467 increase in operating lease liabilities.
Investing Activities
For the three months ended March 31, 2024, and 2023, the cash used was attributable to the purchase of property and equipment of $156,945 and $14,002, respectively.
Financing Activities
For the three months ended March 31, 2024, the cash provided was due to the $3,375,458 proceeds from issuance of class A common stock and pre-funded warrants, net of issuance costs, $549,185 net proceeds from loan payable, $200,000 proceeds for issuance of convertible series A preferred stock, $500,000 proceeds from convertible note payable offset by $1,032,540 payments on loan payable, $276,013 repayment on note payable and $100,000 repayment on convertible debentures.
For the three months ended March 31, 2023, the cash provided was due to the $650,000 of proceeds from issuance of convertible debentures offset by $176,931 repayment of note payable.
48
The Company’s consolidated results of operations for the years ended December 31, 2023 compared to December 31, 2022 were significantly impacted by acquisitions.
Results of Operations for the years ended December 31, 2023 and 2022:
| Year Ended December 31, | ||||||||||||||||
| 2023 | 2022 | $ Change | % Change | |||||||||||||
| Service revenue | $ | 11,879,934 | $ | 7,032,800 | 4,847,134 | 69 | % | |||||||||
| Product revenue | 4,795,459 | 2,801,978 | 1,993,481 | 71 | % | |||||||||||
| Total revenue | 16,675,393 | 9,834,778 | 6,840,615 | 70 | % | |||||||||||
| Operating expenses | ||||||||||||||||
| Cost of service revenue (exclusive of depreciation and amortization, shown separately below) | 9,700,963 | 5,308,104 | 4,392,859 | 83 | % | |||||||||||
| Cost of product revenue (exclusive of depreciation and amortization, shown separately below) | 3,420,515 | 1,981,046 | 1,439,469 | 73 | % | |||||||||||
| General and administrative expenses | 9,476,287 | 5,467,642 | 4,008,645 | 73 | % | |||||||||||
| Debt extinguishment loss | 16,105 | - | 16,105 | 100 | % | |||||||||||
| Depreciation and amortization | 1,252,539 | 596,124 | 656,415 | 110 | % | |||||||||||
| Total operating expenses | 23,866,409 | 13,352,916 | 10,513,493 | 79 | % | |||||||||||
| Loss from operations | (7,191,016 | ) | (3,518,138 | ) | (3,672,878 | ) | 104 | % | ||||||||
| Other income (expenses): | ||||||||||||||||
| Interest income | 21 | 1,021 | (1,000 | ) | -98 | % | ||||||||||
| Interest expense | (2,538,710 | ) | (1,425,260 | ) | (1,113,450 | ) | 78 | % | ||||||||
| Loss on debt modification | (927,054 | ) | - | (927,054 | ) | 100 | % | |||||||||
| Beneficial conversion feature | (4,137,261 | ) | - | (4,137,261 | ) | 100 | % | |||||||||
| Other income | 1,134 | 357 | 777 | 218 | % | |||||||||||
| Total other expenses | (7,601,870 | ) | (1,423,882 | ) | (6,177,988 | ) | 434 | % | ||||||||
| Loss before income taxes | (14,792,886 | ) | (4,942,020 | ) | (9,850,866 | ) | 199 | % | ||||||||
| Benefit for income taxes | - | 30,094 | (30,094 | ) | -100 | % | ||||||||||
| Net loss | (14,792,886 | ) | (4,911,926 | ) | (9,880,960 | ) | 201 | % | ||||||||
| Dividend on convertible series A preferred stock | (271,245 | ) | - | (271,245 | ) | 100 | % | |||||||||
| Net loss attributable to class A and B common stockholders | $ | (15,064,131 | ) | $ | (4,911,926 | ) | ######### | 207 | % | |||||||
| Net loss per Class A and B common shares: | ||||||||||||||||
| Basic and diluted | $ | (3.48 | ) | $ | (1.14 | ) | ||||||||||
| Weighted average shares outstanding per Class A and B common shares: | ||||||||||||||||
| Basic and diluted | 4,323,925 | 4,308,602 | ||||||||||||||
Revenue
The following table presents the breakdown of revenue between products and services:
| For the Year Ended December 31, | December 31, 2023 vs. 2022 | |||||||||||||||
| 2023 | 2022 | Variance in Dollars | Variance in Percent | |||||||||||||
| Revenue: | ||||||||||||||||
| Service Revenue | $ | 11,879,934 | $ | 7,032,800 | $ | 4,847,134 | 69 | % | ||||||||
| Percentage of revenue | 71 | % | 72 | % | ||||||||||||
| Product Revenue | 4,795,459 | 2,801,978 | 1,993,481 | 71 | % | |||||||||||
| Percentage of revenue | 29 | % | 28 | % | ||||||||||||
| Total | $ | 16,675,393 | $ | 9,834,778 | $ | 6,840,615 | 70 | % | ||||||||
49
| Average Daily Service Revenue for the Year Ended | December 31, 2023 vs. 2022 | |||||||||||||||
| Animal Hospital & Clinics | December 31, 2023 | December 31, 2022 | $ Change | % Change | ||||||||||||
| Kauai Veterinary Clinic | $ | 4,134 | $ | 3,625 | $ | 509 | 14 | % | ||||||||
| Chiefland Animal Hospital | 1,631 | 1,440 | 191 | 13 | % | |||||||||||
| Pets & Friends Animal Hospital | 2,676 | 2,598 | 78 | 3 | % | |||||||||||
| Advanced Veterinary Care of Pasco | 1,888 | 2,009 | (121 | ) | -6 | % | ||||||||||
| Lytle Veterinary Clinic | 1,759 | 2,898 | (1,139 | ) | -39 | % | ||||||||||
| Southern Kern Veterinary Clinic | 2,809 | 2,929 | (120 | ) | -4 | % | ||||||||||
| Bartow Animal Clinic | 2,350 | 2,475 | (125 | ) | -5 | % | ||||||||||
| Dietz Family Pet Hospital | 1,804 | 1,790 | 14 | 1 | % | |||||||||||
| Aberdeen Veterinary Clinic | 1,718 | 1,003 | 714 | 71 | % | |||||||||||
| All Breed Pet Care Veterinary Clinic | 2,838 | 2,551 | 287 | 11 | % | |||||||||||
| Pony Express Veterinary Hospital | 4,070 | 2,740 | 1,331 | 49 | % | |||||||||||
| Williamsburg Animal Clinic | 2,252 | 1,753 | 498 | 28 | % | |||||||||||
| Old 41 Animal Hospital | 2,227 | 2,179 | 48 | 2 | % | |||||||||||
| Valley Veterinary Services Animal Hospital | 2,699 | - | 2,699 | 100 | % | |||||||||||
| Total Daily Service Revenue | $ | 34,855 | $ | 29,991 | $ | 4,864 | ||||||||||
| Average Daily Product Revenue for the Year Ended | December 31, 2023 vs. 2022 | |||||||||||||||
| Animal Hospital & Clinics | December 31, 2023 | December 31, 2022 | $ Change | % Change | ||||||||||||
| Kauai Veterinary Clinic | $ | 1,810 | $ | 1,827 | $ | (17 | ) | -1 | % | |||||||
| Chiefland Animal Hospital | 1,033 | 1,215 | (183 | ) | -15 | % | ||||||||||
| Pets & Friends Animal Hospital | 911 | 906 | 5 | 1 | % | |||||||||||
| Advanced Veterinary Care of Pasco | 816 | 921 | (105 | ) | -11 | % | ||||||||||
| Lytle Veterinary Clinic | 914 | 392 | 523 | 133 | % | |||||||||||
| Southern Kern Veterinary Clinic | 530 | 812 | (282 | ) | -35 | % | ||||||||||
| Bartow Animal Clinic | 1,027 | 212 | 815 | 385 | % | |||||||||||
| Dietz Family Pet Hospital | 853 | 889 | (35 | ) | -4 | % | ||||||||||
| Aberdeen Veterinary Clinic | 573 | 1,064 | (491 | ) | -46 | % | ||||||||||
| All Breed Pet Care Veterinary Clinic | 1,287 | 1,025 | 262 | 26 | % | |||||||||||
| Pony Express Veterinary Hospital | 1,815 | 1,402 | 413 | 29 | % | |||||||||||
| Williamsburg Animal Clinic | 744 | 513 | 231 | 45 | % | |||||||||||
| Old 41 Animal Hospital | 648 | 1,141 | (493 | ) | -43 | % | ||||||||||
| Valley Veterinary Services Animal Hospital | 1,219 | - | 1,219 | 100 | % | |||||||||||
| Total Daily Product Revenue | $ | 14,180 | $ | 12,318 | $ | 1,862 | ||||||||||
50
Revenue in General: The Company believes the breakdown of gross revenue into service revenue and product revenue categories produces meaningful measures to Company management and the Company’s investors in light of the Company’s objective to protect the service channel and derive the majority of its revenue from services and expertise which are not capable of disruption from other channels. To achieve this objective, the Company seeks to match the industry target metric of 70% to 80% of gross revenue being derived from services: examination fees, diagnostics fees, laboratory work, surgery and other veterinary services. The Company believes these service revenue sources require veterinary professionals to preside over care delivery and, unlike some veterinary care products, cannot be replaced or sold by other non-veterinary hospital channels such as retail (including over-the-counter and online). Accordingly, the Company views products such as parasite controls, veterinary nutrition products and additives as important, but the Company does not rely on product revenue to account for more than 20% to 30% of gross revenue. Medications and therapeutics which only a licensed veterinary doctor or licensed technician can administer, while still making up part of the 20% to 30% of gross revenue, are less easily diverted to non-veterinary hospital channels as they require licensed professionals to prescribe or utilize them.
The Company uses these percentages in concert with metrics such as Revenue Per Patient Per day (“RPP”) and Average Patient Charge (“APC”) to analyze the comprehensive nature of diagnostics and services provided by each veterinary hospital. Sometimes referred to “quality medicine” metrics within the veterinary service industry, the Company uses RPP and APC to determine how a doctor’s time is being utilized (inclusive of all diagnostics and therapies). RPP and APC metrics are consolidated into the presentation of average daily service revenue and average daily product revenue. The Company believes these analyses helps the Company ensure that its caseload is revenue positive to avoid clinicians spending time on patient work which underutilizes their time and erodes labor profitability. The Company also believes these metrics are useful to investors and potential investors to compare the Company’s service-to-product revenue mix against generally accepted industry targets and specific veterinary care service provider competitors.
The services revenue and product revenue metrics are measured in dollars as calculated by the practice management software we provide to each of our clinics to track medical notes, treatment plans, services and products prescribed and provided, as well as to manage invoicing related to all of the above. Reports are generated which allow Company management to view each of these as line-items as well as measure the ratio of service revenue versus product revenue within our revenue mix.
The Company believes the ratio metric is useful for the management and its investors for several reasons:
| ● | The Company and its medical leadership teach and enable its medical staff to provide comprehensive medical care which is appropriate for each animal patient. For example, charges to a client which skew too heavily toward products and do not include necessary services may be an indicator that medical cases are not being fully diagnosed using an appropriate standard of available and appropriate diagnostics and care. This broad analysis can indicate more questions should be asked about how cases are managed by certain providers, particularly if patterns emerge; |
| ● | Comprehensive care for pets means physical exams, dental care, blood work and many other service related line-items. An overreliance on product revenue alone (which products may be available over-the-counter outside of the veterinary channel) leaves veterinary clinics susceptible to sales transfer to other channels. In addition, appropriate veterinary care (as defined by market practice and some state licensing boards) does not include prescribing products without the delivery of diagnostic and care services. |
| ● | Advancements in veterinary care within the last decade such as anesthetic protocols, pain management, fear free medicine and other services have shown great efficacy for the betterment of patients and their recovery from illness or surgeries. The absence of certain services and procedures within, for instance, a surgery package for a patient, would indicate an opportunity to improve outcomes for a patient and extend life expectancy. These are positive outcomes for clients and, therefore, of interest and value to the Company and our investors. |
Service Revenues: The Company recognizes service revenue from health exams, pet grooming, veterinary care, and certain other services performed at our animal hospitals or clinics and is recognized once the service is completed, as this is when the customer has the ability to direct the use of and obtain the benefits of the services. Payment terms are at the point of sale but may also occur upon completion of the service. The increase in service revenue was driven primarily by acquisitions of animal hospitals and clinics accumulated from the prior year and increasing the prices of our services throughout our clinics and animal hospitals that resulted in organic growth. 9 of 14 animal hospitals and clinics experienced increased daily service revenue compared to the year prior. In addition to the Valley Veterinary services acquisition in November 2023.
51
Product Revenues: Product revenue is recognized when control passes, which occurs at a point in time when the customer completes a transaction at our animal hospitals or clinics and receives the product. The increase in product revenue was driven primarily by acquisitions of animal hospitals and clinics accumulated from the prior year and increasing the prices of several products to pass along the higher cost of those products to the customer. We had organic growth with our daily product revenue increasing by $643 during the year ended December 31, 2023 compared to the prior year. In addition to the Valley Veterinary services acquisition in November 2023.
Cost of revenue
| For the Year Ended | December 31, 2023 vs. 2022 | |||||||||||||||
| December 31, 2023 | December 31, 2022 | Variance in Dollars | Variance in Percent | |||||||||||||
| Cost of services revenue | $ | 9,700,963 | $ | 5,308,104 | $ | 4,392,859 | 83 | % | ||||||||
| Cost of product revenue | 3,420,515 | 1,981,046 | 1,439,469 | 73 | % | |||||||||||
| Total cost of revenues (exclusive of depreciation and amortization, shown separately below) | $ | 13,121,478 | $ | 7,289,150 | $ | 5,832,328 | 80 | % | ||||||||
Cost of service revenue (exclusive of depreciation and amortization): Cost of service revenue consists of cost directly related to the animal services provided at the Company’s veterinary clinics and animal hospitals, which primarily includes personnel-related compensation costs of the employees at the Company’s veterinary clinics or animal hospitals, laboratory costs, pet supply costs, third-party veterinarian contractors, office rent, utilities, supplies, and other cost arising as a result of the services being performed, excluding depreciation and amortization. The increase in cost of service revenue sold excluding depreciation and amortization was driven primarily by acquisitions of animal hospitals and clinics completed in the prior year in addition to inflationary pressures such as increased wages and veterinary supplies used in services.
Cost of product revenue (exclusive of depreciation and amortization): Cost of product revenue consists of cost directly related to the product sales at the Company’s veterinary clinics and animal hospitals, which primarily includes personnel-related compensation costs of the employees at the Company’s veterinary clinics or animal hospitals, purchase price of the medication we dispense, and purchase price of product sold, excluding depreciation and amortization. The increase in cost of product revenue excluding depreciation and amortization was driven primarily by acquisitions of animal hospitals and clinics completed in the prior year in addition to inflationary pressures that increased the cost of products and increased wages.
General and Administrative Expense: General and administrative expenses include personnel-related compensation costs for corporate employees, such as management, accounting, legal, acquisition related and non-recurring expenses, insurance and other expenses used to operate the business. The increase was primarily due to the Company’s initial public offering that closed in August 2023 and the additional cost of becoming a public company in addition to higher wages and 3rd party cost due to inflationary pressures.
Depreciation and Amortization Expense: Depreciation and amortization expenses mainly relate to the assets used in generating revenue. The increase was primarily due to the acquisition of depreciable or amortizable assets as part of the acquisitions of animal hospitals and clinics.
Other Expenses: Other expenses are composed primarily of interest expenses and small denomination bank fee charges. The increase was primarily the result of the Company incurring indebtedness in the form of bank loans and other indebtedness to finance the acquisition of animal hospitals and clinics, the beneficial conversion feature on the convertible debenture and series A preferred stock recognized upon the completion of the IPO and for general working capital.
Net Loss: The net loss is primarily attributable to the operating expenses associated with the Company’s animal hospitals and clinics, the beneficial conversion feature on the convertible debenture and series A preferred stock recognized upon the completion of the IPO and to the acquisition cost related to the Valley Veterinary Services, Inc. acquisition. The Company also incurred additional costs associated with the initial public offering that closed on August 31, 2023 and of becoming a public company.
52
Liquidity and Capital Resources
Since inception, we have financed our operations from a combination of:
| ● | issuance and sale of senior convertible notes; |
| ● | issuance of convertible debentures; |
| ● | borrowings under other debt consisting of: (i) a principal lending relationship with Farmers National Bank of Danville; (ii)a principal lending relationship with First Southern National Bank; (iii) short term financing arrangements under merchant cash advance agreement; |
| ● | common stock purchase agreement with Tumim Stone Capital LLC, |
| ● | proceeds from issuance of equity; and |
| ● | cash generated from operations. |
The Company has experienced operating losses since its inception and had a total accumulated deficit of $21,215,257 as of December 31, 2023. The Company expects to incur additional costs and require additional capital as the Company continues to acquire additional veterinary hospitals, clinics and practices. For the year ended December 31, 2023, the Company’s cash used in operations was $3,820,771.
The Company’s primary short-term cash requirements are to fund working capital, lease obligations and short-term debt, including current maturities of long-term debt. Working capital requirements can vary significantly from period to period, particularly as a result of additional business acquisitions. The Company’s medium-term to long-term cash requirements are to service and repay debt, to expand through acquisitions, and to invest in facilities and equipment for growth initiatives.
The Company’s ability to fund its cash needs will depend, in part, on its ability to generate cash in the future, which depends on future financial results. The Company’s future results are subject to general economic, financial, competitive, legislative and regulatory factors that may be outside of our control. The Company’s future access to, and the availability of credit on acceptable terms and conditions, is impacted by many factors, including capital market liquidity and overall economic conditions.
These financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred recurring losses and as of December 31, 2023, had an accumulated deficit of $21,215,257. For the year ended December 31, 2023, the Company sustained a net loss of $15,064,131. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern for the next twelve months from the date these financial statements were issued. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that may be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is contingent upon its ability to obtain additional financing and to generate revenue and cash flow to meet its obligations on a timely basis. The Company will continue to seek to raise additional funding through debt or equity financing during the next twelve months. Management believes that actions presently being taken to obtain additional funding provide the opportunity for the Company to continue as a going concern. There is no guarantee the Company will be successful in achieving these objectives.
We cannot be sure that future funding will be available to us on acceptable terms, or at all. Due to often volatile nature of the financial markets, equity and debt financing may be difficult to obtain.
We may seek to raise any necessary additional capital through a combination of private or public equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights or future revenue streams on terms that may not be favorable to us. If we raise additional capital through private or public equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.
As of the date of this filing, the Company was in compliance with all covenants and restrictions associated with our debt agreements. The Company is not aware of any instances of breaches or non-compliance with its covenants and commitments under its debt agreements.
53
Master Lending and Credit Facility
On June 25, 2021, the Company entered into a master line of credit loan agreement (“MLOCA”) with Wealth South a division of Farmers National Bank of Danville, Kentucky (“FNBD”). The MLOCA provides for a $2,000,000 revolving secured credit facility (“Revolving Line”) to be drawn for the initial purchase of veterinary clinical practices (“Practices”) and a $8,000,000 closed end line of credit (“Closed End Line”) to be disbursed as individual loans (Term Loans) to paydown draws on the Revolving Line and to provide longer term financing of the purchase of Practices. Each draw on the Revolving Line shall be repaid with a Term Loan out of the Closed End Line within one hundred and twenty (120) days of the draw on the Revolving Line. Each draw on the Revolving Line and the Closed End Line shall not exceed eighty-five (85%) percent of the purchase price of the Practice. The Company shall contribute and maintain equity of a minimum of fifteen (15%) percent of the initial purchase price of a Practice as long as any draw on the Revolving Line or a Term Loan remains unpaid with FNBD. The Revolving Line has an interest rate equal to the New York Prime Rate plus 0.50% that shall never be less than 3.57%. Each Term Loan issued under the Closed End Line shall have a fixed interest rate of 3.98% for the first five years of the loan. Immediately following the fixed rate period, the rate of interest rate will equal to the New York Prime Rate plus 0.65% that shall never be less than 3.57%. Each Practice to be acquired must have a minimum projected debt-service coverage ratio (“DSCR”) of 1.0x, defined as earnings before interest depreciation and amortization (“EBIDA”)/Annual Debt Service Requirement.
Under the MLOCA the Term Loans to acquire a Practice shall not exceed 10 years. The first twelve months of the Term Loan may be interest only. Thereafter, the Loan will convert to an amortizing loan with monthly principal and interest payments. For Practice only Term Loans (“Practice Term Loans”), after the initial twelve-month interest only period, the balance will amortize over 9 years. For Loans made to purchase real property (“RE Term Loans”), after the initial twelve-month interest only period, the balance will amortize over a 19-year period.
There is no prepayment penalty on payments on the Revolving Line. The Term Loans are subject to a refinance fee of 2% of the then outstanding principal balance of the Term Loan if paid within two years of entering into the Term Loan and 1% of the then outstanding principal balance of the Term Loan if paid within three to five years of entering into the Term Loan. The refinance fee is due only if the Term Loan is paid off by refinancing. Borrowing under the MLOCA are guaranteed by Kimball Carr, CEO & President of the Company.
On August 18, 2022 the MLOCA was amended and restated to terminate the revolving feature on the Revolving Line and convert the line of credit to a closed end draw note (“Closed End Draw Note”) that mature on August 18, 2024. Each draw on the Closed End Draw Note shall not exceed eighty-five (85%) percent of the purchase price of the Practice. The Company shall contribute and maintain equity of a minimum of fifteen (15%) percent of the initial purchase price of a Practice as long as any draw on the Closed End Draw Note or a Term Loan remains unpaid with FNBD. The interest rate charge on all sums advance under the amended and restated MLOCA shall be 5.25% for the first five years of the loan. Immediately following the fixed rate period, the rate of interest will be equal to the New York Prime Rate plus 0.65% that shall never be less than 4.75%. Each Practice to be acquired must have a minimum projected DSCR of 1.0x, defined as EBIDA/Annual Debt Service Requirement. The MLOCA terminates and the Closed End Draw Note matures on August 18, 2024.
Notes payable to FNBD as of December 31, 2023 and 2022 consisted of the following:
| Original | December 31, | December 31, | Issuance | |||||||||||||||||||||||
| Principal | Acquisition | Entered | Maturity | Interest | 2023 | 2022 | Cost | |||||||||||||||||||
| $ | 237,272 | CAH | 12/27/2021 | 12/27/2041 | 3.98 | % | $ | 228,785 | $ | 237,272 | $ | 6,108 | ||||||||||||||
| 231,987 | CAH | 12/27/2021 | 12/27/2031 | 3.98 | % | 210,161 | 231,987 | 6,108 | ||||||||||||||||||
| 216,750 | P&F | 12/27/2021 | 12/27/2041 | 3.98 | % | 208,997 | 216,750 | 5,370 | ||||||||||||||||||
| 318,750 | P&F | 12/27/2021 | 12/27/2031 | 3.98 | % | 288,761 | 318,750 | 5,370 | ||||||||||||||||||
| 817,135 | Pasco | 1/14/2022 | 1/14/2032 | 3.98 | % | 746,733 | 817,135 | 3,085 | ||||||||||||||||||
| 478,098 | Lytle | 3/15/2022 | 3/15/2032 | 3.98 | % | 444,593 | 478,098 | 1,898 | ||||||||||||||||||
| 663,000 | Lytle | 3/15/2022 | 3/15/2042 | 3.98 | % | 645,392 | 663,000 | 11,875 | ||||||||||||||||||
| 425,000 | Kern | 3/22/2022 | 3/22/2042 | 3.98 | % | 413,713 | 425,000 | 7,855 | ||||||||||||||||||
| 1,275,000 | Kern | 3/22/2022 | 3/22/2032 | 3.98 | % | 1,185,648 | 1,275,000 | 4,688 | ||||||||||||||||||
| 246,500 | Bartow | 5/18/2022 | 5/18/2042 | 3.98 | % | 241,429 | 246,500 | 5,072 | ||||||||||||||||||
| 722,500 | Bartow | 5/18/2022 | 5/18/2032 | 3.98 | % | 683,262 | 722,500 | 2,754 | ||||||||||||||||||
| 382,500 | Dietz | 6/15/2022 | 6/15/2032 | 3.98 | % | 364,708 | 382,500 | 1,564 | ||||||||||||||||||
| 445,981 | Aberdeen | 7/19/2022 | 7/29/2032 | 3.98 | % | 428,747 | 445,981 | 1,786 | ||||||||||||||||||
| 1,020,000 | All Breed | 8/12/2022 | 8/12/2042 | 3.98 | % | 1,008,039 | 1,020,000 | 8,702 | ||||||||||||||||||
| 519,527 | All Breed | 8/12/2022 | 8/12/2032 | 3.98 | % | 503,471 | 519,527 | 3,159 | ||||||||||||||||||
| 225,923 | All Breed | 8/12/2022 | 8/12/2032 | 5.25 | % | 219,347 | 225,923 | 3,159 | ||||||||||||||||||
| 637,500 | Williamsburg | 12/8/2022 | 12/8/2032 | 5.25 | % | 637,500 | 637,500 | 2,556 | ||||||||||||||||||
| 850,000 | Valley Vet | 11/8/2023 | 11/8/2033 | 5.25 | % | 850,000 | - | 3,315 | ||||||||||||||||||
| $ | 9,713,423 | $ | 9,309,286 | $ | 8,863,423 | $ | 84,424 | |||||||||||||||||||
54
The Company amortized $7,152 and $6,813 of issuance cost in the aggregate during the year ending December 31, 2023 and 2022, respectively, for the FNBD notes payable.
FSB Commercial Loans
On January 11, 2021, the Company entered into three separate commercial loans with First Southern National Bank (“FSB”) as part of the Kauai Veterinary Clinic, LLC acquisition. The first commercial loan in the amount of $1,105,000 has a fixed interest rate of 4.35% and a maturity date of January 15, 2024. The commercial loan was modified in January 2021 to extend the maturity date to February 25, 2041. The fixed rate loan has monthly payments of $6,903 and the interest rate remained at 4.35%. The commercial loan had issuance costs of $13,264 for the year ended December 31, 2021 that was capitalized and is being amortized straight line over the life of the loan.
The second commercial loan with FSB entered into on January 11, 2021 in the amount of $1,278,400 has a fixed interest rate of 4.35% and a maturity date of September 1, 2024. The commercial loan was modified in January 2021 to extend the maturity date to January 25, 2031. The fixed rate loan has monthly payments of $13,157 and the interest rate remained at 4.35%. The commercial loan had issuance costs of $10,085 for the year ended December 31, 2021 that was capitalized and is being amortized straight line over the life of the loan.
The third commercial loan with FSB entered into on January 11, 2021 in the amount of $450,000 has a fixed interest rate of 5.05% and a maturity date of September 11, 2021. The commercial loan was modified on August 25, 2021 to extend the maturity date to February 25, 2023 and increase the principal amount to $469,914. The fixed rate loan has monthly payments of $27,164 and the interest rate remained at 5.05%. The commercial loan had issuance costs of $753 for the year ended December 31, 2021 that was capitalized and is being amortized straight line over the life of the loan.
On October 31, 2022 the company entered into three separate commercial loans with FSB as part of the Pony Express Practice acquisition. The first loan with FSB that was entered into on October 31, 2022, was in the amount of $2,086,921. The loan has a fixed interest rate of 5.97% and a maturity date of October 31, 2025. The fixed rate loan has monthly payments of $23,138 except for a final monthly payment of $1,608,530. The commercial loan had issuance costs of $25,575 for the year ended December 31, 2022, that was capitalized and is being amortized straight line over the life of the loan.
The second loan with FSB that was entered into on October 31, 2022, was in the amount of $400,000. The loan has a fixed interest rate of 5.97% and a maturity date of October 31, 2042. The fixed rate loan has monthly payments of $2,859. The commercial loan had issuance costs of $3,277 for the year ended December 31, 2022, that was capitalized and is being amortized straight line over the life of the loan.
The third loan with FSB that was entered into on October 31, 2022, was in the amount of $700,000. The loan has a fixed interest rate of 6.75% and a maturity date of April 1, 2023. The fixed rate loan has monthly payments of $6,903 except for a final monthly payment of $423,278. The commercial loan did not have any issuance costs that were capitalized.
On December 16, 2022, the company entered into two separate commercial loans with FSB as part of the Old 41 Practice acquisition. The first loan with FSB that was entered into on December 16, 2022, was in the amount of $568,000. The loan has a fixed interest rate of 6.50% and a maturity date of December 16, 2025. The fixed rate loan has monthly payments of $4,772, except for a final payment of 593,039. The loan had issuance costs of $4,531 for the year ended December 31, 2022, that was capitalized and is being amortized straight line over the life of the loan.
The second loan with FSB that was entered into December 16, 2022, was in the amount of $640,000. The loan has a fixed interest rate of 6.50% and a maturity date of December 16, 2025. The fixed rate loan has twelve monthly payments of approximately $2,830, followed by monthly payments of $7,443. and the interest rate is 6.50%. The loan had issuance costs of $5,077 for the year ended December 31, 2022, that was capitalized and is being amortized straight line over the life of the loan.
The FSB commercial loans are guaranteed by Kimball Carr, Chief Executive Officer and President and Charles Stith Keiser, our Vice Chairman and former Chief Operating Officer.
55
Notes payable to FSB as of December 31, 2023 and 2022 consisted of the following:
| Original | December 31, | December 31, | Issuance | |||||||||||||||||||||||
| Principal | Acquisition | Entered | Maturity | Interest | 2023 | 2022 | Cost | |||||||||||||||||||
| $ | 1,105,000 | KVC | 1/25/2021 | 2/25/2041 | 4.35 | % | $ | 997,010 | $ | 1,035,558 | $ | 13,264 | ||||||||||||||
| 1,278,400 | KVC | 1/25/2021 | 1/25/2031 | 4.35 | % | 960,849 | 1,074,251 | 10,085 | ||||||||||||||||||
| 469,914 | KVC | 1/25/2021 | 2/25/2023 | 5.05 | % | - | 53,964 | 753 | ||||||||||||||||||
| 2,086,921 | Pony Express | 10/31/2022 | 10/31/2025 | 5.97 | % | 1,902,452 | 2,061,346 | 25,575 | ||||||||||||||||||
| 400,000 | Pony Express | 10/31/2022 | 10/31/2042 | 5.97 | % | 387,433 | 398,258 | 3,277 | ||||||||||||||||||
| 700,000 | Pony Express | 10/31/2022 | 8/16/2023 | 7.17 | % | - | 700,000 | - | ||||||||||||||||||
| 568,000 | Old 41 | 12/16/2022 | 12/16/2025 | 6.50 | % | 520,697 | 568,000 | 4,531 | ||||||||||||||||||
| 640,000 | Old 41 | 12/16/2022 | 12/16/2025 | 6.50 | % | 623,861 | 640,000 | 5,077 | ||||||||||||||||||
| 375,000 | Valley Vet | 11/8/2023 | 11/8/2024 | 8.50 | % | 375,000 | - | 6,877 | ||||||||||||||||||
| $ | 7,623,235 | $ | 5,767,302 | $ | 6,531,377 | $ | 69,439 | |||||||||||||||||||
The Company amortized $14,611 and $3,635 of issuance cost in the aggregate during the year ended December 31, 2023 and 2022, respectively, for the FSB notes payable.
Notes payable as of December 31, 2023 and 2022 consisted of the following:
| December 31, | December 31, | |||||||
| 2023 | 2022 | |||||||
| FNBD Notes Payable | $ | 9,309,286 | $ | 8,863,423 | ||||
| FSB Notes Payable | 5,767,302 | 6,531,377 | ||||||
| Car loan | - | 6,653 | ||||||
| Total notes payable | 15,076,588 | 15,401,453 | ||||||
| Unamortized debt issuance costs | (124,170 | ) | (135,240 | ) | ||||
| Notes payable, net of issuance cost | 14,952,418 | 15,266,213 | ||||||
| Less current portion | (1,469,043 | ) | (1,549,861 | ) | ||||
| Long-term portion | $ | 13,483,375 | $ | 13,716,353 | ||||
Notes payable repayment requirements as of December 31, 2023, in the succeeding years are summarized as follows:
| 2024 | $ | 1,469,043 | ||
| 2025 | 3,776,189 | |||
| 2026 | 1,008,110 | |||
| 2027 | 1,052,832 | |||
| 2028 | 1,098,387 | |||
| Thereafter | $ | 6,672,027 |
Loan Payable
On May 30, 2023, the Company entered into a Merchant Cash Advance Agreement for gross proceeds of $1,050,000 with an unrelated third-party financial institution. Under the terms of the agreement, the Company must pay $57,346 each week for 26 weeks with the first payment being due June 6, 2023. The financing arrangement has an effective interest rate of 49%. The financing arrangement includes an original issuance discount (“OID”) of $441,000 and issuance costs of $50,000. The OID and issuance cost associated with the financing arrangement are presented in the balance sheets as a direct deduction from the carrying amount of the financing arrangement and is amortized using the effective interest method.
56
On August 10, 2023, the Company amended the financing arrangement to borrow an additional $507,460 resulting in the weekly repayments increasing to $76,071 to be paid over 28 weeks. This amendment decreased the effective interest rate to 41%. The refinancing resulted in a loss on debt modification of $441,618.
On November 28, 2023, the Company amended the financing arrangement to borrow an additional $531,071 resulting in the weekly payments to decrease to $56,800 to be paid over 40 weeks. This amendment increased the effective rate to 49%. The refinancing resulted in a loss on debt modification of $485,436.
During the year ended December 31, 2023, the Company amortized $671,719 of OID and issuance cost included in interest expense on the statement of operations. During the year ended December 31, 2023, the Company made $1,923,474 in payments on the loan payable. The outstanding balance of the loan payable as of December 31, 2023, is $2,063,058. The financing arrangement is secured by an interest in virtually all assets of the Company with a first security interest in accounts receivable. The financing arrangement is guaranteed by the Company’s CEO.
Operating leases
The future minimum lease payments required under leases as of December 31, 2023, were as follows:
| Fiscal Year | Operating Leases | |||
| 2024 | $ | 249,808 | ||
| 2025 | 230,198 | |||
| 2026 | 231,959 | |||
| 2027 | 233,619 | |||
| 2028 | 238,078 | |||
| Thereafter | 1,100,287 | |||
| Undiscounted cash flows | 2,283,949 | |||
| Less: imputed interest | (628,214 | ) | ||
| Lease liability | $ | 1,655,735 | ||
Cash Flows for The Year Ended December 31, 2023 and 2022
The following table provides detailed information about our net cash flows for the periods indicated:
| Year Ended December 31, | ||||||||
| 2023 | 2022 | |||||||
| Net cash used in operating activities | $ | (3,820,772 | ) | $ | (2,658,309 | ) | ||
| Net cash used in investing activities | (1,869,529 | ) | (14,666,796 | ) | ||||
| Net cash provided by financing activities | 5,625,008 | 15,710,940 | ||||||
| Net increase (decrease) in cash and cash equivalents | $ | (19,879 | ) | $ | (1,614,165 | ) | ||
Operating Activities
Our primary source of cash from operating activities is the revenue generated from our animal hospitals and clinics. Our primary uses of cash from operating activities are the funding of our payroll and veterinary animal hospital and clinic related cost as well as the costs of supplied used in providing veterinary services. The Company incurred higher costs related to the initial public offering that closed in August 2023 and higher costs associated with being a public company. For the year ended December 31, 2023 cash flow from operations included a $14.8 million net loss, an increase of $8.8 million compared to 2022, non-cash add-backs to net loss of $8.0 million, and a $3.0 million increase in cash flows from changes in operating assets and liabilities, driven primarily by increased outstanding accounts payable and accrued expenses. Such activity, along with the timing of cash payments, are the primary drivers of the year over year changes in net cash used in operating activities.
Investing Activities
Our uses of cash for investing activities are capital expenditures for purchases of property and equipment for our animal hospital and clinics and payments for acquisition of the Valley Veterinary Services, Inc. acquisition in August 2023.
57
Financing Activities
Our primary sources of cash from financing activities are the proceeds from our initial public offering that closed in August 2023, proceeds from issuance of convertible debentures, proceeds from notes payable used in our acquisition of Valley Veterinary Services, Inc. in November 2023 and proceeds from loan payable. Our primary uses of cash in financing activities are for repayments of convertible debentures upon the initial public offering at the election of the holder, repayments of notes payable and repayment on the loan payment.
Quantitative and Qualitative Disclosures About Market Risk
We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily the result of fluctuations in interest rates, regulatory, and inflation.
Interest Rate Risk
Our credit facilities bear interest at a floating rate, generally equal to the New York Prime Rate plus an applicable margin. As a result, we are exposed to fluctuations in interest rates to the extent of our net borrowings under the Master Lending and Credit Facility, which were $15,076,588 as of December 31, 2023. The exposure to interest rate fluctuations for the Company is considered minimal. The Company’s term loans issued under the Master Lending and Credit Facility have a fixed interest rate for the initial five years followed by a variable interest rate. The Company has not used any financial instruments to hedge potential fluctuations in interest rates.
As interest rates rise, there is risk in the form of more expensive loans which would negatively impact the valuation and profitability of each hospital which is purchased.
Inflation Risk
We do not believe that inflation has had a material effect on our business, financial condition or results of operations. If our costs become subject to significant inflationary pressures, we may not be able to fully offset such higher costs through price increases. Our inability or failure to do so could harm our business, financial condition, and operating results.
Critical Accounting Policies and Significant Judgments and Estimates
A summary of our significant accounting policies is included in Note 2 of our audited consolidated financial statements included in this Form 10-K. The preparation of consolidated financial statements requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Our estimates and assumptions are based on historical experiences and changes in the business environment. However, actual results may differ from estimates under different conditions, sometimes materially. Critical accounting policies and estimates are defined as those that are both most important to the portrayal of our financial condition and results of operations and require management judgment. Our critical accounting policies and estimates are described below.
Acquisitions
The Company enters into acquisitions primarily with existing veterinary hospitals throughout the United States. When we acquire a business or assets that are determined to meet the definition of a business, we allocate the purchase consideration paid to acquire the business to the assets and liabilities acquired based on estimated fair values at the acquisition date, with the excess of purchase price over the estimated fair value of the net assets acquired recorded as goodwill. If during the measurement period (a period not to exceed 12 months from the acquisition date) we receive additional information that existed as of the acquisition date but at the time of the original allocation described above was unknown to us, we make the appropriate adjustments to the purchase price allocation in the reporting period that the amounts are determined.
Goodwill
Goodwill represents the excess of the cost of an acquired business over the amounts assigned to its net assets. Goodwill is not amortized but is tested for impairment at a reporting unit level on an annual basis or when an event occurs, or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Events or changes in circumstances that may trigger interim impairment reviews include significant changes in business climate, operating results, planned investments in the reporting unit, or an expectation that the carrying amount may not be recoverable, among other factors.
58
The Company may first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events and circumstances, the Company determines it is more likely than not that the fair value of the reporting unit is greater than it’s carrying amount, an impairment test is unnecessary. If an impairment test is necessary, the Company will estimate the fair value of its related reporting units. If the carrying value of a reporting unit exceeds its fair value, the goodwill of that reporting unit is determined to be impaired, and the Company will proceed with recording an impairment charge equal to the excess of the carrying value over the related fair value.
Intangible Assets
Intangible assets consist of client list, trademark and non-compete intangibles that result from the acquisition of veterinary hospitals or practices. Client list intangible represent the value of the long-term client relationship from the veterinary hospitals and practices. Trademark intangible assets represent the value associated with the brand names in place at the date of the acquisition. Non-compete intangible assets represent the value associated with non-compete agreements for former employees and owners in place at the date of the acquisition. The client lists and trademark are included in other intangibles, net reported in the balance sheet which are being amortized over a 5-year term based on the estimated economic useful life of the client list and trademark. The non-compete intangible asset included in other intangibles, net is amortized over a 2-year term based on the estimated useful life of the asset. The amortization of the intangible asset is computed using the straight-line method. The intangibles are evaluated for impairment on an annual basis or more frequently whenever events or circumstances occur indicating that the carrying amount may not be recoverable.
The Company uses the Multi-Period Excess Earnings Method (“MPEEM”), a form of the income approach to determine the fair market value of the client list (customer relationship) intangible assets acquired as part of the acquisitions of veterinary hospitals or practices. The principle behind the MPEEM is that the value of an intangible asset is equal to the present value of the incremental after-tax cash flows attributable only to the subject intangible asset after deducting contributory asset charges (“CAC”).
The principle behind a contributory asset charge is that an intangible asset “rents” or “leases” from a hypothetical third party all the assets it requires to produce the cash flows resulting from its development, that each project rents only those assets it needs (including elements of goodwill) and not the ones that it does not, and that each project pays the owner of the assets a fair return on (and of, when appropriate) the fair value of the rented assets. Thus, any net cash flows remaining after such charges are attributable to the subject intangible asset being valued. The incremental after–tax cash flows attributable to the subject intangible asset are then discounted to their present value. CACs generally reflect an estimate of the amount a typical market participant would have to pay to use these contributory assets to generate income with the intangible asset.
The most significant assumptions used in our application of the MPEEM and in the valuation analysis of acquired client lists are:
| ● | A useful life of 15 years where after 10 years the remaining customer base results in small positive cash flows and no terminal value was calculated. |
| ● | A discount rate of 19.6% was selected to calculate the present value of the prospective after–tax cash flows associated with the customer base and business development relationships. |
| ● | We utilized an annual Company sales retention rate of 74.0% (Veterinary Services industry rate) for the Customer Base. |
| ● | The contributory asset charges are based on returns (8.3% to 19.7%) for Net Working Capital (normalized); Fixed Assets; Assembled Workforce; Trade Name; and Non-Competes. |
59
As of December 31, 2023 our intangible assets and goodwill balances were as follows:
| December 31, | ||||
| 2023 | ||||
| Client List | $ | 2,071,000 | ||
| Noncompete Agreement | 398,300 | |||
| Trademark | 1,117,200 | |||
| Other Intangible Assets | 45,835 | |||
| Goodwill | 8,147,590 | |||
| $ | 11,779,925 | |||
Our valuations of the intangible assets apart of our veterinary clinics and animal hospital acquisitions has a relatively small value allocated to the client list (customer relationship) due to our use of the Veterinary Services industry rate of 74% for the retention rate in our valuations. An increase in the rate by 6% to 80% in our valuation would result in an increase of approximately $100 thousand to the client list and a decrease of approximately $100 thousand to goodwill. We have elected to use the industry standard as our Company has minimal historical operations with less than 3 years of revenue producing activities through December 31, 2023. The company acquired Valley Veterinary Services on November 8, 2023. Management continues to evaluate the inputs used in our valuations based on quantitative and qualitative information available to the Company.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements.
60
OUR BUSINESS
Overview
Inspire Veterinary is a c-corporation originally incorporated in the state of Delaware in 2020. On June 29, 2022, the Company converted into a Nevada c-corporation. The Company owns and operates veterinary hospitals throughout the United States. The Company specializes in small animal general practice hospitals which serve all manner of companion pets, emphasizing canine and feline breeds. As we expand, additional modalities are continuing to become a part of the services offered at our hospitals, including equine care and emergency/specialty services.
As of the date of this prospectus, the Company has fourteen veterinary hospitals located in ten states. Inspire Veterinary has expanded and plans to further expand through acquisitions of existing hospital which it believes have attractive financial track records, marketplace advantages and future growth potential. Because the Company leverages a leadership and support structure which is distributed throughout the United States, its acquisitions are not centralized to one geographic area. The Company operates its business as one operating and one reportable segment.
Services provided at owned hospitals include preventive care for companion animals consisting of annual health exams which include: parasite control; dental health; nutrition and body condition counseling; neurological examinations; radiology; bloodwork; skin and coat health and many breed specific preventive care services. Surgical offerings include all soft tissue procedures such as spays and neuters, mass removals, splenectomies and can also include gastropexies, orthopedic procedures and other types of surgical offerings based on a doctor’s training. In many locations additional means of care and alternative procedures are also offered such as acupuncture, chiropractic and various other health and wellness offerings.
Oversight and support of the hospitals is achieved via in-house leadership which includes medical and operations expertise from within the veterinary field and others. Our staff provides on-site coaching and support across the country.
The Company is able to own and operate locations throughout the country by leveraging a national consultancy model. The Company directly employs medical and operations leadership which serve as direct line management (that is, Company-employed managers who directly manage mid-level and front-line employees and processes who are directly accountable to such senior leadership) to employees in each hospital or veterinary practice. These Inspire medical and operations leaders are experienced in the practice of veterinary medicine and they direct strategic planning, growth, changes in hospital- and veterinary practice-level management, cost controls, human capital selection processes, and otherwise generally guide all policies and procedures under which the hospitals and veterinary practices operate.
61
Our veterinary practice acquisition and management experts work with our veterinary practice leadership teams to teach specific skills, problem solve operational matters with individual hospital teams, find operational efficiencies to encourage growth and reduce expenses, and otherwise disseminate veterinary medicine practice expertise. Our acquisition and management experts execute our acquisition strategy by:
| ● | preparing valuation packages of potential acquisitions (including the gathering of pertinent information, financial and background data, completion of deal packets and financial projection worksheets used by the Company to calculate practice values); |
| ● | instituting turnover protocols and procedures of hospitals immediately post-purchase, systems reporting, and the formulation of individual hospital goals and targets; and |
| ● | providing on-going monthly support of hospital units (including medical and operational coaching, business growth projections, establishment of financial targets and margin improvements, growth milestones) and recruiting support. |
Our field-based trainers are trained, credentialed and experienced problem solvers who work with the senior officers and managers of Inspire to direct and oversee daily operations at the individual veterinary clinics.
To afford the Company with state structures which allow legal and licensure as well as other business details to be managed state by state, the Company uses limited liability companies (and one limited partnership in California).These entities are pass-through in nature and nearly all management and administration is provided at the parent company level. In the states of Texas and Indiana, ownership is held by a separate entity owned by a doctor of veterinary medicine. These two relationships are managed via operating and management agreements, which provide that that while the doctor of veterinary medicine oversees and manages all clinical aspects of operations, the non-veterinary services including administration, human resources, accounting, corporate housekeeping, and management services are provided by Inspire.
As noted elsewhere as the Company continues to grow, ‘in fill’ purchases of new locations will take place as opportunities are available to do so. These locations will be geographically located within close proximity of other company locations and may also specialize, for instance, in emergency or overnight care. Hence, this ‘in-fill’ strategy will allow the Company to share talent and resources among multiple locations and also share caseload and refer patients between company owned clinics.
As of the date of this prospectus, our clinics are located in the following states:
| ● | 1 location in the State of California; |
| ● | 1 location in the State of Colorado; |
| ● | 4 locations in the State of Florida; |
| ● | 1 location in the State of Hawaii; |
| ● | 1 location in the State of Indiana; |
| ● | 1 location in the State of Maryland; |
| ● | 1 location in the State of Massachusetts. |
| ● | 1 location in the State of Ohio; |
| ● | 1 location in the State of Pennsylvania; and |
| ● | 2 locations in the State of Texas; |
62
Corporate History
The company was incorporated as a corporation in the state of Delaware in 2020. In June 2022, the Company converted into a Nevada c-corporation. The Company has two consolidating holding companies: IVP Practice Holdings Co., LLC and IVP Real Estate Co., LLC. Each of IVP Practice Holdings Co., LLC and IVP Real Estate Co., LLC are passive intermediate holding companies with no employees, no operations and no assets other than the equity in the respective subsidiaries.
63
IVP Practices Holdings Co., LLC is used to acquire hospitals in various states and jurisdictions and is the holding company for subsidiaries:
| ● | IVP CA Holding Co. LLP, |
| ● | IVP CO Holding Company, LLC, |
| ● | IVP FL Holding Company, LLC, |
| ● | IVP IN Holding Co, LLC, |
| ● | IVP KVC Holding Company, LLC, |
| ● | IVP MA Managing Co., LLC, |
| ● | IVP MD Holding Co. LLC, |
| ● | IVP OH Holding Co, LLC, | |
| ● | IVP PA Holding Company, LLC, and |
| ● | IVP Texas Holding Co, LLC. |
IVP Real Estate Holdings Co., LLC is used to acquire the real property owned by the acquired hospitals and is the holding company for the real estate assets related to our subsidiaries:
| ● | IVP CA Properties, LLC, |
| ● | IVP CO Properties, LLC, |
| ● | IVP FL Properties, LLC, |
| ● | IVP IN Properties, LLC, |
| ● | IVP KVC Properties, LLC, |
| ● | IVP MD Properties, LLC, |
| ● | IVP OH Properties, LLC, |
| ● | IVP PA Properties, LLC, and | |
| ● | IVP TX Properties, LLC. |
Business Acquisitions
The Company utilizes standardized “form” purchase agreements to consummate its acquisitions of veterinary practices and related real estate assets, with transaction-specific adjustments and additions as may be negotiated by the sellers of the individual veterinary practices, in each case, in consultation with our business advisors and external legal counsel and subject to review and authorization of our board of directors.
The foregoing description of the Form of Asset Purchase Agreement and Form of Real Estate Purchase Agreement are qualified in their entirety by the full text of the same, which are attached hereto as Exhibits 10.6 and 10.7 and are herein incorporated by reference.
Kauai Veterinary Clinic, (KVC)
In January 2021, the Company completed the stock purchase of Kauai Veterinary Clinic, Inc. from the stockholders of such clinic for $1,505,000. In October 2021, the stock corporation was converted to a limited liability company, Kauai Veterinary Clinic, LLC under a plan of conversion executed by the stockholders whereby each share of the Corporation’s outstanding common stock was converted to one unit of ownership interest in the limited liability company. This entity is owned by IVP HI Practice Holding Company, LLC, a wholly-owned subsidiary of the Company. On the same date they completed the acquisition of the real estate for $1,300.0000 which is owned by IVP HI Properties, LLC. These acquisitions were financed by First Southern National Bank for a total of $2,383,400.
64
Chiefland Animal Hospital (CAH)
In August 2021, the Company completed the acquisition of Chiefland Animal Hospital and related assets from Polycontec, Inc for $285,000. This entity is owned by IVP FL Practice Holding Company, LLC, a wholly-owned subsidiary of the Company. On the same date they completed the acquisition of the real estate for $279,500 which is owned by IVP FL Properties, LLC. These acquisitions were financed by WealthSouth for a total of $469,259.
Pets & Friends Animal Hospital LLC (P&F)
In December 2021, the Company completed the acquisition of Pets & Friends Animal Hospital LLC and related assets from Pets & Friends Animal Hospital, LLC for $318,750 for the practice. This entity is owned by IVP CO Practice Holding Company, LLC, a wholly-owned subsidiary of the Company. On the same date they completed the acquisition of the real estate for $216,750 which is owned by CO Properties, LLC. These acquisitions were financed by WealthSouth for a total of $535,500.
Advanced Veterinary Care of Pasco, LLC (AVCP)
In January 2022, the Company completed the acquisition of Advanced Veterinary Care of Pasco, LLC and related assets from Advanced Veterinary Care of Pasco, LLC and DJA Asset Management, LLC for $1,014,000 for the practice and associated assets. These assets are owned by IVP FL Holding Company LLC, a wholly-owned subsidiary of the Company, and were financed by promissory notes from WealthSouth for a total of $817,135 at a Wall Street Journal prime rate plus 0.65 percent.
Lytle Veterinary Clinic, Inc. (LVC)
In February 2022, the Company completed the acquisition of Lytle Veterinary Clinic related assets from Lytle Veterinary Clinic, Inc. for $662,469 for the practice and related assets. This is owned by IVP TX Practice Holding Company, LLC, a wholly-owned subsidiary of the Company. On the same date they completed the acquisition of the real estate for $780,000 which is owned by IVP TX Properties, LLC. These acquisitions were financed by WealthSouth for a total of $1,141,098. A portion of the consideration for Lytle Veterinary Clinic was paid in the form of a convertible promissory note in principal amount of $100,000. A description of the convertible promissory note is set forth below under the caption, “Acquisition Convertible Promissory Notes.”
Southern Kern Veterinary Clinic, Inc. (SKVC)
In February 2022, the Company completed the acquisition of Southern Kern Veterinary Clinic, Inc. and related assets from Southern Kern Veterinary Clinic, Inc. for $1,500,000 for the practice. This is owned by IVP CA Practice Holding Company, LLC, a wholly-owned subsidiary of the Company. On the same date they completed the acquisition of the related real estate for $500,000 which is owned by IVP CA Properties, LLC. These acquisitions were financed by WealthSouth for a total of $1,700,000.
Bartow Animal Hospital
In May 2022, the Company completed the acquisition of Bartow Animal Hospital and related assets from Winter Park Veterinary Clinic, Inc. for $950,000. This is owned by IVP FL Practice Holding Company, LLC, a wholly-owned subsidiary of the Company. On the same date they completed the acquisition of the related real estate for $350,000 which is owned by IVP FL Properties, LLC, a wholly-owned subsidiary of the Company. These acquisitions were financed by WealthSouth for a total of $969,000. A portion of the consideration for Bartow Animal Hospital was paid in the form of a convertible promissory note in principal amount of $100,000. A description of the convertible promissory note is set forth below under the caption, “Acquisition Convertible Promissory Notes.”
Dietz Family Pet Hospital
In June 2022, the Company completed the acquisition of Dietz Family Pet Hospital and related assets from Dietz Family Pet Hospital, P.A. for $500,000 for the practice. This is owned by IVP TX Holding Company, LLC, a wholly-owned subsidiary of the Company. This acquisition was financed by WealthSouth for a total of $382,500. A portion of the consideration for Dietz Family Pet Hospital was paid in the form of a convertible promissory note in principal amount of $50,000. A description of the convertible promissory note is set forth below under the caption, “Acquisition Convertible Promissory Notes.”
65
Aberdeen Veterinary Clinic
In July 2022, the Company completed the acquisition of Aberdeen Veterinary Clinic and related assets from Heidi Fritz for $574,683.04 for the practice. This is owned by IVP MD Holding Company, LLC, a wholly-owned subsidiary of the Company. This acquisition was financed by WealthSouth for a total of $445,981. A portion of the consideration for Aberdeen Veterinary Clinic was paid in the form of a convertible promissory note in principal amount of $50,000. A description of the convertible promissory note is set forth below under the caption, “Acquisition Convertible Promissory Notes.”
All Breed Pet Care
In August 2022, the Company completed the acquisition of All Breed Pet Care and related assets from Tejal Rege for $952,000 for the practice. This practice is owned by IVP IN Holding Company, LLC. On the same date they completed the acquisition of the real estate for $1,200,000 which is owned by IVP IN Properties, LLC. These acquisitions were financed by WealthSouth for a total of $2,077,000. A portion of the consideration for All Breed Pet Care was paid in the form of a convertible promissory note in principal amount of $75,000. A description of the convertible promissory note is set forth below under the caption, “Acquisition Convertible Promissory Notes.”
The Pony Express Veterinary Hospital
In September 2022, the Company completed the acquisition of The Pony Express Veterinary Hospital, Inc. and related real estate. This practice is owned by IVP Texas Holding Co, LLC and the related real estate is owned by IVP TX Properties, LLC. The purchase price $2,608,652 for the veterinary hospital and $500,000 for the associated real estate and was financed by WealthSouth. A portion of the consideration for The Pony Express Veterinary Hospital, Inc. was paid in the form of a convertible promissory note in principal amount of $200,000. A description of the convertible promissory note is set forth below under the caption, “Acquisition Convertible Promissory Notes.”
Williamsburg Animal Clinic
In December 2022, the Company completed the acquisition of Williamsburg Animal Clinic LLC. This practice is owned by IVP MA Managing Co., LLC. The purchase price of $850,000 for the veterinary hospital and was financed by WealthSouth. The consideration for the hospital included a convertible note in the amount of $100,000. A description of the convertible promissory note is set forth below under the caption, “Acquisition Convertible Promissory Notes.”
The Old 41 Animal Hospital
Also in December 2022, the Company completed the acquisition of The Old 41 Animal Hospital and related real estate. This practice is owned by IVP FL Holding Co, LLC and the related real estate is owned by IVP FL Properties, LLC. The purchase price of $711,000 for the veterinary hospital and $800,000 for the associated real estate and was financed by WealthSouth. The consideration for the hospital included a convertible note in the amount of $50,000. A description of the convertible promissory note is set forth below under the caption, “Acquisition Convertible Promissory Notes.”
Valley Veterinary Services Acquisition
On November 8, 2023, the Company completed the acquisition of Valley Veterinary Services animal hospital and related real estate. This practice is owned by IVP PA Holding Company, LLC, a Delaware limited liability company and wholly-owned subsidiary of the Company. The purchase price was $1,400,000 plus the assumed liabilities described below, consisting of $1,000,000 to be paid in cash at the closing of the acquisition plus 4,082 restricted shares of the Company’s Class A common stock, which was equal to the quotient obtained by dividing $400,000 by the official closing price of one share of Class A common stock as reported by Nasdaq on the trading date immediately prior to the closing.
Acquisition Convertible Promissory Notes
The convertible promissory notes issued in connection with the above-noted acquisitions bear interest at a rate of 6% per annum commencing on March 1, 2023, are payable annually, and mature upon the earliest of September 9, 2027, the Company’s initial public offering, or the Company’s sale of substantially all of its assets and real estate or a controlling interest of Company stock. All payments and rights under the convertible promissory notes are subordinate to all senior indebtedness of the Company. The notes are convertible at the option of the holder to convert into shares of Class A common stock upon the occurrence of an initial public offering or liquidation of the Company. The notes convert at a conversion rate equal to a price reflecting a twenty-five percent discount to the initial public offering price or liquidation price, in each case as determined by the Board of Directors in connection with such conversion event. The notes are governed by the laws of the Commonwealth of Virginia.
66
Anticipated Capital Needs through 2024
Forecasting a growth rate of ten new acquisitions per year, with some variability in the size and make up of these locations, the Company anticipates it will need $15 to 20 million in new capital through 2024 in order to purchase new locations, expand existing facilities and seek strategic opportunities to purchase other revenue-bearing assets like grooming or boarding facilities and specialty hospitals.
Market Opportunity
Inspire Veterinary expects to target a ten-unit per year acquisition pipeline with the five-year goal to acquire 50 locations throughout the United States. Additional growth through the acquisition of newer practices is not expected to be ruled out but management’s emphasis is expected to focus on acquiring existing veterinary hospitals throughout the United States. In years two through five the Company will seek to expand purchases beyond the small companion animal only hospital to include mixed animal (including bovine and additional equine care) and add specialty care to our geographies. With over 28,000 veterinary hospitals in the United States and less than 30% of those having been consolidated, management believes large upside potential exists and the addressable market for new acquisitions is large.
Sales and Marketing
Inspire Veterinary has established contacts with most major veterinary brokerages and has purchased locations in every region of the United States, providing visibility and establishing a pipeline of deals which allow the Company to extend a letter of intent on approximately 10% of the hospitals which are analyzed. The acquisitions and valuation team is sufficient for current levels of acquisition activity and personnel have already been identified for expanding this team to provide deeper integration at industry events, generating organic leads and leveraging deep relationships with service and product suppliers across the industry.
Intellectual Property
We depend upon the skills, knowledge and experience of our management personnel, as well as that of our other employees, advisors, consultants and contractors, none of which are patentable. To help protect our know-how, we require all of our employees, consultants, advisors and other contractors to enter into customary confidentiality agreements that prohibit the disclosure of confidential information.
Competition
The veterinary industry, as of early 2022, consists of approximately 13 national consolidators and 30 regional consolidators. These groups combined currently own or operate around 6,000 of the nearly 30,000 veterinary hospitals in the United States.
Competitors range in size from the largest such as Mars and NVA, which collectively own approximately 4,000 hospitals, to other national and regional groups such as Pathway/Thrive, VetcCor, Southern Vet Partners, Community Veterinary Partners, and others. Growth in recent years has centered primarily on mid-sized and small platforms coming into the industry and/or acquiring existing hospitals in order to achieve location numbers between 50 and 200 units. In select cases, large to mid-sized groups have absorbed competitors in order to grow numbers or move into other modes of care. Examples include Pathway’s purchase of Thrive or NVA acquiring Compassion First. More than 30 groups comprise those entities owning less than 100 individual hospitals.
Increasingly, owner/operators of veterinary groups are also purchasing facilities and technology within the space, such as Pathway’s purchase of Vetspire Practice software. Additionally, as the line between general practice and more specialized modes of care becomes less defined, formerly general practice-only groups are branching into additional service offerings.
Competitors of the Company possess the advantages of years in operation and the resulting brand awareness which comes with their size and time in existence. Additional advantages are the financial and infrastructure resources possessed by larger competitors such as Mars, Pathway, Southern Vet Partners, Community Vet Partners and others.
67
The Company has an opportunity to differentiate itself from these competitors via the following:
| ● | A broad equity offering to a large group of employees which is not offered at other veterinary entities via an Employee Stock Option Plan. |
| ● | A personalized and approach to purchasing and integrating hospitals into the Company which is not matched by other groups. Because the Company works closely with acquired locations to allow them to sustain their own practices, methods and identities, this is an approach preferred by sellers to the more homogenized model used by competitors. |
| ● | A coaching and development-based workflow which is customized for each clinician and professional, all of which provide a more one to one environment than the larger consolidators can provide. |
| ● | Disciplined approach to acquiring locations based on a depth of financials and purchase of profitable locations versus relying on trailing twelve measures or buying at high multiples of EBITDA or revenue. |
Government Regulation
With practice acts that govern veterinary care and ownership guidelines on a state-by-state basis, Inspire Veterinary has processes and structures in place to provide the ability to own and operate in any state where it chooses to acquire locations. Governmental regulations regarding care for pets while also preserving pets as property are favorable to the continued growth of the veterinary channel.
The following descriptions of regulations constitute all applicable regulations to the Company’s operations.
Veterinary Ownership Restrictions in Certain States
The State of Texas’ Veterinary Licensing Act’s, or V.T.C.A., Occupations Code Section 801.506 – Prohibited Practices Relating to Certain Entities prohibits non-licensed veterinary persons from owning or operating veterinary clinics in the state of Texas. The Company currently operates two clinics in Texas and believes it is in compliance with applicable state law.
The State of Indiana’ Indiana Code, Article 38.1 Veterinarians, contains very little guidance dealing directly with veterinary practice ownership. There is no statute or regulation that explicitly defines what it means to have “ownership” of a veterinary practice in Indiana. Generally, if the veterinary clinic is owned by a limited liability company, at least one member of the limited liability company must be a veterinarian, subject to the discretion of the Indiana Board of Veterinary Medical Examiners. The Company operates one clinic in Indiana and believes it is in compliance with applicable state law.
Limitations for Duties for Non-Credentialed Employees
New York State, and certain other states, have language in their individual veterinary practice acts which require credentials in the form of licensure or certifications to be held by veterinary personnel who perform certain duties. This requirement varies by state, with many states having very few limitations of duties which can be performed by non-credentialled personnel while other states (such as New York) utilize language in their practice acts which can be interpreted as a blanket prohibition against employees without certification working with pets. The Company does not currently operate any clinics in New York State. There can be no assurance, however, that the Company may not seek to acquire a clinic or clinics in the New York State.
Drug Enforcement Agency (DEA) Regulations
With veterinary care requiring the use of some controlled and scheduled drugs, utilization logs and security procedures must be maintained in order for hospitals and clinics to be compliant with federal law. Inventory of controlled drugs is conducted, and scheduled drugs are kept secured and locked for access and use, by Company veterinarian or acceptable registered technician only pursuant to applicable federal law.
In each of these cases, Inspire has and will create structures which conform to legal standards and mitigate risk so as to allow the Company to acquire and operate in the states in which it chooses to do so.
68
Employees
As of June 21 2024, we had 156 employees. None of our employees are represented by labor unions or covered by collective bargaining agreements.
Properties
With a decentralized leadership team, our company does not have a physical headquarters, but rather, has a distributed leadership team working from home offices across several states.
Kauai Veterinary Clinic, (KVC)
The real estate underlying Kauai Veterinary Clinic is located at 1864 Haleukana Street, Lihue, Hawaii, and is owned by KVC Properties, LLC, a 100%-owned subsidiary of the Company. The property was purchased for $1,300.000 and was financed by a loan from First Southern National Bank. The loan bears interest at a rate of 4.35% per annum.
Chiefland Animal Hospital (CAH)
The real estate underlying Chiefland Animal Hospital is located at 2630 North Young Boulevard, Chiefland, Florida, and is owned by IVP FL Properties, LLC, a 100%-owned subsidiary of the Company. The property was purchased for $279,500 and was financed by WealthSouth, a division of Farmers National Bank (“WealthSouth”). The material terms of the WealthSouth loan are summarized below.
Pets& Friends Animal Hospital LLC (P&F)
The real estate underlying Pets & Friends Animal Hospital is located at 3625 Baltimore Ave, Pueblo, Colorado, and is owned by IVP CO Properties, LLC, a 100%-owned subsidiary of the Company. The property was purchased for $216,750 and was financed by WealthSouth. The material terms of the WealthSouth loan are summarized below.
Advanced Veterinary Care of Pasco, LLC (AVCP)
The real estate underlying our Advanced Veterinary Care of Pasco facility, located at 12116 Cobble Stone Drive, Hudson, Florida, is leased from Remappa Family Limited Partnership for one year with two additional possible three-year renewals. The initial rent in the first year of the lease is $2,350 per month increasing in annual increments for a total of 0.75% over ten years. The lease consists of 2,442 square feet of commercial space zoned to permit the provision of veterinary services.
Lytle Veterinary Clinic, Inc. (LVC)
The real estate underlying Lytle Veterinary Clinic is located at 63245 Texas State Highway 132, Lytle, Texas, and is owned by IVP TX Properties, LLC, a 100%-owned subsidiary of the Company. The property was purchased for $780,000 and financed by WealthSouth. The material terms of the WealthSouth loan are summarized below.
Southern Kern Veterinary Clinic, Inc. (SKVC)
The real estate underlying Southern Kern Veterinary Clinic is located at 4455 West Rosamond Boulevard, Rosamond, California, and is owned by IVP CA Properties, LLC, a 100%-owned subsidiary of the Company. The property was purchased for $500,000 and financed by WealthSouth. The material terms of the WealthSouth loan are summarized below.
Bartow Animal Hospital
The real estate underlying Bartow Animal Hospital is located at 1515 US Highway 17 South, Bartow, Florida, and is owned by IVP FL Properties, LLC, a 100%-owned subsidiary of the Company. The property was purchased for $350,000 and financed by WealthSouth. The material terms of the WealthSouth loan are summarized below.
Dietz Family Pet Hospital
The real estate underlying Dietz Family Pet Hospital is located at 7002 Hand Road, Richmond, Texas, and is leased from Clarence and Erna Thielemann for a one-year term, with optional monthly renewals thereafter. The rent is $2,000 per month. The lease consists of 1,880 square feet of commercial space zoned to permit the provision of veterinary services.
69
Aberdeen Veterinary Clinic
The real estate underlying Aberdeen Veterinary Clinic is located at 728 South Philadelphia Boulevard, Aberdeen, Maryland, and is leased from H R Fritz LLC for a five-year term, with three additional optional 5-year renewals. The rent is $4,166.67 per month, increasing 3% annually. The lease consists of 2,653 square feet of commercial space zoned to permit the provision of veterinary services.
All Breed Pet Care
The real estate underlying the All Breed Pet Care facility is located at 7501 Peachwood Drive, Newburgh, Indiana, and is owned by IVP IN Properties, LLC, a 100%-owned subsidiary of the Company. The property was purchased for $1,200,000 and was financed by WealthSouth. The material terms of the WealthSouth loan are summarized below.
The Pony Express Veterinary Hospital
The real estate underlying The Pony Express Veterinary Hospital is located at 893 Lower Bellbrook Road, Xenia, Ohio and is owned by IVP TX Properties, LLC, a 100%-owned subsidiary of the Company. The property was purchased for $500,000 and was financed by WealthSouth. The material terms of the WealthSouth loan are summarized below.
The Old 41 Animal Hospital
The real estate underlying The Old 41 Animal Hospital facility is located at 27551 Old 41 Road, Bonita Springs, Florida and 27567 Old 41 Road, Bonita Springs, Florida, and is owned by IVP FL Properties, LLC, a 100%-owned subsidiary of the Company. The property was purchased for $800,000 and was financed by WealthSouth. The material terms of the WealthSouth loan are summarized below.
Valley Veterinary Services
The real estate underlying Valley Veterinary Services facility is located 408 Grace Lane, Rostraver Township, Pennsylvania 15012 (Parcel Nos. 56-12-00-0-148 and 56-12-00-0-144) and is owned by IVP PA Properties, LLC, a 100%-owned subsidiary of the Company. The property was purchased for $590,000 and was financed by WealthSouth. The material terms of the WealthSouth loan are summarized below.
WealthSouth Real Estate Loans
Each WealthSouth loan bears a variable interest rate charged on all sum outstanding equal to the New York Prime Rate plus 0.50%, however, such rate can never be less than 3.57% per annum. The Form of Master Lending and Credit Facility Agreement with WealthSouth is attached hereto as Exhibit 10.2 and is herein incorporated by reference.
Legal Proceedings
We may from time to time become a party to various legal or administrative proceedings arising in the ordinary course of our business. As of the date hereof, neither we nor any of our subsidiaries is a party to any pending legal proceedings, nor are we aware of any such proceedings threatened against us or our subsidiaries.
70
MANAGEMENT AND BOARD OF DIRECTORS
Executive Officers and Directors
The following table sets forth information regarding our current directors, executive officers, and independent director nominees as of the date of this prospectus:
| Name | Age | Position | ||
| Kimball Carr | 53 | Chair, President and Chief Executive Officer | ||
| Richard Paul Frank | 56 | Chief Financial Officer | ||
| Larry Alexander | 42 | Director | ||
| Charles Stith Keiser | 38 | Director, Vice-Chair | ||
| Peter Lau | 69 | Director | ||
| Anne Murphy | 56 | Director | ||
| John Suprock | 69 | Director | ||
| Erinn Thomas-Mackey, DMV | 35 | Director | ||
| Timothy Watters | 60 | Director |
Executive Officers
Kimball Carr – Mr. Carr has served as our Chair, President and Chief Executive Officer since February 2021. Mr. Carr has over a varied 30-year career in many roles with private and public business entities. With early education in journalism and continuing education at the University of Virginia’s Darden Business School, Mr. Carr’s leadership career includes elevated roles for Starbucks Coffee Company, Mars Incorporated and Trupanion Medical Insurance. From March 2018 through the present, Mr. Carr served as President of Ocean 35 Inc., owner of retail brands focused on the sports of surfing and skateboarding as well as education and support of youth participation in the sports. From March 2018, Mr. Carr was the owner and founder of Grom Coast Surf & Skate, a regional commercial surf shop (subsequently closed). From December 2019 through February 2021, Mr. Carr was the director of learning and development of Blue Heron Consulting, offering comprehensive operational, financial, and medical team coaching for veterinarians and animal health care industry professionals across the country. During his tenure as a business leader, he has built multi-year growth strategies, led teams of over 2,000 professionals and delivered collective revenues in excess of $1 billion. He brings deep experience in veterinary and field operations, start-up processes, leadership development, growth strategies and turn arounds. He has led the acquisition and de novo opening of hundreds of company units over the course of his career and has built highly effective field leadership teams which have delivered industry-leading results. His connection to the pet care industry is highlighted by deep relationships he has across the sector, providing access to talent which IVP intends to leverage. Mr. Carr’s volunteer work includes service as President of the Banfield Associate Relief fund, an employee assistance program founded in relation to his role in the recovery for Banfield associates from Hurricane Sandy in the Northeast United States. Mr. Carr is not obligated to dedicate all of his time or resources or any specific portion of his time exclusively to the Company. Mr. Carr attended Tidewater Community College in October 1991 and attended the University of Virginia Darden Business School executive master’s of business administration from 2004 to 2006. We believe Mr. Carr is qualified to serve on the board due to his extensive background in retail business, his demonstrated success in entrepreneurial enterprises and his more than a decade of expertise in the veterinary medicine services industry.
Richard Paul Frank – Mr. Frank is our Chief Financial Officer whose appointment as Chief Financial Officer became effective upon the listing of the Company’s Class A common stock on The Nasdaq Capital Market. From 2021 through the present, Mr. Frank has been Chief Executive Officer of Purcell Flanagan Hay & Greene, a law firm based in Jacksonville, Florida. From 2020 through 2021, he served as Chief Financial Officer of Skygeek.com, an aviation parts e-commerce company. From 2019 to 2020, he was an independent consultant with PKF O’Connor Davies, an accounting and advisory firm. Mr. Frank also served as Chief Operating Officer and Chief Financial Officer of Beval Saddlery, LLC, a private equity owned multi-location retailer/wholesaler and e-commerce company from 2014 through 2019. Earlier in his career he was engaged in senior management positions with Blue Chip Farms, LLC, the largest equine breeding farm in New York State, Medical Recruitment Solutions, Inc., private equity owned medical staffing start-up enterprise, Indotronix International Corporation, an information technology staffing company, Microcast, Inc., a video streaming start-up enterprise, and Factset Research Systems, Inc., a SaaS financial information company with operations in the United Kingdom, Australia and Japan. He has over twenty years of experience directing all aspects of enterprise-wide finance, operations, business development, marketing, administration and customer service, including experienced in private equity owned companies, start-ups and companies with greater than $100 million per year in revenue. Mr. Frank graduated with a Bachelor of Science in Finance in 1992 from Mercy College in Yorktown, New York.
Directors
Larry Alexander – Mr. Alexander is a Director whose appointment became effective upon the listing of the Company’s Class A common stock on The Nasdaq Capital Market. He is currently the Vice President of Operations for CarepathRx, holding that role since January 2022. Previously, Mr. Alexander served as Managing Director of First Financial Bank from September 2017 through December 2021. Earlier in his career, he worked for McKesson Corporation from June 2002 through 2017, most recently as Vice President, Strategic Solutions and National Accounts from January 2010 through August 2017. Mr. Alexander brings over 20 years of experience, serving in senior leadership positions in Fortune 5, private equity, non-profit, and privately held companies, with an outstanding record of business growth and profitability across multiple industries. His career has focused on developing people and his engaged and high performing teams. Alexander’s proven results and leadership experience include leading multi-billion dollar negotiations, facilitating M&A engagements, and new business development. He has revived and started new businesses, with a deep focus on culture and growth. He gives generously of his time by serving many worthy organizations; chairing capital campaigns in his community; instituting college scholarship programs; leading hurricane disaster relief efforts; guest lecturing at universities; and has served on several boards of directors. Mr. Alexander graduated with a Bachelor of Science Degree in Industrial Distribution in May 2002 from Texas A&M University. We believe Mr. Alexander is qualified to serve on the board in light of his decades of experience in business operations in public and private enterprises across multiple industries,
71
Charles Stith Keiser – Mr. Keiser has served as our Director and Vice-Chair since early January 1, 2022. He has served as Chief Executive Officer of Blue Heron Consulting, a veterinary consulting company serving hospitals of all sizes and specialties across North America, since March 2015. Earlier in his career, he served as Director of Student Programs for the American Animal Hospital Association from September of 2011 through March of 2015. He grew up in veterinary medicine as the son of a practice owning veterinarian and has spent his entire career in the industry. In addition to his employment, Mr. Keiser continues to volunteer as a facilitator and lecturer for professional skills curriculum at veterinary schools across the country. Mr. Keiser continues to develop and deliver professional development content as an adjunct faculty member at several U.S. veterinary schools. Mr. Keiser’s volunteer experience includes serving as Chair of VetCAN (Veterinary Career Advisory Network), terms as President of VetPartner’s Career Development and Practice Management Special Interest Groups, participation in Washington State University’s CVM “Diagnostic Challenge” and a seat on the AVMA’s Economics Advisory Research Council Financial Literacy task force. Mr. Keiser has served in the veterinary profession since his graduation from Hope College with a degree in Business, Management and Accounting in 2008. Mr. Keiser is not obligated to dedicate all of his time or resources or any specific portion of his time exclusively to the Company. We believe Mr. Keiser is qualified to serve on the board due to his substantial experience in the practice of veterinary medicine and his leadership roles teaching and serving in veterinary schools and industry groups.
Peter Lau – Mr. Lau has served as a Director of the Company since November 2020. Mr. Lau also has served as a Managing Member of Star Circle Advisory Group, LLC, an investment advisory and advisory services firm with legal, management and consulting, accounting and media production expertise, since March 2020. From 2001 through October 2019, Mr. Lau was a Managing Director of Investment Banking for Buckman, Buckman and Reid, where he was also a principal since 2006. Mr. Lau is a certified public accountant and has held a series 7, 63 and 79 securities licenses. Earlier in his career, he working as an accountant at Deloitte, Squibb Corporate Federal Government. He has over 40 years’ experience in both the domestic and international financial service markets0. Mr. Lau graduated undergraduate and graduate school from the University of Hartford. We believe Mr. Lau is qualified to serve on the board due to his many decades working in investment banking, investment advisory, accounting and financial services.
Anne Murphy – Ms. Murphy is Director whose appointment became effective upon the listing of the Company’s Class A common stock on The Nasdaq Capital Market. Currently, Ms. Murphy serves as Vice President, Business Solutions and Applications at American Electric Power since January 2021. Previously, Ms. Murphy served as the Chief Information Officer for Best Buy Health and Greatcall, Inc., from November 2017 through March 2020, and Chief Information Officer for Banfield Pet Hospital from 2015 through 2017. Earlier in her career, Ms. Murphy served as Technology Vice President/Senior Director at Target Corporation from 2008-2014. Ms. Murphy is the owner and president of a consulting company, Claro Vista LLC since 2014. Ms. Murphy brings over 30 years of technology and transformational leadership experience in public, private, and private equity companies supporting utility, retail, direct to consumer and veterinary sectors. Ms. Murphy’s volunteer work includes serving as Board Trustee and Operations Committee Chair at United Through Reading since 2018, Board member for Banfield Foundation in 2017, Habitat for Humanity Women’s Build 2013-2014 and Ordway Circle of Stars Board member 2008-2010. Ms. Murphy graduated from University of St. Thomas in 2004 with a Master’s of Business of Administration, and graduated from Metropolitan State University in 1998 with a Bachelor of Science in Business Administration. We believe Ms. Murphy is qualified to serve on the board due to her multiple decades in business administration and technology leadership roles in a variety of industries, including veterinary services and her demonstrated commitment to public service.
John L. Suprock – Mr. Suprock is Director whose appointment became effective upon the listing of the Company’s Class A common stock on The Nasdaq Capital Market. Mr. John L Suprock served as President of PCS Advisors, LLC, a small business consulting firm, from January 2007 through July 2014. Since 2014 Mr. Suprock has been retired and managing a personal real estate portfolio. He brings over 30 years of experience in business operations and management. Mr. Suprock’s decades-long career includes the construction and real estate sectors as well as brokering and merger and acquisition representation for firms in the $10 million to $200 million value range. He has counseled on business transactions in the pharmacy, utility and energy sectors and has consulted with the Small Business Administration, helping small businesses achieve their plans. Mr. Suprock has advised on tax strategies as well as valuations during M&A transactions and he has been a member of the International Business Brokers Association (IBBA) and the Alliance of Mergers and Acquisitions Advisors. He graduated from California State University Long Beach in January 1976 with a Bachelor of Science in Business. We believe Mr. Suprock is qualified to serve on the board due to his varied experience as a business consultant across multiple sectors and his deep knowledge of, and expertise in, merger and acquisition transaction.
72
Erinn Thomas-Mackey, DVM – Dr. Erinn Thomas-Mackey is Director whose appointment became effective upon the listing of the Company’s Class A common stock on The Nasdaq Capital Market. She was the Founder and Managing Member of SeaPath Advisory LLC from 2022 to present, Managing Member and Founder for Thomas-Mackey Veterinary Service from 2021 to present, and Managing Member and Founder or TwoMacks Properties LLC from 2019 to present. Earlier in Dr. Thomas-Mackey’s career she was employed as an Associate Emergency Veterinarian at Animal Emergency Service, a privately owned emergency veterinary practice in Long Island, NY from August 2017 to October 2021 and as an Associate General Practice Veterinarian at Assisi Veterinary Hospital, a privately owned Veterinary practice in Malverne, NY from June 2015 to June 2017. While working as full-time veterinarian, Dr. Thomas-Mackey started her pre-diem veterinary business and real estate investment company. She brings years of hands-on experience in both emergency veterinary medicine and general veterinary practice along with the unique understanding of the day-to-day needs and challenges of both veterinary doctors and practice owners alike. In addition, Dr. Thomas-Mackey has successfully navigated everyday issues practice owners face around staffing needs, optimizing practice flow, and driving revenue to increase profit margins. She also has hands-on experience with negotiating real estate deals, property evaluation, and property management. Dr. Thomas-Mackey graduated from the Tuskegee University College of Agriculture, Environment and Nutrition Sciences in 2010 with a Bachelor of Science in Biology and a Bachelor of Animal, Poultry, and Veterinary Science, and from the Tuskegee University College of Veterinary Medicine in 2014 with a Doctor of Veterinary Medicine. We believe Dr. Thomas-Mackey’s broad experience in both the practice of veterinary medicine and ownership and management of veterinary practices and veterinary practice real estate, as well as her demonstrated educational and professional excellence, qualifies her to serve on the board.
Timothy Watters – Mr. Watters is Director whose appointment became effective upon the listing of the Company’s Class A common stock on The Nasdaq Capital Market. Mr. Watters currently serves as Chief Financial Officer of North Fork Native Plants, a wholesale plant nursery serving the Intermountain West and Pacific Northwest, a position he has held since July 2019. Previously, Mr. Watters served as Chief Operating Officer of North Fork Native Plants from May 2008 through June 2019. Earlier in his career, Mr. Watters owned a wholesale camping business, SKI International, Inc. from June 1994 through January 2008. He also worked in finance serving as Vice President of A.G. Edwards and Sons in St. Louis, Missouri from January 1990 through May 1994 and Vice President at PNC Financial Corp in Philadelphia, PA from September 1985 through September 1990. Mr. Watters brings over 38 years of experience in finance and small business ownership. Mr. Watters volunteer work includes service as Board Chair of the Community Foundation of Teton Valley, Board Chair of the Teton Valley Community School, Treasurer of Friends of the Teton River and Chair of the Teton County Planning and Zoning Commission. Mr. Watters graduated from Denison University in June of 1985 with a Bachelor of Arts in Economics. We believe Mr. Watters is qualified to serve on the board in light of his many decades of leadership of multiple commercial businesses and financial services firms.
Committees of the Board of Directors
Audit Committee
The Audit Committee is composed of three independent directors: Timothy Watters, John Suprock and Erinn Thomas-Mackey, DMV, with Mr. Watters serving as Chair. Each member of the Audit Committee is an independent director as defined by the rules of the Commission and Nasdaq. The Audit Committee has the sole authority and responsibility to select, evaluate and engage independent auditors for the Company. The Audit Committee reviews with the auditors and with the Company’s financial management all matters relating to the annual audit of the Company.
The Audit Committee monitors the integrity of our financial statements, monitors the independent registered public accounting firm’s qualifications and independence, monitors the performance of our internal audit function and the auditors, and monitors our compliance with legal and regulatory requirements. The Audit Committee also meets with our auditors to review the results of their audit and review of our annual and interim financial statements.
The Audit Committee meets at least on a quarterly basis to discuss with management the annual audited financial statements and quarterly financial statements and meets from time to time to discuss general corporate matters.
Audit Committee Financial Expert
Our Board determined that Mr. Watters is qualified as an Audit Committee Financial Expert, as that term is defined by the rules of the Commission, in compliance with the Sarbanes-Oxley Act of 2002.
73
Compensation Committee
The Compensation Committee, which currently consists of Anne Murphy, John Suprock and Larry Alexander, each of whom meets the independence requirements of all other applicable laws, rules and regulations governing director independence, as determined by the Board, with Ms. Murphy serving as Chair. Among other things, the Compensation Committee reviews, recommends and approves salaries and other compensation of the Company’s executive officers, and administers the Company’s equity incentive plans (including reviewing, recommending and approving stock option and other equity incentive grants to executive officers).
The Compensation Committee meets in executive session to determine the compensation of the Chief Executive Officer of the Company. In determining the amount, form, and terms of such compensation, the Committee considers the annual performance evaluation of the Chief Executive Officer conducted by the Board in light of company goals and objectives relevant to Chief Executive Officer compensation, competitive market data pertaining to Chief Executive Officer compensation at comparable companies, and such other factors as it deems relevant, and is guided by, and seeks to promote, the best interests of the Company and its shareholders.
In addition, subject to existing agreements, the Compensation Committee determines the salaries, bonuses, and other matters relating to compensation of the executive officers of the Company using similar parameters. It sets performance targets for determining periodic bonuses payable to executive officers. It also reviews and makes recommendations to the Board regarding executive and employee compensation and benefit plans and programs generally, including employee bonus and retirement plans and programs (except to the extent specifically delegated to a Board appointed committee with authority to administer a particular plan). In addition, the Compensation Committee approves the compensation of non-employee directors and reports it to the full Board.
The Compensation Committee also reviews and makes recommendations with respect to stockholder proposals related to compensation matters. The committee administers the Company’s equity incentive plans, including the review and grant of stock options and other equity incentive grants to executive officers and other employees and consultants.
The Compensation Committee may, in its sole discretion and at the Company’s cost, retain or obtain the advice of a compensation consultant, legal counsel or other adviser. The Compensation Committee is directly responsible for the appointment, compensation and oversight of the work of any compensation consultant, legal counsel and other adviser retained by the committee.
Compensation Committee Interlocks and Insider Participation
Our Compensation Committee was established upon the consummation of our initial public offering on August 31, 2023. Prior to that date, no current members of our Compensation Committee served as members of our Board. Accordingly, during the fiscal year ended December 31, 2022 (our last completed fiscal year), no member of our Compensation Committee:
| ● | was an officer or employee of the Company, | |
| ● | had or will have any relationships with the Company of the type that is required to be disclosed under Item 404 of Regulation S-K. |
None of our executive officers serves or has served as a member of the board of directors or managers, compensation committee or other committee performing equivalent functions of any entity that has one or more executive officers serving as one of our Directors or members of our Compensation Committee.
Governance and Nominating Committee
The Governance and Nominating Committee consists of Larry Alexander and Timothy Watters, each of whom meets the independence requirements of all other applicable laws, rules and regulations governing director independence, as determined by the Board, with Mr. Alexander serving as Chair.
The Governance and Nominating Committee identifies individuals qualified to become members of the Board, consistent with criteria approved by the Board; recommends to the Board the director nominees for the next annual meeting of stockholders or special meeting of stockholders at which directors are to be elected; recommends to the Board candidates to fill any vacancies on the Board; develops, recommends to the Board, and reviews the corporate governance guidelines applicable to the Company; and oversees the evaluation of the Board and management.
74
In recommending director nominees for the next annual meeting of stockholders, the Governance and Nominating Committee ensures the Company complies with its contractual obligations, if any, governing the nomination of directors. It considers and recruits candidates to fill positions on the Board, including as a result of the removal, resignation or retirement of any director, an increase in the size of the Board or otherwise. The Committee conducts, subject to applicable law, any and all inquiries into the background and qualifications of any candidate for the Board and such candidate’s compliance with the independence and other qualification requirements established by the Committee. The Committee also recommends candidates to fill positions on committees of the Board.
In selecting and recommending candidates for election to the Board or appointment to any committee of the Board, the Committee does not believe that it is appropriate to select nominees through mechanical application of specified criteria. Rather, the Committee shall consider such factors at it deems appropriate, including, without limitation, the following: personal and professional integrity, ethics and values; experience in corporate management, such as serving as an officer or former officer of a publicly-held company; experience in the Company’s industry; experience as a board member of another publicly-held company; diversity of expertise and experience in substantive matters pertaining to the Company’s business relative to other directors of the Company; practical and mature business judgment; and composition of the Board (including its size and structure).
The Committee develops and recommends to the Board a policy regarding the consideration of director candidates recommended by the Company’s stockholders and procedures for submission by stockholders of director nominee recommendations.
In appropriate circumstances, the Committee, in its discretion, will consider and may recommend the removal of a director, in accordance with the applicable provisions of the Company’s articles of incorporation and bylaws. If the Company is subject to a binding obligation that requires director removal structure inconsistent with the foregoing, then the removal of a director shall be governed by such instrument.
The Committee oversees the evaluation of the Board and management. It also develops and recommends to the Board a set of corporate governance guidelines applicable to the Company, which the Committee shall periodically review and revise as appropriate. In discharging its oversight role, the Committee is empowered to investigate any matter brought to its attention.
Board Diversity
While we do not have a formal policy on diversity, the Board considers diversity to include the skill set, background, reputation, type and length of business experience of the Board members as well as a particular nominee’s contributions to that mix. The Board believes that diversity brings a variety of ideas, judgments and considerations that benefit the Company and its stockholders. Although there are many other factors, the Board seeks individuals with experience on operating and growing businesses.
| Board Diversity Matrix (as of the date of this prospectus) | ||||
| Total Number of Directors: | 8 | |||
| Female | Male | Non- Binary | Did Not Disclose Gender | |||||
| Part 1: Gender Identity | ||||||||
| Directors | 2 | 5 | 0 | 1 | ||||
| Part II: Demographic Background | ||||||||
| African American or Black | 1 | 0 | 0 | 0 | ||||
| Alaskan Native or Native American | 0 | 0 | 0 | 0 | ||||
| Asian | 0 | 1 | 0 | 0 | ||||
| Hispanic or Latino/Latina | 0 | 0 | 0 | 0 | ||||
| Native Hawaiian or Pacific Islander | 0 | 0 | 0 | 0 | ||||
| White | 1 | 4 | 0 | 0 | ||||
| Two or More Races or Ethnicities | 0 | 0 | 0 | 0 | ||||
| LGBTQ+ | 0 | |||||||
| Did Not Disclose Demographic Background | 1 | |||||||
75
Board Leadership Structure
Kimball Carr serves as the Chair of the Board and regularly communicates with other members of management, the Board and Company counsel. Mr. Keiser serves as Vice-Chair of the Board.
Board Risk Oversight
The Company’s risk management function is overseen by the Board. The Company’s management keeps the Board apprised of material risks and provides its directors access to all information necessary for them to understand and evaluate how these risks interrelate, how they affect us, and how management addresses those risks. Kimball Carr, our Chair, President and Chief Executive Officer, works closely together with the other members of the Board when material risks are identified on how to best address such risks. If the identified risk poses an actual or potential conflict with management, the Company’s independent directors may conduct the assessment. Presently, the primary risk affecting us are our liquidity and the lack of material revenue.
Family Relationships
None of our other directors or officers have any known family relationships with other directors or officers of the Company.
Involvement in Legal Proceedings
We are not aware of any of our directors or officers being involved in any legal proceedings in the past ten years relating to any matters in bankruptcy, insolvency, criminal proceedings (other than traffic and other minor offenses) or being subject to any of the items set forth under Item 401(f) of Regulation S-K.
Code of Ethics
The Board has adopted a Code of Business Conduct and Ethics (the “Code of Ethics”) that applies to all of the Company’s employees, including the Company’s Chief Executive Officer and Chief Financial Officer. Although not required, the Code of Ethics also applies to the Company’s directors. The Code of Ethics provides written standards that we believe are reasonably designed to deter wrongdoing and promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships, full, fair, accurate, timely and understandable disclosure and compliance with laws, rules and regulations and the prompt reporting of illegal or unethical behavior, and accountability for adherence to the Code of Ethics.
76
EXECUTIVE AND DIRECTOR COMPENSATION
This section discusses the material components of the executive compensation program for our directors and our Named Executive Officers who are named in the “2023 and 2022 Summary Compensation Table” below. In 2023, our directors and “Named Executive Officers” and their positions were as follows:
| ● | Kimball Carr, Chair, President and Chief Executive Officer; |
| ● | Richard Frank, Chief Financial Officer; and |
| ● | Alexandra Quatri, DMV, Vice President of Medical Operations. |
This discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that we adopt may differ materially from the currently planned programs summarized in this discussion.
2023 and 2022 Summary Named Executive Officer Compensation Table
The following table sets forth information concerning the compensation of our named executive officers and directors for the years ended December 31, 2023 and 2022.
| Name and Principal Position | Year | Salary ($) | Bonus ($) | Option Awards ($) | Non-Equity Incentive Plan Compensation ($) | All
Other Compensation ($)(2) | Total | |||||||||||||||||||||
| Kimball Carr (1) | 2023 | 233,630 | - | (1) | - | 8,857 | 242,487 | |||||||||||||||||||||
| Chair, President and Chief Executive Officer | 2022 | 224,589 | - | - | - | 6,692 | 231,281 | |||||||||||||||||||||
| Richard Frank | 2023 | 191,781 | - | - | - | 1,308 | 193,088 | |||||||||||||||||||||
| Chief Financial Officer | 2022 | - | - | - | - | - | - | |||||||||||||||||||||
| Alexandra Quatri, DVM | 2023 | 199,250 | - | - | - | 2,148 | 201,398 | |||||||||||||||||||||
| Vice President of Medical Operations | 2022 | 97,500 | (3) | - | - | - | 642 | 98,142 | ||||||||||||||||||||
| (1) | On September 1, 2022, the board of directors of the Company authorized a grant of 500 shares of Class A common stock issuable upon exercise of a cashless warrant to Mr. Carr in recognition of Mr. Carr’s guaranty of certain Company loans. The warrant was issued to Mr. Carr on January 1, 2023. |
| (2) | “All Other Compensation ($)” consists of Company contributions to medical benefit premiums. |
| (3) | Employment began June 1, 2022, represents pro-rata annual salary of $195,000. |
Employment Agreements
Kimball Carr Employment
The Company entered into an employment agreement (the “Employment Agreement”) with Kimball Carr, the Company’s Chair, President and Chief Executive Officer, on July 8, 2021. The Employment Agreement provides for a three-year term with the ability to renew, upon the affirmative vote of the board of directors (with Mr. Carr abstaining) for successive one-year terms.
Pursuant to the Employment Agreement, Mr. Carr’s duties consist of devoting as much time as is necessary to perform the duties and services required under the Employment Agreement and as may be designated by the Board, and devoting his best efforts to the business and affairs of Inspire and promoting the interests of Inspire. Mr. Carr is barred from directly or indirectly, engaging in any other business that could reasonably be expected to detract from his ability to apply his best efforts in the performance of his duties to Inspire.
Base salary
Mr. Carr’s base salary under the Employment Agreement is tied to annual revenue targets, as follows:
| Annual Revenue | Base Salary | ||||
| Up to $7,500,000 | $ | 175,000 | |||
| $ | 7,500,000 | $ | 225,000 | ||
| $ | 15,000,000 | $ | 250,000 | ||
| $ | 20,000,000 | $ | 300,000 | ||
| $ | 25,000,000 | To be negotiated by the parties | |||
77
Mr. Carr is eligible for annual bouses under the Employment Agreement is tied to annual revenue targets, as follows:
Annual Revenue Bonus
| Actual Revenue Compared to Revenue Target | Revenue Bonus | |
| 110% or greater | 125% of Revenue Bonus Target | |
| 100-109% | 100% of Revenue Bonus Target | |
| 95-99% | 95% of Revenue Bonus Target | |
| 90-94% | 90% of Revenue Bonus Target | |
| Below 90% | No Revenue Bonus |
Profit Bonus
| Actual Profit Compared to Profit Target | Profit Bonus | |
| 110% or greater | 125% of Profit Bonus Target | |
| 100-109% | 100% of Profit Bonus Target | |
| 95-99% | 95% of Profit Bonus Target | |
| 90-94% | 90% of Profit Bonus Target | |
| Below 90% | No Profit Bonus |
Stock Bonus
The Board may, in its sole discretion, determine with additional bonus in the form of shares of Class A or Class B common stock may be awarded, taking into account the Company’s performance for the calendar year based on the revenue bonus targets and profit targets. If the Board determines that a stock bonus is warranted, the value of the shares will be equal to between 10% and 14% of Mr. Carr’s base salary for such calendar year.
Benefits
Mr. Carr is entitled to participate in the employee benefit plans offered to the Company’s employees on the same terms and conditions as other employees.
Covenants
The Employment Agreement contains certain non-disclosure and confidentiality provisions applicable to Mr. Carr for the benefit of the Company. Mr. Carr has also agreed, during the term of his employment and for a two-year period following the termination of his employment not to solicit for employment any employee or any person who was employed by the Company within the prior six months. Mr. Carr is also barred from soliciting any client or certain former clients for a period of two years following the termination of his employment with the Company.
Termination
The Company may terminate Mr. Carr’s employment immediately for cause includes:
| ● | his death; |
| ● | his mental or physical incapacity that prevents him, with or without reasonable accommodation, from performing his essential duties for a period of 60 consecutive days or longer; |
| ● | disloyalty or dishonesty towards the Company; |
| ● | gross or intentional neglect of in the performance of his duties and services or material fail to perform his duties and services; |
| ● | his violation of any law, rule, or regulation (other than minor traffic violations) related to his duties; |
78
| ● | his material breach of any provision of the Employment Agreement or any written Inspire policy, if such breach is not cured within 10 days after written notice; and |
| ● | any other act or omission which harms or may reasonably be expected to harm the reputation or business interests of the Company. |
Mr. Carr may terminate the Employment Agreement immediately for good reason, which is defined to include:
| ● | a material breach of the Employment Agreement by the Company, if such breach is not cured within 10 days after written notice; |
| ● | a material reduction in his duties or responsibilities without his consent, if such breach is not cured within 10 days after written notice; |
| ● | a relocation of his office to a location more than 30 miles from Virginia Beach, Virginia without his consent, if such relocation is not reversed within 10 days after written notice; and |
| ● | a change in control of the Company, provided that he gives notice of termination based on such change in control within six months. |
Miscellaneous
Mr. Carr is entitled to severance payments in certain circumstances. The Employment Agreement is governed by the laws of the Commonwealth of Virginia. The foregoing description of the Employment Agreement is qualified in its entirety by the full text of the Employment Agreement, which is attached hereto as Exhibit 10.4 and is herein incorporated by reference.
2022 Equity Incentive Plan
Effective October 18, 2022, shareholders of Company approved the Company’s 2022 Equity Incentive Plan (the “Plan”). The Plan provides for the award of stock options (incentive and non-qualified), stock awards and stock appreciation rights to officers, directors, employees and consultants who provide services to the Company.
Under the plan, the capital stock available for issuance under the Plan are the shares of the Company’s authorized but unissued common stock. The number of shares issued may not exceed, at any given time, ten percent (10%) of the total of: (a) the issued and outstanding shares of the Company’s common stock, and (b) all shares common stock issuable upon conversion or exercise of any outstanding securities of the Company which are convertible or exercisable into shares of common stock.
The Board may terminate the Plan at any time. Unless sooner terminated, the Plan will terminate ten years after the effective date of the Plan. The number of shares of common stock covered by each outstanding stock right, and the number of shares of common stock which have been authorized for issuance under the Plan as well as the price per share of common stock (or cash, as applicable) covered by each such outstanding option or stock appreciation rights, shall be proportionately adjusted for any increases or decrease in the number of issued shares of common stock resulting from a stock split, reverse stock split, stock dividend, combination or reclassification, or any other increase or decrease in the number of issued shares of common stock effected without receipt of consideration by the Company.
The foregoing description of the 2022 Equity Incentive Plan is qualified in its entirety by the full text of the 2022 Equity Incentive Plan, which is attached hereto as Exhibit 10.5 and is herein incorporated by reference.
Outstanding Equity Awards
No equity awards to our named executive officers were outstanding at December 31, 2023 or as of the date of this prospectus.
79
Executive Incentive Compensation Recovery Policy
We have adopted an executive incentive compensation recovery policy (the “Executive Incentive Compensation Recovery Policy”) pursuant to Section 10D of the Exchange Act, Rule 10D-1 promulgated under the Exchange Act (“Rule 10D-1”), and Listing Rule 5608 adopted by Nasdaq (the “Listing Standards”). The purpose of the Executive Incentive Compensation Recovery Policy is to provide for the recovery of certain incentive-based compensation in the event of an accounting restatement. In the event of an accounting restatement, it is the Company’s policy to recover reasonably promptly the amount of any erroneously awarded compensation received during the recovery period. An accounting restatement involves a restatement of the Company’s financial statements due to material noncompliance with any financial reporting requirement under the federal securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.
The amount of “erroneously awarded compensation” generally means the amount of incentive-based compensation (compensation that is granted, earned, or vested based wholly or in part upon the attainment of a financial reporting measure) received by a covered executive that exceeds the amount of incentive-based compensation on that otherwise would have been received had it been determined based on the restated financial statements. The Company need not recover any “erroneously awarded compensation” if and to the extent that the Compensation Committee or a majority of the independent members of the Board determines that such recovery is impracticable and not required under Rule 10D-1 and the Listing Standards, including if the Compensation Committee or a majority of the independent members of the Board determines that: (i) the direct expense paid to a third party to assist in enforcing the policy would exceed the amount to be recovered after making a reasonable attempt to recover, or (ii) recovery would likely cause an otherwise tax-qualified broad-based retirement plan to fail the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended, and regulations thereunder.
The policy is administered by our Compensation Committee, except that the Board may decide to act as the administrator in lieu of the Compensation Committee or designate another committee of the Board (including a special committee) to act as the administrator other than the determination that recovery of “erroneously awarded compensation” is impracticable and not required (as described above).
The foregoing description of the Executive Incentive Compensation Recovery Policy is qualified in its entirety by the full text of the same, which is attached hereto as Exhibit 10.14 and which is herein incorporated by reference.
Director Compensation
No compensation has been paid to our directors for services rendered during the fiscal year ended December 31, 2023 or as of the date of this prospectus.
80
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table lists, as of the date of this prospectus, the number of shares of common stock beneficially owned by:
| (i) | each of our Named Executive Officers; | |
| (ii) | each of our directors; | |
| (iii) | all executive officers and directors as a group; and | |
| (iv) | each person, entity or group (as that term is used in Section 13(d)(3) of the Exchange Act) known to the Company to be the beneficial owner of more than 5% of the outstanding common stock. |
Information relating to beneficial ownership of common stock by our principal stockholders and management is based upon information furnished by each person using “beneficial ownership” concepts under the rules of the Commission. Under these rules, a person is deemed to be a beneficial owner of a security if that person directly or indirectly has or shares voting power, which includes the power to vote or direct the voting of the security, or investment power, which includes the power to dispose or direct the disposition of the security. The person is also deemed to be a beneficial owner of any security of which that person has a right to acquire beneficial ownership within 60 days. Under the Commission rules, more than one person may be deemed to be a beneficial owner of the same securities, and a person may be deemed to be a beneficial owner of securities as to which he or she may not have any pecuniary interest.
The calculations of the applicable percentage of beneficial ownership are based on:
| ● | 958,033 shares of Class A common stock; |
| ● | 3,891,500 shares of Class B common stock; and |
| ● | 28,591 shares of Series A preferred stock |
issued and outstanding as of June 20 2024.
The calculations of the applicable percentage of voting power include the beneficial ownership and also includes:
| ● | the voting power of 263,710 shares of Class A common stock that are potentially issuable upon conversion of shares of Series A preferred stock outstanding as of the date of this prospectus; and |
| ● | the voting power of 3,891,500 shares of Class B common stock outstanding as of the date of this prospectus (each share of Class B common stock entitles the holder of record to twenty-five (25) votes on all matters submitted to a vote of stockholders). |
81
Except as otherwise indicated, all shares are owned directly. Each indicated holder has sole voting power and sole investment power over the shares indicated in the table below:
| Name and Address of Beneficial Owner (1) | Title | Class
of Voting Stock Beneficially Owned |
Number
of Shares Beneficially Owned |
% Owned |
Total Combined% Voting |
|||||||||||||
| NAMED EXECUTIVE OFFICERS | ||||||||||||||||||
| Kimball Carr | Class A common | 777 | (2) | * | 8.5 | % | ||||||||||||
| Class B common | 333,250 | 8.6 | % | |||||||||||||||
| Preferred | - | * | ||||||||||||||||
| Richard Frank | Class A common | - | * | * | ||||||||||||||
| Class B common | - | * | ||||||||||||||||
| Preferred | - | * | ||||||||||||||||
| Alexandra Quatri | Class A common | - | * | * | ||||||||||||||
| Class B common | - | * | ||||||||||||||||
| Preferred | - | * | ||||||||||||||||
| DIRECTORS | ||||||||||||||||||
| Lawrence Alexander | Director | Class A common | 10 | * | * | |||||||||||||
| Class B common | - | * | ||||||||||||||||
| Preferred | - | * | ||||||||||||||||
| Charles Stith Keiser | Director | Class A common | 245 | * | 54.6 | % | ||||||||||||
| Class B common | 2,150,000 | (3) | 55.2 | % | ||||||||||||||
| Preferred | - | * | ||||||||||||||||
| Peter Lau | Director | Class A common | - | * | 13.6 | % | ||||||||||||
| Class B common | 537,500 | 13.8 | % | |||||||||||||||
| Preferred | - | * | ||||||||||||||||
| Dr. Thomas-Mackey | Director | Class A common | 56 | * | * | |||||||||||||
| Class B common | - | * | ||||||||||||||||
| Preferred | - | * | ||||||||||||||||
| John Suprock | Director | Class A common | - | * | * | |||||||||||||
| Class B common | - | * | ||||||||||||||||
| Preferred | - | * | ||||||||||||||||
| Timothy Watters | Director | Class A common | - | * | * | |||||||||||||
| Class B common | - | * | ||||||||||||||||
| Preferred | - | * | ||||||||||||||||
82
| Name and Address of Beneficial Owner (1) | Title | Class
of Voting Stock Beneficially Owned |
Number
of Shares Beneficially Owned |
%
Owned |
Total
Combined% Voting |
|||||||||||||
| 5% OWNERS | ||||||||||||||||||
| Best Future Investment, LLC (4) | Class A common | - | * | 13.6 | % | |||||||||||||
| Class B common | 537,500 | 13.8 | % | |||||||||||||||
| Series A preferred | - | * | ||||||||||||||||
| Richard Martin | Class A common | - | * | 8.5 | % | |||||||||||||
| Class B common | 333,250 | 8.6 | % | |||||||||||||||
| Series A preferred | - | * | ||||||||||||||||
| 622 Capital LLC (5) | Class A common | 1,121 | (6) | * | * | |||||||||||||
| Class B common | - | * | ||||||||||||||||
| Series A preferred | - | * | ||||||||||||||||
| Dragon Dynamic Catalytic Bridge SAC Fund (7) | Class A common | 561 | (6) | * | * | |||||||||||||
| Class B common | - | * | ||||||||||||||||
| Series A preferred | - | * | ||||||||||||||||
| Target Capital 1 LLC (8) | Class A common | 6,614 | (6) | * | * | |||||||||||||
| Class B common | - | * | ||||||||||||||||
| Series A preferred | 28,591 | 100 | % | |||||||||||||||
| Wilderness Trace Veterinary Partners, LLC (9) | Class A common | - | * | 54.6 | % | |||||||||||||
| Class B common | 2,150,000 | 55.2 | % | |||||||||||||||
| Series A preferred | - | * | ||||||||||||||||
| * | Represents ownership of less than 1%. |
| (1) | Unless otherwise indicated, the business address of each of the individuals is 780 Lynnhaven Parkway, Suite 400, Virginia Beach, Virginia 23452 |
| (2) | Includes a warrant for 500 shares of Class A common stock. The warrant was issued effective as of January 1, 2023 and is exercisable at any time and from time to time by the holder for a period of five (5) years from January 1, 2023 at an exercise price per share equal to $400.00, multiplied by 0.60, subject to adjustment for subsequent stock splits, stock combinations, stock dividends, and recapitalizations. |
| (3) | Beneficially owned by Wilderness Trace Veterinary Partners, LLC, which is controlled by Charles Stith Keiser, the Company’s Vice-Chair and director. |
| (4) | Beneficially owned by Best Future Investment, LLC, which is owned and controlled by James Coleman, a former director of the Company. |
| (5) | 622 Capital LLC is controlled by its manager Gary Clyburn Jr. and its principal address is: 1334 Northampton Street, Easton, Pennsylvania 18042. |
| (6) | Constitutes “New Warrants” issued in connection with the Company’s initial public offering. See “Description of Capital Stock — Warrants — New Warrants.” New Warrants are exercisable at the option of the holder at any time or from time to time after the date of issuance through the fifth (5th) anniversary of the date of issuance. |
| (7) | Dragon Dynamic Catalytic Bridge SAC Fund is controlled by its Director Gary Carr and its principal address is: 5 Chapel Lan, Paget, Bermuda PG 02. |
| (8) | Target Capital 1 LLC is controlled by its Manager Dmitriy Shapiro and its principal address is: 13600 Carr 968, Apt. 64, Rio Grande 745, Puerto Rico 00745. |
| (9) | Wilderness Trace Veterinary Partners, LLC is 100% owned and controlled by Charles Stith Keiser, the Company’s Vice-Chair and director. |
| (10) | Holders of Series A preferred stock have the right to vote as-if-converted, on all matters submitted to a vote of holders of the Company’s common stock, including the election of directors, and all other matters as required by law, subject to the certain limits on beneficial ownership contained in the Certificate of Designations relating to the Series A preferred stock. |
83
| Outstanding Equity Awards at Fiscal Year-End | ||||||||||||||||||||||||||||||||||||
| Option awards | Stock awards | |||||||||||||||||||||||||||||||||||
| Name | Number
of securities underlying unexercised options (#) exercisable | Number
of securities underlying unexercised options (#) unexercisable | Equity
incentive plan awards: Number of securities underlying unexercised unearned options (#) | Option
exercise price ($) | Option expiration date | Number of shares or units of stock that have not vested (#) | Market value of shares of units of stock that have not vested ($) | Equity | Equity
incentive plan awards: Market or payout value of unearned shares, units or other rights that have not vested ($) | |||||||||||||||||||||||||||
| (a) | (b) | (c) | (d) | (e) | (f) | (g) | (h) | (i) | (j) | |||||||||||||||||||||||||||
| Kimball Carr1 | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||
| Charles Stith Keiser2 | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||
| Peter Lau3 | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||
| 1 | On September 1, 2022, the board of directors, by unanimous vote, agreed to grant Mr. Carr a cashless warrant for 500 shares of Class A common stock as consideration of Mr. Carr’s personal guaranty of loans of the Company. The warrant was issued effective as of January 1, 2023. |
| 2 | Mr. Keiser was formerly our Chief Operating Officer. Mr. Keiser resigned effective November 14, 2023. Mr. Keiser’s resignation did not result from any disagreement with the Company, the Board or the Company’s independent auditors. |
| 3 | Mr. Lau was formerly our Interim Chief Financial Officer. Mr. Lau resigned effective August 31, 2023. Mr. Lau’s resignation did not result from any disagreement with the Company, the Board or the Company’s independent auditors. |
Change-in-Control Agreements
Other than a provision in the Employment Agreement with Mr. Carr, our Chair, President and Chief Executive Officer, which provides that Mr. Carr may terminate his employment with the Company within six-months following a change in control of the Company, the Company does not have any change-in-control agreements with any of its executive officers.
84
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Keiser Loans
On August 10, 2022, Charles Stith Keiser, our director, Vice-Chair and former Chief Operating Officer and Charles Hurst Keiser, DVM, our former director, advanced $150,000 each for a total of $300,000 to the Company for working capital needs. The advances were pursuant to an oral agreement, were interest-free, required the Company to pay a $5,000 fee to each lender as consideration for the advances and were payable upon demand by either lender. All amount payable in satisfaction of loans to the Company made by Mr. Keiser or Dr. Keiser were repaid prior to the consummation of the Company’s initial public offering on August 31, 2023.
Operating Leases with Related Parties
The Company has intercompany leases between its subsidiaries, and these transactions and balance have been eliminated in the consolidated financial statements.
Consulting Agreements
The Company also received acquisition, business and financial advisory services from Blue Heron Consulting (“BHC”) pursuant to a consulting agreement (the “BHC Consulting Agreement”). Charles Stith Keiser, our director and Vice-Chair, is the Chief Operating Officer of BHC and our director Dr. Charles “Chuck” Keiser is the Chief Visionary Officer of BHC. As of the date of this prospectus, the Company paid $1,090,788.16 to BHC pursuant to this agreement. The BHC Consulting Agreement was terminated without cause by the Company on in the third quarter of 2023. The foregoing description of the BHC Consulting Agreement is qualified in its entirety by the full text of the BHC Consulting Agreement, which is attached hereto as Exhibit 10.11 and is herein incorporated by reference.
The Company previously received financial consulting services from Star Circle Advisory Group, LLC (“Star Circle”), which is owned and controlled by our former directors Messrs. Coleman and Marten and our current director Mr. Lau, pursuant to a Financial Consulting Agreement between the Company and Star Circle dated August 2, 2022. The Company paid $866,900 to Star Circle pursuant to the Financial Consulting Agreement prior to termination. The Financial Consulting Agreement was terminated without cause by the Company on September 18, 2023. The foregoing description of the Financial Consulting Agreement is qualified in its entirety by the full text of the Financial Consulting Agreement, which is attached hereto as Exhibit 10.12 and is herein incorporated by reference.
85
DESCRIPTION OF CAPITAL STOCK
General
Our authorized capital stock consists of one hundred seventy million (170,000,000) shares of stock, consisting of three (3) classes of stock designated, respectively, as “Class A common stock,” “Class B common stock” and “Preferred Stock,” each such share having a par value of $0.0001 per share. The total number of authorized shares are: one hundred million (100,000,000) shares of Class A common stock; twenty million (20,000,000) shares of Class B common stock; and fifty million (50,000,000) shares of Preferred Stock.
The foregoing description of our Amended and Restated Articles of Incorporation, the Articles of Conversion to a Nevada corporation, Second Amended and Restated By-Laws, Certificate of Designations relating to Series A preferred stock and First Amendment to Certificate of Designations relating to Series A preferred stock, is qualified in its entirety by the full text of the same, which are attached hereto as Exhibits 3.1 through 3.5, and which are herein incorporated by reference.
Reverse Stock Split
On April 22, 2024, we filed a certificate of change to our Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada to effect the 1-for-100 Reverse Stock Split of our authorized and issued and outstanding Class A common stock, which became effective as of May 8, 2024. As of June 20 2024, we had 958,033 shares of Class A common stock issued and outstanding.
Increase of Authorized
On April 26, 2024, the holders of a majority of the issued and outstanding voting securities of the Company (the “Majority Stockholders”), approved, by written consent an amendment to the Company’s Articles of Incorporation to increase the total number of authorized shares of Class A Common Stock to one hundred million (100,000,000) shares (the “Amendment”). The effectiveness of the Majority Stockholders’ approval of the Amendment shall automatically take effect on June 16, 2024.
Class A Common Stock
Holders of our Class A common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders. No holder of shares of Class A common stock has the right to cumulate votes.
Holders of our Class A common stock are entitled to receive dividends when and if declared by our board of directors out of funds legally available therefor, subject to any statutory or contractual restrictions on the payment of dividends and to any restrictions on the payment of dividends imposed by the terms of any outstanding shares of Preferred Stock.
Upon the liquidation, dissolution or winding up of the Company, after payment in full of all amounts required to be paid to creditors and to the holders of our Preferred Stock having liquidation preferences, if any, the holders of our Class A common stock are entitled to share, along with the holders of our Class A common stock and holders of Preferred Stock which are not entitled to any liquidation preference, ratably in all assets remaining.
Holders of Class A common stock have no preemptive or redemption rights and no right to convert their common stock into any other securities. All outstanding shares of Class B common stock are fully paid and non-assessable.
86
Class B Common Stock
Holders of our Class B common stock are entitled to twenty-five (25) votes for each share held of record on all matters submitted to a vote of stockholders. No holder of shares of Class B common stock has the right to cumulate votes.
Subject to the rights of holders of Preferred Stock having preference as to dividends, the holders of our Class A common stock are entitled to receive dividends when, as and if declared by our board of directors out of legally available funds.
Upon our liquidation, dissolution or winding up of the affairs of the Company, subject to any preference right of holder of the Preferred Stock of the Company, the holders of our Class B common stock shall share equally and ratably, along with the holders of our Class A common stock and holders of Preferred Stock which are not entitled to any liquidation preference, in the Company’s assets. The merger, conversion, exchange or consolidation of the Company is not deemed a liquidation, dissolution or winding up of the affairs of the Company.
Our Class B common stock may be convertible at the option of the holders, without the payment of additional consideration, at any time, into shares of Class A common stock at a conversion rate of one share of Class A common stock for each share of Class B common stock. The conversion rate of the Class B common stock will be adjusted proportionately if the Company, at any time or from time to time, (a) pays a dividend or makes a distribution for no consideration to holders of our Class A common stock, (b) subdivides (by stock split, recapitalization or otherwise) our outstanding Class A common stock into a greater number of shares, or (c) combines its outstanding Class A common stock into a smaller number of shares.
The holders of Class B common stock do not have any redemption or preemptive rights.
Preferred Stock
Pursuant to our articles of incorporation, our board of directors has the authority, without further action by the stockholders, to issue up to fifty million (500,000) shares of Preferred Stock, in one or more series. Our board of directors has the authority, without further action by the shareholders, to issue shares of Preferred Stock in one or more series and to fix the rights, preferences, privileges and restrictions granted to or imposed upon the preferred stock. Preferred Stock may be designated and issued without authorization of shareholders unless such authorization is required by applicable law, the rules of the principal market or other securities exchange on which our stock is then listed or admitted to trading.
Our board of directors may authorize the issuance of Preferred Stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our Class A common stock or Class B common stock. The issuance of Preferred Stock, while providing flexibility in connection with possible acquisitions and other corporate purposes could, under some circumstances, have the effect of delaying, deferring or preventing a change in control of the Company.
The description of Preferred Stock in this prospectus and the description of the terms of a particular series of preferred stock in any applicable prospectus supplement are not complete. You should refer to any applicable certificate of designation for complete information.
All shares of Preferred Stock offered hereby will, when issued, be fully paid and nonassessable, including shares of Preferred Stock issued upon the exercise of preferred stock warrants or subscription rights, if any.
87
Series A preferred stock
Our board of directors amended articles of incorporation on June 30, 2023 to authorize the issuance of Series A preferred stock (the “Series A preferred stock”) by the filing of a certificate of designation (as amended as of the date of this prospectus, the “Series A Certificate of Designation”), with each such share having a stated value of $10.00 per share. The board further amended the articles of incorporation on November 7, 2023 to increase the number of shares of Series A preferred stock authorized under the Company’s articles of incorporation to twenty thousand (20,000) preferred shares of Series A preferred stock and to modify the minimal conversion price of the Series A preferred stock as described below.
Holders of shares of the Series A preferred stock are entitled to a liquidation preference in the event of any dissolution, liquidation or winding up of the Company equal to the stated value plus any accrued and unpaid dividends on such stock. Holders of shares of Series A preferred stock are also entitled to convert such shares at any time and from time, at the option of such holder, into a number of shares of Class A common stock equal to the stated value divided by a conversion price. The conversion price is equal to 60% of the dollar volume-weighted average price for shares for the Company’s Class A common stock for the three trading days immediately preceding the date of the conversion. However, the conversion price can never be less than $0.25 per-share.
The Series A Certificate of Designation also contains certain beneficial ownership limitations on the holders of the Series A preferred stock, as more fully described in the Series A Certificate of Designation. The holders of the Series A preferred stock have the right to vote on all matters submitted to a vote of shareholders on an as-if-converted basis together with the holders of shares of the Company’s Class A and Class B common stock, voting together as a single class.
The foregoing description of the Series A Certificate of Designation is qualified in its entirety by the full text of the same, which is attached hereto as Exhibit 3.4 and Exhibit 3.5 and which are herein incorporated by reference.
Warrants to be issued in this offering
The following summary of certain terms and provisions of the Warrants included in the Units offered hereby is not complete and is subject to, and qualified in its entirety by the provisions of the form of Warrant, which is filed as an exhibit to the registration statement of which this prospectus is a part. Prospective investors should carefully review the terms and provisions set forth in the form of Warrant.
Exercisability. The Warrants are exercisable immediately and at any time up to the date that is six months after their original issuance. The Warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and by payment in full for the number of shares of Class A common stock purchased upon such exercise. No fractional shares of Class A common stock will be issued in connection with the exercise of a Warrant. In lieu of fractional shares, we will in our election either pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price or round up to the nearest whole share.
Exercise Limitation. A holder will not have the right to exercise any portion of the Warrant if the holder (together with its affiliates) would beneficially own in excess of 4.99% (or, at the election of the investor, 9.99%) of the number of shares of our Class A common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Warrants. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days following notice from the holder to us.
Exercise Price. The exercise price per whole share of Class A common stock purchasable upon exercise of the Warrants is equal to 100% of the offering price per Unit. The exercise price is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock.
Transferability. Subject to applicable laws, the Warrants may be offered for sale, sold, transferred or assigned without our consent.
88
Adjustments; Fundamental Transactions. The exercise price and the number of shares underlying the Warrants are subject to appropriate adjustment in the event of stock splits, stock dividends on our shares of Class A common stock, stock combinations or similar events affecting our shares of common stock. In addition, in the event of a fundamental transaction, as described in the Warrants and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of the voting power of our outstanding capital stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding capital stock, the holders of the Warrants will be entitled to receive upon exercise of the Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the Warrants immediately prior to such fundamental transaction.
Rights as a Stockholder. Except as otherwise provided in the Warrants or by virtue of such holder’s ownership of shares of our Class A common stock, the holder of a Warrant does not have the rights or privileges of a holder of our common stock, including any voting rights, until the holder exercises the Warrant.
Exchange Listing. We do not intend to apply for the listing of the Warrants offered in this offering on any stock exchange. Without an active trading market, the liquidity of the Warrants will be limited.
Amendment. The Warrants may be modified or amended with the written consent of the Company and the holders thereof.
Pre-Funded Warrants to be issued in this offering
The following summary of certain terms and provisions of the Pre-Funded Warrants offered hereby is not complete and is subject to, and qualified in its entirety by the provisions of the form of Pre-Funded Warrant, which is filed as an exhibit to the registration statement of which this prospectus is a part. Prospective investors should carefully review the terms and provisions set forth in the form of Pre-Funded Warrant.
The term “pre-funded” refers to the fact that the purchase price of our Common Stock in this offering includes almost the entire exercise price that will be paid under the Pre-Funded Warrants, except for a nominal remaining exercise price of $0.001. The purpose of the Pre-Funded Warrants is to enable investors that may have restrictions on their ability to beneficially own more than 4.99% (or, upon election of the holder, 9.99%) of our outstanding Class A common stock following the consummation of this offering the opportunity to invest capital into our Company without triggering their ownership restrictions, by receiving Pre-Funded Warrants in lieu of our Class A common stock which would result in such ownership of more than 4.99% (or 9.99%), and receive the ability to exercise their option to purchase the shares underlying the Pre-Funded Warrants at such nominal price at a later date.
Duration. The Pre-Funded Warrants offered hereby will entitle the holders thereof to purchase shares of our Class A common stock at a nominal exercise price of $0.001 per share, at any time after its original issuance until exercised in full.
Exercise Limitation. A holder will not have the right to exercise any portion of the Pre-Funded Warrant if the holder (together with its affiliates and certain related parties) would beneficially own in excess of 4.99% (or, upon election of the holder, 9.99%) of the number of shares of our Class A common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants. However, any holder may increase, but not in excess of 9.99%, or decrease such percentage, provided that any increase will not be effective until the sixty-first (61st) day after such election
Exercise Price. The Pre-Funded Warrants will have an exercise price of $0.001 per share. The exercise price is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our Class A common stock and also upon any distributions of assets, including cash, stock or other property to our stockholders.
Warrant Certificate. The Pre-Funded Warrants will be issued in certificated form.
Transferability. Subject to applicable laws, the Pre-Funded Warrants may be offered for sale, sold, transferred or assigned without our consent.
Exchange Listing. There is no established public trading market for the Pre-Funded Warrants being offered in this offering, and we do not expect a market to develop. In addition, we do not intend to apply to list the Pre-Funded Warrants on any national securities exchange or other nationally recognized trading system, including the Nasdaq Capital Market. Without an active trading market, the liquidity of Pre-Funded Warrants will be limited.
89
Fundamental Transactions. If a fundamental transaction occurs, then the successor entity will succeed to, and be substituted for us, and may exercise every right and power that we may exercise and will assume all of our obligations under the Pre-Funded Warrants with the same effect as if such successor entity had been named in the Pre-Funded Warrant itself. If holders of our Class A common stock are given a choice as to the securities, cash or property to be received in a fundamental transaction, then the holder shall be given the same choice as to the consideration it receives upon any exercise of the Pre-Funded Warrant following such fundamental transaction.
Rights as a Stockholder. Except as otherwise provided in the Pre-Funded Warrants or by virtue of such holder’s ownership of shares of our Class A common stock, the holder of a Pre-Funded Warrant does not have the rights or privileges of a holder of our Class A common stock, including any voting rights, until the holder exercises the Pre-Funded Warrant.
Modification of Shareholder Rights
Pursuant to Nevada Revised Statutes Article 79.390, any amendment to the articles of association (other than a change in number of authorized shares of class or series) to affect or modify shareholders’ rights requires (i) a resolution adopted by the board of directors setting forth the proposed amendment and submission of the proposed amendment to the stockholders for approval; (ii) affirmative vote of stockholders holding shares in the corporation representing at least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, approving the amendment; and (iii) a certificate signed by an authorized officer setting forth the amendment, the vote by which the amendment was adopted, and filing of the certificate with the Secretary of State of Nevada.
Warrants
Exchange Listing Warrant
In connection with the Company’s entry into a capital market advisory agreement (the “Advisory Agreement”), dated as of December 28, 2021, with Exchange Listing, LLC (“Exchange Listing”), the Company issued a warrant (the “Exchange Listing Warrant”) to Exchange Listing to purchase up to 120 shares of Class A common stock. The Exchange Listing Warrant is exercisable at any time and from time to time by the holder for a period of three (3) years from December 28, 2021, the date of issuance, at an exercise price of $300.00 per share, subject to adjustment for subsequent stock splits, stock combinations, stock dividends, and recapitalizations. The Exchange Listing Warrant was issued in a privately negotiated transaction exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). There were no cash proceeds from the issuances of the Exchange Listing Warrant.
Pursuant to the Advisory Agreement, Exchange Listing provided capital market advisory services to assist the Company in obtaining a national listing on either the Nasdaq or NYSE stock exchange. The Advisory Agreement expired in August 2023 upon the listing of our Class A common stock on the Nasdaq.
The foregoing description of the Advisory Agreement is qualified in its entirety by the full text of the Advisory Agreement, which is attached hereto as Exhibit 10.10 and is herein incorporated by reference.
Kimball Carr Warrant
On September 1, 2022, the Company issued to Kimball Carr, the Company’s Chair, President and Chief Executive Officer, a warrant (the “Carr Warrant”) for up to 500 shares of Class A common stock as consideration of Mr. Carr’s personal guaranty of certain loans of the Company. The warrant was issued effective as of January 1, 2023 and is exercisable at any time and from time to time by the holder for a period of five (5) years from January 1, 2023, The Carr Warrant is subject to an exercise price per share equal to $400.00, which was the initial offering price of the Class A common stock issued in our initial public offering, multiplied by 0.60, subject to adjustment for subsequent stock splits, stock combinations, stock dividends, and recapitalizations. The Carr Warrant was issued in a privately negotiated transaction exempt from registration pursuant to Section 4(a)(2) of the Securities Act. There were no cash proceeds from the issuances of the Carr Warrant.
The foregoing description of the Carr Warrant is qualified in its entirety by the full text of the Carr Warrant, which is attached hereto as Exhibit 4.1 and is herein incorporated by reference.
New Warrants
Effective June 30, 2023, the Company exchanged certain then-outstanding indebtedness held by the Company’s senior secured lenders, Dragon Dynamic Catalytic Bridge SAC Fund, Target Capital 1 LLC and 622 Capital LLC (the “New Warrant Holders”), for shares of Series A preferred stock.
90
In connection with the exchange of certain then-outstanding indebtedness of the Company and certain existing outstanding warrants, the Company issued warrants (the “New Warrants”) to the New Warrant Holders to purchase additional shares of Class A common stock, at any time and from time to time at the option of the New Warrant Holders.. The exercise price of the shares to be issued pursuant to the New Warrants is $400 per share, which was the price per shares of Class A Common Stock issued in our initial public offering. The New Warrants may be exercised for a total of 8,296 shares of Class A Common Stock, which is equal to the quotient of 75% of the outstanding Series A preferred stock value divided by the $400.00 per share exercise price. The New Warrants were issued in privately negotiated transactions exempt from registration pursuant to Section 4(a)(2) of the Securities Act. There were no cash proceeds from the issuances of the New Warrants.
The foregoing description of the New Warrants are qualified in its entirety by the full text of the New Warrants, which are attached hereto as Exhibits 4.2, 4.3 and 4.4 and are herein incorporated by reference.
Spartan IPO Warrant
In connection with our initial public offering, on August 31, 2023 the Company issued to the underwriter in our initial public offering, Spartan Capital Securities, LLC (“Spartan”), a warrant (the “Spartan IPO Warrant”) to purchase up to 800 shares of Class A common stock. The Spartan IPO Warrant is exercisable at any time and from time to time, beginning 180 days after August 29, 2023, the effective date of our registration statement filed in connection with the initial public offering and expiring on a date which is three (3) years from the commencement of sales of the public offering in compliance with FINRA Rule 5110(e)(1)(A). The Spartan IPO Warrant is exercisable for an exercise price of $55.00 per share, which is 110% of the public offering price of our Class A common stock in the initial public offering,
The Spartan IPO Warrant was deemed compensation by FINRA and is therefore subject to a 180-day lock-up pursuant to FINRA Rule 5110(e). Spartan may not sell, transfer, assign, pledge, or hypothecate the Spartan IPO Warrant or the securities underlying such warrant, nor will they engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of such warrants or the underlying securities for a period of 180 days following the date of commencement of sales pursuant to the offering.
In addition, the Spartan IPO Warrant provides for “piggy- back” registration rights with respect to the shares underlying such warrants, exercisable for a period of seven (7) years from the August 29, 2023, the effective date of our registration statement filed in connection with the initial public offering in compliance with FINRA Rule 5110(g)(8)(D). The exercise price and number of shares issuable upon exercise of the Spartan IPO Warrant may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary cash dividend or our recapitalization, reorganization, merger or consolidation. However, the exercise price of the Spartan IPO Warrant or the underlying shares of such warrants will not be adjusted for issuances of shares of Class A common stock at a price below such warrants’ exercise price.
The Spartan IPO Warrant was issued in a privately negotiated transaction exempt from registration pursuant to Section 4(a)(2) of the Securities Act. There were no cash proceeds from the issuances of the Spartan IPO Warrant.
The foregoing description of the Spartan IPO Warrant is qualified in its entirety by the full text of the Spartan IPO Warrant, which is attached hereto as Exhibit 4.5 and is herein incorporated by reference.
February 2024 Spartan Warrant
The February 2024 Spartan Warrant was issuable upon the consummation of the issuance of shares of Class A common stock, and wis exercisable at any time and from time to time, in whole or in part, at Spartan’s option during the four and a half-year period following such issuance of the February 2024 Spartan Warrant. The February 2024 Spartan Warrant will be exercisable at a price of $9.35 per share of Class A Common Stock.
In connection with the issuance of the February 2024 Spartan Warrant, we agreed to provide Spartan with registration rights for the shares of Class A common stock underlying such warrants (including a one-time demand registration right and customary piggyback rights, subject and pursuant to a registration rights agreement to-be-agreed upon by the parties), cashless exercise and customary anti-dilution provisions.
91
Anti-Takeover Effects of Provisions of Our Amended and Restated Articles of Incorporation, Our Amended and Restated Bylaws and Nevada Law
Nevada Anti-Takeover Law
The Nevada Revised Statutes (“NRS”) contain several provisions which may make a hostile take-over or change of control of our Company more difficult to accomplish. They include the following:
Under Nevada law, any one or all of the directors of a corporation may be removed by the holders of not less than two-thirds of the voting power of a corporation’s issued and outstanding stock. All vacancies on the board of directors of a Nevada corporation may be filled by a majority of the remaining directors, though less than a quorum, unless the articles of incorporation provide otherwise. In addition, unless otherwise provided in the articles of incorporation, the board may fill the vacancies for the entire remainder of the term of office of the resigning director or directors. Our Articles of Incorporation do not provide otherwise.
In addition, Nevada law provides that unless otherwise provided in a corporation’s articles of incorporation or bylaws, shareholders do not have the right to call special meetings. Our articles of incorporation and our bylaws do not give shareholders this right. In accordance with Nevada law, we also require advance notice of any shareholder proposals.
Nevada law provides that, unless otherwise prohibited by any bylaws adopted by the shareholders, the board of directors may amend any bylaw, including any bylaw adopted by the shareholders. Pursuant to Nevada law, our articles of incorporation grant the authority to adopt, amend or repeal bylaws exclusively to our directors.
Nevada’s “combinations with interested stockholders” statutes prohibit certain business “combinations” between certain Nevada corporations and any person deemed to be an “interested stockholder” for two years after the such person first becomes an “interested stockholder” unless (i) the corporation’s board of directors approves the combination (or the transaction by which such person becomes an “interested stockholder”) in advance, or (ii) the combination is approved by the board of directors and sixty percent of the corporation’s voting power not beneficially owned by the interested stockholder, its affiliates and associates. Furthermore, in the absence of prior approval, certain restrictions may apply even after such two-year period. For purposes of these statutes, an “interested stockholder” is any person who is (x) the beneficial owner, directly or indirectly, of ten percent or more of the voting power of the outstanding voting shares of the corporation, or (y) an affiliate or associate of the corporation and at any time within the two previous years was the beneficial owner, directly or indirectly, of ten percent or more of the voting power of the then outstanding shares of the corporation. Subject to certain timing requirements set forth in the statutes, a corporation may elect not to be governed by these statutes. However, we have not included any such provision in our Articles of Incorporation or Bylaws, which means these provisions apply to us.
Nevada’s “acquisition of controlling interest” statutes contain provisions governing the acquisition of a controlling interest in certain Nevada corporations. These “control share” laws provide generally that any person who acquires a “controlling interest” in certain Nevada corporations may be denied certain voting rights, unless a majority of the disinterested stockholders of the corporation elects to restore such voting rights. These statutes provide that a person acquires a “controlling interest” whenever a person acquires shares of a subject corporation that, but for the application of these provisions of the NRS, would enable that person to exercise (1) one-fifth or more, but less than one-third, (2) one-third or more, but less than a majority or (3) a majority or more, of all of the voting power of the corporation in the election of directors. Once an acquirer crosses one of these thresholds, shares which it acquired in the transaction taking it over the threshold and within the 90 days immediately preceding the date when the acquiring person acquired or offered to acquire a controlling interest become “control shares” to which the voting restrictions described above apply. Our Articles of Incorporation and Bylaws currently contain no provisions relating to these statutes, and unless our Articles of Incorporation or Bylaws in effect on the tenth day after the acquisition of a controlling interest were to provide otherwise, these laws would apply to us if we were to (i) have 200 or more stockholders of record (at least 100 of which have addresses in the State of Nevada appearing on our stock ledger) and (ii) do business in the State of Nevada directly or through an affiliated corporation. As of the date of this prospectus, we have less than 100 record stockholders with Nevada addresses. However, if these laws were to apply to us, they might discourage companies or persons interested in acquiring a significant interest in or control of the Company, regardless of whether such acquisition may be in the interest of our stockholders.
Listing
Our Class A common stock is listed on the Nasdaq under the symbol “IVP”.
Transfer Agent and Registrar
The transfer agent and registrar for our Class A common stock is VStock Transfer, LLC.
92
PLAN OF DISTRIBUTION
We are offering up to 9,125,475 Units, at an assumed offering price of $1.315 per Unit, which was the closing price of our Class A Common Stock on June 20, 2024, for gross proceeds of up to approximately $12 million before deduction of placement agent commissions and offering expenses, in a best-efforts offering.
Pursuant to a placement agent agreement (the “Placement Agent Agreement”), dated as of , 2024, we have engaged Spartan Capital Securities, LLC to act as our exclusive placement agent (“Spartan” or the “Placement Agent”) to solicit offers to purchase the securities offered by this prospectus. The Placement Agent is not purchasing or selling any securities, nor is it required to arrange for the purchase and sale of any specific number or dollar amount of securities, other than to use its “reasonable best efforts” to arrange for the sale of the securities by us. Therefore, we may not sell the entire amount of securities being offered. There is no minimum amount of proceeds that is a condition to closing of this offering. We will enter into a securities purchase agreement directly with the investors , at the investor’s option, who purchase our securities in this offering. Investors who do not enter into a securities purchase agreement shall rely solely on this prospectus in connection with the purchase of our securities in this offering. The Placement Agent may engage one or more subagents or selected dealers in connection with this offering.
The Placement Agent Agreement provides that the Placement Agent’s obligations are subject to conditions contained in the Placement Agent Agreement.
We will deliver the securities being issued to the investors upon receipt of investor funds for the purchase of the securities offered pursuant to this prospectus. We expect that investors in this offering may enter into an agreement, substantially in the form of the securities purchase agreement attached hereto as an exhibit to this prospectus and incorporated herein by reference (the “Form of Securities Purchase Agreement”), with the Company to purchase shares of Class A common stock or pre-funded warrants to participate in the offering. We expect to deliver the securities being offered pursuant to this prospectus on or about , 2024.
Placement Agent Fees, Commissions and Expenses
Upon the closing of this offering, we will pay the Placement Agent a cash transaction fee equal to eight percent (8.0%) of the aggregate gross cash proceeds to us from the sale of the securities in the offering. Pursuant to the Placement Agent Agreement, we will agree to reimburse the Placement Agent a maximum of $125,000 for reasonable out-of-pocket accountable expenses including “road show”, diligence, and reasonable documented legal fees and disbursements for its legal counsel. The Placement Agent Agreement, however, will provide that in the event this offering is terminated, the Placement Agent will only be entitled to the reimbursement of out-of-pocket accountable expenses actually incurred in accordance with Financial Industry Regulatory Authority, Inc. (“FINRA”) Rule 5110(f)(2)(C). Additionally, we will reimburse the Placement Agent one percent (1.0%) of the gross proceeds of the offering for non-accountable expenses.
The following table shows the assumed public offering price, Placement Agent fees and proceeds, before expenses, to us.
| Per Unit (including a share of Class A common stock) | Per Unit (including a Pre-Funded Warrant) | Total | ||||||||||
| Public offering price | $ | |||||||||||
| Placement agent fees (8%) | $ | |||||||||||
| Proceeds, before expenses, to us | $ | |||||||||||
We estimate that the total expenses of the offering, including registration, filing and listing fees, printing fees and legal and accounting expenses, but excluding the Placement Agent commission, will be approximately $200,000, all of which are payable by us. This figure does not include, among other things, the Placement Agent’s fees and expenses (including the legal fees, costs and expenses for the Placement Agent’s legal counsel) up to $125,000.
93
Tail Financing
The Placement Agent shall be entitled to a cash fee equal to eight percent (8.0%) of the gross proceeds received by the Company from an investment made by any investor actually introduced by Spartan to the Company during the Engagement Period (a “Tail Financing”), and such Tail Financing is consummated at any time during the twelve (12) month period following the expiration or termination of the Engagement Period, provided that such financing is by a party actually introduced to the Company in an offering in which the Company has direct knowledge of such party’s participation. The Placement Agent will provide the company with a list of all parties introduced to the Company.
Lock-Up
The Company, on behalf of itself and any successor entity, will agree that, without the prior written consent of the Placement Agent, it will not, for a period of 360 days after the date of the Placement Agent Agreement, other than certain exempt issuances, (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company; (ii) file or caused to be filed any registration statement with the Commission relating to the offering of any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company; or (iii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of capital stock of the Company, whether any such transaction described in clause (i), (ii) or (iii) above is to be settled by delivery of shares of capital stock of the Company or such other securities, in cash or otherwise.
The directors and executive officers of the Company and each of the holders of 5% or more of the Company’s Class A common stock will not until the date that is ninety (90) days after the date of this prospectus, subject to certain customary exceptions, directly or indirectly, (a) offer, sell, agree to offer or sell, solicit offers to purchase, grant any call option or purchase any put option with respect to, pledge, encumber, assign, borrow or otherwise dispose of (each a “Transfer”) any shares of Class A common stock, any unit, any warrant to purchase shares of Class A common stock or any other security of the Company or any other entity that is convertible into, or exercisable or exchangeable for, Class A common stock or any other equity security of the Company (each a “Relevant Security”), or (b) establish or increase any “put equivalent position” or liquidate or decrease any “call equivalent position” with respect to any Relevant Security (in each case within the meaning of Section 16 of the Exchange Act, and the rules and regulations thereunder) with respect to any Relevant Security or otherwise enter into any swap, derivative or other transaction or arrangement that Transfers to another, in whole or in part, any economic consequence of ownership of a Relevant Security, whether or not such transaction is to be settled by the delivery of Relevant Securities, other securities, cash or other consideration, with respect to the undersigned’s holdings, or otherwise publicly disclose the intention to do so.
The foregoing description of the compensation arrangements between the Company and the Placement Agent are set forth in the Placement Agent Agreement, dated , 2024, between the Company and the Placement Agent is qualified in its entirety by reference to the Placement Agent Agreement, a copy of which is attached hereto as Exhibit 1.1 and which is incorporated herein by reference.
Indemnification
We have agreed to indemnify the Placement Agent against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the Placement Agent may be required to make for these liabilities.
94
Regulation M
The Placement Agent may be deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act, and any commissions received by it and any profit realized on the resale of the securities sold by it while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. As an underwriter, the Placement Agent would be required to comply with the requirements of the Securities Act and the Exchange Act, including, without limitation, Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of our securities by the Placement Agent acting as principal. Under these rules and regulations, the Placement Agent (i) may not engage in any stabilization activity in connection with our securities and (ii) may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until it has completed its participation in the distribution.
Determination of Offering Price
The actual offering price of the securities we are offering, and the exercise price of the pre-funded warrants included that we are offering, were negotiated between us, the Placement Agent and the investors in the offering based on the trading of our shares of Class A common stock prior to the offering, among other things. Other factors considered in determining the public offering price of the securities we are offering, as well as the exercise price of the pre-funded warrants that we are offering include our history and prospects, the stage of development of our business, our business plans for the future and the extent to which they have been implemented, an assessment of our management, the general conditions of the securities markets at the time of the offering and such other factors as were deemed relevant.
Electronic Distribution
A prospectus in electronic format may be made available on a website maintained by the Placement Agent. In connection with the offering, the Placement Agent or selected dealers may distribute prospectuses electronically. No forms of electronic prospectus other than prospectuses that are printable as Adobe® PDF will be used in connection with this offering.
Other than the prospectus in electronic format, the information on the Placement Agent’s website and any information contained in any other website maintained by the Placement Agent is not part of the prospectus or the registration statement of which this prospectus forms a part, has not been approved and/or endorsed by us or the Placement Agent in its capacity as Placement Agent and should not be relied upon by investors.
Certain Relationships
The Placement Agent and its affiliates have and may in the future provide, from time to time, investment banking and financial advisory services to us in the ordinary course of business, for which they may receive customary fees and commissions.
95
LEGAL MATTERS
The Crone Law Group, P.C., is acting as our counsel in connection with the registration of our securities under the Securities Act, and as such, will pass upon the validity of the securities offered in this offering. Sichenzia Ross Ference Carmel LLP is acting as counsel to the Placement Agent.
EXPERTS
The consolidated financial statements as of December 31, 2023 and December 31, 2022 included in this prospectus and in the registration statement have been so included in reliance on the report of Kreit & Chiu, LLP, an independent registered public accounting firm, appearing elsewhere herein and in the registration statement, given on the authority of said firm as experts in auditing and accounting.
WHERE YOU CAN FIND MORE INFORMATION
We have filed with the Commission a registration statement on Form S-1 under the Securities Act with respect to the securities we are offering by this prospectus. This prospectus does not contain all of the information included in the registration statement. For further information about us and our securities, you should refer to the registration statement and the exhibits and schedules filed with the registration statement. Whenever we make reference in this prospectus to any of our contracts, agreements or other documents, the references are materially complete but may not include a description of all aspects of such contracts, agreements or other documents, and you should refer to the exhibits attached to the registration statement for copies of the actual contract, agreement or other document.
Upon completion of this offering, we will be subject to the information requirements of the Exchange Act and will file annual, quarterly and current event reports, proxy statements and other information with the Commission. You can read our Commission filings, including the registration statement, over the Internet at the Commission’s website at www.sec.gov. You may also read and copy any document we file with the Commission at its public reference facility at 100 F Street, N.E., Washington, D.C. 20549.
You may also obtain copies of the documents at prescribed rates by writing to the Public Reference Section of the Commission at 100 F Street, N.E., Washington, D.C. 20549. Please call the Commission at 1-800-SEC-0330 for further information on the operation of the public reference facilities.
96
INDEX TO THE INSPIRE VETERINARY PARTNERS, INC AND SUBISIDIARIES FINANCIAL STATEMENTS
F-1
Inspire Veterinary Partners, Inc. and Subsidiaries
Unaudited Condensed Consolidated Balance Sheets
| March 31, | December 31, | |||||||
| 2024 | 2023 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Accounts receivable, net | ||||||||
| Due from former owners | ||||||||
| Inventory | ||||||||
| Refundable income tax | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Total current assets | ||||||||
| Restricted cash - non-current | ||||||||
| Property and equipment, net | ||||||||
| Right-of-use assets | ||||||||
| Other intangibles, net | ||||||||
| Goodwill | ||||||||
| Other assets | ||||||||
| Total assets | $ | $ | ||||||
| Liabilities and Stockholder’s Deficit | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued expenses | ||||||||
| Cumulative Series A preferred stock dividends payable | ||||||||
| Operating lease liabilities | ||||||||
| Loan payable, net of discount | ||||||||
| Bridge note, net of discount | ||||||||
| Convertible note payable | ||||||||
| Convertible debentures, net of issuance costs | ||||||||
| Notes payable, net of discount | ||||||||
| Total current liabilities | ||||||||
| Operating lease liabilities, non-current | ||||||||
| Notes payable - noncurrent | ||||||||
| Total liabilities | ||||||||
| COMMITMENTS AND CONTINGENCIES (Note 12) | ||||||||
| STOCKHOLDER’S EQUITY (DEFICIT) | ||||||||
| Common stock - Class A, $ | ||||||||
| Common stock - Class B, $ | ||||||||
| Convertible series A preferred stock, $ | ||||||||
| Additional paid in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total stockholder’s equity (deficit) | ( | ) | ||||||
| Total liabilities and stockholder’s equity (deficit) | $ | $ | ||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
F-2
Inspire Veterinary Partners, Inc. and Subsidiaries
Unaudited Condensed Consolidated Statements of Operations
| For the Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Service revenue | $ | $ | ||||||
| Product revenue | ||||||||
| Total revenue | ||||||||
| Operating expenses | ||||||||
| Cost of service revenue (exclusive of depreciation and amortization, shown separately below) | ||||||||
| Cost of product revenue (exclusive of depreciation and amortization, shown separately below) | ||||||||
| General and administrative expenses | ||||||||
| Debt extinguishment loss | ||||||||
| Depreciation and amortization | ||||||||
| Total operating expenses | ||||||||
| Loss from operations | ( | ) | ( | ) | ||||
| Other income (expenses): | ||||||||
| Interest income | ||||||||
| Interest expense | ( | ) | ( | ) | ||||
| Other income | ||||||||
| Total other expenses | ( | ) | ( | ) | ||||
| Loss before income taxes | ( | ) | ( | ) | ||||
| Benefit for income taxes | ||||||||
| Net loss | ( | ) | ( | ) | ||||
| Dividend on convertible series A preferred stock | ( | ) | ||||||
| Net loss attributable to class A and B common stockholders | $ | ( | ) | $ | ( | ) | ||
| Net loss per Class A and B common shares: | ||||||||
| $ | ( | ) | $ | ( | ) | |||
| Weighted average shares outstanding per Class A and B common shares: | ||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
F-3
Inspire Veterinary Partners, Inc. and Subsidiaries
Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)
| Convertible Series A | Class A | Class B | ||||||||||||||||||||||||||||||||||
| Preferred Stock | Common Stock | Common Stock | Additional | Accumulated | Stockholders’ | |||||||||||||||||||||||||||||||
| No. of Shares | Amount | No. of Shares | Amount | No. of Shares | Amount | Paid-in Capital | Deficit (As Restated) | Equity
(Deficit) (As Restated) | ||||||||||||||||||||||||||||
| December 31, 2022 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
| Issuance of warrants to CEO | - | - | - | |||||||||||||||||||||||||||||||||
| Net loss | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||
| March 31, 2023 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
| Convertible Series A | Class A | Class B | ||||||||||||||||||||||||||||||||||
| Preferred Stock | Common Stock | Common Stock | Additional | Accumulated | Stockholders’ | |||||||||||||||||||||||||||||||
| No. of Shares | Amount | No. of Shares | Amount | No. of Shares | Amount | Paid-in Capital | Deficit (As Restated) | Deficit (As Restated) | ||||||||||||||||||||||||||||
| December 31, 2023 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
| Issuance of class A common stock and pre-funded warrants, net of issuance costs | ||||||||||||||||||||||||||||||||||||
| Exercise of pre-funded warrants | ( | ) | ||||||||||||||||||||||||||||||||||
| Issuance of Class A common stock and pre-funded warrants in connection with commitment shares | ||||||||||||||||||||||||||||||||||||
| Issuance of convertible series A preferred stock | ||||||||||||||||||||||||||||||||||||
| Issuance of class A common stock for services | ||||||||||||||||||||||||||||||||||||
| Issuance of class A common stock in connection with gernal release agreement | ||||||||||||||||||||||||||||||||||||
| Conversion of convertible series A preferred stock into class A common stock | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
| Convertible series A preferred stock cumulative dividends | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||
| Convertible series A preferred stock dividend | - | ( | ) | |||||||||||||||||||||||||||||||||
| Net loss | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||
| March 31, 2024 | $ | $ | $ | $ | ( | ) | $ | |||||||||||||||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
F-4
Inspire Veterinary Partners, Inc. and Subsidiaries
Unaudited Condensed Consolidated Statements of Cash Flows
| For the Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | ( |
) | $ | ( |
) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | ||||||||
| Amortization of debt issuance costs | ||||||||
| Amortization of debt discount | ||||||||
| Amortization of operating right of use assets | ||||||||
| Issuance of warrants to CEO | ||||||||
| Issuance of class A common stock for services | ||||||||
| Loss on debt modification | ||||||||
| Issuance of class A common stock in connection with general release agreement | ||||||||
| Issuance of Class A common stock and pre-funded warrants in connection with commitment shares | ||||||||
| Changes in operating assets and liabilities, net of effect of acquisitions: | ||||||||
| Accounts receivable | ( |
) | ( |
) | ||||
| Due from former owners | ||||||||
| Inventory | ( |
) | ||||||
| Prepaid expenses and other current assets | ( |
) | ||||||
| Other assets | ( |
) | ( |
) | ||||
| Accounts payable | ||||||||
| Accrued expenses | ( |
) | ||||||
| Cumulative Series A preferred stock dividends payable | ( |
) | ||||||
| Operating lease liabilities | ( |
) | ( |
) | ||||
| Net cash used in operating activities | ( |
) | ( |
) | ||||
| Cash flows from investing activities: | ||||||||
| Purchase of property and equipment | ( |
) | ( |
) | ||||
| Net cash used in investing activities | ( |
) | ( |
) | ||||
| Cash flows from financing activities: | ||||||||
| Proceeds from issuance of class A common stock and pre-funded warrants, net of issuance costs | ||||||||
| Net proceeds from loan payable | ||||||||
| Payments on loan payable | ( |
) | ||||||
| Proceeds from issuance of convertible series A preferred stock | ||||||||
| Proceeds from convertible note payable | ||||||||
| Repayment of note payable | ( |
) | ( |
) | ||||
| Proceeds from issuance of convertible debentures | ||||||||
| Repayment of convertible debentures | ( |
) | ||||||
| Net cash provided by financing activities | ||||||||
| Net increase (decrease) in cash, cash equivalents and restricted cash | ( |
) | ||||||
| Cash, cash equivalents and restricted cash, beginning of period | ||||||||
| Cash, cash equivalents and restricted cash, end of period | $ | $ | ||||||
| Supplemental Disclosure of Cash Flow Information | ||||||||
| Interest payments during the year | $ | $ | ||||||
| Income taxes paid (refunded) | $ | $ | ( |
) | ||||
| Noncash investing and financing activity | ||||||||
| Series A Preferred Stock Dividend Paid-in-Kind | $ | $ | ||||||
The accompanying notes are an integral part of these consolidated financial statements.
F-5
Notes to Unaudited Condensed Consolidated Financial Statements
March 31, 2024
| 1. | Description of Business |
Business Description
Inspire Veterinary Partners, Inc. (the “Company” or “Inspire”) is a C-corporation which incorporated in the state of Delaware on December 2, 2020. On June 29, 2022, the Company converted into a Nevada C-corporation (“Conversion”). The Conversion did not result in any change in the corporate name, business, management fiscal year, accounting, location of the principal executive officer, capitalization structure, or assets or liabilities of the Company. The Company owns and operates veterinary hospitals throughout the United States. The Company specializes in small animal general practice hospitals which serve all manner of companion pets, emphasizing canine and feline breeds.
As the Company expands, additional modalities are becoming a part of the offerings at its hospital, including equine care. With 14 clinics located in 10 states as of the date of this filing, Inspire purchases existing hospitals which have the financial track record, marketplace advantages and future growth potential to make them worthy acquisition targets. Because the company leverages a leadership and support structure which is distributed throughout the United States, acquisitions are not centralized to one geographic area. The Company operates its business as one operating and one reportable segment.
Services provided at owned hospitals include preventive care for companion animals consisting of annual health exams which include: parasite control; dental health; nutrition and body condition counseling; neurological examinations; radiology; bloodwork; skin and coat health and many breed specific preventive care services. Surgical offerings include all soft tissue procedures such as spays and neuters, mass removals, splenectomies and can also include gastropexies, orthopedic procedures and other types of surgical offerings based on a doctor’s training. In many locations additional means of care and alternative procedures are also offered such as acupuncture, chiropractic and various other health and wellness offerings.
The Company is the managing member of IVP Practice Holdings Co., LLC (“Holdco”), a Delaware limited liability company, which is the managing member of IVP CO Holding, LLC (“CO Holdco”), a Delaware limited liability company, IVP FL Holding Co., LLC (“FL Holdco”), a Delaware limited liability company, IVP Texas Holding Company, LLC (“TX Holdco”), a Delaware limited liability company, KVC Holding Company, LLC (“KVC Holdco”), a Hawaii limited liability company, and IVP CA Holding Co., LLC (“CA Holdco”), a Delaware limited liability company, IVP MD Holding Company, LLC (“MD Holdco”), a Delaware limited liability company, IVP OH Holding (“OH Holdco”), Co, LLC, a Delaware limited liability company, IVP IN Holding Co., LLC (“IN Holdco”), a Delaware limited liability company, IVP MA Managing Co., LLC, a Delaware limited liability company (“MA Holdco”), and IVP PA Holding Company, LLC, a Delaware limited liability company (“PA Holdco”). The Company through Holdco, operates and controls all business and affairs of CO Holdco, FL Holdco, TX Holdco, KVC Holdco, CA Holdco, MD Holdco. Holdco, OH Holdco, IN Holdco, MA Holdco and PA Holdco is used to acquire hospitals in various states and jurisdictions.
The Company is the managing member of IVP Real Estate Holding Co., LLC (“IVP RE”), a Delaware limited liability company, which is the managing member of IVP CO Properties, LLC (“CO RE”), a Delaware limited liability company, IVP FL Properties, LLC (“FL RE”), a Delaware limited liability company, IVP TX Properties, LLC (“TX RE”), a Delaware limited liability company, KVC Properties, LLC, (“KVC RE”), a Hawaii limited liability company, IVP CA Properties, LLC (“CA RE”), a Delaware limited liability company, IVP MD Properties, LLC (“MD RE”), a Delaware limited liability company, IVP OH Properties, LLC (“OH RE”), a Delaware limited liability company, IVP IN Properties, LLC (“IN RE”), a Delaware limited liability company, and IVP PA Properties, LLC (“PA RE”), a Delaware limited liability company. The Company through IVP RE operates and controls all business and affairs of CO RE, FL RE, TX RE, KVC RE, CA RE, MD RE, OH RE, IN RE and PA RE. IVP RE is used to acquire real property in various states and jurisdictions.
F-6
Initial Public Offering
On August 31, 2023, we closed our IPO
of
| 2. | RETROSPECTIVE ADJUSTMENTS |
| 3. | Significant Accounting Policies and Basis of Presentation |
Basis of Presentation
The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2023, which are included with the Company’s Annual Report on Form 10-K and related amendments filed with the United States Securities Exchange Commission (“SEC”). Furthermore, the Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the years ended December 31, 2023 and 2022, included in the Company’s Annual Report on Form 10-K filed with the SEC. Since the date of those audited consolidated financial statements, there have been no changes to the Company’s significant accounting policies, except as noted below.
The accompanying unaudited interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification(“ASC”) and as amended by Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).
In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements for the periods presented reflect all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the Company’s financial position, results of operations, and cash flows. The December 31, 2023, condensed consolidated balance sheet was derived from audited financial statements, but does not include all GAAP disclosures. The unaudited condensed consolidated financial statements for the interim periods are not necessarily indicative of results for the full year.
On October 20, 2022, the Company amended
and restated the articles of incorporation to change the designation of the Class A common stock and the Class B common stock, whereas
the Class A common stock prior to the amendment had
Going Concern
These financial statements have been
prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course
of business. The Company has incurred recurring losses and as of March 31, 2024, had an accumulated deficit of $
F-7
Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of sales and expenses during the reporting period. Actual results could differ from those estimates.
Accounts Receivable and Allowance for Expected Credit Losses
Accounts receivable consist of amounts
due from veterinary customers. The Company records an allowance for current expected credit losses for estimated losses inherent in its
trade accounts receivable portfolio. In establishing the required allowance, management considers historical losses adjusted for current
market conditions, the financial condition of the customer, the amount of receivables in dispute, and the current receivables aging and
payment patterns. The Company does not have any off-balance sheet credit exposure related to its customers. The allowance for current
expected credit losses was $
Basic and Diluted Net Loss Per Share
Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during each period. Diluted net loss per share of common shares includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, share options and warrants, which would result in the issuance of incremental shares of common shares. For diluted net loss per share, the weighted-average number of common shares is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. For all periods presented, basic and diluted net loss per share are the same, as any additional share equivalents would be anti-dilutive. As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share.
| March 31, | ||||||||
| 2024 | 2023 | |||||||
| Warrants | ||||||||
| Convertible Series A Preferred Shares | ||||||||
| Total | ||||||||
Emerging Growth Company Status
The Company is an Emerging Growth Company, as defined in Section 2(a) of the Securities Act of 1933, as modified by the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these unaudited condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.
F-8
| 4. | Property and equipment |
| March 31, | December 31, | |||||||
| 2024 | 2023 | |||||||
| Land | $ | $ | ||||||
| Computers and equipment | ||||||||
| Furniture and fixtures | ||||||||
| Automobile | ||||||||
| Leasehold improvements | ||||||||
| Buildings | ||||||||
| Less - accumulated depreciation | ( | ) | ( | ) | ||||
| Property and Equipment, net | $ | $ | ||||||
Depreciation expense was $
| 5. | Goodwill and Intangible Assets |
| March 31, | December 31, | |||||||
| 2024 | 2023 | |||||||
| Client List | $ | $ | ||||||
| Noncompete Agreement | ||||||||
| Trademark | ||||||||
| Other Intangible Assets | ||||||||
| Accumulated amortization | ( | ) | ( | ) | ||||
| $ | $ | |||||||
Amortization expense was $
| Remainder of 2024 | ||||
| 2025 | ||||
| 2026 | ||||
| 2027 | ||||
| 2028 | ||||
| $ |
F-9
| 6. | Business acquisitions |
Valley Veterinary Service
On November 8, 2023, the Company acquired
the animal hospital and related assets of Valley Veterinary Service, Inc., a Pennsylvania corporation (“Valley Vet Practice”)
by entering into an Asset Purchase Agreement (“Valley Vet APA”) with Michelle Bartus, VMD and Peter Nelson, VMD (“Valley
Vet”) in exchange for the payment of $
The total consideration paid for the
combined acquisitions from the Valley Vet animal hospital in the amount of $
| Consideration: | ||||
| Cash paid prior to the time of closing | $ | |||
| Convertible Note Payable | ||||
| Acquisition costs included in general and administrative | ||||
| Recognized amounts of identifiable assets acquired | ||||
| Inventory | ||||
| Building | ||||
| Land | ||||
| Furniture, fixtures & equipment | ||||
| Trademark ( | ||||
| Non-compete agreement ( | ||||
| Client list ( | ||||
| Total identifiable net assets assumed | ||||
| Goodwill | ||||
| Total | $ | |||
Pro-Forma Financial Information (Unaudited)
The following unaudited pro forma information
presents the consolidated results of Valley Vet Practice included in the Company’s consolidated statement of operations for the
three months ended March 31, 2023, as if the acquisitions were made on
F-10
| For the Three Months Ended March 31, 2023 | ||||
| Revenue | $ | |||
| Net Income (Loss) | ( | ) | ||
| 7. | Debt |
Master Lending and Credit Facility
On June 25, 2021, the Company entered
into a master line of credit loan agreement (“MLOCA”) with Wealth South a division of Farmers National Bank of Danville,
Kentucky (“FNBD”). The MLOCA provides for a $
Under the MLOCA the Term Loans to acquire
a Practice shall not exceed
There is no prepayment penalty on payments
on the Revolving Line. The Term Loans are subject to a refinance fee of
On
F-11
| Original Principal | Acquisition | Entered | Maturity | Interest | March 31, 2024 | December 31, 2023 | Issuance Cost | |||||||||||||||||
| $ | % | $ | $ | $ | ||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| $ | $ | $ | $ | |||||||||||||||||||||
The Company amortized $
FSB Commercial Loans
On January 11, 2021, the Company entered
into three separate commercial loans with First Southern National Bank (“FSB”) as part of the Kauai Veterinary Clinic, LLC
acquisition. The first commercial loan in the amount of $
The second commercial loan with FSB
entered into on January 11, 2021 in the amount of $
F-12
The third commercial loan with FSB
entered into on January 11, 2021 in the amount of $
On October 31, 2022 the company entered
into three separate commercial loans with FSB as part of the Pony Express Practice acquisition. The first loan with FSB that was entered
into on October 31, 2022, was in the amount of $
The second loan with FSB that was entered
into on October 31, 2022, was in the amount of $
The third loan with FSB that was entered
into on October 31, 2022, was in the amount of $
On December 16, 2022, the company entered
into two separate commercial loans with FSB as part of the Old 41 Practice acquisition. The first loan with FSB that was entered into
on December 16, 2022, was in the amount of $
The second loan with FSB that was entered
into December 16, 2022, was in the amount of $
The FSB commercial loans are guaranteed by Kimball Carr, Chief Executive Officer and President and Charles Stith Keiser, our Vice Chairman and Chief Operating Officer.
F-13
| Original Principal | Acquisition | Entered | Maturity | Interest | March 31, 2024 | December 31, 2023 | Issuance Cost | |||||||||||||||||
| $ | % | $ | $ | $ | ||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | - | |||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| $ | $ | $ | $ | |||||||||||||||||||||
| March 31, | December 31, | |||||||
| 2024 | 2023 | |||||||
| FNBD Notes Payable | $ | $ | ||||||
| FSNB Notes Payable | ||||||||
| Total notes payable | ||||||||
| Unamortized debt issuance costs | ( | ) | ( | ) | ||||
| Notes payable, net of issuance cost | ||||||||
| Less current portion | ( | ) | ( | ) | ||||
| Long-term portion | $ | $ | ||||||
| Remainder of 2024 | $ | |||
| 2025 | ||||
| 2026 | ||||
| 2027 | ||||
| 2028 | ||||
| Thereafter | $ |
Bridge Note
In December 2021, the Company entered
into two bridge loans in the aggregate amount of $
F-14
In conjunction with the Bridge Note
the Company issued warrants on January 24, 2022 to Target Capital 1, LLC and Dragon Dynamic Catalytic Bridge SAC Fund (collectively the
“Bridge Lenders”). The warrants entitled the Bridge Lenders to purchase the Company’s Class A common stock, at a purchase
price equal to the per share price in an IPO. The quantity of the Company’s common stock of subject to purchase upon exercise of
the warrants is equal to
On November 18, 2022, the Company entered
into an Original Issue Discount Secured Convertible Note loan with Target Capital 1, LLC for $
In conjunction with the Original Issue
Discount Secured Convertible Note with Target Capital 1, LLC the company issued the holder
On November 18, 2022, the Company entered
into an Original Issue Discount Secured Convertible Note with 622 Capital LLC for $
F-15
In conjunction with the Original Issue
Discount Secured Convertible Note with 662 Capital LLC the company issued the holder equity classified warrants that entitle the holder
to purchase the Company’s common stock at a purchase price equal to the per share price in an IPO. The quantity of the Company’s
common stock of subject to purchase upon exercise of the warrants is equal to
The warrants were deemed legally detachable
from the Bridge Note and were fair valued using the Black Scholes Method to determine the relative fair values of the Bridge Note and
the detachable warrants. The significant inputs for the Black Scholes calculation included the exercise price and common share price
of $
| Bridge notes, December 31, 2022 | ||||
| Amortization of original issue discount | ||||
| Amortization of warrant discount | ||||
| Amortization of debt issuance costs | ||||
| Bridge notes, March 31, 2023 | $ |
On June 30, 2023, the Company entered
into exchange agreements (the “Exchange Agreements”) with each of the Company’s Bridge Note lenders, pursuant to which
the lenders exchanged their existing Bridge Notes for
Convertible Debenture
Between March 18 and December 28, 2021,
the Company issued $
Upon the Company’s IPO closing
on August 31, 2023, the majority of Convertible Debenture holders elected to convert an aggregate of $
Loan Payable
On May 30, 2023, the Company entered
into a Merchant Cash Advance Agreement for gross proceeds of $
On August 10, 2023, the Company amended
the financing arrangement to borrow an additional $
F-16
On November 28, 2023, the Company amended
the financing arrangement to borrow an additional $
On January 18, 2024, the Company amended
the financing arrangement to borrow an additional $
During the three months ended March
31, 2024, the Company amortized $
Convertible Note Payable
On March 26, Inspire Veterinary entered
into a securities purchase agreement (the “Purchase Agreement”) with certain investor. Pursuant to the Purchase Agreement,
Inspire Veterinary issued to investors Increasing OID Senior Note (“Convertible Note Payable”) for $
The Convertible Note Payable contain
an original issued discount (“OID”) which shall be: (i) fifteen percent (
The Convertible Note Payable must be repaid in full from any future capital raises (debt, equity or any other form of capital raise) of Inspire Veterinary. All of the funds raised must be used to repay the Convertible Note Payable until the Convertible Note Payable are repaid in full
The Convertible Note Payable are convertible
into shares of common stock of Inspire Veterinary, in full or in part, at any time after issuance at the discretion of the noteholder
at a fixed conversion price of $
If the Convertible Note Payable is
not repaid by the Maturity Date the default provisions are as follow: (i) The Face Value (as such term is defined in the Convertible
Note Payable) of the Convertible Note Payable will increase by
| 8. | Related Party Transactions |
Blue Heron
The Company entered into a consulting
agreement with Blue Heron Consulting (“BHC”) on June 24, 2021, pursuant to which BHC will consult with the Company on an
on-going basis in connection with the Company’s acquisition of veterinary practices throughout the United States and will serve
as the Company’s business and financial advisor with respect to its acquisition strategy and in connection with specific acquisition
targets. The Company’s director and Chief Operating Officer Charles Stith Keiser is the Chief Operating Officer of BHC, and the
Company’s director Dr. Charles “Chuck” Keiser is the Chief Visionary Officer of BHC. During the fourth quarter of 2023
management terminated the service agreement with Blue Heron, however, still uses Blue Heron on an ad-hoc basis for services and has incurred
$
Under the Consulting Agreement, BHC is entitled to a monthly fee for on-going services including:
| ● | the preparation of valuation packages of potential acquisitions (including the gathering of pertinent information, financial and background data, completion of deal packets and financial projection worksheets used by the Company to calculate practice values); |
| ● | the institution of turnover protocols and procedures of hospitals immediately post-purchase; systems reporting; the formulation of individual hospital goals and targets; |
| ● | on-going monthly support of hospital units (including medical and operational coaching, business growth projections, establishment of financial targets and margin improvements, growth milestones) and recruiting support. |
Upon termination, all accrued, but not yet paid fees and expenses, whether invoiced or not, must be paid to BHC.
F-17
Star Circle Advisory
The Company entered into a consulting
agreement with Star Circle Advisory Group, LLC (“Star Circle”) on August 2, 2022 to serve as financial consultant, on a non-exclusive
basis, to assist with arranging bridge financing and the initial public offering of the Company. Star Circle is owned and controlled
by Kimball Carr, Chairman, Chief Executive Officer and President, Peter Lau, Interim Chief Financial Officer and Director, James Coleman,
Director, and Richard Marten, Director. Star Circle is entitled to a monthly fee of $
CEO Warrant
On January 1, 2023, the board of directors
issued
| 9. | Stockholders’ Equity |
The Company is authorized to issue
is
Each outstanding share of Class A common
stock is entitled to vote on each matter on which the stockholders of the Company is entitled to vote, and each holder of Class A common
stock is entitled to
Each outstanding share of Class B common
stock is entitled to vote on each matter on which the stockholders of the Company is entitled to vote, and each holder of Class B common
stock is entitled to
All shares of Class A common stock and Class B common stock (collectively “common stock”) will be identical and will entitle the holders thereof to the same rights and privileges, except as otherwise provided above.
On November 15, 2022, the companies
amended the consulting agreement with Alchemy Advisory, LLC until June 30, 2023. The contract amendment stipulates an additional fee
of $
On November 15, 2022, the Company entered
into a consulting agreement with 662 Capital LLC until June 30, 2023. The contract stipulates the Company will issue
F-18
Convertible Series A Preferred Stock
On June 30, 2023, the Company amended
its articles of incorporation by the filing of a certificate of designation for the Series A Preferred Stock. One million shares of the
Series A Preferred Stock are authorized under the Series A Certificate of Designation, with each having a stated value of $
Holders of shares of the Series A Preferred
Stock are entitled to a liquidation preference in the event of any dissolution, liquidation or winding up of the Company equal to the
stated value plus any accrued and unpaid dividends on such stock. Holders of shares of Series A Preferred Stock are also entitled to
convert such shares at any time and from time, at the option of such holder, into a number of shares of Class A common stock equal to
the stated value divided by a conversion price. The conversion price is equal to
On November 7, 2023, the Company amended
its article of incorporation to increase the total authorized preferred stock by
The conversion price of the convertible
series A preferred stock to be no less than $
The holders of the Series A Preferred Stock have the right to vote on all matters submitted to a vote of shareholders on an as-if-converted basis together with the holders of shares of the Company’s Class A and Class B common stock, voting together as a single class.
On June 30, 2023, the Company issued
In connection with the Exchange, the
Company also issued warrants (the “New Warrants”) to purchase additional shares of Class A common stock. The New Warrants
were issued in exchange for the existing warrants held by the former Bridge Note holders. The exercise price of the shares to be issued
pursuant to the New Warrants is the price of the shares of Class A common stock to be issued in this offering. The number of shares to
be issued upon exercise of the New Warrants is equal to the quotient of
| 10. | Retirement Plan |
During the year ending December 31,
2022, the Company implemented a qualified 401(K) retirement plan. The Company offers eligible domestic full-time employees participation
in certain 401K plans. The plans provide for a discretionary annual company contribution. In addition, employees may contribute a portion
of their salary to the plans, which certain of the 401K plans, is partially matched by the Company. The plans may be amended or terminated
at any time. The Company contributed and expensed approximately $
| 11. | Income Taxes |
The Company has incurred losses since inception, which have generated net operating loss (“NOL”) carryforwards. As of March 31, 2024 and December 31, 2023, tax benefit was reported with respect to these NOL carry-forwards in the accompanying financial statements because the Company believes the realization of the Company’s net deferred tax assets for the NOL for combined federal and state jurisdictions was considered more likely than not that it will not be realized and accordingly, the potential tax benefits of the net loss carry-forwards are fully offset by a full valuation allowance. The Company’s effective tax rate is different than the federal statutory tax rate because the Company has established a full valuation allowance against its net deferred income tax asset.
F-19
| 12. | Leases |
Accounting for Leases as Lessee
The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use assets (“ROU”), operating lease liabilities, and operating lease liabilities, non-current. Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. None of the leases entered into have an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future payments. Incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in economic environments where the leased asset is located. The ROU assets also include any prepaid lease payments made and initial direct costs incurred and excludes lease incentives. The Company’s lease terms may include options to extend or terminate the lease, which is recognized when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet.
The Company has operating leases for real estate. The Company has certain intercompany leases between its subsidiaries, and these transactions and balances have been eliminated in consolidation and are not reflected in the tables and information presented below.
| For the Three Months Ended March 31, | ||||||||||
| Operating lease expense: | Expense Classification | 2024 | 2023 | |||||||
| Amortization of ROU asset | General and administrative | $ | ||||||||
| Accretion of operating lease liability | General and administrative | |||||||||
| Total operating lease expense | $ | |||||||||
| Other lease expense | General and administrative | ( | ) | |||||||
| Total | $ | |||||||||
| As of March 31, | As of December 31, | |||||||
| 2024 | 2023 | |||||||
| Weighted-average remaining lease term: | ||||||||
| Operating leases (in years) | ||||||||
| Weighted-average Discount rate: | ||||||||
| Operating leases | % | % | ||||||
F-20
| As of March 31, | As of December 31, | |||||||||
| Balance Sheet Classification | 2024 | 2023 | ||||||||
| Assets: | ||||||||||
| Operating lease assets | Right-of-use assets | $ | $ | |||||||
| Liabilities: | ||||||||||
| Operating lease liabilities | Operating lease liabilities | $ | ||||||||
| Operating lease liabilities | Operating lease liabilities, non-current | |||||||||
| Total lease liabilities | $ | $ | ||||||||
| Fiscal Year | Operating Leases | |||
| Remainder of 2024 | $ | |||
| 2025 | ||||
| 2026 | ||||
| 2027 | ||||
| 2028 | ||||
| Thereafter | ||||
| Undiscounted cash flows | ||||
| Less: imputed interest | ( | ) | ||
| Lease liability | $ | |||
| 13. | Commitments and Contingencies |
As of March 31, 2024, substantially all of the Company’s assets were pledged as collateral for the Company’s credit facilities.
On November 30, 2023, the Company entered
into a common stock purchase agreement with a 3rd party investor (the “Investor”), to which the investor
committed to purchase up to $
Under the terms and subject to the
conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to the Investor, and the Investor is
obligated to purchase, shares of Class A common stock in an amount up to $
F-21
Purchase Price
The shares of Class A common stock
to be issued by the Company and purchased by the Investor will be sold at a purchase price equal to
Actual sales of shares of Class A common stock to the Investor will depend on a variety of factors to be determined by the Company from time-to-time, including, among other things, market conditions, the trading price of the Company’s Class A common stock, and the working capital needs, if any, of the Company.
The net proceeds from sales, if any, under the Purchase Agreement to the Company will depend on the frequency and prices at which the Company sells shares of Class A common stock to the Investor. the Company expects that any proceeds received by the Company from such sales to the Investor will be used for working capital and general corporate purposes.
Purchase Limits
Pursuant to the Purchase Agreement,
Consistent with certain applicable
Nasdaq rules, the Company may not issue to the Investor more than
Fees
As consideration for the Investor’s
irrevocable commitment to purchase shares of Class A Common Stock, upon execution of the Purchase Agreement, the Company became obligated
to issue to the Investor a number of shares of Class A Common Stock equal to $
F-22
Certain Representations, Warranties and Covenants
The Purchase Agreement contains customary representations, warranties, conditions, and indemnification obligations of each of the Company and the Investor. Pursuant to the Purchase Agreement, the Investor has agreed not to enter into or effect, in any manner whatsoever, directly or indirectly, any short sales of the Company’s Class A Common Stock or hedging transaction which establishes a net short position with respect to the Class A Common Stock. In addition, the Company has covenanted, among other things, through the 24-month anniversary of the signing of the Purchase Agreement, to not effect or enter into any agreement to issue any shares of Class A Common Stock or securities convertible into or exercisable or exchangeable into shares of Class A Common Stock except in limited circumstances.
The Company has the right to terminate
the Purchase Agreement at any time following the satisfaction of certain conditions precedent relating to the initial sale of shares
to the Investor, subject to the Company paying all documented fees and amounts to the Investor’s legal counsel and, if the agreement
is terminated prior to effectiveness of the resale registration statement, the Company paying the $
The Purchase Agreement will automatically terminate on (i) the 24-month anniversary of the effective date of the initial resale registration statement filed with the Commission, (ii) the date when the Investor purchases the Total Commitment, (iii) the date when the shares of Class A Common Stock are no longer listed on the Nasdaq Capital Market or another eligible national stock exchange, or (iv) when the Company is subject to a voluntary or involuntary bankruptcy or insolvency proceeding.
In addition, the Investor may terminate the Purchase Agreement upon (i) the occurrence of an event constituting a material adverse effect (as defined in the Purchase Agreement), (ii) the occurrence of a change of control transaction of the Company, (iii) the failure by the Company to file a registration statement by the applicable deadline set forth in the Registration Rights Agreement, (iv) the lapse of the effectiveness, or unavailability of, a registration statement filed by the Company pursuant to the Registration Rights Agreement in certain other circumstances set forth in the Purchase Agreement, (v) the suspension of trading of the Class A Common Stock for a period of three (3) consecutive trading days, or (vi) the material breach of the Purchase Agreement by the Company, which breach is not cured within the 10 trading days after receipt of notice of such breach.
On December 28, 2023, the Company amended
the agreement to provide that, if the number of commitment shares required to be issued by the Company to the Investor and its affiliates
(as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 promulgated thereunder) pursuant
to the Purchase Agreement would result in the beneficial ownership by the Investor of more than
The amendment further provide that,
if the issuance of the total number of commitment shares of Class A common stock and Warrant Shares by the Company to the Investor would
cause the beneficial ownership of the Investor and its affiliates to exceed
F-23
On February 14, 2024, the Company issued
Holdback Agreement
As part of the Valley Veterinary Services,
Inc. acquisition in November 2023, a portion of the purchase price in the amount of $
As the contingent consideration arrangement in which the Holdback amounts are automatically forfeited if the employment of the former owners (now employees of the Company) terminates is accounted for as compensation for post combination services. The Company will recognize the contingent consideration from the Holdback Agreement when probable.
| 14. | Subsequent Events |
The Company follows the guidance in FASB ASC 855-10 for the disclosure of subsequent events. The Company evaluated subsequent events through the date the financial statements were issued and determined the Company had the following subsequent events:
Refinancing Loan Payable
On May 7, 2024, the Company amended
the financing arrangement to borrow an additional $
New Loan Payable
On April 4, 2024, the Company entered
into a new financing arrangement to borrow $
F-24
Report of Independent Registered Public Accounting Firm
Board of Directors and Shareholders
Inspire Veterinary Partners, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Inspire Veterinary Partners, Inc. (the “Company”) as of December 31, 2023 and 2022, and the related consolidated statements of operations, changes in stockholders’ equity (deficit), and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the “financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of Inspire Veterinary Partners, Inc. as of December 31, 2023 and 2022, and the consolidated results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.
Explanatory Paragraph – Going Concern
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 2 to the financial statements, the Company has incurred recurring losses and at December 31, 2023, had an accumulated deficit of $21,215,257 and a working capital deficit of $6,229,695. For the year ended December 31, 2023, the Company sustained a net loss of $14,792,886 and used $3,820,722 in operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might become necessary should the Company be unable to continue as a going concern.
Basis for Opinion
These financial statements are the responsibility of the entity’s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to Inspire Veterinary Partners, Inc. in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Inspire Veterinary Partners, Inc. is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ Kreit & Chiu CPA LLP
We have served as Inspire Veterinary Partners, Inc.’s auditor since 2021.
New York, New York
April 8, 2024, except for the effect of the reverse stock split described in Note 2 for which the date is June 20, 2024
F-25
Inspire Veterinary Partners, Inc. and Subsidiaries
Consolidated Balance Sheets
| December 31, | December 31, | |||||||
| 2023 | 2022 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Accounts receivable, net | ||||||||
| Due from former owners | ||||||||
| Inventory | ||||||||
| Refundable income tax | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Total current assets | ||||||||
| Restricted cash - non-current | ||||||||
| Property and equipment, net | ||||||||
| Right-of-use assets | ||||||||
| Other intangibles, net | ||||||||
| Goodwill | ||||||||
| Other assets | ||||||||
| Total assets | $ | $ | ||||||
| Liabilities and Stockholder’s Deficit | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued expenses | ||||||||
| Cumulative Series A preferred stock dividends payable | ||||||||
| Operating lease liabilities | ||||||||
| Loan payable, net of discount | ||||||||
| Bridge note, net of discount | ||||||||
| Convertible debentures, net of issuance costs | ||||||||
| Notes payable, net of discount | ||||||||
| Total current liabilities | ||||||||
| Operating lease liabilities, non-current | ||||||||
| Convertible debentures, net of issuance costs | ||||||||
| Notes payable - noncurrent | ||||||||
| Total liabilities | ||||||||
| COMMITMENTS AND CONTINGENCIES (Note 12) | ||||||||
| STOCKHOLDER’S EQUITY (DEFICIT) | ||||||||
| Common stock - Class A, $ | ||||||||
| Common stock - Class B, $ | ||||||||
| Convertible series A preferred stock, $ | ||||||||
| Additional paid in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total stockholder’s equity (deficit) | ( | ) | ( | ) | ||||
| Total liabilities and stockholder’s equity (deficit) | $ | $ | ||||||
The accompanying notes are an integral part of these consolidated financial statements.
F-26
Inspire Veterinary Partners, Inc. and Subsidiaries
Consolidated Statements of Operations
| Year Ended December 31, | ||||||||
| 2023 | 2022 | |||||||
| Service revenue | $ | $ | ||||||
| Product revenue | ||||||||
| Total revenue | ||||||||
| Operating expenses | ||||||||
| Cost of service revenue (exclusive of depreciation and amortization, shown separately below) | ||||||||
| Cost of product revenue (exclusive of depreciation and amortization, shown separately below) | ||||||||
| General and administrative expenses | ||||||||
| Debt extinguishment loss | ||||||||
| Depreciation and amortization | ||||||||
| Total operating expenses | ||||||||
| Loss from operations | ( | ) | ( | ) | ||||
| Other income (expenses): | ||||||||
| Interest income | ||||||||
| Interest expense | ( | ) | ( | ) | ||||
| Loss on debt modification | ( | ) | ||||||
| Beneficial conversion feature | ( | ) | ||||||
| Other income | ||||||||
| Total other expenses | ( | ) | ( | ) | ||||
| Loss before income taxes | ( | ) | ( | ) | ||||
| Benefit for income taxes | ||||||||
| Net loss | ( | ) | ( | ) | ||||
| Dividend on convertible series A preferred stock | ( | ) | ||||||
| Net loss attributable to class A and B common stockholders | $ | ( | ) | $ | ( | ) | ||
| Net loss per Class A and B common shares: | ||||||||
| $ | ( | ) | $ | ( | ) | |||
| Weighted average shares outstanding per Class A and B common shares: | ||||||||
The accompanying notes are an integral part of these consolidated financial statements.
F-27
Inspire Veterinary Partners, Inc. and Subsidiaries
Consolidated Statements of Changes in Stockholders’ Equity (Deficit)
| Convertible Series A Preferred Stock | Class A Common Stock | Class B Common Stock | Additional | Accumulated | Stockholders’ Equity | |||||||||||||||||||||||||||||||
| No. of Shares | Amount | No. of Shares | Amount | No. of Shares | Amount | Paid-in Capital | Deficit (As Restated) | (Deficit) (As Restated) | ||||||||||||||||||||||||||||
| Balance as of December 31, 2021 | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
| Issuance of warrants as part of bridge loan received | - | - | ||||||||||||||||||||||||||||||||||
| Issuance of class A common stock for services | - | - | ||||||||||||||||||||||||||||||||||
| Net Loss | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
| Balance as of December 31, 2022 | - | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||
| Issuance of warrants to CEO | - | - | - | |||||||||||||||||||||||||||||||||
| Issuance of convertible series A preferred stock in exchange for bridge note | - | - | ||||||||||||||||||||||||||||||||||
| Issuance of class A common stock in connection with initial public offering, net of issuance costs | - | - | ||||||||||||||||||||||||||||||||||
| Conversion of convertible debentures into class A common stock | - | - | ||||||||||||||||||||||||||||||||||
| Conversion of class B common stock into class A common stock | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
| Conversion of convertible series A preferred stock into class A common stock | ( | ) | ( | ) | - | |||||||||||||||||||||||||||||||
| Convertible series A preferred stock cumulative dividends | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||
| Convertible series A preferred stock dividend | - | - | ( | ) | ||||||||||||||||||||||||||||||||
| Issuance of common stock in connection with business acquisition | - | - | - | |||||||||||||||||||||||||||||||||
| Issuance of common stock for services | - | - | - | |||||||||||||||||||||||||||||||||
| Beneficial conversion feature on convertible debentures | - | - | - | |||||||||||||||||||||||||||||||||
| Beneficial conversion feature on convertible series A preferred stock | - | - | - | |||||||||||||||||||||||||||||||||
| Net Loss | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
| Balance as of December 31, 2023 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
The accompanying notes are an integral part of these consolidated financial statements.
F-28
Inspire Veterinary Partners, Inc. and Subsidiaries
Consolidated Statements of Cash Flows
| Year Ended December 31, | ||||||||
| 2023 | 2022 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | ||||||||
| Bad debt provision | ||||||||
| Amortization of debt issuance costs | ||||||||
| Amortization of debt discount | ||||||||
| Amortization of operating right of use assets | ||||||||
| Debt extinguishment loss | ||||||||
| Issuance of warrants to CEO | ||||||||
| Issuance of class A common stock for services | ||||||||
| Loss on debt modification | ||||||||
| Beneficial conversion feature | ||||||||
| Changes in operating assets and liabilities, net of effect of acquisitions: | ||||||||
| Accounts receivable | ( | ) | ||||||
| Due from former owners | ( | ) | ||||||
| Inventory | ( | ) | ||||||
| Refundable income tax | ||||||||
| Prepaid expenses and other current assets | ( | ) | ( | ) | ||||
| Other assets | ||||||||
| Accounts payable | ||||||||
| Accrued expenses | ||||||||
| Operating lease liabilities | ( | ) | ( | ) | ||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| Cash flows from investing activities: | ||||||||
| Purchase of property and equipment | ( | ) | ( | ) | ||||
| Purchase of intangible assets | ( | ) | ||||||
| Payment for acquisition of businesses | ( | ) | ( | ) | ||||
| Advances for target acquisitions | ||||||||
| Net cash used in investing activities | ( | ) | ( | ) | ||||
| Cash flows from financing activities: | ||||||||
| Proceeds from issuance of class A common stock in connection with initial public offering, net of offering costs | ||||||||
| Net proceeds from loan payable | ||||||||
| Payments on loan payable | ( | ) | ||||||
| Proceeds from note payable, net of discount | ||||||||
| Debt issuance costs | ( | ) | ||||||
| Repayment of note payable | ( | ) | ( | ) | ||||
| Proceeds from issuance of bridge notes | ||||||||
| Proceeds from issuance of convertible debentures | ||||||||
| Repayment of convertible debentures | ( | ) | ||||||
| Net cash provided by financing activities | ||||||||
| Net increase (decrease) in Cash, cash equivalents and restricted cash | ( | ) | ( | ) | ||||
| Cash, cash equivalents and restricted cash, beginning of period | ||||||||
| Cash, cash equivalents and restricted cash, end of period | $ | $ | ||||||
| Supplemental Disclosure of Cash Flow Information | ||||||||
| Interest payments during the year | $ | $ | ||||||
| Income tax refund | $ | $ | ||||||
| Noncash investing and financing activity | ||||||||
| Acquisition of assets through operating leases | $ | $ | ||||||
| Series A Preferred Stock Dividend | $ | $ | ||||||
| Issuance of common stock in connection with business acquisition | $ | $ | ||||||
| Issuance of convertible series A preferred stock due to conversion of bridge notes | $ | $ | ||||||
| Issuance of class A common stock due to conversion of convertible debentures | $ | $ | ||||||
The accompanying notes are an integral part of these consolidated financial statements.
F-29
Inspire Veterinary Partners, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
December 31, 2023
| 1. | Description of Business |
Business Description
Inspire Veterinary Partners, Inc. (the “Company” or “Inspire”) is a C-corporation which incorporated in the state of Delaware on December 2, 2020. On June 29, 2022, the Company converted into a Nevada C-corporation (“Conversion”). The Conversion did not result in any change in the corporate name, business, management, fiscal year, accounting, location of the principal executive officer, capitalization structure, or assets or liabilities of the Company. The Company owns and operates veterinary hospitals throughout the United States. The Company specializes in small animal general practice hospitals which serve all manner of companion pets, emphasizing canine and feline breeds.
As we expand, additional modalities are becoming a part of the services offered at our hospitals, including equine care. With 14 clinics located in 11 states as of March 31, 2024, Inspire purchases existing hospitals which have the financial track record, marketplace advantages and future growth potential to make them worthy acquisition targets. Because the Company leverages a leadership and support structure which is distributed throughout the United States, acquisitions are not centralized to one geographic area. The Company operates its business as one operating and one reportable segment.
Services provided at owned hospitals include preventive care for companion animals consisting of annual health exams which include: parasite control; dental health; nutrition and body condition counseling; neurological examinations; radiology; bloodwork; skin and coat health and many breed specific preventive care services. Surgical offerings include all soft tissue procedures such as spays and neuters, mass removals, splenectomies and can also include gastropexies, orthopedic procedures and other types of surgical offerings based on a doctor’s training. In many locations additional means of care and alternative procedures are also offered such as acupuncture, chiropractic and various other health and wellness offerings.
The Company is the managing member of IVP Practice Holdings Co., LLC (“Holdco”), a Delaware limited liability company, which is the managing member of IVP CO Holding, LLC (“CO Holdco”), a Delaware limited liability company, IVP FL Holding Co., LLC (“FL Holdco”), a Delaware limited liability company, IVP Texas Holding Company, LLC (“TX Holdco”), a Delaware limited liability company, KVC Holding Company, LLC (“KVC Holdco”), a Hawaii limited liability company, and IVP CA Holding Co., LLC (“CA Holdco”), a Delaware limited liability company, IVP MD Holding Company, LLC (“MD Holdco”), a Delaware limited liability company, IVP OH Holding (“OH Holdco”), Co, LLC, a Delaware limited liability company, IVP IN Holding Co., LLC (“IN Holdco”), a Delaware limited liability company, IVP MA Managing Co., LLC, a Delaware limited liability company (“MA Holdco”), and IVP PA Holding Company, LLC, a Delaware limited liability company (“PA Holdco”). The Company through Holdco, operates and controls all business and affairs of CO Holdco, FL Holdco, TX Holdco, KVC Holdco, CA Holdco, MD Holdco. Holdco, OH Holdco, IN Holdco, MA Holdco and PA Holdco are used to acquire hospitals in various states and jurisdictions.
The Company is the managing member of IVP Real Estate Holding Co., LLC (“IVP RE”), a Delaware limited liability company, which is the managing member of IVP CO Properties, LLC (“CO RE”), a Delaware limited liability company, IVP FL Properties, LLC (“FL RE”), a Delaware limited liability company, IVP TX Properties, LLC (“TX RE”), a Delaware limited liability company, KVC Properties, LLC, (“KVC RE”), a Hawaii limited liability company, IVP CA Properties, LLC (“CA RE”), a Delaware limited liability company, IVP MD Properties, LLC (“MD RE”), a Delaware limited liability company, IVP OH Properties, LLC (“OH RE”), a Delaware limited liability company, IVP IN Properties, LLC (“IN RE”), a Delaware limited liability company, and IVP PA Properties, LLC (“PA RE”), a Delaware limited liability company. The Company through IVP RE operates and controls all business and affairs of CO RE, FL RE, TX RE, KVC RE, CA RE, MD RE, OH RE, IN RE and PA RE. IVP RE are used to acquire real property in various states and jurisdictions.
F-30
| 2. | Significant Accounting Policies and Basis of Presentation |
Retrospective Adjustments
On May 8, 2024, the Company effected
a
Basis of Presentation
The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).
On October 20, 2022, the Company amended
and restated the articles of incorporation to change the designation of the Class A common stock and the Class B common stock, whereas
the Class A common stock prior to the amendment had
Going Concern
These financial statements have been
prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course
of business. The Company has incurred recurring losses and as of December 31, 2023, had an accumulated deficit of $
Principles of Consolidation
The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of sales and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents
The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of December 31, 2023 and 2022 the Company had no cash equivalents.
Financial instruments that potentially
subject the Company to a significant concentration of credit risk consist of cash. Cash is deposited in checking accounts at accredited
financial institutions with high credit-quality and is insured by the Federal Deposit Insurance Corporation (FDIC) up to $
F-31
Restricted Cash
Restricted Cash consisted of cash designated to settle a holdback agreement related to our acquisition of Valley Veterinary Services, Inc. to be settled by February 8, 2026 if specific contingencies are met (see note 12 for more information).
Accounts Receivable and Allowance for Expected Credit Losses
Accounts receivable consist of amounts
due from veterinary customers. The Company records an allowance for current expected credit losses for estimated losses inherent in its
trade accounts receivable portfolio. In establishing the required allowance, management considers historical losses adjusted for current
market conditions, the financial condition of the customer, the amount of receivables in dispute, and the current receivables aging and
payment patterns. The Company does not have any off-balance sheet credit exposure related to its customers. The allowance for current
expected credit losses was $
Due from Former Owners
The Company enters into asset purchase agreements related to the acquisitions of veterinary hospitals and as part of these agreements contractually obligates the former owners of the veterinary hospitals to reimburse the Company for any monies collected by the former owners for revenues earned subsequent to the closing date of the acquisition, less monies paid by the former owner on behalf of the Company for expenses incurred subsequent to the closing date of the acquisition. Any adjustments relating to pre-acquisition amounts will be reflected in goodwill.
Inventory
Inventory is recorded at the lower of cost or net realizable value. Cost is using the weighted average method. Inventory consists of inventoriable supplies used for veterinary care and services.
Leases
The Company reviews all arrangements for potential leases, and at inception, determines whether a lease is an operating or finance lease. Lease assets and liabilities, which generally represent the present value of future minimum lease payments over the term of the lease, are recognized as of the commencement date. Leases with an initial lease term of twelve months or less are classified as short-term leases and are not recognized in the balance sheets unless the lease contains a purchase option that is reasonably certain to be exercised.
Lease term, discount rate, variable lease costs and future minimum lease payment determinations require the use of judgment and are based on the facts and circumstances related to the specific lease. Lease terms are generally based on their initial non-cancellable terms, unless there is a renewal option that is reasonably certain to be exercised. Various factors, including economic incentives, intent, past history and business needs are considered to determine if a renewal option is reasonably certain to be exercised. The implicit rate in a lease agreement is used when it can be determined to value the lease obligation. Otherwise, the Company’s incremental borrowing rate, which is based on information available as of the lease commencement date, including applicable lease terms and the current economic environment, is used to determine the value of the lease obligation.
Property and Equipment
Property and equipment are recorded at cost, less accumulated depreciation. Depreciation of property and equipment is determined using the straight line method over the estimated useful lives of the related assets up to the salvage value. Expenditures for repairs and maintenance are charged to expense as incurred, and expenditures for betterments and major Improvements are capitalized and depreciated over the remaining useful lives of the assets. The carrying amount of the assets sold or retired and the related accumulated depreciation are eliminated in the year of disposal, with resulting gains or losses included in operations.
F-32
| Computers and equipment | ||||
| Furniture and fixtures | ||||
| Automobile | ||||
| Leasehold improvements | ||||
| Buildings |
Acquisitions
The Company enters into acquisitions primarily with existing veterinary hospitals throughout the United States. When we acquire a business or assets that are determined to meet the definition of a business, we allocate the purchase consideration paid to acquire the business to the assets and liabilities acquired based on estimated fair values at the acquisition date, with the excess of purchase price over the estimated fair value of the net assets acquired recorded as goodwill. If during the measurement period (a period not to exceed 12 months from the acquisition date) we receive additional information that existed as of the acquisition date but at the time of the original allocation described above was unknown to us, we make the appropriate adjustments to the purchase price allocation in the reporting period that the amounts are determined.
Goodwill
Goodwill represents the excess of the cost of an acquired business over the fair value assigned to its net assets. Goodwill is not amortized but is tested for impairment at a reporting unit level on an annual basis or when an event occurs, or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Events or changes in circumstances that may trigger interim impairment reviews include significant changes in business climate, operating results, planned investments in the reporting unit, or an expectation that the carrying amount may not be recoverable, among other factors.
The Company may first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events and circumstances, the Company determines it is more likely than not that the fair value of the reporting unit is greater than it’s carrying amount, an impairment test is unnecessary. If an impairment test is necessary, the Company will estimate the fair value of its related reporting units. If the carrying value of a reporting unit exceeds its fair value, the goodwill of that reporting unit is determined to be impaired, and the Company will proceed with recording an impairment charge equal to the excess of the carrying value over the related fair value.
The Company has recorded Goodwill in connection with business acquisitions during the years ended December 31, 2023 and 2022 (see Note 5). During the years ended December 31, 2023 and 2022, the Company recorded no impairment of Goodwill.
Intangible Assets
Intangible assets consist of client
list, trademark and non-compete intangibles that result from the acquisition of veterinary hospitals or practices. Client list intangible
assets represent the value of the long-term client relationship from the veterinary hospitals and practices. Trademark intangible assets
represent the value associated with the brand names in place at the date of the acquisition. Non-compete intangible assets represent
the value associated with non-compete agreements for former employees and owners in place at the date of the acquisition. The client
lists and trademarks’ are included in intangible assets reported in the balance sheet which are being amortized over a
F-33
Revenue Recognition
The Company recognizes service revenue from veterinary care services once the service is completed, as this is when the customer has the ability to direct the use of and obtain the benefits of the service. Payment terms are typically at the point of sale but may also occur upon completion of the service. The Company’s service contracts are primarily with veterinary customers. Product revenue is recognized when control passes, which occurs at a point in time when the customer completes a transaction at our animal hospitals or clinics and receives the product. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account for revenue recognition. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company’s performance obligations are the delivery of veterinary services at the estimated net realizable amount for those services and goods. The Company’s accounting methodologies and processes include an evaluation of the historical collection and consideration of whether contractual allowances are necessary based on historical experience. Revenue is reported net of sales discounts and excludes sales taxes.
Cost of service revenue (exclusive of depreciation and amortization)
Cost of service revenue consists of cost directly related to the animal services provided at the Company’s veterinary clinics and animal hospitals, which primarily includes personnel-related compensation costs of the employees at the Company’s veterinary clinics or animal hospitals, laboratory costs, pet supply costs, third-party veterinarian contractors, office rent, utilities, supplies, and other cost arising as a result of the services being performed, excluding depreciation and amortization.
Cost of product revenue (exclusive of depreciation and amortization)
Cost of product revenue consists of cost directly related to the product sales at the Company’s veterinary clinics and animal hospitals, which primarily includes personnel-related compensation costs of the employees at the Company’s veterinary clinics or animal hospitals, purchase price of the medication we dispense, and purchase price of product sold, excluding depreciation and amortization.
General and administrative expenses
General and administrative expenses include personnel-related compensation costs for corporate employees, such as management, accounting, legal, acquisition related and non-recurring expenses, insurance and other expenses used to operate the business.
Depreciation and Amortization Expense
Depreciation and amortization expenses mainly relate to the assets used in generating revenue.
Convertible Instruments
The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities”.
Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.
The Company accounts for convertible
instruments (when we have determined that the embedded conversion options should not be bifurcated from their host instruments) as follows:
The Company records when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments
based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the
effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt
to their stated date of redemption. The Company recognized a beneficial conversion feature of $
F-34
The Company records a discount to convertible notes and convertible preferred stock for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note, if applicable. Debt discounts under these arrangements are amortized to noncash interest expense using the effective interest rate method over the term of the related debt to their date of maturity. If a security or instrument becomes convertible only upon the occurrence of a future event outside the control of the Company, or, is convertible from inception, but contains conversion terms that change upon the occurrence of a future event, then any contingent beneficial conversion feature is measured and recognized when the triggering event occurs and contingency has been resolved.
Beneficial Conversion Feature of Convertible Debt
The Company accounts for convertible debt in accordance with the guidelines established by FASB ASC 470-20, “Debt with Conversion and Other Options”. The Beneficial Conversion Feature (“BCF”) of convertible debt is normally characterized as the convertible portion or feature of certain debt that provide a rate of conversion that is below market value or in-the-money when issued. The Company records a BCF related to the issuance of convertible debt when issued, and also records the estimated fair value. Beneficial conversion features that are contingent upon the occurrence of a future event are recorded when the event is resolved.
Debt Issuance Costs
Debt issuance costs are specifically identifiable costs associated with issuance of a new debt instrument. Debt issuance costs are reported on the consolidated balance sheet as a direct deduction from the face amount of the related debt. Debt issuance costs are amortized to interest expense over the term of the related debt.
Advertising Costs
The Company expenses advertising costs
as they are incurred. Advertising expenses were $
Stock Warrants
Certain warrants that were granted by the Company for lenders through convertible bridge loans transactions (see also Note 6 Debt - Bridge Note) are classified as a component of permanent equity since they are freestanding financial instruments that are legally detachable and separately exercisable, do not embody an obligation for the Company to repurchase its own shares, and permit the holders to receive a fixed number of shares of common stock upon exercise for a fixed exercise price and thus, are considered as indexed to the Company’s own stock. In addition, the warrants must require physical settlement and may not provide any guarantee of value or return. We present the allocated value for the warrants within additional paid-in capital in our consolidated balance sheet. The value assigned to the warrants was determined based on a relative fair value allocation between the warrants and related debt. The fair value of the warrants was determined using a Black Scholes valuation and applying a discount for the lack of marketability for the warrants.
Stock-Based Compensation
The Company follows FASB ASC Topic 718 which requires that new, modified and unvested share-based payment transactions with employees, such as grants of stock options and restricted stock, be recognized in the consolidated financial statements based on their fair value at the grant date and recognized as compensation expense over their vesting periods, which typically conform to the performance period. The Company estimates the fair value of stock options as of the date of grant using the Black-Scholes option pricing model and restricted stock based on the quoted market price or the value of the services provided, whichever is more readily determinable. The Company also follows the guidance in FASB ASC Topic 505 for equity based payments to non-employees for equity instruments issued to consultants and other non-employees.
F-35
Income Tax
The Company and its U.S. subsidiaries file a consolidated federal income tax return and is taxed as a C-Corporation, whereby it is subject to federal and state income taxes. The Company accounts for income taxes in accordance with ASC 740, “Income Taxes”. ASC 740 requires an asset and liability approach for financial accounting and reporting for income taxes and established for all the entities a minimum threshold for financial statement recognition of the benefit of tax positions and requires certain expanded disclosures. The provision for income taxes is based upon income or loss after adjustment for those permanent items that are not considered in the determination of taxable income. Deferred income taxes represent the tax effects of differences between the financial reporting and tax basis of the Company’s assets and liabilities at the enacted tax rates in effect for the years in which the differences are expected to reverse. The Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that some portion or all the deferred tax assets will not be realized. Management makes judgments as to the interpretation of the tax laws that might be challenged upon an audit and cause changes to previous estimates of tax liability. In management’s opinion, adequate provisions for income taxes have been made. If actual taxable income by tax jurisdiction varies from estimates, additional allowances or reversals of reserves may be necessary.
Basic and Diluted Net Loss Per Share
Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during each period. Diluted net loss per share of common shares includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, share options and warrants, which would result in the issuance of incremental shares of common shares. For diluted net loss per share, the weighted-average number of common shares is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. For all periods presented, basic and diluted net loss per share are the same, as any additional share equivalents would be anti-dilutive.
| December 31, | ||||||||
| 2023 | 2022 | |||||||
| Warrants | ||||||||
| Convertible Series A Preferred Shares | ||||||||
| Total | ||||||||
Recently Issued Accounting Pronouncements
In September 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instrument (“ASU 2016-13”). ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 was effective for the Company beginning January 1, 2023. The adoption of ASU 2016-13 did not have a material impact on the Company’s financial position, results of operations and cash flows.
The FASB and other entities issued new or modifications to, or interpretations of, existing accounting guidance during 2023. Management has carefully considered the new pronouncements that altered generally accepted accounting principles and does not believe that any other new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term.
Emerging Growth Company Status
The Company is an Emerging Growth Company, as defined in Section 2(a) of the Securities Act of 1933, as modified by the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.
F-36
| 3. | Property and equipment |
| December 31, | December 31, | |||||||
| 2023 | 2022 | |||||||
| Land | $ | $ | ||||||
| Buildings | ||||||||
| Computers and equipment | ||||||||
| Furniture and fixtures | ||||||||
| Automobile | ||||||||
| Leasehold improvements | ||||||||
| Less - accumulated depreciation | ( | ) | ( | ) | ||||
| Property and Equipment, net | $ | $ | ||||||
Depreciation expense was $
| 4. | Goodwill and Intangible Assets |
| Goodwill as of December 31, 2021 | $ | |||
| Acquisitions | ||||
| Goodwill as of December 31, 2022 | ||||
| Acquisitions | ||||
| Goodwill as of December 31, 2023 | $ |
There was no goodwill impairment recognized in the years ended December 31, 2023 and 2022.
| December 31, | December 31, | |||||||
| 2023 | 2022 | |||||||
| Client List | $ | $ | ||||||
| Noncompete Agreement | ||||||||
| Trademark | ||||||||
| Other Intangible Assets | ||||||||
| Accumulated amortization | ( | ) | ( | ) | ||||
| $ | $ | |||||||
Amortization expenses were $
| 2024 | $ | |||
| 2025 | ||||
| 2026 | ||||
| 2027 | ||||
| 2028 | ||||
| $ |
F-37
| 5. | Business acquisitions |
Advanced Veterinary Care of Pasco
On January 14, 2022, the Company acquired
the veterinary practice and related assets of Advanced Veterinary Care of Pasco in Hudson, FL by entering into an Asset Purchase Agreement
(“Advanced Veterinary APA”) with Advanced Veterinary Care of Pasco, LLC (“AVP”) and DJA Asset Management, LLC,
(“DJA”) (the “Pasco Practice” or collectively “Pasco”) in exchange for the payment of $
This acquisition was financed by a
loan provided by Farmers National Bank of Danville Kentucky for a total of $
The total cash consideration paid for
the combined acquisitions from the Pasco Practice in the amount of $
| Consideration: | ||||
| Cash paid prior to the time of closing | $ | |||
| Note Payable | ||||
| Acquisition costs included in general and administrative | ||||
| Recognized amounts of identifiable assets acquired | ||||
| Inventory | ||||
| Furniture, fixtures & equipment | ||||
| Trademark (5-year life) | ||||
| Non-compete agreement (2-year life) | ||||
| Client list (5-year life) | ||||
| Total identifiable net assets assumed | ||||
| Goodwill | ||||
| Total | $ | |||
Since we first reported the preliminary
purchase price allocation for the Pasco transaction as of June 30, 2022, the Company made measurement periodic adjustment, which composed
of a $
Lytle Veterinary Clinic
On March 15, 2022, the Company acquired
the veterinary practice and related assets of Lytle Veterinary Clinic in Texas by entering into an Asset Purchase Agreement (“Lytle
APA”) with Lytle Veterinary Clinic, Inc. (“Lytle”) in exchange for the payment of $
This acquisition was financed by two
loans provided by Farmers National Bank of Danville Kentucky for a total of $
F-38
The total cash consideration paid for
the combined acquisitions from the Lytle Practice in the amount of $
| Consideration: | ||||
| Cash paid prior to the time of closing | $ | |||
| Note Payable | ||||
| Acquisition costs included in general and administrative | ||||
| Recognized amounts of identifiable assets acquired | ||||
| Inventory | ||||
| Buildings | ||||
| Land | ||||
| Furniture, fixtures & equipment | ||||
| Tradename – trademarks (5-year life) | ||||
| Non-compete agreement (2-year life) | ||||
| Client list (5-year life) | ||||
| Total identifiable net assets assumed | ||||
| Goodwill | ||||
| Total | $ | |||
Since we first reported the preliminary
purchase price allocation for the Lytle transaction as of June 30, 2022, the Company made measurement period adjustment, which composed
of a $
Southern Kern Veterinary Clinic
On March 22, 2022, the Company acquired
the veterinary practice and related assets of Southern Kern Veterinary Clinic in California by entering into an Asset Purchase Agreement
(“Kern APA”) with Southern Kern Veterinary Clinic, Inc. (“Kern”) in exchange for the payment of $
The total cash consideration paid for
the combined acquisitions from the Kern Practice in the amount of $
| Consideration: | ||||
| Cash paid prior to the time of closing | $ | |||
| Acquisition costs included in general and administrative | ||||
| Recognized amounts of identifiable assets acquired | ||||
| Inventory | ||||
| Buildings | ||||
| Land | ||||
| Furniture, fixtures & equipment | ||||
| Tradename – Trademarks (5-year life) | ||||
| Non-compete agreement (2-year life) | ||||
| Client list (5-year life) | ||||
| Total identifiable net assets assumed | ||||
| Goodwill | ||||
| Total | $ | |||
F-39
Since we first reported the preliminary
purchase price allocation for the Kern transaction as of June 30, 2022, the Company made measurement period adjustment, which composed
of a $
Bartow Animal Clinic
On May 18, 2022, the Company acquired
the veterinary practice and related assets of Bartow Animal Clinic in Bartow, FL by entering into an Asset Purchase Agreement (“Bartow
APA”) with Winter Park Veterinary Clinic, Inc. (“Bartow”) in exchange for the payment of $
This acquisition was financed by two
loans provided by Farmers National Bank of Danville Kentucky for a total of $
The total cash consideration paid for
the combined acquisitions from the Bartow Practice in the amount of $
| Consideration: | ||||
| Cash paid prior to the time of closing | $ | |||
| Notes Payable | ||||
| Acquisition costs included in general and administrative | ||||
| Recognized amounts of identifiable assets acquired | ||||
| Inventory | ||||
| Buildings | ||||
| Land | ||||
| Furniture, fixtures & equipment | ||||
| Tradename – Trademarks (5-year life) | ||||
| Non-compete agreement (2-year life) | ||||
| Client list (5-year life) | ||||
| Total identifiable net assets assumed | ||||
| Goodwill | ||||
| Total | $ | |||
Since we first reported the preliminary
purchase price allocation for the Bartow transaction as of June 30, 2022, the Company made measurement period adjustment, which composed
of a $
F-40
Dietz Family Pet Hospital
On June 15, 2022, the Company acquired
the veterinary practice and related assets of Dietz Family Pet Hospital in Richmond, TX by entering into an Asset Purchase Agreement
(“Dietz APA”) with Dietz Family Pet Hospital, P.A. (“Dietz”) in exchange for the payment of $
This acquisition was financed by a
loan provided by Farmers National Bank of Danville Kentucky for a total of $
The total cash consideration paid for
the acquisition of the Dietz Practice in the amount of $
| Consideration: | ||||
| Cash paid prior to the time of closing | $ | |||
| Notes Payable | ||||
| Acquisition costs included in general and administrative | ||||
| Recognized amounts of identifiable assets acquired | ||||
| Inventory | ||||
| Furniture, fixtures & equipment | ||||
| Tradename – trademarks (5-year life) | ||||
| Non-compete agreement (2-year life) | ||||
| Customer Lists (5-year life) | ||||
| Total identifiable net assets assumed | ||||
| Goodwill | ||||
| Total | $ | |||
Since we first reported the preliminary
purchase price allocation for the Dietz transaction as of June 30, 2022, the Company made measurement period adjustment, which composed
of a $
Aberdeen Veterinary Clinic
On July 29, 2022, the Company acquired
the veterinary practice and related assets of Aberdeen Veterinary Clinic in Aberdeen, MD (“Aberdeen Practice”) by entering
into an Asset Purchase Agreement (“Aberdeen APA”) with Fritz Enterprises, Inc. in exchange for the payment of $
F-41
This acquisition was financed by a
loan provided by Farmers National Bank of Danville Kentucky for a total of $
The total cash consideration paid for
the acquisition from the Aberdeen Practice in the amount of $
| Consideration: | ||||
| Cash paid prior to the time of closing | $ | |||
| Convertible Notes Payable | ||||
| Acquisition costs included in general and administrative | ||||
| Recognized amounts of identifiable assets acquired | ||||
| Inventory | ||||
| Furniture, fixtures & equipment | ||||
| Trademark (5-year life) | ||||
| Non-compete agreement (2-year life) | ||||
| Client list (5-year life) | ||||
| Total identifiable net assets assumed | ||||
| Goodwill | ||||
| Total | $ | |||
Since we first reported the preliminary
purchase price allocation for the Aberdeen transaction as of June 30, 2022, the Company made measurement period adjustment, which composed
of a $
All Breed Pet Care
On August 12, 2022, the Company acquired
the veterinary practice and related assets of All Breed Pet Care veterinary clinic in Newburgh, IN by entering into an Asset Purchase
Agreement (“All Breed APA”) with Tejal Rege (the “All Breed Practice” or collectively “All Breed”)
in exchange for the payment of $
These acquisitions were financed by
three loans provided by Farmers National Bank of Danville Kentucky for a total $
F-42
The total cash consideration paid for
the acquisition of the All Breed Practice in the amount of $
| Consideration: | ||||
| Cash paid prior to the time of closing | $ | |||
| Convertible Notes Payable | ||||
| Acquisition costs included in general and administrative | ||||
| Recognized amounts of identifiable assets acquired | ||||
| Inventory | ||||
| Building | ||||
| Land | ||||
| Furniture, fixtures & equipment | ||||
| Trademark (5-year life) | ||||
| Non-compete agreement (2-year life) | ||||
| Client list (5-year life) | ||||
| Total identifiable net assets assumed | ||||
| Goodwill | ||||
| Total | $ | |||
Since we first reported the preliminary
purchase price allocation for the All Breed transaction as of June 30, 2022, the Company made measurement period adjustments, which composed
of a $
Pony Express
On October 31, 2022, the Company acquired
the veterinary practice and related assets of Pony Express Veterinary Clinic in Xenia, OH (“Pony Express Practice” or collectively
“Pony Express”) by entering into an Asset Purchase Agreement (“Pony Express APA”) with Pony Express Veterinary
Hospital, Inc. in exchange for the payment of $
This acquisition was financed by three
loans provided by First Southern National Bank for a total of $
F-43
The total cash consideration paid for
the acquisition from the Pony Express Practice in the amount of $
| Consideration: | ||||
| Cash paid prior to the time of closing | $ | |||
| Convertible Note Payable | ||||
| Acquisition costs included in general and administrative | ||||
| Recognized amounts of identifiable assets acquired | ||||
| Inventory | ||||
| Building | ||||
| Land | ||||
| Furniture, fixtures & equipment | ||||
| Trademark (5-year life) | ||||
| Non-compete agreement (2-year life) | ||||
| Client list (5-year life) | ||||
| Total identifiable net assets assumed | ||||
| Goodwill | ||||
| Total | $ | |||
Williamsburg
On December 9, 2022, the Company acquired
the veterinary practice and related assets of Williamsburg Veterinary Clinic in Williamsburg, MA (“Williamsburg Practice”)
by entering into an Asset Purchase Agreement (“Williamsburg APA”) with Williamsburg Animal Clinic, LLC in exchange for the
payment of $
This acquisition was financed by a
loan provided by Farmers National Bank of Danville Kentucky for a total of $
The total cash consideration paid for
the acquisition from the Williamsburg Practice in the amount of $
| Consideration: | ||||
| Cash paid prior to the time of closing | $ | |||
| Convertible Note Payable | ||||
| Acquisition costs included in general and administrative | ||||
| Recognized amounts of identifiable assets acquired | ||||
| Inventory | ||||
| Building | - | |||
| Land | - | |||
| Furniture, fixtures & equipment | ||||
| Trademark (5-year life) | ||||
| Non-compete agreement (2-year life) | ||||
| Client list (5-year life) | ||||
| Total identifiable net assets assumed | ||||
| Goodwill | ||||
| Total | $ | |||
Old 41
On December 16, 2022, the Company acquired
the veterinary practice and related assets of The Old 41 Veterinary Clinic in Bonita Springs, FL (“Old 41 Practice” or collectively
“Old 41”) by entering into an Asset Purchase Agreement (“Old 41 APA”) with The Old 41 Animal Hospital, LLC in
exchange for the payment of $
F-44
This acquisition was financed by two
loans provided by First Southern National Bank for a total of $
The total cash consideration paid for
the acquisition from the Old 41 Practice in the amount of $
| Consideration: | ||||
| Cash paid prior to the time of closing | $ | |||
| Convertible Note Payable | ||||
| Acquisition costs included in general and administrative | ||||
| Recognized amounts of identifiable assets acquired | ||||
| Inventory | ||||
| Building | ||||
| Land | ||||
| Furniture, fixtures & equipment | ||||
| Trademark (5-year life) | ||||
| Non-compete agreement (2-year life) | ||||
| Client list (5-year life) | ||||
| Total identifiable net assets assumed | ||||
| Goodwill | ||||
| Total | $ | |||
Valley Veterinary Service
On November 8, 2023, the Company acquired
the animal hospital and related assets of Valley Veterinary Service, Inc., a Pennsylvania corporation (“Valley Vet Practice”)
by entering into an Asset Purchase Agreement (“Valley Vet APA”) with Michelle Bartus, VMD and Peter Nelson, VMD (“Valley
Vet”) in exchange for the payment of $
The total consideration paid for the
combined acquisitions from the Valley Vet animal hospital in the amount of $
| Consideration: | ||||
| Cash paid prior to the time of closing | $ | |||
| Consideration paid in Common Stock | ||||
| Acquisition costs included in general and administrative | ||||
| Recognized amounts of identifiable assets acquired | ||||
| Inventory | ||||
| Building | ||||
| Land | ||||
| Furniture, fixtures & equipment | ||||
| Trademark (5-year life) | ||||
| Non-compete agreement (2-year life) | ||||
| Client list (5-year life) | ||||
| Total identifiable net assets assumed | ||||
| Goodwill | ||||
| Total | $ | |||
F-45
Pro-Forma Financial Information (Unaudited)
The following unaudited pro forma information
presents the consolidated results of Valley Vet Practice included in the Company’s consolidated statement of operations for the
year end December 31, 2023, as if the acquisitions were made on January 1, 2023. The following unaudited pro forma information presents
the consolidated results of Pasco Practice, Kern Practice, Lytle Practice, Bartow Practice, Dietz Practice, Aberdeen Practice, All Breed
Practice, Pony Express Practice, Williamsburg Practice, Old 41 Practice and Valley Vet Practice included in the Company’s consolidated
statement of operations for the year end December 31, 2022, as if the acquisitions were made on January 1, 2022. The unaudited pro forma
information is presented for illustrative purposes only. It is not necessarily indicative of the results of operations of future periods,
or the results of operations that actually would have been realized had the entities been a single company during the periods presented
or the results that the combined company will experience after the acquisition. The unaudited pro forma information does not give effect
to the potential impact of current financial conditions, regulatory matters or any anticipated synergies, operating efficiencies or cost
savings that may be associated with the acquisition. The unaudited pro forma information also does not include any integration costs
or remaining future transaction costs that the companies may incur related to the acquisition as part of combining the operations of
the companies. As a result of the adjustment, $
| Year Ended | Year Ended | |||||||
| December 31, 2023 | December 31, 2022 | |||||||
| Revenue | $ | $ | ||||||
| Net loss | $ | ( | ) | ( | ) | |||
| 6. | Debt |
Master Lending and Credit Facility
On June 25, 2021, the Company entered
into a master line of credit loan agreement (“MLOCA”) with Wealth South a division of Farmers National Bank of Danville,
Kentucky (“FNBD”). The MLOCA provides for a $
Under the MLOCA the Term Loans to acquire
a Practice shall not exceed
F-46
There is no prepayment penalty on payments
on the Revolving Line. The Term Loans are subject to a refinance fee of
On
| Original | December 31, | December 31, | Issuance | |||||||||||||||||||||
| Principal | Acquisition | Entered | Maturity | Interest | 2023 | 2022 | Cost | |||||||||||||||||
| $ | % | $ | $ | $ | ||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | - | |||||||||||||||||||||||
| $ | $ | $ | $ | |||||||||||||||||||||
The Company amortized $
FSB Commercial Loans
On January 11, 2021, the Company entered
into three separate commercial loans with First Southern National Bank (“FSB”) as part of the Kauai Veterinary Clinic, LLC
acquisition. The first commercial loan in the amount of $
F-47
The second commercial loan with FSB
entered into on January 11, 2021 in the amount of $
The third commercial loan with FSB
entered into on January 11, 2021 in the amount of $
On October 31, 2022 the Company entered
into three separate commercial loans with FSB as part of the Pony Express Practice acquisition. The first loan with FSB that was entered
into on October 31, 2022, was in the amount of $
The second loan with FSB that was entered
into on October 31, 2022, was in the amount of $
The third loan with FSB that was entered
into on October 31, 2022, was in the amount of $
On December 16, 2022, the Company entered
into two separate commercial loans with FSB as part of the Old 41 Practice acquisition. The first loan with FSB that was entered into
on December 16, 2022, was in the amount of $
The second loan with FSB that was entered
into December 16, 2022, was in the amount of $
On November 8, 2023, the Company entered
into a commercial loan with FSB as part of the Valley Vet acquisition. The loan with FSB was entered into on November 8, 2023, in the
amount of $
F-48
The FSB commercial loans are guaranteed by Kimball Carr, the Company’s Chief Executive Officer and President and Charles Stith Keiser, the Company’s Vice Chairman and Chief Operating Officer.
| Original | December 31, | December 31, | Issuance | |||||||||||||||||||||
| Principal | Acquisition | Entered | Maturity | Interest | 2023 | 2022 | Cost | |||||||||||||||||
| $ | % | $ | $ | $ | ||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| % | ||||||||||||||||||||||||
| $ | $ | $ | $ | |||||||||||||||||||||
The Company amortized $
| December 31, | December 31, | |||||||
| 2023 | 2022 | |||||||
| FNBD Notes Payable | $ | $ | ||||||
| FSB Notes Payable | ||||||||
| Car loan | ||||||||
| Total notes payable | ||||||||
| Unamortized debt issuance costs | ( | ) | ( | ) | ||||
| Notes payable, net of issuance cost | ||||||||
| Less current portion | ( | ) | ( | ) | ||||
| Long-term portion | $ | $ | ||||||
| 2024 | $ | |||
| 2025 | ||||
| 2026 | ||||
| 2027 | ||||
| 2028 | ||||
| Thereafter | $ |
F-49
Bridge Note
In December 2021, the Company entered
into two bridge loans in the aggregate of $
In conjunction with the Bridge Note
the Company issued warrants on January 24, 2022 to Target Capital 1, LLC and Dragon Dynamic Catalytic Bridge SAC Fund (collectively the
“Bridge Lenders”). The warrants entitled the Bridge Lenders to purchase the Company’s Class A common stock, at a purchase
price equal to the per share price in an IPO. The quantity of the Company’s common stock of subject to purchase upon exercise of
the warrants is equal to
On November 18, 2022, the Company entered
into an Original Issue Discount Secured Convertible Note loan (“bridge loan”) with Target Capital 1, LLC for $
In conjunction with the Original Issue
Discount Secured Convertible Note with Target Capital 1, LLC the company issued the holder
F-50
On November 18, 2022, the Company entered
into an Original Issue Discount Secured Convertible Note with 622 Capital LLC for $
In conjunction with the Original Issue
Discount Secured Convertible Note with 662 Capital LLC the company issued the holder equity classified warrants that entitle the holder
to purchase the Company’s common stock at a purchase price equal to the per share price in an IPO. The quantity of the Company’s
common stock of subject to purchase upon exercise of the warrants is equal to
The warrants were deemed legally detachable
from the Bridge Note and were fair valued using the Black Scholes Method to determine the relative fair values of the Bridge Note and
the detachable warrants. The significant inputs for the Black Scholes calculation included the exercise price and common share price
of $
On June 30, 2023, the Company entered
into exchange agreements (the “Exchange Agreements”) with each of the Company’s Bridge Note lenders, pursuant to which
the lenders exchanged their existing Bridge Notes for
F-51
In connection with the Exchange, the Company also issued warrants to purchase additional shares of Class A common stock. The New Warrants were issued in exchange for the existing warrants held by the former Bridge Note lenders. See Note 8 for further information on the Series A preferred stock and the Warrants issued.
| Bridge notes, December 31, 2021 | ||||
| Issued for cash | ||||
| Amortization of original issue discount | ||||
| Warrant discount | ( | ) | ||
| Amortization of warrant discount | ||||
| Debt issuance costs | ( | ) | ||
| Amortization of debt issuance costs | ||||
| Bridge notes, December 31, 2022 | ||||
| Amortization of original issue discount | ||||
| Amortization of warrant discount | ||||
| Amortization of debt issuance costs | ||||
| Extinguishment of bridge notes in exchange for Series A preferred stock upon IPO on August 31, 2023 | ( | ) | ||
| Bridge notes, December 31, 2023 | $ |
Convertible Debenture
Between March 18 and December 28, 2021,
the Company issued $
Upon the Company’s IPO closing
on August 31, 2023, the majority of Convertible Debenture holders elected to convert an aggregate of $
F-52
Loan Payable
On May 30, 2023, the Company entered
into a Merchant Cash Advance Agreement for gross proceeds of $
On August 10, 2023, the Company amended
the financing arrangement to borrow an additional $
On November 28, 2023, the Company amended
the financing arrangement to borrow an additional $
During the year ended December 31,
2023, the Company amortized $
| 7. | Related Party Transactions |
Blue Heron
The Company entered into a consulting
agreement with Blue Heron Consulting (“BHC”) on June 24, 2021, pursuant to which BHC will consult with the Company on an
on-going basis in connection with the Company’s acquisition of veterinary practices throughout the United States and will serve
as the Company’s business and financial advisor with respect to its acquisition strategy and in connection with specific acquisition
targets. The Company’s director and Chief Operating Officer Charles Stith Keiser is the Chief Operating Officer of BHC, and the
Company’s director Dr. Charles “Chuck” Keiser is the Chief Visionary Officer of BHC. The Company has incurred $
Under the Consulting Agreement, BHC is entitled to a monthly fee for on-going services including:
| ● | the preparation of valuation packages of potential acquisitions (including the gathering of pertinent information, financial and background data, completion of deal packets and financial projection worksheets used by the Company to calculate practice values); | |
| ● | the institution of turnover protocols and procedures of hospitals immediately post-purchase; systems reporting; the formulation of individual hospital goals and targets; | |
| ● | on-going monthly support of hospital units (including medical and operational coaching, business growth projections, establishment of financial targets and margin improvements, growth milestones) and recruiting support. |
The Consulting Agreement may be terminated at any time without cause and without penalty upon thirty days’ notice to the other party. Upon termination, all accrued, but not yet paid fees and expenses, whether invoiced or not, must be paid to BHC.
F-53
Star Circle Advisory
The Company entered into a consulting
agreement with Star Circle Advisory Group, LLC (“Star Circle”) on August 2, 2022, to serve as financial consultant, on a
non-exclusive basis, to assist with arranging bridge financing and the initial public offering of the Company. Star Circle is owned and
controlled by Kimball Carr, Chairman and Chief Executive Officer (“CEO”), Peter Lau, former Interim Chief Financial Officer
and Director, James Coleman, Director, and Richard Marten, Director. Star Circle is entitled to a monthly fee of $
Chief Executive Officer’s Warrant
On January 1, 2023, the board of directors
issued
| 8. | Stockholders’ Equity |
The Company is authorized to issue
Each outstanding share of Class A Common
Stock is entitled to vote on each matter on which the stockholders of the Company is entitled to vote, and each holder of Class A Common
Stock is entitled to
Each outstanding share of Class B Common
Stock is entitled to vote on each matter on which the stockholders of the Company is entitled to vote, and each holder of Class B Common
Stock is entitled to
All shares of Class A Common Stock and Class B Common Stock (collectively “Common Stock”) will be identical and will entitle the holders thereof to the same rights and privileges, except as otherwise provided above.
F-54
On November 15, 2022, the Company amended
the consulting agreement with Alchemy Advisory, LLC until June 30, 2023. The contract amendment stipulates an additional fee of $
On November 15, 2022, the Company entered
into a consulting agreement with 662 Capital LLC. The contract stipulates the Company will issue
Convertible Series A preferred stock
On June 30, 2023, the Company amended
its articles of incorporation by the filing of a certificate of designation for the Series A preferred stock.
Holders of shares of the Series A preferred
stock are entitled to a liquidation preference in the event of any dissolution, liquidation or winding up of the Company equal to the
stated value plus any accrued and unpaid dividends on such stock. Holders of shares of Series A preferred stock are also entitled to
convert such shares at any time and from time, at the option of such holder, into a number of shares of Class A common stock equal to
the stated value divided by a conversion price. The conversion price is equal to
On November 7, 2023, the Company amended
its article of incorporation to increase the total authorized preferred stock by
The holders of the Series A preferred stock have the right to vote on all matters submitted to a vote of shareholders on an as-if-converted basis together with the holders of shares of the Company’s Class A and Class B common stock, voting together as a single class.
On June 30, 2023, the Company issued
In connection with the Exchange, the
Company also issued warrants (the “New Warrants”) to purchase additional shares of Class A common stock. The New Warrants
were issued in exchange for the existing warrants held by the former Bridge Note holders. The exercise price of the shares to be issued
pursuant to the New Warrants is the price of the shares of Class A common stock to be issued in this offering. The number of shares to
be issued upon exercise of the New Warrants is equal to the quotient of
F-55
| 9. | Retirement Plan |
The Company, through its acquisition
of KVC sponsors a Savings Incentive Match Plan for former KVC Employees (SIMPLE IRA). The SIMPLE IRA plan provides for voluntary employee
contributions up to statutory IRA limitations. KVC makes a dollar-for-dollar matching contribution equal to the elective deferral of
each participant up to a maximum of
During the year ending December 31,
2022, the Company implemented a qualified 401(K) retirement plan. The Company offers eligible domestic full-time employees participation
in certain 401K plans. The plans provide for a discretionary annual company contribution. In addition, employees may contribute a portion
of their salary to the plans, which certain of the 401K plans, is partially matched by the Company. The plans may be amended or terminated
at any time. The Company contributed and expensed approximately $
| 10. | Income Taxes |
The Company estimated NOL carry-forwards
for Federal and State income tax purposes of $
| Year ended December 31, | ||||||||
| 2023 | 2022 | |||||||
| Deferred tax assets: | ||||||||
| Net Operating Loss Carryforwards | $ | $ | ||||||
| Accrued Expenses | ||||||||
| Stock Based Compensation | ||||||||
| Charitable Contribution Carryforward | ||||||||
| ROU Asset | ( | ) | ( | ) | ||||
| Lease Liability | ||||||||
| R&D Sec 174 | ||||||||
| Total deferred tax assets | ||||||||
| Deferred tax liabilities: | ||||||||
| Amortization/Depreciation | ||||||||
| Total deferred tax liabilities | ||||||||
| Valuation allowance | ( | ) | ( | ) | ||||
| Net deferred Tax Assets (Liabilities) | $ | |||||||
F-56
| 2023 | 2022 | |||||||
| Tax benefit at statutory tax rate | ( | ) | ( | ) | ||||
| State benefit, net of federal benefit | ( | ) | ( | ) | ||||
| Beneficial conversion feature | ||||||||
| Other permanent differences | ( | ) | ||||||
| Valuation allowance | ||||||||
| Other | ( | ) | ( | ) | ||||
| $ | ( | ) | $ | ( | ) | |||
| December 31 2023 | December 31 2022 | |||||||
| Current income benefit expense | ||||||||
| Federal | $ | $ | ||||||
| State | ( | ) | ||||||
| $ | $ | |||||||
| 11. | Leases |
Accounting for Leases as Lessee
The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use assets (“ROU”), operating lease liabilities, and operating lease liabilities, non-current. Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. None of the leases entered into have an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future payments. Incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in economic environments where the leased asset is located. The ROU assets also include any prepaid lease payments made and initial direct costs incurred and excludes lease incentives. The Company’s lease terms may include options to extend or terminate the lease, which is recognized when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet.
The Company has operating leases for real estate. The Company has certain intercompany leases between its subsidiaries, and these transactions and balances have been eliminated in consolidation and are not reflected in the tables and information presented below.
F-57
| For the Year Ended December 31, | ||||||||||
| Expense Classification | 2023 | 2022 | ||||||||
| Operating lease expense: | ||||||||||
| Amortization of ROU asset | General and administrative | $ | $ | |||||||
| Accretion of Operating lease liability | General and administrative | |||||||||
| Total operating lease expense | $ | $ | ||||||||
| Other lease expense | General and administrative | |||||||||
| Total | $ | $ | ||||||||
| As of December 31, | ||||||||
| 2023 | 2022 | |||||||
| Remaining lease term: | ||||||||
| Operating leases (in years) | ||||||||
| Discount rate: | ||||||||
| Operating leases | % | % | ||||||
| As of December 31, | ||||||||||
| Balance Sheet Classification | 2023 | 2022 | ||||||||
| Assets: | ||||||||||
| Operating lease assets | Right-of-use assets | $ | $ | |||||||
| Liabilities: | ||||||||||
| Operating lease liabilities | Operating lease liabilities | |||||||||
| Operating lease liabilities | Operating lease liabilities, non-current | |||||||||
| Total lease liabilities | $ | $ | ||||||||
| Fiscal Year | Operating Leases | |||
| 2024 | $ | |||
| 2025 | ||||
| 2026 | ||||
| 2027 | ||||
| 2028 | ||||
| Thereafter | ||||
| Undiscounted cash flows | ||||
| Less: imputed interest | ( | ) | ||
| Lease liability | $ | |||
F-58
| 12. | Commitments and Contingencies |
As of December 31, 2023, substantially all of the Company’s assets were pledged as collateral for the Company’s credit facilities.
Common Stock Purchase Agreement
On November 30, 2023, the Company entered
into a common stock purchase agreement with a 3rd party investor (the “Investor”), to which the investor committed
to purchase up to $
Under the terms and subject to the
conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to the Investor, and the Investor is
obligated to purchase, shares of Class A Common Stock in an amount up to $
Purchase Price
The shares of Class A Common Stock
to be issued by the Company and purchased by the Investor will be sold at a purchase price equal to
Actual sales of shares of Class A Common Stock to the Investor will depend on a variety of factors to be determined by the Company from time-to-time, including, among other things, market conditions, the trading price of the Company’s Class A Common Stock, and the working capital needs, if any, of the Company.
The net proceeds from sales, if any, under the Purchase Agreement to the Company will depend on the frequency and prices at which the Company sells shares of Class A Common Stock to the Investor. the Company expects that any proceeds received by the Company from such sales to the Investor will be used for working capital and general corporate purposes.
F-59
Purchase Limits
Pursuant to the Purchase Agreement,
Consistent with certain applicable
Nasdaq rules, the Company may not issue to the Investor more than
Fees
As consideration for the Investor’s
irrevocable commitment to purchase shares of Class A Common Stock, upon execution of the Purchase Agreement, the Company became obligated
to issue to the Investor a number of shares of Class A Common Stock equal to $
Certain Representations, Warranties and Covenants
The Purchase Agreement contains customary representations, warranties, conditions, and indemnification obligations of each of the Company and the Investor. Pursuant to the Purchase Agreement, the Investor has agreed not to enter into or effect, in any manner whatsoever, directly or indirectly, any short sales of the Company’s Class A Common Stock or hedging transaction which establishes a net short position with respect to the Class A Common Stock. In addition, the Company has covenanted, among other things, through the 24-month anniversary of the signing of the Purchase Agreement, to not effect or enter into any agreement to issue any shares of Class A Common Stock or securities convertible into or exercisable or exchangeable into shares of Class A Common Stock except in limited circumstances.
The Company has the right to terminate
the Purchase Agreement at any time following the satisfaction of certain conditions precedent relating to the initial sale of shares
to the Investor, subject to the Company paying all documented fees and amounts to the Investor’s legal counsel and, if the agreement
is terminated prior to effectiveness of the resale registration statement, the Company paying the $
F-60
The Purchase Agreement will automatically terminate on (i) the 24-month anniversary of the effective date of the initial resale registration statement filed with the Commission, (ii) the date when the Investor purchases the Total Commitment, (iii) the date when the shares of Class A Common Stock are no longer listed on the Nasdaq Capital Market or another eligible national stock exchange, or (iv) when the Company is subject to a voluntary or involuntary bankruptcy or insolvency proceeding.
In addition, the Investor may terminate the Purchase Agreement upon (i) the occurrence of an event constituting a material adverse effect (as defined in the Purchase Agreement), (ii) the occurrence of a change of control transaction of the Company, (iii) the failure by the Company to file a registration statement by the applicable deadline set forth in the Registration Rights Agreement, (iv) the lapse of the effectiveness, or unavailability of, a registration statement filed by the Company pursuant to the Registration Rights Agreement in certain other circumstances set forth in the Purchase Agreement, (v) the suspension of trading of the Class A Common Stock for a period of three (3) consecutive trading days, or (vi) the material breach of the Purchase Agreement by the Company, which breach is not cured within the 10 trading days after receipt of notice of such breach.
On December 28, 2023, the Company amended
the agreement to provide that, if the number of commitment shares required to be issued by the Company to the Investor and its affiliates
(as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 promulgated thereunder) pursuant
to the Purchase Agreement would result in the beneficial ownership by the Investor of more than
The amendment further provide that,
if the issuance of the total number of commitment shares of Class A common stock and Warrant Shares by the Company to the Investor would
cause the beneficial ownership of the Investor and its affiliates to exceed
Also pursuant to the Agreement, the Company and the Investor amended the Registration Rights Agreement to extend the filing deadline by which the Company must file an initial registration statement with the U.S. Securities and Exchange Commission (the “Commission”) with respect to the resale by the Investor of the shares of Class A common stock of the Company issuable to the Investor pursuant to the Purchase Agreement, including the commitment shares and the Warrant Shares, to January 31, 2024.
Holdback Agreement
As part of the Valley Veterinary Services,
Inc. acquisition in November 2023, a portion of the purchase price in the amount of $
As the contingent consideration arrangement in which the Holdback amounts are automatically forfeited if the employment of the former owners (now employees of the Company) terminates is accounted for as compensation for post combination services. The Company will recognize the contingent consideration from the Holdback Agreement when probable.
F-61
| 13. | Subsequent Events |
The Company follows the guidance in FASB ASC 855-10 for the disclosure of subsequent events. The Company evaluated subsequent events through the date the financial statements were issued and determined the Company had the following subsequent events:
Series A Preferred Stock Issuance
On January 2, 2024, the Company entered
into a subscription agreement (the “Subscription Agreement”) with Target Capital 1, LLC (“Target”), pursuant
to which Target purchased
“Best-Efforts” Offering of Class A Common Stock
On January 26, 2024, the Company filed
an amended registration statement on Form S-1/A to register the Company’s public offering and sale, on a reasonable best-efforts
basis, of up to
IR Agency Consulting Agreement
On February 8, 2024, the Company entered into a consulting agreement with a provider of investor relations-related services (“IR Agency”). Pursuant to the IR Agency Consulting Agreement, the Company has engaged IR Agency, on a non-exclusive basis, to prepare marketing materials and leverage digital newsletters to build a digital community of potential investors in the Company.
As consideration for its performance
under the IR Agency Consulting Agreement, the Company will pay IR Agency a non-refundable fee of $
The IR Agency Consulting Agreement has a term of six (6) months and may be terminated by written notice, with or without cause, by Inspire at any time.
Consulting Agreement
On February 8, 2024, the Company entered into a Consulting Agreement with unrelated third party pursuant to which the Company engaged to provide business consulting services in the veterinary medicine sector.
As consideration for its performance
under the Consulting Agreement, the Company will pay the consultant a fee of $
F-62
Common Stock Purchase Agreement
On February 14, 2024, the Company issued
Consulting Payment
On March 6, 2024, the Company entered into a Consulting Agreement with Charles “Chuck” Keiser, DVM, an experienced professional of veterinary medicine and the business of veterinary medicine, and a former member of the board of directors of the Company, pursuant to which the Company agreed to compensate Dr. Keiser for certain consulting services that he has provided to the Company relating to veterinary medicine business support and other related activities.
As consideration for Dr. Keiser’s
consulting services to the Company, the Company issued to Dr. Kesier $
General Release
On March 6, 2024, the Company entered
into a General Release Agreement with Kenneth Seth Lundquist, DVM, Charles “Chuck” Keiser, DVM, and Don I. Williamson, Jr.
DVM, and the Estate of Gregory Armstrong (each, a “Releasor” and collectively, the “Releasors”), pursuant to
which the Company agreed to issue to each Releasor $
Securities Purchase Agreement
On March 26, Inspire Veterinary entered
into a securities purchase agreement (the “Purchase Agreement”) with certain investors. Pursuant to the Purchase Agreement,
Inspire Veterinary issued to certain investors two Increasing OID Senior Notes (each a “Note” and collectively the “Notes”)
each for $
The Notes contain an original issue
discount (“OID”) which shall be: (i) fifteen percent (
The Notes must be repaid in full from any future capital raises (debt, equity or any other form of capital raise) of Inspire Veterinary. All of the funds raised must be used to repay the Notes until the Notes are repaid in full.
The Notes are convertible into shares
of common stock of Inspire Veterinary, in full or in part, at any time after issuance at the discretion of the noteholder at a fixed
conversion price of $
If the Notes are not repaid by the
Maturity Date the default provisions are as follow: (i) The Face Value (as such term is defined in the Notes) of the Notes will increase
by
Loan Payable
On March 26, 2024, the Company entered
into a Merchant Cash Advance Agreement for gross proceeds of $
F-63
PRELIMINARY PROSPECTUS
Up to 9,125,475 Units, Each Unit Consisting
of One Share of Class A Common Stock or One Pre-Funded Warrant
to Purchase One Share of Class A Common Stock and One Warrant to Purchase One Share of
Class A Common Stock
, 2024
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Unless otherwise indicated, all references to “Inspire Veterinary,” the “company,” “we,” “our,” “us” or similar terms refer to Inspire Veterinary Partners, Inc.
Item 13. Other Expenses of Issuance and Distribution.
The following table sets forth all expenses to be paid by us, other than underwriting discounts and commissions, in connection with this offering. All amounts shown are estimates except for the Commission registration fee, the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee and the exchange listing fee.
| SEC registration fee | $ | 3,542.40 | ||
| FINRA filing fee | $ | 4,100 | ||
| Printing and engraving expenses | $ | - | ||
| Legal fees and expenses | $ | 175,000 | ||
| Accounting fees and expenses | $ | 10,000 | ||
| Transfer agent and registrar fees | $ | - | ||
| Miscellaneous expenses | $ | 10,000 | ||
| Total | $ | 202,642.40 |
Item 14. Indemnification of Directors and Officers.
Section 78.7502(1) of the Nevada Revised Statutes (“NRS”) provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (except an action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding if such person: (i) is not liable for a breach of fiduciary duties that involved intentional misconduct, fraud or a knowing violation of law; or (ii) acted in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.
NRS Section 78.7502(2) further provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses, including amounts paid in settlement and attorneys’ fees actually and reasonably incurred in connection with the defense or settlement of the action or suit if such person: (i) is not liable for a breach of fiduciary duties that involved intentional misconduct, fraud or a knowing violation of law; or (ii) acted in good faith and in a manner that he or she reasonably believed to be in or not opposed to the best interests of the corporation. Indemnification may not be made for any claim, issue or matter as to which such a person has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals therefrom, to be liable to the corporation or for amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case the person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.
To the extent that a director, officer, employee or agent of a corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in subsections (1) and (2) of NRS Section 78.7502, as described above, or in defense of any claim, issue or matter therein, the corporation shall indemnify him or her against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense.
The amended and restated articles of incorporation and the amended and restated bylaws of the Company provide that the Company shall, to the fullest extent permitted by the NRS, as now or hereafter in effect, indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right of the Company, by reason of the fact that he is or was a director, officer, employee or agent of the Company, or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses, including attorneys’ fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with the action, suit or proceeding if he: (i) is not liable pursuant to NRS Section 78.138; or (ii) acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.
II-1
Item 15. Recent Sales of Unregistered Securities.
Tumim Transaction — Commitment Shares
On November 30, 2023, we entered into a common stock purchase agreement (the “Purchase Agreement”), dated as of November 30, 2023, with Tumim Stone Capital LLC (“Tumim”), pursuant to which Tumim committed to purchase, subject to certain conditions and limitations, up to $30.0 million of shares of Class A common stock, at our direction from time to time, subject to the satisfaction of the terms and conditions in the Purchase Agreement. Also, on the same date, we entered into a registration rights agreement (the “Registration Rights Agreement”) with Tumim, pursuant to which pursuant to which we agreed to file with the Commission a registration statement to register for resale under the Securities Act the shares of our Class A common stock that may be issued to Tumim under the Purchase Agreement.
As consideration for Tumim’s irrevocable commitment to purchase shares of Class A common stock, upon execution of the Purchase Agreement, we became obligated to issue to Tumim a number of shares of Class A common stock (the “Commitment Shares”) equal to $600,000 divided by the average daily volume-weighted average price for the Class A common stock on The Nasdaq Capital Market (“Nasdaq”) during the five consecutive trading days ending on the trading date immediately prior to Inspire’s filing of an initial registration statement covering Tumim’s resales pursuant to the Registration Rights Agreement described below. The Company issued Tumim 12,143 (post split) commitment shares in the first quarter of 2024.
We may not issue or sell any shares of Class A common stock to Tumim which, when aggregated with all other shares of the Company’s Class A common stock then beneficially owned by Tumim and its affiliates (as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Rule 13d-3 promulgated thereunder), would result in Tumim beneficially owning more than 4.99% of the issued and outstanding shares of the Company’s Class A common stock, unless such limit is increased or waived by Tumim.
Acquisition Shares — Valley Veterinary Services
On November 8, 2023, we completed the acquisition of Valley Veterinary Services animal hospital pursuant to an asset purchase agreement, dated October 27, 2023 (the “Asset Purchase Agreement”), by and among the Company, IVP PA Holding Company, LLC (“AcquisitionSub”), a Delaware limited liability company and wholly-owned subsidiary of the Company and Valley Veterinary Service, Inc., a Pennsylvania corporation, Michelle Bartus, VMD and Peter Nelson, VMD (collectively, the “Seller Parties”).
As partial consideration for the purchase of the Valley Veterinary Services animal hospital, we issued 4,082 restricted shares of Class A common stock to the Seller Parties, which was equal to the quotient obtained by dividing $400,000 by the official closing price of one share of Class A common stock as reported by Nasdaq on the trading date immediately prior to the acquisition closing. The issuance of restricted shares of Class A common stock to the Seller Parties was consummated in a privately negotiated transaction exempt from registration pursuant to Rule 506(b) of Regulation D under the Securities Act of 1933, as amended. There were no proceeds from the issuance of the shares of Class A common stock.
II-2
Founders’ Shares of Class B common stock
On December 20, 2020, the Company entered into subscription agreements with Wilderness Trace Veterinary Partners, LLC (“Wilderness”) and Star Circle Advisory Group, LLC (“Star Circle”), pursuant to which each of Wilderness and Star Circle purchased 21,250 shares of the Company’s Class B common stock (for an aggregate number of 43,000 shares), at a purchase price of $0.0001 per share and aggregate consideration of $215.00. The sale of shares to Wilderness and Star Circle were consummated in privately negotiated transactions exempt from registration pursuant to Rule 506(b) of Regulation D under the Securities Act of 1933, as amended. The proceeds of the sale of the shares were used for general working capital purposes.
Private Placement of Shares of Class A common stock
Beginning on December 30, 2020 through 2022, the Company entered into subscription agreements with an initial round of equity investors to purchase 6,750 shares of the Company’s Class A common stock, at a purchase price of $0.36 per share and aggregate consideration of $387,000.00. The sales of Class A common stock were consummated in privately negotiated transactions exempt from registration pursuant to Rule 506(b) of Regulation D under the Securities Act of 1933, as amended. The proceeds of the sale of the shares were used for general working capital purposes.
Private Placement of Convertible Debentures
Between March 18 and December 28, 2021, the Company issued $2,102,500 in aggregate principal amount of 6.00% subordinated convertible promissory note (“Convertible Debenture”). The Convertible Debenture is convertible into shares of the Company’s Class A common stock upon an initial public offering of the Company’s common stock and the listing of the common stock on a “national securities exchange” as defined in Section 6 of the Securities Exchange Act of 1934, as amended (such public offering and listing, a “Qualified Financing”). The purchasers of the Convertible Debenture were accredited investors, as defined by Regulation D under the Securities Act of 1933, as amended, and consisted of a “friends and family” round of investment in the Company. At the holder’s election, the accrued interest and principal may be paid in cash or Class A common stock (such number of shares reflecting a twenty-five percent (25%) discount of the opening price per share of Class A common stock). The Convertible Debenture mature 5 years from the date of issuance to each holder. Prior to the maturity date, the holder is entitled to convert the Convertible Note into Class A common stock upon the Company’s Qualified Financing. Upon a Qualified Financing, the accrued and unpaid interest is due and payable in cash on the first business day of the following month of March for any balance not elected to be converted into the Class A common stock. Subsequently, the Company issued an additional $800,000 in aggregate principal of Convertible Debenture. The sale of the Convertible Debenture was consummated in privately negotiated transactions exempt from registration pursuant to Rule 506(b) of Regulation D under the Securities Act of 1933, as amended. The proceeds of the sale of the Convertible Debenture were used for veterinary practice acquisitions and for general working capital purposes.
As of the date of this prospectus, all Convertible Debentures have converted into shares of Class A common stock or have been paid off by the Company, other than one Convertible Debenture which balance appears as a payable on our consolidated financial statements.
2023 Private Placement of Convertible Debentures
Between February 27 and March 10, 2023, the Company issued $650,000 in aggregate principal amount of 6.00% subordinated convertible promissory note (“2023 Convertible Debenture”). The 2023 Convertible Debenture is convertible into shares of the Company’s Class A common stock upon the consummation of a Qualified Financing. The purchasers of the 2023 Convertible Debenture were accredited investors, as defined by Regulation D under the Securities Act of 1933, as amended, and consisted of a second “friends and family” round of investment in the Company. At the holder’s election, the accrued interest and principal may be paid in cash or Class A common stock (such number of shares reflecting a twenty-five percent (25%) discount of the opening price per share of Class A common stock). The 2023 Convertible Debenture mature 5 years from the date of issuance to each holder. Prior to the maturity date, the holder is entitled to convert the Convertible Note into Class A common stock upon the Company’s Qualified Financing. Upon a Qualified Financing, the accrued and unpaid interest is due and payable in cash on the first business day of the following month of March for any balance not elected to be converted into the Class A common stock. The proceeds of the sale of the 2023 Convertible Debenture were used for veterinary practice acquisitions and for general working capital purposes. The 2023 Convertible Debentures were issued in privately negotiated transactions exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended.
As of the date of this prospectus, no 2023 Convertible Debentures remain outstanding,
II-3
Series A Preferred Stock
Effective June 30, 2023, the Company exchanged the Company’s previously issued 12% original issue discount secured convertible notes held by Dragon Dynamic Catalytic Bridge SAC Fund, Target Capital 1 LLC and 622 Capital LLC, the Company’s senior secured lenders, for an aggregate of 4,425 shares of Series A preferred stock.
As a result of the Exchange, all of the Company’s senior secured indebtedness with those lenders was extinguished. The Series A preferred stock earns a dividend rate equal to 12% of the stated rate per annum, which such dividend may be payable either in cash or in-kind at the sole option of the Company.
In connection with the Exchange, the Company amended its articles of incorporation by the filing of a certificate of designation for the Series A preferred stock (the “Series A Certificate of Designation”). One million shares of the Series A preferred stock are authorized under the Series A Certificate of Designation, with each such share having a stated value of $10.00 per share.
Holders of shares of the Series A preferred stock are entitled to a liquidation preference in the event of any dissolution, liquidation or winding up of the Company equal to the stated value plus any accrued and unpaid dividends on such stock. Holders of shares of Series A preferred stock are also entitled to convert such shares at any time and from time, at the option of such holder, into a number of shares of Class A common stock equal to the stated value divided by a conversion price. The conversion price is equal to 60% of the dollar volume-weighted average price for shares for the Company’s Class A common stock for the three trading days immediately preceding the date of the conversion. However, the conversion price can never be less than $0.25 per-share. For any conversion during the Company’s initial three days of market trading, the conversion price will be equal to 60% of the price for the Company’s underwritten initial public offering.
The Series A Certificate of Designation also contains certain beneficial ownership limitations on the holders of the Series A preferred stock, as more fully described in the Series A Certificate of Designation. The holders of the Series A preferred stock have the right to vote on all matters submitted to a vote of shareholders on an as-if-converted basis together with the holders of shares of the Company’s Class A and Class B common stock, voting together as a single class.
The issuances of the Series A preferred stock were consummated in privately negotiated transactions exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended. There were no proceeds from the issuance of the Series A preferred stock.
The foregoing description of the Series A preferred stock and the Series A Certificate of Designation, as amended, is qualified in its entirety by the full text of the same, which are attached as Exhibits 3.4 and 3.5 hereto and are incorporated by reference herein.
Warrants
Exchange Listing Warrant
In connection with the Company’s entry into a capital market advisory agreement (the “Advisory Agreement”), dated as of December 28, 2021, with Exchange Listing, LLC (“Exchange Listing”), the Company issued a warrant (the “Exchange Listing Warrant”) to Exchange Listing to purchase up to 120 shares of Class A common stock. The Exchange Listing Warrant is exercisable at any time and from time to time by the holder for a period of three (3) years from December 28, 2021, the date of issuance, at an exercise price of $300 per share, subject to adjustment for subsequent stock splits, stock combinations, stock dividends, and recapitalizations. The Exchange Listing Warrant was issued in a privately negotiated transaction exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended. There were no cash proceeds from the issuances of the Exchange Listing Warrant.
Kimball Carr Warrant
On September 1, 2022, the Company issued to Kimball Carr, the Company’s Chair, President and Chief Executive Officer, a warrant (the “Carr Warrant”) for up to 500 shares of Class A common stock as consideration of Mr. Carr’s personal guaranty of certain loans of the Company. The warrant was issued effective as of January 1, 2023 and is exercisable at any time and from time to time by the holder for a period of five (5) years from January 1, 2023, The Carr Warrant is subject to an exercise price per share equal to $4.00, which was the initial offering price of the Class A common stock issued in our initial public offering, multiplied by 0.60, subject to adjustment for subsequent stock splits, stock combinations, stock dividends, and recapitalizations. The Carr Warrant was issued in a privately negotiated transaction exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended. There were no cash proceeds from the issuances of the Carr Warrant.
The foregoing description of the Carr Warrant is qualified in its entirety by the full text of the Carr Warrant, which is attached hereto as Exhibit 4.1 and is herein incorporated by reference.
II-4
New Warrants
Effective June 30, 2023, the Company exchanged certain then-outstanding indebtedness held by the Company’s senior secured lenders, Dragon Dynamic Catalytic Bridge SAC Fund, Target Capital 1 LLC and 622 Capital LLC (the “New Warrant Holders”), for shares of Series A preferred stock.
In connection with the Exchange, the Company also issued warrants (the “New Warrants”) to the New Warrant Holders to purchase additional shares of Class A common stock, at any time and from time to time at the option of the New Warrant Holders. The New Warrants were issued in exchange for the existing warrants held by the New Warrant Holders. The exercise price of the shares to be issued pursuant to the New Warrants is $400 per share, which was the price per shares of Class A common stock issued in our initial public offering. The New Warrants may be exercised for a total of 8,296 shares of Class A common stock, which is equal to the quotient of 75% of the outstanding Series A preferred stock value divided by the $400.00 per share exercise price. The New Warrants were issued in privately negotiated transactions exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended. There were no cash proceeds from the issuances of the New Warrants.
The foregoing description of the New Warrants are qualified in its entirety by the full text of the New Warrants, which are attached hereto as Exhibits 4.2, 4.3 and 4.4 and are herein incorporated by reference.
Spartan IPO Warrant
In connection with our initial public offering, on August 31, 2023 the Company issued to the underwriter in our initial public offering, Spartan Capital Securities, LLC (“Spartan”), a warrant (the “Spartan IPO Warrant”) to purchase up to 800 shares of Class A common stock. The Spartan IPO Warrant is exercisable at any time and from time to time, beginning 180 days after August 29, 2023, the effective date of our registration statement filed in connection with the initial public offering and expiring on a date which is three (3) years from the commencement of sales of the public offering in compliance with FINRA Rule 5110(e)(1)(A). The Spartan IPO Warrant is exercisable for an exercise price of $5.50 per share, which is 110% of the public offering price of our Class A common stock in the initial public offering,
The Spartan IPO Warrant was deemed compensation by FINRA and is therefore subject to a 180-day lock-up pursuant to FINRA Rule 5110(e). Spartan may not sell, transfer, assign, pledge, or hypothecate the Spartan IPO Warrant or the securities underlying such warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of such warrants or the underlying securities for a period of 180 days following the date of commencement of sales pursuant to the offering.
In addition, the Spartan IPO Warrant provides for “piggy- back” registration rights with respect to the shares underlying such warrants, exercisable for a period of seven (7) years from the August 29, 2023, the effective date of our registration statement filed in connection with the initial public offering in compliance with FINRA Rule 5110(g)(8)(D). The exercise price and number of shares issuable upon exercise of the Spartan IPO Warrant may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary cash dividend or our recapitalization, reorganization, merger or consolidation. However, the exercise price of the Spartan IPO Warrant or the underlying shares of such warrants will not be adjusted for issuances of shares of Class A common stock at a price below such warrants’ exercise price.
The Spartan IPO Warrant was issued in a privately negotiated transaction exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended. There were no cash proceeds from the issuances of the Spartan IPO Warrant.
The foregoing description of the Spartan IPO Warrant is qualified in its entirety by the full text of the Spartan IPO Warrant, which is attached hereto as Exhibit 4.5 and is herein incorporated by reference.
Series A Preferred Stock Issuance
On January 2, 2024, we issued 20,000 shares of our Series A preferred stock to Target Capital 1, LLC (“Target”), an existing investor and holder of certain shares of our previously issued and outstanding Series A preferred stock, for gross proceeds of $200,000, pursuant to a subscription agreement between Inspire and Target in the form attached as Exhibit 10.16 and which is incorporated herein by reference.
The issuance and sale of the Series A preferred stock to Target was consummated in a privately negotiated transaction exempt from registration pursuant to Rule 506(b) of Regulation D under the Securities Act of 1933, as amended. We expect to use the proceeds of the sale of the Series A preferred stock for general working capital purposes.
II-5
Item 16. Exhibits and Financial Statement Schedules.
(a) Exhibits
II-6
| * | Filed herewith. |
| † | Bank account information or the addresses of certain officers has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both not material and the type of information that the registrant treats as private or confidential. An unredacted copy of the exhibit will be furnished supplementally to the SEC upon request. |
| + | Management contract or compensatory plan or arrangement |
| (a) | Incorporated by reference to Registration Statement on Form S-1/A filed May 23, 2023. |
| (b) | Incorporated by reference to Registration Statement on Form S-1/A filed August 2, 2023. |
| (c) | Incorporated by reference to Registration Statement on Form S-1/A filed July 14, 2023. |
II-7
| (d) | Incorporated by reference to Current Report on Form 8-K filed November 8, 2023. |
| (e) | Incorporated by reference to Current Report on Form 8-K filed December 6, 2023. |
| (f) | Incorporated by reference to Registration Statement on Form S-1/A filed August 23, 2023. |
| (g) | Incorporated by reference to Registration Statement on Form S-1 filed January 4, 2024. |
| (h) | Incorporated by reference to Registration Statement on Form S-1/A filed January 26, 2024. |
| (i) | Incorporated by reference to Registration Statement on Form S-1 filed January 31, 2024. |
| (j) | Incorporated by reference to Current Report on Form 8-K filed February 16, 2024. |
| (k) | Incorporated by reference to Current Report on Form 8-K filed March 12, 2024. |
| (l) | Incorporated by reference to the Current Report on Form 8-K filed on April 4, 2024. |
| (m) | Incorporated by reference to the Form 10-K filed on April 8, 2024. |
| (n) | Incorporated by reference to the Form S-1 filed on June 14, 2024. |
| (o) | Incorporated by reference to the Form S-1/A filed on June 24, 2024. |
Item 17. Undertakings.
The undersigned registrant hereby undertakes:
| 1) | To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: |
| i. | To include any prospectus required by section 10(a)(3) of the Securities Act of 1933; |
| ii. | To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus fi led with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement. |
| iii. | To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; |
| 2) | That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
| 3) | To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. |
| 4) | That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser: |
| i. | If the registrant is relying on Rule 430B: |
| a. | Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and |
II-8
| b. | Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fi de offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. |
| 5) | That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities: |
The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:
| i. | Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; |
| ii. | Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; |
| iii. | The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and | |
| iv. | Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. |
| 6) | Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. |
| 7) | The undersigned registrant hereby undertakes that: |
| i. | For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. |
| ii. | For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fi de offering thereof. |
II-9
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Virginia Beach, Virginia, on July 1, 2024.
| INSPIRE VETERINARY PARTNERS, INC. | |||
| By: | /s/ Kimball Carr | ||
| Name: | Kimball Carr | ||
| Title: | Chair, President and Chief Executive Officer | ||
| (Principal Executive Officer) | |||
| By: | /s/ Richard Frank | ||
| Name: | Richard Frank | ||
| Title: | Chief Financial Officer | ||
| (Principal Financial Officer) | |||
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Kimball Carr and Richard Frank as his or her true and lawful attorney-in-fact, each with full power of substitution and resubstitution for him or her and in his or her name, place and stead, in any and all capacities to sign any and all amendments including pre- and post-effective amendments to this Registration Statement, any subsequent registration statement for the same offering which may be filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and pre- or post-effective amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorney-in-fact or his substitute, each acting alone, may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
| Name | Position | Date | ||
| /s/ Kimball Carr | Chair, President and Chief Executive Officer | July 1, 2024 | ||
| Kimball Carr | (Principal Executive Officer) | |||
| /s/ Richard Frank | Chief Financial Officer, Director | July 1, 2024 | ||
| Richard Frank | (Principal Financial Officer) | |||
| /s/ Larry Alexander | Director | July 1, 2024 | ||
| Larry Alexander | ||||
| /s/ Charles Stith Keiser | Director, Vice Chair | July 1, 2024 | ||
| Charles Stith Keiser | ||||
| /s/ Peter Lau | Director | July 1, 2024 | ||
| Peter Lau | ||||
| /s/ Anne Murphy | Director | July 1, 2024 | ||
| Anne Murphy | ||||
| /s/ John Suprock | Director | July 1, 2024 | ||
| John Suprock | ||||
| /s/ Erinn Thomas-Mackey, DMV Erinn | Director | July 1, 2024 | ||
| Thomas-Mackey, DMV | ||||
| /s/ Timothy Watters | Director | July 1, 2024 | ||
| Timothy Watters |
II-10
